```
=> d his

     (FILE 'HOME' ENTERED AT 10:48:29 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:44 ON 07 OCT 2008
L1             STRUCTURE UPLOADED
L2              13 S L1
L3             875 S L1 FULL

=> d que l3 stat
L1             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L3             875 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  157665 ITERATIONS                             875 ANSWERS
SEARCH TIME: 00.00.04



=> s l3 and ed<06/09/2004
      66718865 ED<06/09/2004
                 (ED<20040609)
L4            537 L3 AND ED<06/09/2004

=> s l3 and ref.caplus<=6
      58154681 REF.CAPLUS<=6
L5            587 L3 AND REF.CAPLUS<=6

=> s l3 not l5
L6            288 L3 NOT L5

=> s ll6 and ed<06/09/2004
               4 LL6
      66718865 ED<06/09/2004
                 (ED<20040609)
L7             2 LL6 AND ED<06/09/2004

=> d 1-2 ide can
```

L7 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 360033-61-0 REGISTRY
ED Entered STN: 03 Oct 2001
CN DNA (Luciola lateralis haplotype LL6 strain L36 country South Korea/Solchon-myon, Muju-gun, Chollabuk province mitochondria gene COI fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN DNA (Luciola lateralis haplotype LL6 strain L36 country South Korea/Solchon-myon, Muju-gun, Chollabuk province mitochondria cytochrome oxidase subunit I gene COI fragment)
CN GenBank AF360907
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:131864

L7 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 184383-51-5 REGISTRY
ED Entered STN: 25 Dec 1996
CN RNA (human immunodeficiency virus 1 strain LL6 gene env fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank U80247
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR GenBank
LC STN Files: CA, CAPLUS, GENBANK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:20345

```
=> del l7
DELETE L7? (Y)/N:y

=> s l6 and ed<06/09/2004
      66718865 ED<06/09/2004
                 (ED<20040609)
L7          115 L6 AND ED<06/09/2004

=> d 1-115 ide can
```

L7 ANSWER 1 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 690697-65-5 REGISTRY
ED Entered STN: 08 Jun 2004
CN Benzenepropanamide, N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
MF C19 H16 Br N O
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 2 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 690650-71-6 REGISTRY
ED Entered STN: 08 Jun 2004
CN Benzamide, N-(4-nitro-1-naphthalenyl)-3,5-bis(trifluoromethyl)- (CA INDEX NAME)
MF C19 H10 F6 N2 O3
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 3 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 686701-39-3 REGISTRY
ED Entered STN: 27 May 2004
CN 1,3-Propanediaminium, N1,N1,N1,N3,N3-pentamethyl-N3-[2-[(4-nitro-1-naphthalenyl)amino]ethyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,3-Propanediaminium, N,N,N,N',N'-pentamethyl-N'-[2-[(4-nitro-1-naphthalenyl)amino]ethyl]- (9CI)
MF C20 H32 N4 O2
CI COM
SR CA



L7 ANSWER 4 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 677779-50-9 REGISTRY
ED Entered STN: 29 Apr 2004
CN 3-Pyridinecarbonitrile, 5-[2-(4-bromo-1-naphthalenyl)hydrazinylidene]-1,2,5,6-tetrahydro-1-(2-hydroxyethyl)-4-methyl-2,6-dioxo- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Pyridinecarbonitrile, 5-[(4-bromo-1-naphthalenyl)hydrazono]-1,2,5,6-tetrahydro-1-(2-hydroxyethyl)-4-methyl-2,6-dioxo- (9CI)
MF C19 H15 Br N4 O3
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 5 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 669696-03-1 REGISTRY
ED Entered STN: 01 Apr 2004
CN Acetamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-2-[4-(1-methylethoxy)phenoxy]- (CA INDEX NAME)
MF C22 H21 Br N2 O3 S
SR Chemical Library
Supplier: Scientific Exchange, Inc.
LC STN Files: CHEMCATS

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 6 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 666713-96-8 REGISTRY
ED Entered STN: 23 Mar 2004
CN Benzamide, 3-bromo-N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
MF C17 H11 Br2 N O
SR Chemical Library
Supplier: AKos Consulting and Solutions GmbH
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 7 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 632299-33-3 REGISTRY
ED Entered STN: 30 Dec 2003
CN Benzamide, 3-nitro-N-(4-nitro-1-naphthalenyl)-4-(2,2,3,3-tetrafluoropropoxy)- (CA INDEX NAME)
MF C20 H13 F4 N3 O6
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 8 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 591735-31-8 REGISTRY
ED Entered STN: 24 Sep 2003
CN Benzamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-2-methoxy-3-methyl- (CA INDEX NAME)
MF C20 H17 Br N2 O2 S
SR Chemical Library
Supplier: AKos Consulting and Solutions GmbH
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 9 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 575496-96-7 REGISTRY
ED Entered STN: 29 Aug 2003
CN 4-Pyridinemethanamine, N-(4-bromo-1-naphthalenyl)-1,2,3,6-tetrahydro-1-methyl- (CA INDEX NAME)
MF C17 H19 Br N2
SR Chemical Library
Supplier: AsInEx



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 10 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 501916-16-1 REGISTRY
ED Entered STN: 07 Apr 2003
CN 3-Pyridinecarboxylic acid, 4-[[(4-bromo-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)
MF C17 H11 Br N2 O3
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 11 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 501916-14-9 REGISTRY
ED Entered STN: 07 Apr 2003
CN 3-Pyridinecarboxylic acid, 2-[[(4-chloro-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)
MF C17 H11 Cl N2 O3
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 12 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 500882-08-6 REGISTRY
ED Entered STN: 28 Mar 2003
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-(4-iodo-1-naphthalenyl)- (CA INDEX NAME)
OTHER NAMES:
CN NSC 167792
MF C13 H12 I N3
CI COM
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 13 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 500864-27-7 REGISTRY
ED Entered STN: 28 Mar 2003
CN 2-Naphthalenecarboxamide, N-(4-bromo-1-naphthalenyl)-1-hydroxy- (CA INDEX NAME)
OTHER NAMES:
CN NSC 601359
MF C21 H14 Br N O2
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 14 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 478033-80-6 REGISTRY
ED Entered STN: 03 Jan 2003
CN 2-Pyridineacetic acid, 3-chloro-α-[[(4-chloro-1-naphthalenyl)amino]methylene]-5-(trifluoromethyl)-, methyl ester (CA INDEX NAME)
MF C20 H13 Cl2 F3 N2 O2
SR Chemical Library
Supplier: Bionet Research Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 15 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 439122-40-4 REGISTRY
ED Entered STN: 17 Jul 2002
CN 4-Pyridinemethanamine, N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
MF C16 H13 Br N2
SR Chemical Library
Supplier: Ambinter



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 16 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 434305-26-7 REGISTRY
ED Entered STN: 27 Jun 2002
CN Benzenepropanamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C19 H16 N2 O3
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 17 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 433949-95-2 REGISTRY
ED Entered STN: 26 Jun 2002
CN Benzamide, 2-chloro-4,5-difluoro-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C17 H9 Cl F2 N2 O3
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 18 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 433704-24-6 REGISTRY
ED Entered STN: 26 Jun 2002
CN Butanamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-3-methyl- (CA INDEX NAME)
MF C16 H17 Br N2 O S
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 19 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 433328-56-4 REGISTRY
ED Entered STN: 25 Jun 2002
CN Benzamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-3-(1-methylethoxy)- (CA INDEX NAME)
MF C21 H19 Br N2 O2 S
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 20 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 429648-08-8 REGISTRY
ED Entered STN: 13 Jun 2002
CN Benzamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-4-chloro- (CA INDEX NAME)
MF C18 H12 Br Cl N2 O S
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 21 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 428845-17-4 REGISTRY
ED Entered STN: 12 Jun 2002
CN 2-Thiophenecarboxamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]- (CA INDEX NAME)
MF C16 H11 Br N2 O S2
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 22 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 413583-66-1 REGISTRY
ED Entered STN: 12 May 2002
CN 1-Naphthalenamine, 4-nitro-N-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)
MF C17 H7 F7 N2 O2
SR Chemical Library
Supplier: ChemBridge Corporation



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 23 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 402954-06-7 REGISTRY
ED Entered STN: 27 Mar 2002
CN Acetamide, 2-[[6-amino-3,5-dicyano-4-(2-furanyl)-1,4-dihydro-2-pyridinyl]thio]-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C23 H16 N6 O4 S
SR Chemical Library
Supplier: Ambinter



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 24 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 401825-59-0 REGISTRY
ED Entered STN: 19 Mar 2002
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[[tetrahydro-1-(1-naphthalenyl)-2,4,6-trioxo-5(2H)-pyrimidinylidene]methyl]- (CA INDEX NAME)
MF C26 H17 Br N4 O4
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 25 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 401825-51-2 REGISTRY
ED Entered STN: 19 Mar 2002
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[[(4-bromo-1-naphthalenyl)amino]methylene]-1-(1-naphthalenyl)- (CA INDEX NAME)
MF C25 H16 Br N3 O3
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 26 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 401825-37-4 REGISTRY
ED Entered STN: 19 Mar 2002
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[[1-(4-fluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]methyl]- (CA INDEX NAME)
MF C22 H16 Br F N4 O2
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 27 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 401824-50-8 REGISTRY
ED Entered STN: 19 Mar 2002
CN 3-Pyridinecarbonitrile, 5-[[(4-bromo-1-naphthalenyl)amino]methylene]-1,2,5,6-tetrahydro-4-methyl-2,6-dioxo- (CA INDEX NAME)
MF C18 H12 Br N3 O2
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 28 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 401821-95-2 REGISTRY
ED Entered STN: 19 Mar 2002
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[[5-cyano-1,6-dihydro-4-methyl-2,6-dioxo-1-(phenylmethyl)-3(2H)-pyridinylidene]methyl]- (CA INDEX NAME)
MF C26 H19 Br N4 O3
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 29 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 392701-78-9 REGISTRY
ED Entered STN: 15 Feb 2002
CN 2,4-Pyrimidinediamine, N2-(4-bromo-1-naphthalenyl)-N4-(2-methoxyphenyl)-6-methyl-5-nitro- (CA INDEX NAME)
MF C22 H18 Br N5 O3
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 30 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 385377-34-4 REGISTRY
ED Entered STN: 22 Jan 2002
CN 2-Propenamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-3-phenyl- (CA INDEX NAME)
MF C20 H15 Br N2 O S
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 31 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 384811-47-6 REGISTRY
ED Entered STN: 20 Jan 2002
CN 4-Pyridinamine, 2,3,5,6-tetrafluoro-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C15 H7 F4 N3 O2
SR Chemical Library
Supplier: Ambinter



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 32 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 380307-78-8 REGISTRY
ED Entered STN: 03 Jan 2002
CN Benzamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-3-butoxy- (CA INDEX NAME)
MF C22 H21 Br N2 O2 S
SR Chemical Library
Supplier: Ambinter
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 33 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 362609-82-3 REGISTRY
ED Entered STN: 17 Oct 2001
CN 2-Benzoxazoleacetaldehyde, α-[[(4-bromo-1-naphthalenyl)amino]methylene]-5-chloro- (CA INDEX NAME)
MF C20 H12 Br Cl N2 O2
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 34 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 362500-27-4 REGISTRY
ED Entered STN: 16 Oct 2001
CN 2-Benzoxazoleacetaldehyde, α-[[(4-bromo-1-naphthalenyl)amino]methylene]- (CA INDEX NAME)
MF C20 H13 Br N2 O2
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 35 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 362499-90-9 REGISTRY
ED Entered STN: 16 Oct 2001
CN 3-Pyridinecarbonitrile, 5-[[(4-bromo-1-naphthalenyl)amino]methylene]-1,2,5,6-tetrahydro-1,4-dimethyl-2,6-dioxo- (CA INDEX NAME)
MF C19 H14 Br N3 O2
SR Chemical Library
Supplier: LaboTest
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 36 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 354996-44-4 REGISTRY
ED Entered STN: 06 Sep 2001
CN 3H-Pyrazol-3-one, 4-[[(4-bromo-1-naphthalenyl)amino]methylene]-2,4-dihydro-5-methyl-2-(4-methylphenyl)- (CA INDEX NAME)
MF C22 H18 Br N3 O
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 37 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 352683-65-9 REGISTRY
ED Entered STN: 27 Aug 2001
CN 3H-Pyrazol-3-one, 4-[[(4-bromo-1-naphthalenyl)amino]methylene]-2-(4-bromophenyl)-2,4-dihydro-5-methyl- (CA INDEX NAME)
MF C21 H15 Br2 N3 O
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 38 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 352682-52-1 REGISTRY
ED Entered STN: 27 Aug 2001
CN 3H-Pyrazol-3-one, 4-[[(4-bromo-1-naphthalenyl)amino]methylene]-2-(2,4-dimethylphenyl)-2,4-dihydro-5-methyl- (CA INDEX NAME)
MF C23 H20 Br N3 O
SR Chemical Library
Supplier: Interchim
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 39 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 347340-34-5 REGISTRY
ED Entered STN: 22 Jul 2001
CN Benzamide, N-[[(4-bromo-1-naphthalenyl)amino]thioxomethyl]-3,4-dimethoxy- (CA INDEX NAME)
MF C20 H17 Br N2 O3 S
SR Chemical Library
Supplier: Interbioscreen Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 40 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 346641-12-1 REGISTRY
ED Entered STN: 18 Jul 2001
CN Benzamide, N-(4-fluoro-1-naphthalenyl)-2-methoxy- (CA INDEX NAME)
MF C18 H14 F N O2
SR Chemical Library
Supplier: Scientific Exchange, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 41 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 345614-76-8 REGISTRY
ED Entered STN: 12 Jul 2001
CN 2,4(1H,3H)-Pyrimidinedione, 6-[(4-fluoro-1-naphthalenyl)amino]- (CA INDEX NAME)
MF C14 H10 F N3 O2
SR Chemical Library
Supplier: ChemStar, Ltd.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 42 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 345309-66-2 REGISTRY
ED Entered STN: 11 Jul 2001
CN 2-Naphthalenecarboxaldehyde, 2-(4-chloro-1-naphthalenyl)hydrazone (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthalenecarboxaldehyde, (4-chloro-1-naphthalenyl)hydrazone (9CI)
MF C21 H15 Cl N2
SR Reaction Database
LC STN Files: CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 43 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 345208-50-6 REGISTRY
ED Entered STN: 10 Jul 2001
CN Benzaldehyde, 2-(4-chloro-1-naphthalenyl)hydrazone (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzaldehyde, (4-chloro-1-naphthalenyl)hydrazone (9CI)
MF C17 H13 Cl N2
SR Reaction Database
LC STN Files: CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 44 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 343842-37-5 REGISTRY
ED Entered STN: 28 Jun 2001
CN 2H-1-Benzopyran-3-carboxamide, N-(4-bromo-1-naphthalenyl)-2-oxo- (CA INDEX NAME)
MF C20 H12 Br N O3
SR Reaction Database
LC STN Files: CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 45 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-95-1 REGISTRY
ED Entered STN: 22 May 2001
CN Tetradecanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C31 H47 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 46 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-93-9 REGISTRY
ED Entered STN: 22 May 2001
CN 2-Propenamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)-3-phenyl- (CA INDEX NAME)
MF C26 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 47 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-92-8 REGISTRY
ED Entered STN: 22 May 2001
CN Propanamide, N-(4-bromo-1-naphthalenyl)-3-[(1-methylpropyl)[2-(phenylmethoxy)acetyl]amino]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propanamide, N-(4-bromo-1-naphthalenyl)-3-[(1-methylpropyl)[(phenylmethoxy)acetyl]amino]- (9CI)
MF C26 H29 Br N2 O3
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 48 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-91-7 REGISTRY
ED Entered STN: 22 May 2001
CN Butanoic acid, 4-[[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl](1-methylpropyl)amino]-4-oxo-, ethyl ester (CA INDEX NAME)
MF C23 H29 Br N2 O4
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 49 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-90-6 REGISTRY
ED Entered STN: 22 May 2001
CN Butanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-3-methyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C22 H29 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 50 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-89-3 REGISTRY
ED Entered STN: 22 May 2001
CN Dodecanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C29 H43 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 51 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-88-2 REGISTRY
ED Entered STN: 22 May 2001
CN Nonanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C26 H37 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 52 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-87-1 REGISTRY
ED Entered STN: 22 May 2001
CN Heptanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H33 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 53 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-86-0 REGISTRY
ED Entered STN: 22 May 2001
CN Decanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C27 H39 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 54 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-85-9 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-4-ethyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C26 H29 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 55 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-84-8 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-3-methoxy-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H27 Br N2 O3
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 56 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-83-7 REGISTRY
ED Entered STN: 22 May 2001
CN 1-Naphthalenecarboxamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C28 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 57 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-82-6 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-3-fluoro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H24 Br F N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 58 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-81-5 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2-fluoro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H24 Br F N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 59 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-79-1 REGISTRY
ED Entered STN: 22 May 2001
CN Benzeneacetamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-4-methoxy-N-(1-methylpropyl)- (CA INDEX NAME)
MF C26 H29 Br N2 O3
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 60 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-78-0 REGISTRY
ED Entered STN: 22 May 2001
CN Benzenepropanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C26 H29 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 61 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-76-8 REGISTRY
ED Entered STN: 22 May 2001
CN Hexanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2-ethyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H35 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 62 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-75-7 REGISTRY
ED Entered STN: 22 May 2001
CN 2-Thiopheneacetamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C23 H25 Br N2 O2 S
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 63 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-74-6 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2-methyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 64 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-73-5 REGISTRY
ED Entered STN: 22 May 2001
CN Hexanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C23 H31 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 65 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-71-3 REGISTRY
ED Entered STN: 22 May 2001
CN 2-Thiophenecarboxamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C22 H23 Br N2 O2 S
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 66 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-70-2 REGISTRY
ED Entered STN: 22 May 2001
CN Cyclopentanepropanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H33 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 67 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-69-9 REGISTRY
ED Entered STN: 22 May 2001
CN Cyclohexanecarboxamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H31 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 68 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-68-8 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-4-methyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 69 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-67-7 REGISTRY
ED Entered STN: 22 May 2001
CN Octanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H35 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 70 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-66-6 REGISTRY
ED Entered STN: 22 May 2001
CN Propanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2-methyl-N-(1-methylpropyl)- (CA INDEX NAME)
MF C21 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 71 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-64-4 REGISTRY
ED Entered STN: 22 May 2001
CN Butanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-4-chloro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C21 H26 Br Cl N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 72 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-62-2 REGISTRY
ED Entered STN: 22 May 2001
CN Benzeneacetamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C25 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 73 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-61-1 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2,4-dichloro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H23 Br Cl2 N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 74 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-59-7 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-2-chloro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H24 Br Cl N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 75 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-57-5 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-4-fluoro-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H24 Br F N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 76 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-56-4 REGISTRY
ED Entered STN: 22 May 2001
CN Benzamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C24 H25 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 77 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-55-3 REGISTRY
ED Entered STN: 22 May 2001
CN Butanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C21 H27 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 78 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 337314-54-2 REGISTRY
ED Entered STN: 22 May 2001
CN Propanamide, N-[3-[(4-bromo-1-naphthalenyl)amino]-3-oxopropyl]-N-(1-methylpropyl)- (CA INDEX NAME)
MF C20 H25 Br N2 O2
SR Chemical Library
Supplier: ComGenex International Inc.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 79 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 333310-84-2 REGISTRY
ED Entered STN: 27 Apr 2001
CN Benzenesulfonamide, 4-ethyl-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C18 H16 N2 O4 S
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 80 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 332029-71-7 REGISTRY
ED Entered STN: 23 Apr 2001
CN 3H-Pyrazol-3-one, 4-[[(4-bromo-1-naphthalenyl)amino]methylene]-2-(3,4-dimethylphenyl)-2,4-dihydro-5-methyl- (CA INDEX NAME)
MF C23 H20 Br N3 O
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 81 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 331971-38-1 REGISTRY
ED Entered STN: 20 Apr 2001
CN 2,4-Pyrimidinediamine, N2,N4-bis(4-bromo-1-naphthalenyl)-6-methyl-5-nitro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Pyrimidinediamine, N,N'-bis(4-bromo-1-naphthalenyl)-6-methyl-5-nitro- (9CI)
MF C25 H17 Br2 N5 O2
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 82 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 325723-47-5 REGISTRY
ED Entered STN: 05 Mar 2001
CN 9H-Thioxanthene-3-carboxamide, N-(4-bromo-1-naphthalenyl)-9-oxo-, 10,10-dioxide (CA INDEX NAME)
MF C24 H14 Br N O4 S
SR Chemical Library
Supplier: Enamine



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 83 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 309292-56-6 REGISTRY
ED Entered STN: 18 Dec 2000
CN 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[[(4-bromo-1-naphthalenyl)amino]methylene]-1-(4-chlorophenyl)- (CA INDEX NAME)
MF C21 H13 Br Cl N3 O3
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 84 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 302603-15-2 REGISTRY
ED Entered STN: 13 Nov 2000
CN 2-Naphthalenesulfonamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
MF C20 H14 N2 O4 S
SR Chemical Library
Supplier: Florida Center for Heterocyclic Compounds, Department of Chemistry, University of Florida
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 85 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 300860-81-5 REGISTRY
ED Entered STN: 02 Nov 2000
CN 1,2-Benzenedicarboxamide, N1,N2-bis(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Benzenedicarboxamide, N,N'-bis(4-bromo-1-naphthalenyl)- (9CI)
MF C28 H18 Br2 N2 O2
SR Chemical Library
Supplier: ChemDiv, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 86 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 275813-61-1 REGISTRY
ED Entered STN: 10 Jul 2000
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]-, mono(trifluoroacetate) (9CI)
FS STEREOSEARCH
MF C30 H35 Cl F N3 O . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 275813-60-0
CMF C30 H35 Cl F N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:164710

REFERENCE 2: 138:204946

REFERENCE 3: 136:69739

REFERENCE 4: 136:69738

L7 ANSWER 86 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE 5: 133:43445

REFERENCE 6: 133:43444

REFERENCE 7: 133:43443

REFERENCE 8: 133:43442

REFERENCE 9: 133:43441

L7 ANSWER 87 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 247234-21-5 REGISTRY
ED Entered STN: 17 Nov 1999
CN Guanidine, N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Guanidine, (4-bromo-1-naphthalenyl)- (9CI)
MF C11 H10 Br N3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 88 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 219861-20-8 REGISTRY
ED Entered STN: 21 Feb 1999
CN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenamide, 2-methyl-N-(4-nitro-1-naphthalenyl)-, polymer with 2-hydroxyethyl 2-methyl-2-propenoate (9CI)
MF (C14 H12 N2 O3 . C6 H10 O3)x
CI PMS, COM
PCT Polyacrylic
SR CA

CM 1

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 2

CRN 868-77-9
CMF C6 H10 O3



L7 ANSWER 89 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 219861-07-1 REGISTRY
ED Entered STN: 21 Feb 1999
CN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with 2-[(4-nitro-1-naphthalenyl)amino]-2-oxoethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenoic acid, 2-methyl-, 2-[(4-nitro-1-naphthalenyl)amino]-2-oxoethyl ester, polymer with 2-hydroxyethyl 2-methyl-2-propenoate (9CI)
MF (C16 H14 N2 O5 . C6 H10 O3)x
CI PMS, COM
PCT Polyacrylic
SR CA

CM 1

CRN 86830-99-1
CMF C16 H14 N2 O5



CM 2

CRN 868-77-9
CMF C6 H10 O3



L7 ANSWER 90 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 212900-39-5 REGISTRY
ED Entered STN: 22 Oct 1998
CN 2-Propenoic acid, 2-methyl-, 2-[(4-nitro-1-naphthalenyl)amino]-2-oxoethyl ester, polymer with 2-hydroxyethyl 2-propenoate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenoic acid, 2-hydroxyethyl ester, polymer with 2-[(4-nitro-1-naphthalenyl)amino]-2-oxoethyl 2-methyl-2-propenoate (9CI)
MF (C16 H14 N2 O5 . C5 H8 O3)x
CI PMS, COM
PCT Polyacrylic
SR CA

CM 1

CRN 86830-99-1
CMF C16 H14 N2 O5



CM 2

CRN 818-61-1
CMF C5 H8 O3



L7 ANSWER 91 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 212889-76-4 REGISTRY
ED Entered STN: 22 Oct 1998
CN 2-Propenoic acid, 2-hydroxyethyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenamide, 2-methyl-N-(4-nitro-1-naphthalenyl)-, polymer with 2-hydroxyethyl 2-propenoate (9CI)
MF (C14 H12 N2 O3 . C5 H8 O3)x
CI PMS, COM
PCT Polyacrylic
SR CA

CM 1

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 2

CRN 818-61-1
CMF C5 H8 O3



L7 ANSWER 92 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 205041-25-4 REGISTRY
ED Entered STN: 06 May 1998
CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide and oxiranylmethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propenamide, 2-methyl-N-(4-nitro-1-naphthalenyl)-, polymer with methyl 2-methyl-2-propenoate and oxiranylmethyl 2-methyl-2-propenoate (9CI)
CN 2-Propenoic acid, 2-methyl-, oxiranylmethyl ester, polymer with methyl 2-methyl-2-propenoate and 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide (9CI)
MF (C14 H12 N2 O3 . C7 H10 O3 . C5 H8 O2)x
CI PMS, COM
PCT Polyacrylic
SR CA

CM 1

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 2

CRN 106-91-2
CMF C7 H10 O3



CM 3

CRN 80-62-6
CMF C5 H8 O2

L7 ANSWER 93 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 168169-11-7 REGISTRY
ED Entered STN: 29 Sep 1995
CN Carbamic acid, N-(4-bromo-1-naphthalenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Carbamic acid, (4-bromo-1-naphthalenyl)-, 1,1-dimethylethyl ester (9CI)
OTHER NAMES:
CN (4-Bromonaphthalen-1-yl)carbamic acid tert-butyl ester
CN N-(tert-Butoxycarbonyl)-4-bromo-1-naphthylamine
CN N-Boc-1-amino-4-bromonaphthalene
CN N-Boc-4-bromo-1-naphthylamine
MF C15 H16 Br N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:441829

REFERENCE 2: 144:150384

REFERENCE 3: 138:24719

REFERENCE 4: 138:24709

REFERENCE 5: 138:14065

REFERENCE 6: 137:325421

REFERENCE 7: 136:247592

REFERENCE 8: 135:5453

REFERENCE 9: 133:252426

REFERENCE 10: 133:120325

L7 ANSWER 94 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 105789-74-0 REGISTRY
ED Entered STN: 21 Dec 1986
CN Acetamide, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetamide, N-(4-chloro-1-naphthyl)- (6CI)
MF C12 H10 Cl N O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CHEMCATS
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 51:5395

REFERENCE 2: 51:5394

REFERENCE 3: 50:12287

REFERENCE 4: 49:28210

REFERENCE 5: 49:27874

REFERENCE 6: 49:23685

REFERENCE 7: 49:15909

REFERENCE 8: 48:71692

REFERENCE 9: 48:71691

REFERENCE 10: 48:24962

L7 ANSWER 95 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 102434-20-8 REGISTRY
ED Entered STN: 31 May 1986
CN Urea, N-(2-bromoethyl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)
MF C13 H12 Br Cl N2 O
SR US National Library of Medicine (NLM)
LC STN Files: CHEMCATS, RTECS*
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 96 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 102434-18-4 REGISTRY
ED Entered STN: 31 May 1986
CN Urea, N-(2-bromoethyl)-N'-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
MF C13 H12 Br2 N2 O
SR US National Library of Medicine (NLM)
LC STN Files: RTECS*
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 97 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 102280-43-3 REGISTRY
ED Entered STN: 26 May 1986
CN 4H-1,3-Thiazin-2-amine, N-(4-chloro-1-naphthalenyl)-5,6-dihydro- (CA INDEX NAME)
OTHER NAMES:
CN NSC 169010
MF C14 H13 Cl N2 S
SR US National Library of Medicine (NLM)
LC STN Files: BEILSTEIN*, RTECS*
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 98 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 102280-42-2 REGISTRY
ED Entered STN: 26 May 1986
CN 1H-Imidazol-2-amine, N-(4-bromo-1-naphthalenyl)-4,5-dihydro-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazol-2-amine, N-(4-bromo-1-naphthalenyl)-4,5-dihydro-, monohydrochloride (9CI)
MF C13 H12 Br N3 . Cl H
SR US National Library of Medicine (NLM)
LC STN Files: CHEMCATS, RTECS*
(*File contains numerically searchable property data)
CRN (746564-02-3)



● HCl

L7 ANSWER 99 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 101564-97-0 REGISTRY
ED Entered STN: 19 Apr 1986
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-(4-iodo-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-(4-iodo-1-naphthalenyl)-, monohydrochloride (9CI)
MF C13 H12 I N3 . Cl H
SR US National Library of Medicine (NLM)
LC STN Files: RTECS*
(*File contains numerically searchable property data)
CRN (500882-08-6)



● HCl

L7 ANSWER 100 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 91394-66-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetamide, N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetamide, N-(4-bromo-1-naphthyl)- (6CI, 7CI)
OTHER NAMES:
CN 4-Bromo-1-acetamidonaphthalene
CN N-(4-Bromo-1-naphthyl)acetamide
CN NSC 38943
MF C12 H10 Br N O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 140:253284

REFERENCE 2: 136:19889

REFERENCE 3: 133:30730

REFERENCE 4: 133:4410

REFERENCE 5: 122:265379

REFERENCE 6: 119:95046

REFERENCE 7: 117:277

REFERENCE 8: 56:66770

REFERENCE 9: 55:43239

REFERENCE 10: 45:16309

L7 ANSWER 101 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 78851-70-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenecarbonitrile, 4-(dimethylamino)- (CA INDEX NAME)
OTHER NAMES:
CN 1-(Dimethylamino)-4-cyanonaphthalene
MF C13 H12 N2
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:352638

REFERENCE 2: 132:293452

REFERENCE 3: 129:223085

REFERENCE 4: 127:10970

REFERENCE 5: 102:87392

REFERENCE 6: 97:215344

REFERENCE 7: 96:6085

REFERENCE 8: 95:105617

L7 ANSWER 102 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 59557-93-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-bromo-N,N-dimethyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, 4-bromo-N,N-di-methyl- (6CI, 7CI)
OTHER NAMES:
CN 1-Bromo-4-(dimethylamino)naphthalene
CN 4-Bromo-N,N-dimethyl-1-naphthylamine
MF C12 H12 Br N
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, GMELIN*, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 147:206829

REFERENCE 2: 146:461975

REFERENCE 3: 145:123952

REFERENCE 4: 144:488091

REFERENCE 5: 142:308776

REFERENCE 6: 140:38359

REFERENCE 7: 138:204921

REFERENCE 8: 135:166772

REFERENCE 9: 128:168723

REFERENCE 10: 123:285466

L7 ANSWER 103 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 59080-14-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenaminium, 4-fluoro-N,N,N-trimethyl- (CA INDEX NAME)
MF C13 H15 F N
CI COM

L7 ANSWER 104 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 58728-64-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenecarbonitrile, 4-amino- (CA INDEX NAME)
OTHER NAMES:
CN 1-Amino-4-cyanonaphthalene
CN 4-Amino-1-naphthalenecarbonitrile
CN 4-Amino-1-naphthonitrile
CN 4-Cyano-1-naphthylamine
MF C11 H8 N2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

69 REFERENCES IN FILE CA (1907 TO DATE)
69 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:55060

REFERENCE 2: 147:277006

REFERENCE 3: 146:481653

REFERENCE 4: 146:434187

REFERENCE 5: 146:269819

REFERENCE 6: 146:121835

REFERENCE 7: 146:114246

REFERENCE 8: 145:103957

REFERENCE 9: 145:62880

REFERENCE 10: 144:488388

L7 ANSWER 105 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 47544-87-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4-Piperidinamine, N-(4-chloro-1-naphthalenyl)-1-[2-(4-chlorophenyl)ethyl]- (CA INDEX NAME)
MF C23 H24 Cl2 N2
CI COM

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 106 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 47491-37-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-(2-phenylethyl)- (CA INDEX NAME)
MF C23 H25 Br N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 ANSWER 107 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 39139-76-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, N,N-dimethyl-4-nitro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, N,N-dimethyl-4-nitro- (7CI)
OTHER NAMES:
CN N,N-Dimethyl-4-nitro-α-naphthylamine
MF C12 H12 N2 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:22007

REFERENCE 2: 138:169773

REFERENCE 3: 132:180210

REFERENCE 4: 121:204591

REFERENCE 5: 110:94360

REFERENCE 6: 109:109706

REFERENCE 7: 107:133673

REFERENCE 8: 99:22064

REFERENCE 9: 88:104361

REFERENCE 10: 87:52434

L7 ANSWER 108 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 24402-72-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetamide, N-(4-nitro-1-naphthyl)- (6CI, 7CI, 8CI)
OTHER NAMES:
CN N-Acetyl-4-nitro-1-naphthylamine
CN NSC 176001
MF C12 H10 N2 O3
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41 REFERENCES IN FILE CA (1907 TO DATE)
41 REFERENCES IN FILE CAPLUS (1907 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:223077

REFERENCE 2: 133:193544

REFERENCE 3: 133:142522

REFERENCE 4: 118:213660

REFERENCE 5: 116:234985

REFERENCE 6: 114:62849

REFERENCE 7: 109:73979

REFERENCE 8: 106:25823

REFERENCE 9: 103:150994

REFERENCE 10: 99:222413

L7 ANSWER 109 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 7000-88-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, N-methyl-4-nitro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, N-methyl-4-nitro- (7CI, 8CI)
MF C11 H10 N2 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:22007

REFERENCE 2: 109:219265

REFERENCE 3: 107:133673

REFERENCE 4: 78:57629

REFERENCE 5: 72:91666

REFERENCE 6: 64:26879

REFERENCE 7: 23:38374

L7 ANSWER 110 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 6708-61-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[4-(2-phenyldiazenyl)phenyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[4-(phenylazo)phenyl]- (9CI)
CN Triazene, 1-(4-nitro-1-naphthyl)-3-[p-(phenylazo)phenyl]- (6CI, 8CI)
OTHER NAMES:
CN Cadion 2B
CN NSC 66472
MF C22 H16 N6 O2
LC STN Files: CA, CAOLD, CAPLUS, CHEMLIST, TOXCENTER
Other Sources: DSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

34 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
34 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 145:109634

REFERENCE 2: 142:492835

REFERENCE 3: 142:151068

REFERENCE 4: 139:341313

REFERENCE 5: 136:209756

REFERENCE 6: 133:328898

REFERENCE 7: 133:98749

REFERENCE 8: 131:35497

REFERENCE 9: 129:156165

REFERENCE 10: 117:61803

L7 ANSWER 110 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN (Continued)

L7 ANSWER 111 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 4684-12-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-chloro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, 4-chloro- (6CI, 7CI, 8CI)
OTHER NAMES:
CN (4-Chloronaphthalen-1-yl)amine
CN 1-Amino-4-chloronaphthalene
CN 4-Chloro-1-naphthalenamine
CN 4-Chloro-1-naphthylamine
CN NSC 60276
MF C10 H8 Cl N
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 148:285200

REFERENCE 2: 148:78550

REFERENCE 3: 148:55060

REFERENCE 4: 147:277006

REFERENCE 5: 147:165759

REFERENCE 6: 146:521639

REFERENCE 7: 146:401994

REFERENCE 8: 146:114231

REFERENCE 9: 146:81855

REFERENCE 10: 145:471325

L7 ANSWER 112 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE 10: 147:226192

L7 ANSWER 112 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 2298-07-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-bromo- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, 4-bromo- (6CI, 7CI, 8CI)
OTHER NAMES:
CN (4-Bromonaphthalen-1-yl)amine
CN 1-Amino-4-bromonaphthalene
CN 1-Bromo-4-aminonaphthalene
CN 4-Bromo-1-naphthalenamine
CN 4-Bromo-1-naphthalenemine
CN 4-Bromo-1-naphthylamine
CN NSC 120524
CN NSC 16028
MF C10 H8 Br N
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

141 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
142 REFERENCES IN FILE CAPLUS (1907 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 148:378810

REFERENCE 2: 148:262264

REFERENCE 3: 148:239465

REFERENCE 4: 148:191728

REFERENCE 5: 147:486303

REFERENCE 6: 147:448959

REFERENCE 7: 147:365277

REFERENCE 8: 147:277006

REFERENCE 9: 147:235009

L7 ANSWER 113 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 776-34-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-nitro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, 4-nitro- (7CI, 8CI)
OTHER NAMES:
CN 1,4-Nitronaphthylamine
CN 1-Amino-4-nitronaphthalene
CN 4-Amino-1-nitronaphthalene
CN 4-Nitro-α-naphthylamine
CN 4-Nitro-1-aminonaphthalene
CN 4-Nitro-1-naphthamine
CN 4-Nitro-1-naphthylamine
CN NSC 614
MF C10 H8 N2 O2
CI COM
LC STN Files: AQUIRE, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

264 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
265 REFERENCES IN FILE CAPLUS (1907 TO DATE)
13 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 149:193223

REFERENCE 2: 148:416802

REFERENCE 3: 148:379313

REFERENCE 4: 148:78550

REFERENCE 5: 147:277006

REFERENCE 6: 147:241945

REFERENCE 7: 146:461975

REFERENCE 8: 146:449253

REFERENCE 9: 146:379654

REFERENCE 10: 146:176163

L7 ANSWER 114 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 438-32-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-fluoro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthylamine, 4-fluoro- (6CI, 8CI)
OTHER NAMES:
CN 1-Amino-4-fluoronaphthalene
MF C10 H8 F N
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:216934

REFERENCE 2: 126:117854

REFERENCE 3: 123:132884

REFERENCE 4: 118:80645

REFERENCE 5: 87:52297

REFERENCE 6: 84:164048

REFERENCE 7: 81:3656

REFERENCE 8: 66:55260

REFERENCE 9: 66:54874

REFERENCE 10: 66:46238

L7 ANSWER 115 OF 115 REGISTRY COPYRIGHT 2008 ACS on STN
RN 317-04-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetamide, N-(4-fluoro-1-naphthalenyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetamide, N-(4-fluoro-1-naphthyl)- (6CI, 7CI, 8CI)
OTHER NAMES:
CN N-(4-Fluoro-1-naphthyl)acetamide
CN N-Acetyl-4-fluoro-1-naphthylamine
MF C12 H10 F N O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 122:81142

REFERENCE 2: 84:164048

REFERENCE 3: 83:163090

REFERENCE 4: 80:59782

REFERENCE 5: 66:55260

REFERENCE 6: 66:54874

REFERENCE 7: 58:66322

REFERENCE 8: 52:97984

REFERENCE 9: 49:84016

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 10:57:25 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Oct 2008  VOL 149 ISS 15
FILE LAST UPDATED: 6 Oct 2008  (20081006/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l3
L8         931 L3

=> s l8 and py<2004
      24009715 PY<2004
L9         765 L8 AND PY<2004

=> d his

     (FILE 'HOME' ENTERED AT 10:48:29 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:44 ON 07 OCT 2008
L1               STRUCTURE UPLOADED
L2            13 S L1
L3           875 S L1 FULL
L4           537 S L3 AND ED<06/09/2004
L5           587 S L3 AND REF.CAPLUS<=6
L6           288 S L3 NOT L5
L7           115 S L6 AND ED<06/09/2004

     FILE 'CAPLUS' ENTERED AT 10:57:25 ON 07 OCT 2008
L8           931 S L3
L9           765 S L8 AND PY<2004

=> s l5
L10        438 L5

=> s l10 and py<2005
      25113211 PY<2005
L11        369 L10 AND PY<2005
```

```
=> s l11 and py<2004
      24009715 PY<2004
L12         347 L11 AND PY<2004

=> => s l12 and thu/rl
       1055027 THU/RL
L13          79 L12 AND THU/RL

=> d 1-79 bib abs hitstr
```

L13 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:994933 CAPLUS
DN 145:377335
TI Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO U.S., 358pp., Cont.-in-part of Ser. No. 939,374.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 7112600	B1	20060926	US 2002-180558	20020626	
	WO 2001047883	A1	20010705	WO 2000-JP9181	20001222	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	JP 2001247550	A	20010911	JP 2000-391904	20001225	<--
	US 20030050320	A1	20030313	US 2001-939374	20010824	<--
	US 6770666	B2	20040803			
	ZA 2003001393	A	20040715	ZA 2003-1393	20020626	<--
	US 20070032497	A1	20070208	US 2005-93208	20050328	
PRAI	JP 1999-369008	A	19991227			
	WO 2000-JP9181	A2	20001222			
	JP 2000-391904	A	20001225			
	JP 2001-193786	A	20010626			
	US 2001-939374	A2	20010824			
	JP 2001-351537	A	20011116			
	US 2002-180558	A3	20020626			

OS MARPAT 145:377335
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.
IT 347171-27-1P 347171-97-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)
RN 347171-27-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[(4-chloro-1-

L13 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



RN 347171-97-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:331776 CAPLUS
DN 140:357318
TI Preparation of fused succinimides as modulators of nuclear hormone receptor function
IN Salvati, Mark E.; Balog, James Aaron; Pickering, Dacia A.; Giese, Soren; Pura, Aberra; Li, Wenying; Patel, Ramesh N.; Hanson, Ronald L.; Mitt, Toomas; Roberge, Jacques Y.; Corte, James R.; Spergel, Steven H.; Rampulla, Richard A.; Misra, Raj N.; Xiao, Hai-Yun
PA USA
SO U.S. Pat. Appl. Publ., 378 pp., Cont.-in-part of U.S. Ser. No. 25,116, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20040077605	A1	20040422	US 2002-322077	20021218	<--
	US 20020173445	A1	20021121	US 2001-885827	20010620	<--
	US 6960474	B2	20051101			
	US 20040176324	A1	20040909	US 2001-885381	20010620	<--
	EP 1854798	A2	20071114	EP 2007-15374	20021218	
	EP 1854798	A3	20071128			
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, AL, LT, LV, MK, RO					
	US 20060223832	A1	20061005	US 2004-917031	20040812	
	US 20050192253	A1	20050901	US 2004-974049	20041025	
	US 7141578	B2	20061128			
	US 20050256048	A1	20051117	US 2005-130935	20050517	
	US 20050272799	A1	20051208	US 2005-176810	20050707	
	US 20060264459	A1	20061123	US 2006-338587	20060215	
	US 20080214643	A1	20080904	US 2008-34690	20080221	
PRAI	US 2001-885381	A2	20010620			
	US 2001-885827	A2	20010620			
	US 2001-25116	B2	20011219			
	US 2000-214392P	P	20000628			
	US 2000-233519P	P	20000919			
	US 2001-284438P	P	20010418			
	US 2001-284617P	P	20010418			
	US 2001-284730P	P	20010418			
	EP 2002-797421	A3	20021218			
	US 2002-322077	B3	20021218			
	US 2004-917031	A1	20040812			
	US 2004-974049	A1	20041025			

OS MARPAT 140:357318
GI



I

AB Title compds. [I; G = (substituted) aryl, heterocyclyl; Z1, Z2 = O, S, NH, NR6; A1, A2 = CR7, N; Y = JJ'J"; J, J' = (CR7R7')n; n = 0-3, J" = bond, O, S, SO, SO2, NH, NR7, CR7R7', R2PO, R2PS, R2OPO, R2NHPO, OPOOR2, OPONHR2, OSO2, NHNH, NHNR6, NR6NH, N:N, (substituted) cycloalk(en)yl, heterocyclo; W = CR7R7'CR7R7, CR7R7'CO, COCO, CR7R7'C:CH2, C:CH2C:CH2, CR7R7C:NR1, C:NR1C:NR1, NR9CR7R7, N:N, (substituted) cycloalk(en)yl, heterocyclo, aryl, etc.; Q1, Q2 = H, (substituted) alkyl, alkenyl, cycloalk(en)yl,

L13 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
heterocycloalkyl, aryl(alkyl), alkynyl, heterocyclo, halo, CN, R1O2C, R4CO, R5R6NCO, HOCR7R7', NO2, R10CH2, R10, NH2, COSR1, SO2R1, NR4R5; L = bond, (CR7R7')n, NH, NR5, NH(CR7R7')n, NR5(CR7R7')n; R1, R1' = H, R2; R2 = (substituted) alkyl, alkenyl, alkynyl, cycloalk(en)yl, heterocyclo, cycloalk(en)ylalkyl, heterocycloalkyl, aryl(alkyl); R3, R3' = R1, halo, CN, hydroxylamine, hydroxamide, (substituted) alkoxy, alkylthio, amino, NR1R2, SH; R4 = R1, R1CO, R1O2C, R1NHCO, SO2OR1, SO2R1, SO2NR1R1'; R5 = R2, R1CO, R1NHCO, SO2R1, SO2OR1, SO2NR1R1'; R6 = R5, CN, OH, OR1; R7, R7' = R4, halo, CN, OR4, NO2, hydroxylamine, hydroxylamide, amino, NHR4, NR2R5, NR6R5, NOR1, SH, (substituted) alkylthio, HO2C, R1CO2, NH2CO, SOR1, POSR1R1', R1R1'NCO, COSR1, etc.; with provisos], were prepd. as modulators of nuclear hormone receptor function (no data). Thus, 4-(tert-butyldimethylsiloxy)-2H-thiopyran (prepn. given) and 1-(4-bromo-3-methylphenyl)-1H-pyrrole-2,5-dione (prepn. given) were refluxed 5 h in PhMe to give an enol ether intermediate which was stirred with CF3CO2H in CH2Cl2 to give 22% (3aα,4α,7α,7aα)-2-(4-bromo-3-methylphenyl)tetrahydro-4,7-ethanothiopyrano[3,4-c]pyrrole-1,3,8(2H,4H)-trione.
IT 573760-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused succinimides as modulators of nuclear hormone receptor function)
RN 573760-98-2 CAPLUS
CN Carbamic acid, (4-cyano-1-naphthalenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:220082 CAPLUS
DN 140:253556
TI Preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John; Lombardo, Louis J.; Lee, Francis Y. F.
PA Bristol-Myers Squibb Company, USA
SO U.S. Pat. Appl. Publ., 184 pp., Cont.-in-part of U.S. 6,596,746.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040054186	A1	20040318	US 2003-395503	20030324 <--
	US 7125875	B2	20061024		
	RU 2312860	C2	20071220	RU 2005-107463	20000412
	US 6596746	B1	20030722	US 2000-548929	20000413 <--
	US 20040024208	A1	20040205	US 2003-378372	20030303 <--
	US 6979694	B2	20051227		
	US 20040073026	A1	20040415	US 2003-378461	20030303 <--
	US 7091223	B2	20060815		
	US 20040077875	A1	20040422	US 2003-378373	20030303 <--
	AU 2004223828	A1	20041007	AU 2004-223828	20040323 <--
	AU 2004223828	B2	20080703		
	CA 2519898	A1	20041007	CA 2004-2519898	20040323 <--
	WO 2004085388	A2	20041007	WO 2004-US8827	20040323 <--
	WO 2004085388	A3	20050630		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1610780	A2	20060104	EP 2004-758053	20040323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008782	A	20060328	BR 2004-8782	20040323
	CN 1764454	A	20060426	CN 2004-80007845	20040323
	JP 2006523216	T	20061012	JP 2006-507475	20040323
	CN 1989969	A	20070704	CN 2006-10172441	20040323
	US 20050261305	A1	20051124	US 2005-138793	20050526
	US 7189854	B2	20070313		
	US 20050288303	A1	20051229	US 2005-138942	20050526
	US 7153856	B2	20061226		
	NO 2005004359	A	20051019	NO 2005-4359	20050920
	US 20060079563	A1	20060413	US 2005-271626	20051110
PRAI	US 1999-129510P	P	19990415		
	US 2000-548929	A2	20000413		
	RU 2000-130452	A	20000412		
	US 2003-378373	A1	20030303		
	US 2003-395503	A	20030324		
	CN 2004-80007845	A3	20040323		
	WO 2004-US8827	W	20040323		

L13 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RE.CNT 149 THERE ARE 149 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
OS MARPAT 140:253556
GI



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day. The pharmaceutical composition comprising the title compds. is claimed.
IT 302960-36-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-thiazolecarboxamides as protein tyrosine kinase inhibitors)
RN 302960-36-7 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[[(4-chloro-1-naphthalenyl)amino]carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

L13 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:950057 CAPLUS
DN 140:16647
TI Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases
IN Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; DiPietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030225106	A1	20031204	US 2002-197974	20020717 <--
	US 6878714	B2	20050412		
	US 20030125339	A1	20030703	US 2002-46681	20020110 <--
	US 6995162	B2	20060207		
	AT 361288	T	20070515	AT 2002-717325	20020111
	EP 1798230	A1	20070620	EP 2007-3413	20020111
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
	ES 2284849	T3	20071116	ES 2002-717325	20020111
	ZA 2003005197	A	20040319	ZA 2003-5197	20030704 <--
	CA 2492100	A1	20040122	CA 2003-2492100	20030715 <--
	WO 2004007458	A1	20040122	WO 2003-US22417	20030715 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003252011	A1	20040202	AU 2003-252011	20030715 <--
	AU 2003252011	B2	20071122		
	EP 1537084	A1	20050608	EP 2003-764794	20030715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006501195	T	20060112	JP 2004-521959	20030715
	BG 108012	A	20041130	BG 2003-108012	20030721 <--
	US 20050261313	A1	20051124	US 2004-14184	20041215
	MX 2005PA00584	A	20050419	MX 2005-PA584	20050113
	US 20060040956	A1	20060223	US 2005-234713	20050923
	AU 2006200437	A1	20060223	AU 2006-200437	20060201
PRAI	US 2001-261339P	P	20010112		
	US 2001-323764P	P	20010919		
	US 2002-46681	A2	20020110		
	AU 2002-248340	A3	20020111		
	EP 2002-717325	A3	20020111		
	US 2002-197974	A	20020717		
	WO 2003-US22417	W	20030715		

OS MARPAT 140:16647
GI

L13 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II

AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μM. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

IT 453563-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)

RN 453563-21-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-cyano-1-naphthalenyl)-2-[(4-pyridinylmethyl)amino]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:931340 CAPLUS

DN 140:5060

TI Preparation of pyridazin-3(2H)-ones as Phosphodiesterase 4 (PDE4) inhibitors

IN Dal Piaz, Vittorio; Giovannoni, Maria Paola; Vergelli, Claudia; Aguilar, Izquierdo Nuria

PA Almirall Prodesfarma Sa, Spain; Aguilar Izquierdo, Nuria

SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097613	A1	20031127	WO 2003-EP5056	20030514 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ES 2195785	A1	20031201	ES 2002-1111	20020516 <--
	ES 2195785	B1	20050316		
	CA 2485896	A1	20031127	CA 2003-2485896	20030514 <--
	AU 2003236648	A1	20031202	AU 2003-236648	20030514 <--
	EP 1503992	A1	20050209	EP 2003-735387	20030514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003010106	A	20050222	BR 2003-10106	20030514
	JP 2005533024	T	20051104	JP 2004-505346	20030514
	NZ 536604	A	20060728	NZ 2003-536604	20030514
	RU 2326869	C2	20080620	RU 2004-136977	20030514
	MX 2004PA11209	A	20050214	MX 2004-PA11209	20041111
	ZA 2004009173	A	20050729	ZA 2004-9173	20041111
	IN 2004DN03570	A	20050401	IN 2004-DN3570	20041116
	NO 2004005461	A	20050119	NO 2004-5461	20041215
	US 20060052379	A1	20060309	US 2005-513219	20050629
PRAI	ES 2002-1111	A	20020516		
	WO 2003-EP5056	W	20030514		

OS MARPAT 140:5060

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, acyl, alkoxycarbonyl, monoalkyl/dialkyl/carbamoyl, (un)substituted alkyl, (CH2)n-R6; n = 0 to 4; R6 = cycloalkyl, (un)substituted aryl, 3- to 7-membered heterocyclyl; R2 = R1, (un)substituted alkyl; R3, R5 = independently (un)substituted monocyclic or bicyclic aryl; R4 = H, OH and derivs., NH2 and derivs., (un)substituted alkyl, (CH2)n-R6; with the proviso that when R2 = H and R3, R4 = unsubstituted Ph, R1 is not methyl; and their pharmaceutical acceptable salts] were prepare as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Four pharmaceutical compns. are given. For

L13 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

example, II was prepd. by hydrogenation of 6-ethyl-3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one over Pd/C in ethanol, and reaction of the resulting 4-aminopyridazinone with 3-fluorophenylboronic acid in the presence of Cu(OAc)2/TEA/mol. sieves/CH2Cl2. Selected I exhibited an IC50 value < 20 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

IT 627499-89-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-1-naphthonitrile 627500-60-1P, 5-Acetyl-2-ethyl-4-[(4-nitro-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627500-68-9P, 5-Acetyl-4-[(4-chloro-1-naphthyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 inhibitor; preparation of pyridazinones as PDE4 inhibitors)

RN 627499-89-2 CAPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)



RN 627500-60-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-nitro-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)



RN 627500-68-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-chloro-1-naphthalenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)

L13 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:875249 CAPLUS
DN 139:364824
TI Preparation of indole-2-carboxamide derivatives as glycogen phosphorylase inhibitors for treatment of diabetes
IN Onda, Kenichi; Suzuki, Takayuki; Shiraki, Ryota; Yonetoku, Yasuhiro; Ogiyama, Takashi; Maruyama, Tatsuya; Momose, Kazuhiro
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091213	A1	20031106	WO 2003-JP5198	20030423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003227360	A1	20031110	AU 2003-227360	20030423 <--
PRAI	JP 2002-123926	A	20020425		
	WO 2003-JP5198	W	20030423		
OS	MARPAT 139:364824				
GI					



I



II

AB The title compds. I [wherein ring A = aryl or aromatic heterocyclyl; ring B = benzene or thiophene; R1-R9 = independently H, halo, OH, alkoxy, aryl, aryloxy, alkyl-CO-, alkyl-CH(OH)-, aryl-CO-, aryl-CH(OH)-, HO-alkylene, NH2, CN, CO2H, oxo, CO2-alkyl, aryl-alkylene(oxy), aryl-CONH-, (un)substituted alkyl, -O-alkylene-CO2H, or -O-alkylene-CONH2; R10 = H or alkyl; R11 = H, alkyl, or aryl-alkylene-; R12-R15 = independently H, OH, halo, alkoxy, HO-alkylene-, aryloxy, aromatic heterocyclyl, aryl-alkylene-,

L13 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
HO2C-alkylene-, -alkylene-CO2-alkyl, acyl, alkyl-CO2, alkyl-CH(OH)-, aryl-CH(OH)-, (un)substituted alkyl, -alkylene-CONH2, or aryl; etc.] and salts thereof are prepd. as glycogen phosphorylase inhibitors. I are useful for the treatment of insulin-dependent diabetes (type 1 diabetes), insulin-independent diabetes (type 2 diabetes), insulin resistant disease, and obesity (no data). For example, the compd. II was prepd. in a multi-step synthesis. II showed IC50 of 0.25 μM against human glycogen phosphorylase.
IT 620596-70-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolecarboxamide derivs. as glycogen phosphorylase inhibitors for treatment of diabetes)
RN 620596-70-5 CAPLUS
CN 1H-Indole-2-carboxamide, N-(4-bromo-1-naphthalenyl)-5-chloro- (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:855766 CAPLUS
DN 139:345913
TI Identification of tumor necrosis factor α (TNF-α) modulator compounds, and use for treatment of TNF-mediated diseases
IN Miller, Karen; Diu-Hercend, Anita; Hercend, Thierry; Lang, Paul; Weber, Peter; Golec, Julian; Mortimore, Michael
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088917	A2	20031030	WO 2003-US12262	20030417 <--
	WO 2003088917	A3	20040304		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003225088	A1	20031103	AU 2003-225088	20030417 <--
	US 20040048797	A1	20040311	US 2003-419327	20030417 <--
	EP 1496898	A2	20050126	EP 2003-721795	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-374434P	P	20020419		
	WO 2003-US12262	W	20030417		

AB The invention discloses methods for identifying compds. useful for regulating TNF-α levels and/or activity. The invention also discloses methods for decreasing TNF-α levels and/or activity. Compds. and compns. of the invention are useful for treating TNF-mediated diseases. The invention further discloses kits comprising the compds. and compns. herein and a tool for measuring TNF-α activity and/or levels. Preparation of selected compds., e.g. [3S/R,(2S)]-5-fluoro-4-oxo-3-[(1-(phenothiazine-10-carbonyl)piperidine-2-carbonyl)amino]pentanoic acid, is described.
IT 254749-63-8 254750-51-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNF-α modulator compound identification methods, and use for treatment of TNF-mediated diseases)
RN 254749-63-8 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 254750-51-1 CAPLUS
CN Butanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:826823 CAPLUS
DN 139:317441
TI 2-(3-Hydroxyanilino)-2-oxoacetamide derivatives and interleukin 12 production inhibitors containing them
IN Sato, Masakazu; Matsunaga, Yuiko; Ushiki, Yasunobu; Ito, Nobumasa; Nishimura, Koji
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003300875	A	20031021	JP 2002-106023	20020409 <--
PRAI	JP 2002-106023		20020409		

OS MARPAT 139:317441
AB 3-(HOC6H4)NHCOCONHR [I; R = (un)substituted Ph, (un)substituted naphthyl, (un)substituted pyridyl, quinolinyl, (alkyl)benzothiazolyl, (un)substituted thienyl, (un)substituted pyrazolyl; substituents are given] and their pharmaceutically acceptable salts and interleukin 12 production inhibitors containing I or their salts are claimed. I [R = C6H3(OMe)2-3,4] at 30 μm showed 89.7% inhibition on INF-γ-stimulated production of interleukin 12 by human peripheral blood monocytes.
IT 614721-46-9 614721-65-2 614723-13-6
614723-14-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of 3-hydroxyanilide derivs. [N-(hetero)aryl-N'-(hydroxyphenyl)oxalamides] as 12 production inhibitors)
RN 614721-46-9 CAPLUS
CN Ethanediamide, N1-(3-hydroxyphenyl)-N2-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 614721-65-2 CAPLUS
CN Ethanediamide, N1-(4-bromo-1-naphthalenyl)-N2-(3-hydroxyphenyl)- (CA INDEX NAME)

L13 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L13 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 614723-13-6 CAPLUS
CN Ethanediamide, N1-(4-cyano-1-naphthalenyl)-N2-(3-hydroxyphenyl)- (CA INDEX NAME)



RN 614723-14-7 CAPLUS
CN Ethanediamide, N1-(4-chloro-1-naphthalenyl)-N2-(3-hydroxyphenyl)- (CA INDEX NAME)

L13 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:656594 CAPLUS
DN 139:191460
TI Phospholipids as caspase inhibitor prodrugs
IN Mortimore, Michael; Golec, Julian M. C.
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068242	A1	20030821	WO 2003-US4457	20030211 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003211052	A1	20030904	AU 2003-211052	20030211 <--
	US 20040019017	A1	20040129	US 2003-366192	20030211 <--
	US 7410956	B2	20080812		
	EP 1485107	A1	20041215	EP 2003-739810	20030211 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20080199454	A1	20080821	US 2007-5068	20071221
PRAI	US 2002-355889P	P	20020211		
	US 2003-366192	A3	20030211		
	WO 2003-US4457	W	20030211		

OS MARPAT 139:191460
AB The invention relates to compds. which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. The invention further relates to the release of caspase inhibitors from these compds. through selective bond cleavage. The invention further relates to pharmaceutical compns. comprising these compds., which are particularly well-suited for treatment of caspase-mediated diseases, including inflammatory and degenerative diseases. The invention further relates to methods for preparing compds. of this invention.
IT 254749-63-8 254750-51-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipids as caspase inhibitor prodrugs)
RN 254749-63-8 CAPLUS
CN Pentanoic acid, 5-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 254750-51-1 CAPLUS
CN Butanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
inhibiting activity)
RN 223725-08-4 CAPLUS
CN Urea, N-(4-cyano-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:656575 CAPLUS
DN 139:197476
TI Preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity
IN Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
PA Bayer Corporation, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068223	A1	20030821	WO 2003-US4102	20030211 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2003210969	A1	20030904	AU 2003-210969	20030211 <--
	US 20040023961	A1	20040205	US 2003-361844	20030211 <--
PRAI	US 2002-354948P	P	20020211		
	WO 2003-US4102	W	20030211		

GI



I

AB 283 Of the title ureas useful for treating diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Synthesis of 6 ureas such as I was described. Thus, reacting 3-(tert-butyl)-1-(4-methylphenyl)pyrazole-5-ylamine with 4-(2-morpholin-4-ylethoxy)naphthylamine (prepns. given) and CDI in CH2C12 afforded 80% I which showed IC50 of < 1 μM in in vitro raf kinase and in in vitro Flk-1 ELISA assay.
IT 223725-08-4
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis

L13 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:633512 CAPLUS
DN 139:173823
TI 2,4,6-Triamino-1,3,5-triazine derivative
IN Kubota, Hideki; Suzuki, Takeshi; Miura, Masanori; Nakai, Eiichi; Yahiro, Kiyoshi; Miyake, Akira; Mochizuki, Shinobu; Nakatou, Kazuhiro
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066099	A1	20030814	WO 2003-JP1065	20030203 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2475432	A1	20030814	CA 2003-2475432	20030203 <--
	AU 2003244463	A1	20030902	AU 2003-244463	20030203 <--
	EP 1479397	A1	20041124	EP 2003-737464	20030203 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1625410	A	20050608	CN 2003-803131	20030203
	CN 1939307	A	20070404	CN 2006-10095897	20030203
	IN 2004KN01099	A	20070209	IN 2004-KN1099	20040803
	MX 2004PA07590	A	20041206	MX 2004-PA7590	20040805 <--
	US 20060194803	A1	20060831	US 2004-503494	20040805
	US 7375222	B2	20080520		
	US 20080227785	A1	20080918	US 2008-27246	20080206
PRAI	JP 2002-28844	A	20020205		
	CN 2003-803131	A3	20030203		
	WO 2003-JP1065	W	20030203		
	US 2004-503494	A3	20040805		

AB An antidementia drug contains a BEC1 potassium channel inhibitor as the active ingredient. It is proved that the BEC1 potassium channel inhibitor has an effect of ameliorating learning disability and is useful as a preventive or a remedy for diseases in which the BEC1 potassium channel seemingly participates, preferably dementia. More specifically, it is confirmed that the BEC1 potassium channel inhibitor exhibits an effect of ameliorating learning disability in an in vivo test. It is also found out that a compound having 2,4,6-triamino-1,3,5-triazine has an effect of inhibiting the BEC1 potassium channel.
IT 578013-94-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(2,4,6-triamino-1,3,5-triazine derivative as BEC1 potassium channel inhibitor for treating dementia)
RN 578013-94-2 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4,N6-diphenyl- (CA INDEX NAME)

L13 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:591184 CAPLUS
DN 139:164784
TI Preparation of fused succinimides as modulators of nuclear hormone receptor function
IN Salvati, Mark E.; Balog, James Aaron; Pickering, Darcia A.; Giese, Soren; Fura, Aberra; Li, Wenying; Patel, Ramesh N.; Hanson, Ronald L.; Mitt, Toomas; Roberge, Jacques; Corte, James R.; Spergel, Steven H.; Rampulla, Richard A.; Misra, Raj; Xiao, Hai-yun
PA Bristol-Myers Squibb Pharma Company, USA
SO PCT Int. Appl., 763 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062241	A1	20030731	WO 2002-US40598	20021218 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	TW 263640	B	20061011	TW 2002-91136163	20021213
	CA 2471342	A1	20030731	CA 2002-2471342	20021218 <--
	EP 1458723	A1	20040922	EP 2002-797421	20021218 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015281	A	20041019	BR 2002-15281	20021218 <--
	CN 1589271	A	20050302	CN 2002-828106	20021218
	HU 2004002554	A2	20050329	HU 2004-2554	20021218
	JP 2005523257	T	20050804	JP 2003-562118	20021218
	NZ 533471	A	20070531	NZ 2002-533471	20021218
	EP 1854798	A2	20071114	EP 2007-15374	20021218
	EP 1854798	A3	20071128		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, AL, LT, LV, MK, RO				
	AU 2002361785	B2	20080522	AU 2002-361785	20021218
	RU 2330038	C2	20080727	RU 2004-122403	20021218
	IN 2004DN01687	A	20070525	IN 2004-DN1687	20040615
	MX 2004PA05876	A	20050516	MX 2004-PA5876	20040616
	ZA 2004004812	A	20050826	ZA 2004-4812	20040617
	NO 2004003068	A	20040908	NO 2004-3068	20040716 <--
PRAI	US 2001-25116	A	20011219		
	EP 2002-797421	A3	20021218		
	WO 2002-US40598	W	20021218		

OS MARPAT 139:164784
GI

L13 ANSWER 12 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Title compds. [I; G = (substituted) aryl, heterocyclyl; Z1, Z2 = O, S, NH, NR6; A1, A2 = CR7, N; Y = JJ'J"; J, J" = (CR7R7')n; n = 0-3, J' = bond, O, S, SO, SO2, NH, NR7, CR7R7', R2PO, R2PS, R2OPO, OPOOR2, OPONHR2, OSO2, NHNH, NHNR6, NR6NH, N:N, (substituted) cycloalk(en)yl, heterocyclo; W' = CR7R7'CR7R7, CR7R7'CO, COCO, CR7R7'C:CH2, C:CH2C:CH2, CR7R7C:NR1, C:NR1C:NR1, NR9CR7R7, N:N, (substituted) cycloalk(en)yl, heterocyclo, aryl, etc.; Q1, Q2 = H, (substituted) alkyl, alkenyl, cycloalk(en)yl, heterocycloalkyl, aryl(alkyl), alkynyl, heterocyclo, halo, CN, R1O2C, R4CO, R5R6NCO, HOCR7R7', NO2, R1OCH2, R1O, NH2, COSR1, SO2R1, NR4R5; L = bond, (CR7R7')n, NH, NR5, NH(CR7R7')n, NR5(CR7R7')n; R1, R1' = H, R2; R2 = (substituted) alkyl, alkenyl, alkynyl, cycloalk(en)yl, heterocyclo, cycloalk(en)ylalkyl, heterocycloalkyl, aryl(alkyl); R3, R3' = R1, halo, CN, hydroxylamine, hydroxamide, (substituted) alkoxy, alkylthio, amino, NR1R2, SH; R4 = R1, R1CO, R1O2C, R1NHCO, SO2OR1, SO2R1, SO2NR1R1'; R5 = R2, R1CO, R1NHCO, SO2R1, SO2OR1, SO2NR1R1'; R6 = R5, CN, OH, OR1; R7, R7' = R4, halo, CN, OR4, NO2, hydroxylamine, hydroxylamide, amino, NHR4, NR2R5, NR5R5, NOR1, SH, (substituted) alkylthio, HO2C, R1CO2, NH2CO, SOR1, POSR1R1', R1R1'NCO, COSR1; with provisos], were prepared as modulators of nuclear hormone receptor function (no data). Thus, 4-(tert-butyldimethylsiloxy)-2H-thiopyran (preparation given) and 1-(4-bromo-3-methylphenyl)-1H-pyrrole-2,5-dione (preparation given) were refluxed 5 h in PhMe to give an enol ether intermediate which was stirred with CF3CO2H in CH2Cl2 to give 22% (3aα,4α,7α,7aα)-2-(4-bromo-3-methylphenyl)tetrahydro-4,7-ethanothiopyrano[3,4-c]pyrrole-1,3,8(2H,4H)-trione.

IT 573760-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused succinimides as modulators of nuclear hormone receptor function)

RN 573760-98-2 CAPLUS
CN Carbamic acid, (4-cyano-1-naphthalenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:490975 CAPLUS
DN 139:69297
TI Benzodiazepinone derivatives as bradykinin B2 receptor antagonists, preparation thereof, and use for treating pain
IN Leung, Carmen; Santhakumar, Vijayaratnam; Tomaszewski, Miroslaw; Woo, Simon
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051275	A2	20030626	WO 2002-SE2309	20021211 <--
	WO 2003051275	A3	20031030		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002359126	A1	20030630	AU 2002-359126	20021211 <--
PRAI	SE 2001-4248	A	20011214		
	WO 2002-SE2309	W	20021211		

OS MARPAT 139:69297
GI

AB A method is claimed of treating pain in a warm-blooded animal, comprising the step of administering a therapeutically effective amount of benzodiazepinones (shown as I; variables defined below; e.g. N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(5-isoquinolinyl)thiourea), pharmaceutically acceptable salts thereof, diastereomers thereof, enantiomers thereof, or mixts. thereof. For I: R1 = (un)substituted acyl, alkyloxycarbonyl, alkyl, heteroalkyl, cycloalkyl, aryl, heterocyclyl; aryl-C1-6-alkyl, and heterocyclyl-C1-6-alkyl, or a divalent C1-12 group that together with a 2nd N of X form a ring; X is a divalent group including a 1st N atom and the 2nd N atom, wherein a 1st group is linked to the 1st N atom and R1 is linked to the 2nd N atom, and wherein the 1st and 2nd N atoms are separated by either one C atom, or two C atoms wherein said two C atoms have a double bond there between. R3 is (un)substituted aryl, C1-12alkyl, C3-12cycloalkyl, or heterocyclyl; R4 = H, halogen, (un)substituted alkyl, (un)substituted heteroalkyl, nitro, cyano, hydroxy, OR6, SR6, S(O)R6, S(O)2R6, C(O)R6, C(S)R6, NR7R6, C(O)N7R6, NR7C(O)R6, SO2NR7R6, NR7SO2R6, or C(O)OR6; and R5, R6 and R7 = H, (un)substituted C1-6alkyl. Thirty-three examples of I were tested for binding to B2 bradykinin and ranged from 43-3110 nM (dissociation constant); no individual values are reported. Although the methods of preparation are not

L13 ANSWER 13 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
claimed, 26 example prepns. of I and 31 of intermediates are included. More than 1100 examples of I prepd. combinatorially are tabulated with LCMS anal. results.
IT 548747-01-9P 548747-25-7P 548747-97-3P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of benzodiazepinone derivs. as bradykinin B2 receptor antagonists and use for treating pain)
RN 548747-01-9 CAPLUS
CN Thiourea, N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



RN 548747-25-7 CAPLUS
CN Thiourea, N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)



RN 548747-97-3 CAPLUS
CN Thiourea, N-[7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 13 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L13 ANSWER 14 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:434358 CAPLUS
DN 139:22208
TI Preparation of hydrazonodiaminopyrazoles as integrin-linked kinase inhibitors with antiproliferative activity.
IN Zhang, Zaihui; Daynard, Timothy S.; Chafeev, Mikhail A.; Wang, Shisen; Chopiuk, Greg B.; Sviridov, Serguei V.
PA Kinetek Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045379	A1	20030605	WO 2002-CA1583	20021018 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030060453	A1	20030327	US 2002-77238	20020215 <--
	US 7105503	B2	20060912		
	CA 2468562	A1	20030605	CA 2002-2468562	20021018 <--
	AU 2002333114	A1	20030610	AU 2002-333114	20021018 <--
	AU 2002333114	B2	20080904		
	EP 1450791	A1	20040901	EP 2002-803715	20021018 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005519878	T	20050707	JP 2003-546881	20021018
	CN 1671379	A	20050921	CN 2002-827752	20021018
	RU 2332996	C2	20080910	RU 2004-119957	20021018
	IN 2004DN01594	A	20070316	IN 2004-DN1594	20040608
	US 20050272709	A1	20051208	US 2005-497046	20050420
PRAI	US 2001-335265P	P	20011130		
	US 2002-77238	A	20020215		
	US 2000-544908	A2	20000407		
	US 2000-747563	A2	20001222		
	WO 2002-CA1583	W	20021018		

OS MARPAT 139:22208
GI



I

AB Pharmaceutical compns. comprising hydrazonodiaminopyrazoles [I; n = 0-5; R1, R2 = H, alkyl, aryl, aralkyl, COR6; R1, R2 may form double bond; R3, R4 = N(R7)2, NR7COR6; R5 = (substituted) aryl, heterocyclyl; R6 = H, alkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, alkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, R8OR9; R8 = alkylene; R9 = H, alkyl], are claimed. Thus, p-anisidine in aqueous HCl was treated with aqueous NaNO2 under ice cooling; the resulting mixture was added to malononitrile in aqueous MeOH to give 70% yellow solid. The latter was

L13 ANSWER 14 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
refluxed 3 h with N2H4 in EtOH to give 4-[(4-methoxyphenyl)hydrazono]-4H-pyrazole-3,5-diamine. Integrin linked kinase was inhibited by I but no values are given. Numerous generic I drug formulations are given. The effect of 200 mg/kg of I in an acute mouse ear-swelling edema model was comparable to that produced by dexamethasone, a well-characterized and potent antiinflammatory agent. Several tests showed that I are effective against renal disease.
IT 366802-39-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydrazonodiaminopyrazoles as integrin-linked kinase inhibitors with antiproliferative activity)
RN 366802-39-3 CAPLUS
CN 4H-Pyrazol-4-one, 3,5-diamino-, 2-(4-bromo-1-naphthalenyl)hydrazone (CA INDEX NAME)



IT 366802-41-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydrazonodiaminopyrazoles as integrin-linked kinase inhibitors with antiproliferative activity)
RN 366802-41-7 CAPLUS
CN Propanedinitrile, 2-[2-(4-bromo-1-naphthalenyl)hydrazinylidene]- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:422185 CAPLUS
DN 139:12232
TI Fungicides containing triazoles bearing amide group and their medical uses
IN Uchida, Takuya; Konosu, Toshiyuki
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 59 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003160490	A	20030603	JP 2002-263676	20020910 <--
PRAI JP 2001-274388	A	20010911		

OS MARPAT 139:12232
GI



AB Fungicides contain title compds. I [Ar1 = Ph (mono- to trisubstituted with halo or CF3); Ar2 = phenylene (mono- or disubstituted with F or Cl), naphthylene (mono- or disubstituted with F or Cl); X = S, CH2; R1, R2 = H, C1-3 alkyl; R3 = (un)substituted C6-10 (hetero)aryl, (un)substituted C7-14 aralkyl, etc.], their pharmacol. acceptable prodrugs or salts as active ingredients. Thus, trans-(1R,2R)-I (Ar1 = 2,4-difluorophenyl, Ar2 = 1,4-C6H4, X = S, R1 = Me, R2 = H, R3 = 4-F2CHCF2CH2OC6H4) (preparation given) had MIC value of 0.016 against Candida albicans SANK 51486.
IT 364082-22-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide group-containing triazoles as fungicides)
RN 364082-22-4 CAPLUS
CN Benzamide, N-(4-cyano-1-naphthalenyl)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L13 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L13 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:356252 CAPLUS
DN 138:368891
TI Preparation of arylazolecarboxamides for the treatment of obesity
IN Coish, Philip D. G.; O'Connor, Stephen J.; Wickens, Philip; Zhang, Chengzhi; Zhang, Hai-Jun
PA Bayer Corporation, USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003037332	A1	20030508	WO 2002-US32895	20021015 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463441	A1	20030508	CA 2002-2463441	20021015 <--
AU 2002348440	A1	20030512	AU 2002-348440	20021015 <--
EP 1435951	A1	20040714	EP 2002-782159	20021015 <--
EP 1435951	B1	20060118		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005507932	T	20050324	JP 2003-539676	20021015
ES 2256560	T3	20060716	ES 2002-782159	20021015
US 20050014805	A1	20050120	US 2004-490826	20040326
MX 2004PA02931	A	20050411	MX 2004-PA2931	20040329
PRAI US 2001-329236P	P	20011012		
WO 2002-US32895	W	20021015		

OS MARPAT 138:368891
GI



AB Title compds. [I; R1 = ZCR11R12CO2R13; Z = O, S; R11-R15 = H, alkyl; R2, R3 = H, Me; R1R2 = CH2CH2CH(CHR15CO2R14); Y = NR4, O, S; R4 = H, alkyl, alkoxyalkyl, aryloxyalkyl; R5 = H, alkyl, Ph, halophenyl, alkylphenyl, alkoxyphenyl; R6 = COR61; R61 = OH, alkoxy, benzyloxy, amino, etc.], were prepared for treatment of obesity and complications (no data). Thus, tert-Bu 2-methyl-2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]thio]propionate (preparation given), Me 2-bromo-1H-imidazole-4-carboxylate (preparation given), [1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Cl2, and aqueous NaHCO3 were heated at 85° in PhMe for 48 h to give 99% coupling product. The latter was sequentially saponified with aqueous KOH in BtOH, amidated with (COCl)2/2,4-dimethylaininiline, hydrolyzed with CF3CO2H in CH2Cl2, and salified with NaOH in H2O/MeCN to give Na 2-[[4-[[(2,4-dimethylphenyl)amino]carbonyl]-1-pentyl-1H-imidazol-2-yl]phenyl]thio]-2-methylpropionate.

L13 ANSWER 16 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 521081-06-1P 521081-19-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylazolecarboxamides for the treatment of obesity)
RN 521081-06-1 CAPLUS
CN Propanoic acid, 2-[[4-[4-[[(4-cyano-1-naphthalenyl)amino]carbonyl]-1-pentyl-1H-imidazol-2-yl]phenyl]thio]-2-methyl- (CA INDEX NAME)



RN 521081-19-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[4-[[(4-nitro-1-naphthalenyl)amino]carbonyl]-1-pentyl-1H-imidazol-2-yl]phenyl]thio]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:282524 CAPLUS
DN 138:304064
TI Preparation of phenylurea derivatives as vanilloid receptor agonists
IN Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro, Hiroshi; Mochizuki, Manabu
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029199	A1	20030410	WO 2002-JP9995	20020927 <--
	WO 2003029199	A9	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002332331	A1	20030414	AU 2002-332331	20020927 <--
	EP 1437344	A1	20040714	EP 2002-768103	20020927 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004539061	A	20041202	JP 2002-282514	20020927 <--
	US 20040259912	A1	20041223	US 2004-489621	20040312 <--
PRAI	JP 2001-300564	A	20010928		
	WO 2002-JP9995	W	20020927		

OS MARPAT 138:304064
GI



I

AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.
IT 508216-36-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L13 ANSWER 17 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of phenylurea derivs. as vanilloid receptor agonists)
RN 508216-36-2 CAPLUS
CN Benzoic acid, 5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-2-(diphenylmethoxy)-, methyl ester (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:242296 CAPLUS
DN 138:255256
TI Preparation of triazines as inhibitors of glycated protein-produced induction of the signaling-associated inflammatory response in endothelial cells
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Campbell, Karen A.
PA Reddy US Therapeutics, Inc., USA
SO PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024926	A2	20030327	WO 2002-US30177	20020923 <--
	WO 2003024926	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461074	A1	20030327	CA 2002-2461074	20020923 <--
	AU 2002362314	A1	20030401	AU 2002-362314	20020923 <--
	EP 1436266	A2	20040714	EP 2002-799019	20020923 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1578773	A	20050209	CN 2002-823240	20020923
	JP 2005511509	T	20050428	JP 2003-528774	20020923
	BR 0202012895	A	20050510	BR 2002-12895	20020923
	NZ 532349	A	20070223	NZ 2002-532349	20020923
	NO 2004001187	A	20040519	NO 2004-1187	20040322 <--
	MX 2004PA02680	A	20040618	MX 2004-PA2680	20040322 <--
	IN 2004KN00520	A	20060428	IN 2004-KN520	20040420
PRAI	US 2001-324147P	P	20010921		
	WO 2002-US30177	W	20020923		

OS MARPAT 138:255256
GI



I

AB The present invention relates to methods and compns. comprising triazines (shown as I or an ene, a diene, a triene, or an yne derivative; a saturated derivative; a stereoisomer; or a salt; variables defined below; e.g. N-(4-bromo-1-naphthyl)-N'-cycloheptyl-N''-[(1-ethyl-2-pyrrolidinyl)methyl]-1,3,5-triazine-2,4,6-triamine), particularly triaminotriazines, that treat

L13 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
pathophysiol. conditions arising from inflammatory responses. In particular, the present invention is directed to compds. that inhibit or block glycated protein produced induction of the signaling-assocd. inflammatory response in endothelial cells. The present invention relates to compds. that inhibit smooth muscle proliferation. In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPGs) such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis. For I: R1 = H; alkyl, cycloalkyl, alkenyl, cycloalkenyl, cycloalkadienyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroalkyl, alkoxy, alkylthio, alkylamino, or dialkylamino, each of which having up to 12 C atoms and including linear or branched derivs., cyclic derivs., substituted derivs., heteroatom derivs., or heterocyclic derivs.; aryl; heteroaryl; aryloxy; arylthio; halogen; or amino. G = NR1 or O; E = CH or N; z = 0-3. X1 = R1, NR13+, CN, NO2, CO2R1, C(O)NR12, CH:CR12, C.tplbond.CR1, C(O)R1, SO2R1, SO2OR1, or NC(O)R1, or X1 and X2 together is a fused aryl, pyridine, dioxane, pyrrole, pyrrolidine, furan, or thiophene ring; with the proviso that R1 of C(O)R1 in the X1 position excludes amino or dialkylamino when X1 is C(O). X2 = R1; CXxH3-x, wherein X is a halogen and x = 0-3; OR1; SR1; NR12; CN; C(O)OR1; NC(O)R1; 4-morpholinyl; 4-Me-1-piperazinyl; OR2, wherein R2 = CH2OCH3, CH2OCH2OCH3, CH2OCH2CH2OCH3, CH2SCH3, or C(O)R1; SR3, wherein R3 = CH2OCH3, CH2OCH2CH2OCH3, CH2OCH2CHMe2, CH2NHC(O)CH3, or SR1; OM or SM, wherein M = Li, Na, K, Mg, or Ca. AY1 = halogen, or A = NR1 or O, and Y1 = R1; CR43; NR43; OR4; or SR4; cyclo-Z1Z2Z2m, bicyclo-C(Z2n)(Z2m)(Z2m)Z1, or bicyclo-Z1(Z2m)(Z2n)(Z2nCR1)Z1, n = 0-8, m = 1-8, Z1 = CR1 or N, Z2 = CR12, NR1, O, or S, with the proviso that two O or S atoms are not located adjacent to each other, and the proviso that no more than two Z2 moieties are NR1. R4 = linear or branched alkyl, cycloalkyl, cycloalkenyl, cycloalkadienyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroalkyl, alkoxy, alkylthio, alkylamino, or dialkylamino, each of which having up to 10 C atoms, H, aryl, heteroaryl, aryloxy, arylthio, halogen, amino, NR12-substituted derivs., OR1-substituted derivs., SR1-substituted derivs., or halogen-substituted derivs.; and DY2 is halogen, or D = NR1 or O and Y2 = R1, cyclo-Z1(Z2)5, CHR4(cyclo-Z1(Z2)5) or CHR4(cyclo-Z1(Z2)54), wherein Z1 = N or CR4, with the proviso that two O or S atoms are not located adjacent to each other, and with the proviso that no more than two Z2 are NR1; specific compd. exclusions are given in the claims. Although the methods of prepn. are not claimed, 68 example prepns. of I and several general methods of prepn. of combinatorial libraries are included; characterization data for 100 example of I prepd. combinatorially are included. Results of an anti-proliferation assay using perlecan, cytotoxicity, toxicity to endothelial cells when AGE stimulated, inhibition of TNF-induced IL-6 prodn. and inhibition of TNF-induced heparanase secretion are tabulated for selected examples of I.
IT 502766-18-9P, N2-(4-Bromo-1-naphthyl)-N4-cycloheptyl-N6-[(1-ethylpyrrolidin-2-yl)methyl]-1,3,5-triazine-2,4,6-triamine 502766-20-3P, N2-(4-Chloro-1-naphthyl)-N4-cycloheptyl-N6-[(1-ethylpyrrolidin-2-yl)methyl]-1,3,5-triazine-2,4,6-triamine
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triazines as inhibitors of glycated protein-produced induction of signaling-associated inflammatory response in endothelial cells)
RN 502766-18-9 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)

L13 ANSWER 18 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 502766-20-3 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-chloro-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



L13 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:241994 CAPLUS
DN 138:271672
TI Preparation of hydrazonodiaminopyrazoles with antiproliferative activity.
IN Zhang, Zaihui; Daynard, Timothy Scott; Sviridov, Serguei V.; Chafeev, Mikhail A.; Wang, Shisen
PA Can.
SO U.S. Pat. Appl. Publ., 70 pp., Cont.-in-part of U.S. Ser. No. 747,563. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030060453	A1	20030327	US 2002-77238	20020215 <--
US 7105503	B2	20060912		
US 6214813	B1	20010410	US 2000-544908	20000407 <--
US 20020042501	A1	20020411	US 2000-747563	20001222 <--
US 6436915	B2	20020820		
CA 2468562	A1	20030605	CA 2002-2468562	20021018 <--
WO 2003045379	A1	20030605	WO 2002-CA1583	20021018 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002333114	A1	20030610	AU 2002-333114	20021018 <--
AU 2002333114	B2	20080904		
EP 1450791	A1	20040901	EP 2002-803715	20021018 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005519878	T	20050707	JP 2003-546881	20021018
CN 1671379	A	20050921	CN 2002-827752	20021018
RU 2332996	C2	20080910	RU 2004-119957	20021018
US 20050272709	A1	20051208	US 2005-497046	20050420
PRAI US 2000-544908	A2	20000407		
US 2000-747563	A2	20001222		
US 2001-335265P	P	20011130		
US 2002-77238	A	20020215		
WO 2002-CA1583	W	20021018		

OS MARPAT 138:271672
GI



I

AB Pharmaceutical compns. comprising title compds. [I; n = 0-5; R1, R2 = H, alkyl, aryl, aralkyl, COR6; R1, R2 may form double bond; R3, R4 = N(R7)2, NR7COR6; R5 = (substituted) aryl, heterocyclyl; R6 = H, alkyl, aryl,

L13 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
aralkyl, heterocyclyl, heeterocyclylalkyl; R7 = H, alkyl, haloalkyl, aryl, aralkyl, heterocyclyl, heteerocyclylalkyl, R8OR9; R8 = alkylene; R9 = H, alkyl], are claimed (no data). Thus, p-anisidine in aq. HCl was treated with aq. NaNO2 under ice cooling; the resulting mixt. was added to malononitrile in aq. MeOH to give 70% yellow solid. The latter was refluxed 3 h with NZH4 in EtOH to give 4-[(4-methoxyphenyl)hydrazono]-4H-pyrazole-3,5-diamine. Numerous generic I drug formulations are given.

IT 366802-39-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydrazonodiaminopyrazoles with antiproliferative activity)
RN 366802-39-3 CAPLUS
CN 4H-Pyrazol-4-one, 3,5-diamino-, 2-(4-bromo-1-naphthalenyl)hydrazone (CA INDEX NAME)



IT 366802-41-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydrazonodiaminopyrazoles with antiproliferative activity)
RN 366802-41-7 CAPLUS
CN Propanedinitrile, 2-[2-(4-bromo-1-naphthalenyl)hydrazinylidene]- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:203407 CAPLUS
DN 138:238181
TI Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO U.S. Pat. Appl. Publ., 406 pp., Cont.-in-part of Appl. No. PCT/JP00/09181. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030050320	A1	20030313	US 2001-939374	20010824 <--
US 6770666	B2	20040803		
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001247550	A	20010911	JP 2000-391904	20001225 <--
ZA 2003001393	A	20040715	ZA 2003-1393	20020626 <--
US 7112600	B1	20060926	US 2002-180558	20020626
US 20040097438	A1	20040520	US 2003-615329	20030708 <--
US 7285551	B2	20071023		
US 20070032497	A1	20070208	US 2005-93208	20050328
PRAI JP 1999-369008	A	19991227		
WO 2000-JP9181	A2	20001222		
JP 2000-391904	A	20001225		
JP 2001-193786	A	20010626		
US 2001-939374	A2	20010824		
JP 2001-351537	A	20011116		
US 2002-180558	A3	20020626		

OS MARPAT 138:238181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

IT 347171-27-1P 347171-97-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)
RN 347171-27-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)

L13 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 347171-97-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:150529 CAPLUS
DN 138:205052
TI Preparation of 1-(pyrazol-3-yl)-3-(1-naphthyl)ureas as antiinflammatory agents
IN Cirillo, Pier Francesco; Dinallo, Roger; Regan, John Robinson; Riska, Paul S.; Swinamer, Alan David; Tan, Zhulin; Walter, Brian Andrew
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO U.S., 44 pp., Cont.-in-part of U.S. Ser. No. 879,776, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6525046	B1	20030225	US 2002-165372	20020607 <--
	US 6319921	B1	20011120	US 2000-484638	20000118 <--
	US 6333325	B1	20011225	US 2001-871559	20010531 <--
	US 20020058678	A1	20020516	US 2001-879776	20010612 <--
	US 6329415	B1	20011211	US 2001-891579	20010626 <--
	US 20020065285	A1	20020530	US 2001-891820	20010626 <--
	US 6506748	B2	20030114		
PRAI	US 2000-484638	A3	20000118		
	US 2001-879776	B2	20010612		
	US 1999-116400P	P	19990119		

OS MARPAT 138:205052
GI



I

AB The title compds. Ar1NHC(:X)NHAr2LQ [Ar1 = pyrazolyl, pyrrolyl, imidazolyl, etc.; Ar2 = Ph, naphthyl, quinolyl, etc.; L = alkylene wherein one or more methylene groups are optionally replaced by O, N or S; Q = Ph, naphthyl, pyridyl, etc.; X = O, S], useful for treating diseases involving inflammation such as chronic inflammatory diseases, were prepared E.g., a multi-step synthesis of I, starting from Me 2,2-dimethyl-3-hydroxypropionate, was given. Representative title ureas showed IC50 of < 10 μM against TNF production in THP cells.
IT 285984-26-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(pyrazol-3-yl)-3-(1-naphthyl)ureas as antiinflammatory agents)
RN 285984-26-1 CAPLUS
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-

L13 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:117794 CAPLUS
DN 138:153537
TI Preparation of imidazole-containing heterobicyclic modulators of androgen receptor function
IN Sun, Chongqing; Robl, Jeffrey A.; Salvati, Mark E.; Wang, Tammy; Hamann, Lawrence; Augeri, David
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011824	A1	20030213	WO 2002-US24185	20020731 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002322794	A1	20030217	AU 2002-322794	20020731 <--
	US 20030055094	A1	20030320	US 2002-209461	20020731 <--
	US 6670386	B2	20031230		
	EP 1414795	A1	20040506	EP 2002-756813	20020731 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 20040092559	A1	20040513	US 2003-685020	20031014 <--
	US 6992102	B2	20060131		
PRAI	US 2001-309059P	P	20010731		
	US 2002-209461	A3	20020731		
	WO 2002-US24185	W	20020731		

OS MARPAT 138:153537
GI



I

AB The invention provides imidazole-containing heterobicyclic compds. (shown as I, including all prodrug esters, pharmaceutically acceptable salts and stereoisomers thereof; variables defined below; e.g. tetrahydro-2-(4-nitro-1-naphthalenyl)imidazo[1,5-a]pyridine-1,3(2H,5H)-dione), methods of using such compds. for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and pharmaceutical compns. containing such compds. Pharmacol. assay procedures are described but results for I are not reported. For I: R1 = H, cyano, nitro, halo, heterocyclo, OR4, CO2R5, CONHR5, COR5, S(O)mR5, SO2NR5R5', NHCOR5 and NHSO2R5; R2 = H, alkyl or substituted alkyl, (un)substituted alkenyl, (un)substituted arylalkyl, CO2R5, CONR5R5' and CH2OR5; R3 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted

L13 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
heterocycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, halo, cyano, NHCOR5, NHCO2R5, NHCONR5R5', NHSO2R5 and OR4. R4 = H, (un)substituted alkyl, CHF2, CF3 and COR5; R5 and R5' = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted heterocycloalkyl, (un)substituted arylalkyl, (un)substituted aryl, (un)substituted heteroaryl and cyano; W = (CR6R6')m, CHOH(CR6R6')m, CO(CR6R6')m and C:NOR4(CR6R6')m. R6 and R6' = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, halo, cyano, NHCOR5, NHCO2R5, NHCONR5R5', NHSO2R5 and OR4; X = methylene, O, S(O)m, NCOR5, NCO2R5, NCONHR5R5', NSO2NR5R5'; Y = O, S and H2; E = C:Z, CHR5, SO2, P(O)R5 and P(O)OR5; Z = O, S, NH and NR5; A and B = H, halo, cyano, nitro, (un)substituted alkyl and OR4; m = 0-2; and n = 1-2. Although the methods of prepn. are not claimed, 42 example prepns. are included.

IT 496840-99-4P, (2S)-1-[[(4-Nitro-1-naphthalenyl)amino]carbonyl]-2-pyrrolidinecarboxylic acid methyl ester 496841-10-2P, (2S,3R)-1-[(4-Cyanonaphthalen-1-yl)carbamoyl]-3-hydroxypyrrolidine-2-carboxylic acid methyl ester 496841-38-4P, (2S,3S)-3-(tert-Butyldimethylsilanyloxy)-2-[(4-cyanonaphthalen-1-yl)carbamoyl]pyrrolidine-1-carboxylic acid tert-butyl ester 496841-39-5P, (2S,3S)-3-Hydroxypyrrolidine-2-carboxylic acid (4-cyanonaphthalen-1-yl)amide 496841-43-1P, (2S,4R)-4-Benzyloxy-2-[(4-cyanonaphthalen-1-yl)carbamoyl]pyrrolidine-1-carboxylic acid tert-butyl ester 496841-44-2P, (2S,4R)-4-Benzyloxypyrrolidine-2-carboxylic acid (4-cyanonaphthalen-1-yl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazole-containing heterobicyclic modulators of androgen receptor function)

RN 496840-99-4 CAPLUS
CN L-Proline, 1-[[(4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 496841-10-2 CAPLUS
CN L-Proline, 1-[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 496841-44-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(4-cyano-1-naphthalenyl)-4-(phenylmethoxy)-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 496841-38-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, 1,1-dimethylethyl ester, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496841-39-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(4-cyano-1-naphthalenyl)-3-hydroxy-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 496841-43-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(4-cyano-1-naphthalenyl)amino]carbonyl]-4-(phenylmethoxy)-, 1,1-dimethylethyl ester, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:57886 CAPLUS
DN 138:122641
TI Method of treating cytokine mediated diseases using pyrazolylureas.
IN Moss, Neil; Regan, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
PAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003005999	A2	20030123	WO 2002-US20649	20020701 <--
	WO 2003005999	A3	20030417		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2453147	A1	20030123	CA 2002-2453147	20020701 <--
	AU 2002316459	A1	20030129	AU 2002-316459	20020701 <--
	US 20030130309	A1	20030710	US 2002-187942	20020701 <--
	US 6916814	B2	20050712		
	EP 1408950	A2	20040421	EP 2002-746764	20020701 <--
	EP 1408950	B1	20070425		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004536845	T	20041209	JP 2003-511806	20020701 <--
	EP 1709965	A2	20061011	EP 2006-112554	20020701
	EP 1709965	A3	20061227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 360417	T	20070515	AT 2002-746764	20020701
	ES 2284887	T3	20071116	ES 2002-746764	20020701
	US 20040152725	A1	20040805	US 2004-761913	20040120 <--
PRAI	US 2001-304511P	P	20010711		
	EP 2002-746764	A3	20020701		
	US 2002-187942	A3	20020701		
	WO 2002-US20649	W	20020701		

OS MARPAT 138:122641
GI



I

AB A method of treating lung inflammation, endometriosis, behcet's disease,

L13 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
uveitis, ankylosing spondylitis, pancreatitis, cancer, percutaneous transluminal coronary angioplasty, alzheimer's disease, traumatic arthritis, sepsis, chronic obstructive pulmonary disease, and congestive heart failure comprises administration of Ar1NHC(:X)NHAr2LQ [Ar1 = (substituted) pyrrolyl, pyrrolidinyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, furyl, thienyl; Ar2 = (substituted) Ph, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl, tetrahydroisoquinolinyl, benzimidazolyl, benzofuryl, indanyl, indolyl, etc.; L = (O-, S-, or N-interrupted) (unsatd.) (substituted) alkylene; Q = (substituted) Ph, naphthyl, pyridyl, pyrimidinyl, imidazolyl, tetrahydropyranyl, tetrahydrofuryl, dioxanyl, alkoxy, amino, etc.; X = O, S]. Thus, 5-amino-3-tert-butyl-1-(4-methylphenyl)pyrazole was stirred with COCl2 and NaHCO3 in PhMe/CH2Cl2 at 0-5° for 15 min. The org. residue was stirred overnight with 1-amino-4-(4-pyridinylmethoxy)naphthalene dihydrochloride (prepn. given) and diisopropylethylamine in THF to give title compd. (I). Representative title compds. inhibited TNF prodn. in THP cells with IC50<10 μM.

IT 285984-26-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method of treating cytokine mediated diseases using pyrazolylureas)

RN 285984-26-1 CAPLUS

CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



L13 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4-chloro-1-naphthylamine is reacted with 2,4-diamino-6-(chloromethyl)pteridine•HCl (DMF, K2CO3, 65° ,34 h) to give II. Compds. of the invention were inhibitors of bacterial dihydrofolate reductase (data provided). I are useful in the treatment or prophylaxis of bacterial infections, or their use as antiseptics, sterilizing agents, or disinfectants.

IT 482305-30-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidines and related analogs as selective bacterial dihydrofolate reductase (DHFR) inhibitors)

RN 482305-30-6 CAPLUS

CN 2,4-Pteridinediamine, 6-[[(4-chloro-1-naphthalenyl)amino]methyl]- (CA INDEX NAME)



L13 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:22638 CAPLUS
DN 138:73268
TI Preparation of pyrimidopyrimidines and related analogs as selective bacterial dihydrofolate reductase (DHFR) inhibitors
IN Moe, Scott T.; Clement, Jacob J.; Faerman, Carlos; Perola, Emanuela; Navia, Manuel A.; Ala, Paul J.; Magee, Andrew S.; Will, Paul M.; Marchese, Salvatore A.; Gazzaniga, John V.
PA Essential Therapeutics, Inc., USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003002064	A2	20030109	WO 2002-US20479	20020628 <--
	WO 2003002064	A3	20031023		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451840	A1	20030109	CA 2002-2451840	20020628 <--
	AU 2002313649	A1	20030303	AU 2002-313649	20020628 <--
	US 20030176436	A1	20030918	US 2002-184855	20020628 <--
	US 20030181459	A1	20030925	US 2002-185059	20020628 <--
	US 7345048	B2	20080318		
	EP 1432713	A2	20040630	EP 2002-753353	20020628 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200400043	A	20041015	EE 2004-43	20020628 <--
	CN 1543465	A	20041103	CN 2002-815065	20020628 <--
	CN 1547472	A	20041117	CN 2002-816660	20020628 <--
	HU 2007000061	A2	20070502	HU 2007-61	20020628
	IN 2004DN00187	A	20050401	IN 2004-DN187	20040127
	BG 108548	A	20050531	BG 2004-108548	20040128
	US 20080090847	A1	20080417	US 2007-951214	20071205
PRAI	US 2001-301685P	P	20010628		
	US 2002-185059	A3	20020628		
	WO 2002-US20479	W	20020628		

OS MARPAT 138:73268
GI



AB Title compds. I [A = N, CH, CR15; R14 = (CH2)n-X-Y; n = 1-6; X = O, NH, NH15; Y = (hetero)aryl; R15 = alkyl and analogs] are prepared For instance,

L13 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:964319 CAPLUS
DN 138:39302
TI Preparation of substituted sulfonamides as 5-HT6 receptor modulators for the treatment of CNS disorders, obesity and type II diabetes
IN Beierlein, Katarina; Bremberg, Ulf; Caldirola, Patrizia; Jennalm Jensen, Annika; Johansson, Gary; Mott, Andrew; Tedenborg, Lars; Thor, Markus
PA Biovitrum AB, Swed.
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100822	A1	20021219	WO 2002-SE1126	20020611 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2445653	A1	20021219	CA 2002-2445653	20020611 <--
	AU 2002309435	A1	20021223	AU 2002-309435	20020611 <--
	AU 2002309435	B2	20080814		
	US 20030158202	A1	20030821	US 2002-167141	20020611 <--
	US 7144883	B2	20061205		
	EP 1412325	A1	20040428	EP 2002-778916	20020611 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010291	A	20040713	BR 2002-10291	20020611 <--
	CN 1522245	A	20040818	CN 2002-810377	20020611 <--
	ZA 2003008097	A	20041018	ZA 2003-8097	20020611 <--
	JP 2004536080	T	20041202	JP 2003-503591	20020611 <--
	CN 1800185	A	20060712	CN 2005-10138144	20020611
	NZ 529032	A	20070427	NZ 2002-529032	20020611
	MX 2003PA11083	A	20040708	MX 2003-PA11083	20031202 <--
	IN 2003CN01957	A	20060106	IN 2003-CN1957	20031209
	US 20070066598	A1	20070322	US 2006-509914	20060825
	US 20070066599	A1	20070322	US 2006-509989	20060825
	US 20070066600	A1	20070322	US 2006-510324	20060825
	IN 2007CN03778	A	20071221	IN 2007-CN3778	20070830
	KR 20080080172	A	20080902	KR 2008-716920	20080711
PRAI	SE 2001-2048	A	20010611		
	SE 2001-2386	A	20010703		
	SE 2001-3437	A	20011016		
	CN 2002-810377	A3	20020611		
	US 2002-167141	A3	20020611		
	WO 2002-SE1126	W	20020611		
	IN 2003-CN1957	A3	20031209		
	KR 2003-716203	A3	20031211		

OS MARPAT 138:39302
GI

L13 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I II III



IV

AB The title compds. [I; ring B = II or III (wherein D = 5-membered heterocyclyl of heteroaryl; with the proviso that when D contains O, D is heteroaryl); W = N, CH (not more than three groups W are N in both rings A and B together); P = NR2SO2R1, SO2NR1R2; P and R3 are bound to the same ring and are disposed in meta- or para-positions relative to each other; R1 = alkyl, alkoxyalkyl, aryl, etc.; R2 = H, alkyl, alkoxy, etc.; or R1 and R2 are linked to form (CH2)4O; one of R3 = (un)substituted piperazino, diazepino, 4-piperidinyl, etc.; X, Y = H, halo, alkyl, etc.], potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system, were prepared E.g., a multi-step synthesis of IV.HCl, starting from 1-chloro-4-nitronaphthalene and tert-Bu 1-piperazinecarboxylate, was given. The compds. I have a selective affinity to 5-HT6 receptors with Ki values between 0.5 nM and 5 μM.

IT 478617-31-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamides as 5-HT6 receptor modulators for the treatment of CNS disorders, obesity and type II diabetes)

RN 478617-31-1 CAPLUS

CN Benzenesulfonamide, N-(4-bromo-1-naphthalenyl)-5-fluoro-2-methyl- (CA INDEX NAME)



L13 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 26 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:942809 CAPLUS

DN 138:24709

TI Preparation of pyrazole compounds and bis pyrazole-1H-pyrazole intermediates as antiinflammatory agents

IN Kapadia, Suresh R.; Song, Jinhua J.; Yee, Nathan K.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA

SO U.S., 37 pp., Cont.-in-part of U.S. 6,372,773.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6492529	B1	20021210	US 2002-67492	20020205	<--
	US 6319921	B1	20011120	US 2000-484638	20000118	<--
	US 6333325	B1	20011225	US 2001-871559	20010531	<--
	US 6329415	B1	20011211	US 2001-891579	20010626	<--
	US 20020065285	A1	20020530	US 2001-891820	20010626	<--
	US 6506748	B2	20030114			
	US 6372773	B1	20020416	US 2001-920899	20010802	<--
PRAI	US 2000-484638	A3	20000118			
	US 2001-920899	A2	20010802			
	US 1999-116400P	P	19990119			
	US 2001-891579	A3	20010626			

OS CASREACT 138:24709; MARPAT 138:24709

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazole compds., e.g. I, as well as bis pyrazole-1H-pyrazole intermediate compds. e.g. II, were prepared The compds. are useful in pharmaceutic compns. for treating diseases or pathol. conditions involving inflammation such as chronic inflammatory diseases. All prepared compds. had IC50 < 10 mM for inhibition of TNFα in lipopolysaccharide stimulated THP cells.

IT 285984-26-1P 285984-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole compds. and bis pyrazole-1H-pyrazole intermediates as antiinflammatory agents)

RN 285984-26-1 CAPLUS

CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

L13 ANSWER 26 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 285984-37-4 CAPLUS

CN 4-Pyridinecarboxamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:658116 CAPLUS
DN 137:201332
TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; DiPietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066470	A1	20020829	WO 2002-US743	20020111 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030125339	A1	20030703	US 2002-46681	20020110 <--
	US 6995162	B2	20060207		
	CA 2434277	A1	20020829	CA 2002-2434277	20020111 <--
	AU 2002248340	A1	20020904	AU 2002-248340	20020111 <--
	AU 2002248340	B2	20051103		
	BR 2002006435	A	20030923	BR 2002-6435	20020111 <--
	EP 1358184	A1	20031105	EP 2002-717325	20020111 <--
	EP 1358184	B1	20070502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003002598	A2	20031128	HU 2003-2598	20020111 <--
	EE 200300324	A	20031215	EE 2003-324	20020111 <--
	JP 2004531484	T	20041014	JP 2002-565984	20020111 <--
	NZ 526868	A	20050429	NZ 2002-526868	20020111
	CN 1671700	A	20050921	CN 2002-806202	20020111
	CN 1313464	C	20070502		
	AT 361288	T	20070515	AT 2002-717325	20020111
	EP 1798230	A1	20070620	EP 2007-3413	20020111
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
	ES 2284849	T3	20071116	ES 2002-717325	20020111
	ZA 2003005197	A	20040319	ZA 2003-5197	20030704 <--
	MX 2003PA06179	A	20031211	MX 2003-PA6179	20030710 <--
	NO 2003003181	A	20030911	NO 2003-3181	20030711 <--
	IN 2003CN01070	A	20050422	IN 2003-CN1070	20030711
	KR 848429	B1	20080728	KR 2003-709274	20030711
	BG 108012	A	20041130	BG 2003-108012	20030721 <--
	HK 1060131	A1	20071012	HK 2004-103164	20040505
	US 20060040956	A1	20060223	US 2005-234713	20050923
	AU 2006200437	A1	20060223	AU 2006-200437	20060201
PRAI	US 2001-261339P	P	20010112		
	US 2001-323764P	P	20010919		

L13 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

	US 2002-46681	A	20020110		
	AU 2002-248340	A3	20020111		
	EP 2002-717325	A3	20020111		
	WO 2002-US743	W	20020111		

OS MARPAT 137:201332
GI

I



II

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical comprns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.
IT 453563-21-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)
RN 453563-21-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-cyano-1-naphthalenyl)-2-[(4-pyridinylmethyl)amino]-, hydrochloride (1:?) (CA INDEX NAME)

L13 ANSWER 27 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●x HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:293390 CAPLUS
DN 136:304071
TI Modulation of CCR4 function for disease therapy
IN Collins, Tassie; Dairaghi, Daniel J.; Mahmud, Hoosen; McMaster, Brian E.; Medina, Julio C.; Schall, Thomas J.; Xu, Feng; Wang, Xuemei
PA Tularik Inc., USA; Chemocentryx, Inc.
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030358	A2	20020418	WO 2001-US42625	20011011 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2425259	A1	20020418	CA 2001-2425259	20011011 <--
	AU 2002013467	A	20020422	AU 2002-13467	20011011 <--
	US 20020173524	A1	20021121	US 2001-975566	20011011 <--
	EP 1578341	A2	20050928	EP 2001-981850	20011011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2002094264	A1	20021128	WO 2002-US16393	20020522 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002310084	A1	20021203	AU 2002-310084	20020522 <--
	US 20030018022	A1	20030123	US 2002-155605	20020522 <--
	US 7144903	B2	20061205		
	US 20040039035	A1	20040226	US 2003-654112	20030902 <--
	US 7262204	B2	20070828		
PRAI	US 2000-240022P	P	20001011		
	US 2001-293781P	P	20010523		
	US 2001-975566	B3	20011011		
	WO 2001-US42625	W	20011011		
	WO 2002-US16393	W	20020522		

OS MARPAT 136:304071
AB The present invention is directed to compds. which are modulators of CCR4 chemokine receptor function and are useful in the prevention or treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis and asthma. The invention is also directed to pharmaceutical comprns. comprising these compds. and the use of these compds. and comprns. in the prevention or treatment of diseases in which CCR4 chemokine receptors are involved. Compds. and comprns. are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
IT 412008-22-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modulators of CCR4 chemokine receptor function for prevention and

L13 ANSWER 28 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
treatment of inflammatory conditions and diseases such as allergic diseases, psoriasis, atopic dermatitis, and asthma)
RN 412008-22-1 CAPLUS
CN 2-Thiazolamine, N-(4-chloro-1-naphthalenyl)-4-(1,1-dimethylethyl)- (CA INDEX NAME)



L13 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methoxyphenyl)hydrazonopyrazole (II). II and its demethoxy deriv. showed IC50's of 1 and 0.6 μM, resp., against integrin linked kinase.
IT 366802-41-7P, Propanedinitrile, [(4-bromo-1-naphthalenyl)hydrazono]-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazole compds. as cell proliferation inhibitors for treating hyperproliferative disorders, tumor growth, lymphoproliferative diseases, and angiogenesis or as apoptosis promoters)
RN 366802-41-7 CAPLUS
CN Propanedinitrile, 2-[2-(4-bromo-1-naphthalenyl)hydrazinylidene]- (CA INDEX NAME)



IT 366802-39-3P, 4H-Pyrazol-4-one, 3,5-diamino-, (4-bromo-1-naphthalenyl)hydrazone
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole compds. as cell proliferation inhibitors for treating hyperproliferative disorders, tumor growth, lymphoproliferative diseases, and angiogenesis or as apoptosis promoters)
RN 366802-39-3 CAPLUS
CN 4H-Pyrazol-4-one, 3,5-diamino-, 2-(4-bromo-1-naphthalenyl)hydrazone (CA INDEX NAME)



L13 ANSWER 29 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:276540 CAPLUS
DN 136:309925
TI Preparation of pyrazole compounds as cell proliferation inhibitors
IN Zhang, Zaihui; Yan, Jun; Leung, Danny; Costello, Penelope C.; Sanghera, Jasbinder; Daynard, Timothy Scott; Wang, Shisen; Chafeev, Mikhail
PA Can.
SO U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. 6,214,813.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020042501	A1	20020411	US 2000-747563	20001222 <--
	US 6436915	B2	20020820		
	US 6214813	B1	20010410	US 2000-544908	20000407 <--
	CA 2405408	A1	20011018	CA 2001-2405408	20010126 <--
	WO 2001077080	A2	20011018	WO 2001-CA89	20010126 <--
	WO 2001077080	A3	20020228		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	EP 1276723	A2	20030122	EP 2001-902197	20010126 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 20030060453	A1	20030327	US 2002-77238	20020215 <--
	US 7105503	B2	20060912		
PRAI	US 2000-544908	A2	20000407		
	US 2000-747563	A	20001222		
	WO 2001-CA89	W	20010126		

OS MARPAT 136:309925
GI



I

AB Claimed is a pharmaceutical composition comprising the title compds. [I; R1 = alkyl, aryl, or heteroaryl, which may be substituted with one or more groups selected from C1-C20alkyl, C6-C0laryl, heteroalkyl, and heteroaryl; R2 = H, direct bond; R3, R4 = NH2, NHCOR5; R5 = R6, R7, R8; wherein R6 = alkyl, heteroalkyl, aryl, heteroaryl; R7 = (R6)k-alkylene, (R6)k-heteroalkylene, (R6)k-arylene, (R6)k-heteroarylene; R8 = (R7)k-alkylene, (R7)k-heteroalkylene, (R7)k-arylene, (R7)k-heteroarylene; k = 1, 2, 3, 4, 5; n = 1, 2, 3, 4, 5], stereoisomers, polymorphs, solvates, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, diluent or excipient. Theses compds. have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, and angiogenesis. Thus, diazotization of p-anisidine with NaNO2 in aqueous HCl, followed by coupling with malononitrile and then cyclocondensation with hydrazine hydrate in EtOH under reflux gave 70% 3,5-Diamino-4-(p-

L13 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:276520 CAPLUS
DN 136:310189
TI Preparation of C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IN Karanewsky, Donald S.; Ternansky, Robert J.; Linton, Steven D.; Dinh, Thang
PA Idun Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 745,204.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020042376	A1	20020411	US 2001-765105	20010116 <--
	US 7053056	B2	20060530		
	US 6197750	B1	20010306	US 1998-177549	19981022 <--
	WO 2000001666	A1	20000113	WO 1999-US15074	19990701 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1754475	A1	20070221	EP 2006-125650	19990701
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 20020028774	A1	20020307	US 2000-745204	20001219 <--
	US 6544951	B2	20030408		
	ZA 2001000023	A	20020102	ZA 2001-23	20010102 <--
	CA 2433879	A1	20020725	CA 2002-2433879	20020116 <--
	WO 2002057298	A2	20020725	WO 2002-US1538	20020116 <--
	WO 2002057298	A3	20030515		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002239978	A1	20020730	AU 2002-239978	20020116 <--
	EP 1351975	A2	20031015	EP 2002-705856	20020116 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004521107	T	20040715	JP 2002-557974	20020116 <--
	CN 1525978	A	20040901	CN 2002-805278	20020116 <--
	CN 1283656	C	20061108		
	AU 2002311391	A1	20030320	AU 2002-311391	20021129 <--
	IN 2003DN01088	A	20070316	IN 2003-DN1088	20030711
	US 20050020504	A1	20050127	US 2004-926800	20040825
	US 7183260	B2	20070227		
PRAI	US 1998-91689P	P	19980702		
	US 1998-177549	A2	19981022		
	WO 1999-US15074	A2	19990701		
	US 2000-745204	A2	20001219		
	AU 1999-48569	A3	19990701		
	EP 1999-932211	A3	19990701		
	US 2001-765105	A	20010116		
	WO 2002-US1538	W	20020116		

OS MARPAT 136:310189

L13 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AB Oxamyl dipeptides R1R1'NCOCO-A-NHCH(CO-B)CH2CO2R2 [A is a natural or unnatural amino acid; B = H, D, alkyl, cycloalkyl, (un)substituted Ph or naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, (CH2)ncycloalkyl, (CH2)nphenyl, (CH2)n(1- or 2-naphthyl), (CH2)nheteroaryl (n = 1-4), etc.; R1 = alkyl, cycloalkyl, cycloalkylalkyl, (un)substituted Ph, phenylalkyl, or naphthyl, etc. or R1R1'N form a heterocycle; R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, (un)substituted Ph, phenylalkyl, naphthyl, or naphthylalkyl] were prepared as inhibitors of the ICE/ced-3 family of cysteine proteases (ICE = interleukin-1β converting enzyme). Thus, (3S)-3-[[N-(1-naphthyloxamyl)leucinyl]amino]-4-oxobutanoic acid was prepared via coupling of 1-naphthyloxamic acid with (3S)-3-(leucinylamino)-4-oxobutanoic acid tert-Bu ester semicarbazone.
IT 254749-63-8P 254750-51-1P 409368-86-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C-terminal modified oxamyl dipeptides as inhibitors of ICE/ced-3 family of cysteine proteases)
RN 254749-63-8 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 254750-51-1 CAPLUS
CN Butanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 409368-86-1 CAPLUS
CN Butanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-1-oxopropyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:275952 CAPLUS
DN 136:309770
TI Preparation of naphthylsalicylanilides as antimicrobial and antiinflammatory agents
IN Coburn, Robert A.; Evans, Richard T.; Genco, Robert J.
PA The Research Foundation of State University of New York, USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028819	A1	20020411	WO 2001-US42436	20011002 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2424396	A1	20020411	CA 2001-2424396	20011002 <--
	AU 2002011842	A	20020415	AU 2002-11842	20011002 <--
	US 20020065322	A1	20020530	US 2001-969071	20011002 <--
	US 6407288	B2	20020618		
	EP 1328507	A1	20030723	EP 2001-979927	20011002 <--
	EP 1328507	B1	20070314		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004510756	T	20040408	JP 2002-532406	20011002 <--
	JP 4086658	B2	20080514		
	AT 356798	T	20070415	AT 2001-979927	20011002
	MX 2003PA02891	A	20031015	MX 2003-PA2891	20030402 <--
PRAI	US 2000-237319P	P	20001002		
	WO 2001-US42436	W	20011002		

OS MARPAT 136:309770
GI



AB Naphthylsalicylanilides I [W is a substituted or unsubstituted naphthyl ring; substitution on W includes replacing one or more -H with -OH, alkyl O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof; Y is a substituted or unsubstituted Ph ring or substituted or unsubstituted naphthyl ring] were prepared. These compds. are useful as antibacterial against gram neg. and gram pos. bacteria and as antiinflammatory agents. E.g., 2-hydroxy-5-(naphthalene-1-carbonyl)-N-phenylbenzamide was prepared in a two-step process.
IT 409361-54-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthylsalicylanilides as antimicrobial and antiinflammatory agents)
RN 409361-54-2 CAPLUS
CN Benzamide, N-(4-cyano-1-naphthalenyl)-2-hydroxy-5-(1-naphthalenylcarbonyl)-

L13 ANSWER 31 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 32 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:165042 CAPLUS
DN 136:216746
TI Preparation and use of, e.g., 2-arylimino-1,3-thiazolidines as progesterone receptor binding ligands
IN Dixon, Brian R.; Bagi, Cedo M.; Brennan, Catherine R.; Brittelli, David R.; Bullock, William H.; Chen, Jinshan; Collibee, William L.; Dally, Robert; Johnson, Jeffrey S.; Kluender, Harold C. E.; Lathrop, William F.; Liu, Peiying; Mase, Carol Ann; Redman, Aniko M.; Scott, William J.; Urbahns, Klaus; Wolanin, Donald J.
PA Bayer Corp., USA
SO U.S., 148 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6353006	B1	20020305	US 1999-453613	19991203 <--
US 20030207865	A1	20031106	US 2001-4306	20011023 <--
PRAI US 1999-287573P	P	19990114		
US 1999-453613	A3	19991203		

OS MARPAT 136:216746
GI



I

II

AB Title compds. I [R = substituted Ph, wherein the substituent is selected from T or substituted pyridyl; R1 = (cyclo)alkyl, (cyclo)alkenyl, alkynyl; R2-4 = H, (cyclo)alkyl, (cyclo)alkenyl, oxo, representing two of the groups R2-4; X = S(O)0-2; n = 2; p = sum of non-H substituents R2-4; T = alk(en/yn)yl, alkoxy, NO2, CN, halo; t = 1-5, provided that when T = alk(en/yn)yl, alkoxy, T is optionally substituted; G = halo, alkoxy, (cyclo)alk(en)yl, aryl, CN; g = 0-4, with the exception of halogen, which may be employed up to the perhalo level provided that when substituent G is alkyl, alkenyl, etc. then G is optionally substituted; Q = of (halo)alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, etc.; q = 0-4; with some provisions] were prepared E.g. 2-chloroethylammonium chloride was reacted with (2-methyl-4-nitrophenyl)isothiocyanate (CH2Cl2, Et3N) to give the thiazolidine which was alkylated with i-Bu bromide (DMF, Cs2CO3, 90° C)to give II. Most compds. of the invention at 200 nM caused at least 30% inhibition of progesterone while, e.g., II caused >80% inhibition at the same concentration I are useful in the treatment of luteal deficiency, osteoprosis, hirsutism, etc.
IT 285125-10-2 402754-64-7 402754-90-9,
2-(4-Cyano-1-naphthylimino)-1-thia-3-azaspiro[4.4]nonane
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation and use of, e.g., 2-arylimino-1,3-thiazolidines as progesterone receptor binding ligands)
RN 285125-10-2 CAPLUS
CN 2-Thiazolamine, 4,5-dihydro-4-(2-methylpropyl)-N-(4-nitro-1-naphthalenyl)-

L13 ANSWER 32 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 402754-64-7 CAPLUS
CN 2-Thiazolamine, 4,5-dihydro-4-[(1S)-1-methylpropyl]-N-(4-nitro-1-naphthalenyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 402754-90-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(1-thia-3-azaspiro[4.4]non-2-en-2-ylamino)- (CA INDEX NAME)



RE.CNT 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:935579 CAPLUS
DN 136:69649
TI Preparation of sulfonamides as potent inhibitors of PDE7
IN Haughan, Alan Findlay; Lowe, Christopher; Buckley, George Martin; Dyke, Hazel Joan; Galvin, Frances Celia Anne; Mack, Stephen Robert; Meissner, Johannes Wilhelm Georg; Morgan, Trevor; Watson, Robert John; Picken, Catherine Louise; Runcie, Karen Ann
PA Celltech Chiroscience Limited, UK
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001098274	A2	20011227	WO 2001-GB2705	20010620 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2000-15095	A	20000620		

OS MARPAT 136:69649
GI



I

AB The title compds. [I; W, X, Y and Z = N, CR5 (wherein R5 = H, halo, alkyl, etc.; provided that two or more of W, X, Y and Z = CR5); R1-R3 = an atom or group L1(Alk1)rL2(R6)s (L1, L2 = a bond, liker atom or group; r = 0-1; Alk1 = (hetero)aliphatic chain; s = 1-3; R6 = H, halo, alkyl, etc.; provided that one or more of R1-R3 is a substituent other than a hydrogen atom); R4 = (un)substituted Ph, 1- or 2-naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl] were prepared Thus, reacting 3-(2-nitrophenylcarbamoyl)benzenesulfonyl chloride with tert-Bu 4-aminobenzoate followed by treatment of the resulting sulfonamide with F3CCO2H in CH2Cl2 afforded I [W, X, Y and Z = CH; R1 = 2-NO2; R2-R3 = H; R4 = 4-(HO2C)C6H4]. The compds. I showed IC50 of ≤ 10 μM, typically around 1μM and less in PDE7 assay.
IT 383906-64-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides as potent inhibitors of PDE7)
RN 383906-64-7 CAPLUS
CN Benzoic acid, 2-[[3-[[(4-chloro-1-naphthalenyl)amino]sulfonyl]benzoyl]amino]-, methyl ester (CA INDEX NAME)

L13 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 383906-91-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as potent inhibitors of PDE7)
RN 383906-91-0 CAPLUS
CN Benzoic acid, 2-[[3-[[(4-chloro-1-naphthalenyl)amino]sulfonyl]benzoyl]amino]- (CA INDEX NAME)



L13 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:762972 CAPLUS
DN 135:303883
TI Preparation of pyrazole compounds as cell proliferation inhibitors
IN Zhang, Zaihui; Yan, Jun; Leung, Danny; Costello, Penelope C.; Sanghera, Jasbinder; Daynard, Timothy Scott; Wang, Shisen; Chafeev, Mikhail
PA Kinetek Pharmaceuticals, Inc., Can.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077080	A2	20011018	WO 2001-CA89	20010126 <--
	WO 2001077080	A3	20020228		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	US 6214813	B1	20010410	US 2000-544908	20000407 <--
	US 20020042501	A1	20020411	US 2000-747563	20001222 <--
	US 6436915	B2	20020820		
	CA 2405408	A1	20011018	CA 2001-2405408	20010126 <--
	EP 1276723	A2	20030122	EP 2001-902197	20010126 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRAI	US 2000-544908	A	20000407		
	US 2000-747563	A	20001222		
	WO 2001-CA89	W	20010126		

OS MARPAT 135:303883
GI



I

AB Claimed is a pharmaceutical composition comprising the title compds. [I; R1 = alkyl, aryl, or heteroaryl, which may be substituted with one or more groups selected from C1-C20alkyl, C6-C01aryl, heteroalkyl, and heteroaryl; R2 = H, direct bond; R3, R4 = NH2, NHCOR5; R5 = R6, R7, R8; wherein R6 = alkyl, heteroalkyl, aryl, heteroaryl; R7 = (R6)k-alkylene, (R6)k-heteroalkylene, (R6)k-arylene, (R6)k-heteroarylene; R8 = (R7)k-alkylene, (R7)k-heteroalkylene, (R7)k-arylene, (R7)k-heteroarylene; k = 1, 2, 3, 4, 5; n = 1, 2, 3, 4, 5], stereoisomers, polymorphs, solvates, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, diluent or excipient. Theses compds. have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, and angiogenesis. Thus, diazotization of p-anisidine with NaNO2 in aqueous HCl, followed by coupling with malononitrile and then cyclocondensation with hydrazine hydrate in EtOH under reflux gave 70% 3,5-Diamino-4-(p-methoxyphenyl)hydrazonopyrazole (II; R = OMe). II (R = OMe) and II (R = H) showed IC50 of μg/mL against of 1 and 0.6 μM, resp., against

L13 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
integrin linked kinase.
IT 366802-41-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazole compds. as cell proliferation inhibitors for treating hyperproliferative disorders, tumor growth, lymphoproliferative diseases, and angiogenesis or as apoptosis promoters)
RN 366802-41-7 CAPLUS
CN Propanedinitrile, 2-[2-(4-bromo-1-naphthalenyl)hydrazinylidene]- (CA INDEX NAME)



IT 366802-39-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole compds. as cell proliferation inhibitors for treating hyperproliferative disorders, tumor growth, lymphoproliferative diseases, and angiogenesis or as apoptosis promoters)
RN 366802-39-3 CAPLUS
CN 4H-Pyrazol-4-one, 3,5-diamino-, 2-(4-bromo-1-naphthalenyl)hydrazone (CA INDEX NAME)



L13 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:730736 CAPLUS
DN 135:288785
TI Preparation of triazole derivatives as fungicides
IN Uchida, Takuya; Konosu, Toshiyuki
PA Sankyo Company, Ltd., Japan
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072743	A1	20011004	WO 2001-JP2443	20010327 <--
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	TW 591024	B	20040611	TW 2001-90106942	20010323 <--
	JP 2001342187	A	20011211	JP 2001-87407	20010326 <--
	AU 2001042798	A	20011008	AU 2001-42798	20010327 <--
	CA 2404701	A1	20020926	CA 2001-2404701	20010327 <--
	BR 2001009573	A	20030128	BR 2001-9573	20010327 <--
	EP 1284267	A1	20030219	EP 2001-915807	20010327 <--
	EP 1284267	B1	20041215		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	HU 2003000573	A2	20030828	HU 2003-573	20010327 <--
	NZ 521603	A	20031031	NZ 2001-521603	20010327 <--
	AU 2001242798	B2	20040226	AU 2001-242798	20010327 <--
	RU 2232761	C2	20040720	RU 2002-125872	20010327 <--
	AT 284884	T	20050115	AT 2001-915807	20010327
	PT 1284267	T	20050228	PT 2001-915807	20010327
	IN 2002KN01201	A	20050311	IN 2002-KN1201	20020923
	ZA 2002007710	A	20040102	ZA 2002-7710	20020925 <--
	NO 2002004615	A	20021122	NO 2002-4615	20020926 <--
	MX 2002PA09673	A	20030310	MX 2002-PA9673	20020927 <--
	US 20030176480	A1	20030918	US 2002-259944	20020927 <--
	US 6653330	B2	20031125		
PRAI	JP 2000-86943	A	20000327		
	WO 2001-JP2443	W	20010327		

OS MARPAT 135:288785
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; Ar1 = 4-C6H4, 3-C6H4, 2,6-naphthyl; X = S, CH2; R1 = 4-CNC6H4, 4-CNCH2C6H4, 4-ClC6H4, 4-FC6H4, 4-CF3C6H4, 4-CF3OC6H4, 4-CF3SC6H4, 4-CH3C6H4, 4-BrC6H4, 4-CN-3-ClC6H3, 4-pyridyl, 4-NO2C6H4, 4-CN-2,3,5,6-F4C6, 3,4-(CN)2C6H3, 4-CH3COC6H4, 4-OHC6H4, 4-CH3CO2C6H4, 4-CNC6H4CH2, 2-thiazolyl, 2-benzothiazolyl], stereoisomers, pharmacol. acceptable prodrugs, or salts thereof, exhibiting excellent antimycotic activity are prepared as fungicides. Thus, the title compound II was prepared and biol. tested.
IT 364082-22-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as fungicides)
RN 364082-22-4 CAPLUS
CN Benzamide, N-(4-cyano-1-naphthalenyl)-4-[trans-5-[[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]- (CA INDEX NAME)

L13 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry. Rotation (-).



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:672213 CAPLUS
DN 135:226901
TI Preparation of 3-cyanoquinolines as protein tyrosine kinase inhibitors
IN Wissner, Allan; Tsou, Hwei-ru; Berger, Dan M.; Floyd, Middleton B., Jr.; Hamann, Philip R.; Zhang, Nan; Salvati, Mark E.; Frost, Philip
PA American Cyanamid Company, USA
SO U.S., 68 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6288082	B1	20010911	US 1999-406573	19990924 <--
PRAI US 1998-150693P	P	19980929		
OS MARPAT 135:226901				

GI



I



II

AB The title compds. [I; X = (un)substituted bicyclic aryl or bicyclic heteroaryl ring system of 8-12 atoms where the bicyclic heteroaryl ring contains 1-4 heteroatoms selected from N, O and S; Z = (un)substituted NH, O, S; G1, G2, R1, R4 = H, halo, alkyl, etc.; n = 0-1], useful as antineoplastic agents and in the treatment of polycystic kidney disease, were prepared Thus, Me 2-amino-4,5-diethoxybenzoate was N-condensed with HCNMe2/POCl3 and the product cyclocondensed with MeCN to give, after POCl3 treatment, 4-chloro-6,7-diethoxyquinoline-3-carbonitrile which was aminated by 6-aminoindoline to give title compd II. Data for biol. activity (inhibition of EGFR kinase, KDR, Eck, Mek-Erk) of I were given.
IT 263170-41-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-cyanoquinolines as protein tyrosine kinase inhibitors)
RN 263170-41-8 CAPLUS
CN 3-Quinolinecarbonitrile, 4-[(4-chloro-1-naphthalenyl)amino]-6,7-dimethoxy- (CA INDEX NAME)

L13 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:636061 CAPLUS
DN 135:211055
TI Substituted piperazinylacetamides useful as partial fatty acid oxidation inhibitors
IN Zablocki, Jeff; Elzein, Elfatih; Nudelman, Grigory; Marquart, Tim; Varkhedkar, Vaibhav; Ibrahim, Prabha N.; Palle, Venkata P.; Blackburn, Brent K.
PA CVV Therapeutics, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001062744	A2	20010830	WO 2001-US5606	20010222 <--
WO 2001062744	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400176	A1	20010830	CA 2001-2400176	20010222 <--
US 20010041704	A1	20011115	US 2001-791133	20010222 <--
US 6552023	B2	20030422		
US 20010047001	A1	20011129	US 2001-792167	20010222 <--
US 6451798	B2	20020917		
US 20020016463	A1	20020207	US 2001-791134	20010222 <--
US 6677336	B2	20040113		
EP 1259493	A2	20021127	EP 2001-911085	20010222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531116	T	20031021	JP 2001-562526	20010222 <--
JP 3980885	B2	20070926		
NZ 520782	A	20040326	NZ 2001-520782	20010222 <--
BR 2001008592	A	20040629	BR 2001-8592	20010222 <--
AU 2001238623	B2	20040923	AU 2001-238623	20010222 <--
TW 236471	B	20050721	TW 2001-90104080	20010413
NO 2002003954	A	20020930	NO 2002-3954	20020820 <--
NO 324837	B1	20071217		
MX 2002PA08213	A	20040405	MX 2002-PA8213	20020822 <--
ZA 2002007255	A	20030812	ZA 2002-7255	20020910 <--
US 20030064994	A1	20030403	US 2002-243307	20020913 <--
US 20030176440	A1	20030918	US 2003-365344	20030211 <--
US 6852723	B2	20050208		
JP 2007211009	A	20070823	JP 2007-5347	20070115
PRAI US 2000-184182P	P	20000222		
US 2000-184306P	P	20000222		
US 2000-184457P	P	20000222		
US 2000-206396P	P	20000523		
US 2000-209262P	P	20000605		
JP 2001-562526	A3	20010222		
US 2001-791133	A1	20010222		
US 2001-792167	A1	20010222		
WO 2001-US5606	W	20010222		
OS MARPAT 135:211055				

GI

L13 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Novel compds. (I), and pharmaceutically acceptable acid addition salts thereof, wherein the compds. are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction. I are partial fatty acid oxidation inhibitors with good therapeutic half-lives. Data are presented for inhibition of mitochondrial fatty acid oxidation using palmitoyl CoA and palmitoyl carnitine as substrates; 2-[4-(3-isopropoxy-2-hydroxypropyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide provided 100% inhibition in the former test compared to 75% for Ranolazine. Metabolic stability was measured by incubating with human liver S-9 microsomal fractions and determining the amount I remaining after 30 min at 37° C compared to Ranolazine. In I, X = -(CH2)m-, -(CH2)mO-; m = 1-3. R1, R2, R3, R4 and R5 are each independently H, halo, NO2, CF3, CN, OR23, SR23, N(R23)2, S(O)R22, SO2R22, SO2N(R23)2, NR23CO2R22, NR23CON(R23)2, COR23, CO2R23, CON(R23)2, NR23SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent = halo, NO2, CF3, CN, OR23, SR23, N(R23)2, S(O)R22, and SO2R22, wherein R2 and R3 may join together to form a fused ring system having from three to four carbon atoms, and wherein R4 and R5 may join together to form -CH=CH-CH=CH-. R6, R7 and R8 each independently = H or C1-15 alkyl. R9-R16 independently = H, CO2R23, CON(R23)2, C1-4 alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent = halo, NO2, CF3, CN, OR23, N(R23)2, CO2R23, CON(R23)2 or aryl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl wherein R11 and R13 or R9 and R15 or R9 and R11 or R11 and R15 or R9 and R13 may join together to form a bridging ring system having 1 to 4 carbon atoms and wherein R9 and R10 or R11 and R12 or R13 and R14 or R15 and R16 may join to form a bridging ring system having 1 to 5 carbon atoms with the proviso that R9, R10, R11, R12, R13, R14, R15 and R16 are not all hydrogen when R24 is Ph and when X is -(CH2)mO-. R22 = C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent = halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O-C1-6 alkyl, CF3, or heteroaryl. R23 = H, C1-15, alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent = halo, alkyl, mono- or dialkylamino, alkyl, CN, -O-C1-6 alkyl, or CF3. Several example prepns. are included but the methods of preparation are not claimed. R24 = alkyl, cycloalkyl, and fused phenylcycloalkyl wherein the point of attachment is on the cycloalkyl wherein the alkyl, cycloalkyl, and fused phenylcycloalkyl are optionally substituted with 1-3 substituents = halo, CF3, CN, OR20, SR20, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, C1-2 alkyl, and aryl wherein the optional aryl substituent is optionally substituted with 1-3 substituents = halo, Ph, CF3, CN, OR20, and C1-6 alkyl and aryl (-C6R15R16R17R18R19), wherein R17, R18, R19, R20, and R21 independently = H, halo, NO2, CF3, CN, OR23,

L13 ANSWER 37 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
SR23, N(R23)2, S(O)R22, SO2R22, SO2N(R23)2, NR23CO2R22, NR23CON(R23)2, COR23, CO2R23, CON(R23)2, NR23SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent halo, NO2, CF3, CN, OR23, SR23, N(R23)2, S(O)R22, and SO2R22.

IT 357384-88-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted piperazinylacetamides useful as partial fatty acid oxidation inhibitors)

RN 357384-88-4 CAPLUS

CN 1-Piperazineacetamide, N-(4-chloro-1-naphthalenyl)-4-[(2S)-3-(2-fluorophenoxy)-2-hydroxypropyl]-3-methyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
VEGF-R2A50. Treatment of cancer as well as other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.

IT 351319-48-7P 351319-61-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of heteroarylbenzamides used for inhibiting protein kinases)

RN 351319-48-7 CAPLUS

CN Benzamide, N-(4-bromo-1-naphthalenyl)-3-[(2-pyrazinylthio)methyl]- (CA INDEX NAME)



RN 351319-61-4 CAPLUS

CN Benzamide, N-(4-bromo-1-naphthalenyl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 38 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:545674 CAPLUS
DN 135:137516
TI Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases
IN Bender, Steven Lee; Bhumralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
PAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053274	A1	20010726	WO 2001-US1723	20010119 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394703	A1	20010726	CA 2001-2394703	20010119 <--
	US 20020103203	A1	20020801	US 2001-764306	20010119 <--
	US 6635641	B2	20031021		
	EP 1252146	A1	20021030	EP 2001-906592	20010119 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008025	A	20021105	BR 2001-8025	20010119 <--
	JP 2003529658	T	20031007	JP 2001-553276	20010119 <--
	MX 2002PA07102	A	20030128	MX 2002-PA7102	20020719 <--
	US 20040092747	A1	20040513	US 2003-621979	20030717 <--
PRAI	US 2000-177059P	P	20000121		
	US 2001-764306	A3	20010119		
	WO 2001-US1723	W	20010119		

OS MARPAT 135:137516
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH2, O, S, NH; Y = CH2, O, S, provided at least one of X and Y = CH2 or X and Y form a cyclopropyl ring; R2-3 = H, Me, halo, CF3, CN; R4 = CONHR5, NHCOR6; where R5 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R6 = (un)substituted aryl, heteroaryl, cycloalkyl, etc] are prepared. Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptobenzoic acid was treated with α-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a β-thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μM and had Ki = 2.21 nM for

L13 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:489367 CAPLUS
DN 135:76874
TI Preparation of heterocyclic compounds as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
PAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047883	A1	20010705	WO 2000-JP9181	20001222 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2363274	A1	20010705	CA 2000-2363274	20001222 <--
	EP 1162196	A1	20011212	EP 2000-987728	20001222 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008525	A	20020102	BR 2000-8525	20001222 <--
	TR 200103147	T1	20020621	TR 2001-3147	20001222 <--
	NZ 514403	A	20021025	NZ 2000-514403	20001222 <--
	HU 2002002263	A2	20021228	HU 2002-2263	20001222 <--
	HU 2002002263	A3	20030228		
	AU 763356	B2	20030717	AU 2001-24017	20001222 <--
	RU 2223761	C2	20040220	RU 2001-126283	20001222 <--
	CN 1623984	A	20050608	CN 2004-10055872	20001222
	NO 2001004134	A	20011022	NO 2001-4134	20010824 <--
	US 20030050320	A1	20030313	US 2001-939374	20010824 <--
	US 6770666	B2	20040803		
	MX 2001PA08724	A	20020208	MX 2001-PA8724	20010828 <--
	ZA 2001007870	A	20020925	ZA 2001-7870	20010928 <--
	US 7112600	B1	20060926	US 2002-180558	20020626
	US 20040097438	A1	20040520	US 2003-615329	20030708 <--
	US 7285551	B2	20071023		
	US 20070032497	A1	20070208	US 2005-93208	20050328
PRAI	JP 1999-369008	A	19991227		
	WO 2000-JP9181	W	20001222		
	JP 2000-391904	T	20001225		
	JP 2001-193786	T	20010626		
	US 2001-939374	A2	20010824		
	JP 2001-351537	T	20011116		
	US 2002-180558	A3	20020626		

OS MARPAT 135:76874
GI

L13 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C8 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepared The benzimidazole derivative II in vitro showed IC50 of 0.011 μM against hepatitis C virus polymerase. A formulation is given.

IT 347171-27-1P 347171-97-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as remedies for hepatitis C)

RN 347171-27-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



L13 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 347171-97-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]-1-cyclohexyl- (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:372159 CAPLUS

DN 134:366868

TI Preparation of benzothiazolines as neuropeptide Y receptor antagonists

IN Sato, Yoshiya; Itani, Hiromichi; Tabuchi, Seiichiro; Sakata, Yoshihiko; Ohashi, Hiroko

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001139574	A	20010522	JP 2000-296175	20000928 <--
PRAI AU 1999-3093	A	19990928		

OS MARPAT 134:366868

GI



I

AB The title compds. I [R1 = H, halo; W = S, O; A = (CH2)n, etc.; n = 1 - 6; Z = (un)substituted N-containing heterocyclic ring] are prepared 1-[(5-Chloro-2-oxobenzothiazolin-3-yl)acetyl]piperidine-4-carboxylic acid 4-benzoylanilide showed IC100 of 10-7 M in a neuropeptide Y5 receptor binding assay.

IT 340179-02-4P 340179-11-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazolines as neuropeptide Y receptor antagonists)

RN 340179-02-4 CAPLUS

CN 4-Piperidinecarboxamide, N-(4-chloro-1-naphthalenyl)-1-[2-(5-chloro-2-oxo-3(2H)-benzothiazolyl)acetyl]- (CA INDEX NAME)



RN 340179-11-5 CAPLUS

CN 2(3H)-Benzothiazolone, 5-chloro-3-[2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]-1-piperidinyl]-2-oxoethyl]-, hydrochloride (1:1) (CA INDEX NAME)

L13 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

L13 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:338341 CAPLUS
DN 134:348268
TI Inhibitor for 20-HETE-yielding enzyme
IN Sato, Masakazu; Miyata, Noriyuki; Ishii, Takaaki; Kobayashi, Yuko; Amada, Hideaki
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032164	A1	20010510	WO 2000-JP7694	20001101 <--
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2389378	A1	20010510	CA 2000-2389378	20001101 <--
	AU 2001010533	A	20010514	AU 2001-10533	20001101 <--
	AU 759604	B2	20030417		
	EP 1226819	A1	20020731	EP 2000-971721	20001101 <--
	EP 1226819	B1	20060118		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 315932	T	20060215	AT 2000-971721	20001101
	ES 2256053	T3	20060716	ES 2000-971721	20001101
	JP 4045099	B2	20080213	JP 2001-534369	20001101
	US 6864254	B1	20050308	US 2001-869103	20010622
	KR 767508	B1	20071017	KR 2002-705444	20020427
	HK 1050141	A1	20061013	HK 2003-102329	20030401
	US 20040110830	A1	20040610	US 2003-609547	20030701 <--
	US 7078400	B2	20060718		
	KR 2007067044	A	20070827	KR 2007-715915	20070712
	KR 785148	B1	20071211		
PRAI	JP 1999-311137	A	19991101		
	JP 1999-372347	A	19991228		
	JP 2000-180472	A	20000615		
	JP 2000-180473	A	20000615		
	JP 2000-180476	A	20000615		
	JP 2000-180478	A	20000615		
	WO 2000-JP7694	W	20001101		
	US 2001-869103	A3	20010622		
	KR 2002-705444	A3	20020427		

AB An inhibitor for 20-hydroxyeicosatetraenoic acid (HETE) production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacol. acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacol. acceptable salt thereof is also provided.
IT 339070-43-8P 339071-06-6P 339071-07-7P
339071-15-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydroxyformamidine derivs. as inhibitors for 20-HETE-yielding enzyme for treatment of kidney and cardiovascular diseases)
RN 339070-43-8 CAPLUS
CN Methanimidamide, N-(4-bromo-1-naphthalenyl)-N'-hydroxy- (CA INDEX NAME)

L13 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 339071-06-6 CAPLUS
CN Methanimidamide, N-(4-cyano-1-naphthalenyl)-N'-hydroxy- (CA INDEX NAME)



RN 339071-07-7 CAPLUS
CN Methanimidamide, N-(4-chloro-1-naphthalenyl)-N'-hydroxy- (CA INDEX NAME)



RN 339071-15-7 CAPLUS
CN Methanimidamide, N-hydroxy-N'-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:265404 CAPLUS
DN 134:295842
TI Preparation of triazine kinase inhibitors
IN Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Geuns-Meyer, Stephanie D.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian
PA Kinetix Pharmaceuticals Inc., USA
SO PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025220	A1	20010412	WO 2000-US27811	20001006 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2386218	A1	20010412	CA 2000-2386218	20001006 <--
	EP 1218360	A1	20020703	EP 2000-972036	20001006 <--
	EP 1218360	B1	20080528		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511378	T	20030325	JP 2001-528166	20001006 <--
	AU 770600	B2	20040226	AU 2001-10754	20001006 <--
	AT 396978	T	20080615	AT 2000-972036	20001006
	MX 2002PA03436	A	20020820	MX 2002-PA3436	20020404 <--
PRAI	US 1999-158176P	P	19991007		
	US 1999-166978P	P	19991123		
	US 1999-170378P	P	19991213		
	US 2000-183263P	P	20000217		
	US 2000-215576P	P	20000630		
	US 2000-219801P	P	20000720		
	WO 2000-US27811	W	20001006		

OS MARPAT 134:295842
GI



AB Title triazine compds. (I) [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, or (un)substituted heterocyclyl or alkyl; R3 = independently aryl or (un)substituted Ph or heteroaryl; R5 = independently H, (un)substituted (cyclo)alkyl or alkenyl, alkynyl, cycloalkenyl, aryl, or haloalkyl; R6 = independently COR5, CO2R5, CONR5R5, C(NR5)NR5R5, or SOnR5; R8 = independently (un)substituted mono-, di-, or tricyclic ring system comprising 1-3, 1-6, or 1-9 heteroatoms, resp.; n = 1-2] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl

L13 ANSWER 42 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
transfer. For example, amination of 2,4-dichloro-1,3,5-triazine (prepn. given) with 3,4,5-trimethoxyaniline in DMF, followed by a second amination with 4-aminoveratrole in the presence of diisopropylethylamine in EtOH, yielded II. In kinase inhibition studies, II gave IC50 values of < 0.4 μg/mL for KDR-1, PDGFRB-1, and Flt-1; 0.4 to 2.4 μg/mL for Lck-1; 3.5 to 4.5 μg/mL for EGFR-1, Tek-1, and EPGB4-1; and > 4.5 μg/mL for IGFR-1, AKT3-1, Met-1, Zap-1, Itk-1, PGFR1-1, and Fyn-1. I and compns. comprising them are useful for the treatment of disease or disease symptoms related to kinase inhibition, such as angiogenesis or vasculogenesis (no data).
IT 333731-13-8P 333735-74-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazine kinase inhibitors for inhibiting angiogenesis or vasculogenesis)
RN 333731-13-8 CAPLUS
CN 1,3,5-Triazine-2,4-diamine, N2-(4-bromo-1-naphthalenyl)-N4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 333735-74-3 CAPLUS
CN 1,3,5-Triazine-2,4-diamine, N2-(4-chloro-1-naphthalenyl)-N4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 43 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:12274 CAPLUS
DN 134:86272
TI Preparation of pyrimidine derivatives as Src-family protein tyrosine kinase inhibitor compounds
IN Hunt, Julianne A.; Mills, Sander G.; Sinclair, Peter J.; Zaller, Dennis M.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000214	A1	20010104	WO 2000-US17472	20000626 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2376951	A1	20010104	CA 2000-2376951	20000626 <--
	US 6316444	B1	20011113	US 2000-603699	20000626 <--
	EP 1194152	A1	20020410	EP 2000-944858	20000626 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503354	T	20030128	JP 2001-505923	20000626 <--
PRAI	US 1999-141597P	P	19990630		
	WO 2000-US17472	W	20000626		

OS MARPAT 134:86272
GI



I

AB What are claimed are pyrimidine compds. (shown as I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and

L13 ANSWER 43 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

individual diastereomers, and pharmaceutical compns. including the same and their use as inhibitors of tyrosine kinase enzymes and consequently their use in the prophylaxis and treatment of protein tyrosine kinase-assocd. disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogenesis, atherosclerosis, graft rejection, rheumatoid arthritis and psoriasis. In I, R1, R2 = independently H, halo, OH, SH, CN, NO2, alkyl, alkoxy, acyloxy, alkoxycarbonyloxy, carbamoyloxy, alkylthio, sulfinyl, sulfonyl, acyl, alkoxycarbonyl, carbamoyl, amino, acylamino, alkoxycarbonylamino, ureido, sulfamoyl, sulfonylamino, or R1 and R2 can join together to form a fused methylenedioxy ring or a fused 6-membered arom. ring; terms such as 'alkyl' here and below are further defined in the claims. R3, R5 = independently H, C1-C6-alkyl unsubstituted or substituted with 1-3 substituents, aryl (Ph or naphthyl unsubstituted or substituted with 1-3 substituents), or R3 and R5 taken together can represent :O. R4 = H, C1-C6-alkyl, C1-C6-alkoxyl, or R4 and X can join together to form a 5- or 6-membered ring with substituted methylene or ethylene. X1, X2, X3, X4 in -X1:X2-X3:X4- are substituted CH or N where 0-2 of X1, X2, X3, X4 are N. X5 = N, CH. R7 = H, alkyl, alkoxy, amino. X = O, S, SO, SO2, imino. Z = C:O, SO2, substituted P(:O)(OH) or a single bond. 44 Example prepns. are given, but no preparative method is claimed and no data relating to the usefulness of the compds. are given.

IT 317365-28-9P, (S,S)-2-[-(1-Methyl-4-(N-(4-bromo)naphth-1-ylcarbamoyl)piperazin-2-yl)ethylamino]-4-[5-(pyridin-4-yl)benzimidazol-1-yl]pyrimidine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. acting as inhibitors of Src-family protein tyrosine kinases)

RN 317365-28-9 CAPLUS
CN 1-Piperazinecarboxamide, N-(4-bromo-1-naphthalenyl)-4-methyl-3-[(1S)-1-[[4-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-2-pyrimidinyl]amino]ethyl]-, (3S)-(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 44 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:814447 CAPLUS
DN 133:350056
TI Preparation of aromatic amides useful as CNS agents
IN Bryans, Justin Stephen; O'Toole, John Colm; Horwell, David Christopher
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068184	A1	20001116	WO 2000-GB1788	20000510 <--
	W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2373173	A1	20001116	CA 2000-2373173	20000510 <--
	AU 2000045949	A	20001121	AU 2000-45949	20000510 <--
	BR 2000010465	A	20020213	BR 2000-10465	20000510 <--
	EP 1178963	A1	20020213	EP 2000-927557	20000510 <--
	EP 1178963	B1	20031203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200103245	T2	20020422	TR 2001-3245	20000510 <--
	HU 2002001069	A2	20020729	HU 2002-1069	20000510 <--
	HU 2002001069	A3	20021128		
	JP 2002544186	T	20021224	JP 2000-617165	20000510 <--
	AT 255559	T	20031215	AT 2000-927557	20000510 <--
	PT 1178963	T	20040430	PT 2000-927557	20000510 <--
	ES 2208324	T3	20040616	ES 2000-927557	20000510 <--
	BG 106072	A	20020531	BG 2001-106072	20011101 <--
	NO 2001005412	A	20020109	NO 2001-5412	20011106 <--
	IN 2001MN01376	A	20050304	IN 2001-MN1376	20011107
	US 6846963	B1	20050125	US 2002-19993	20020506
PRAI	US 1999-133359P	P	19990510		
	WO 2000-GB1788	W	20000510		

AB Aromatic and heteroarom. amides R1CONR4XnNR2R3 (R1, R2, R3 = alkyl; X = alkylene; R4 = unsubstituted or substituted aromatic or heteroarom. group such as naphthyl or fluorenyl), CNS agents useful for treating pain, depression, anxiety, seizures, and schizophrenia, were prepared E.g., N-propionyl,N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene was prepared The ability of the aromatic amides to reduce the hyperalgesia effects of carrageenin was determined

IT 305796-12-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic amides useful as CNS agents)

RN 305796-12-7 CAPLUS
CN Propanamide, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 44 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:756524 CAPLUS
DN 133:321878
TI Preparation of cyclic protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Padmanabha, Ramesh; Chen, Ping; Norris, Derek J.; Doweyko, Arthur M. P.; Barrish, Joel C.; Wityak, John
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000062778	A1	20001026	WO 2000-US9753	20000412 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366932	A1	20001026	CA 2000-2366932	20000412 <--
	AU 2000042338	A	20001102	AU 2000-42338	20000412 <--
	AU 779089	B2	20050106		
	EP 1169038	A1	20020109	EP 2000-922102	20000412 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009721	A	20020213	BR 2000-9721	20000412 <--
	TR 200102969	T2	20020821	TR 2001-2969	20000412 <--
	JP 2002542193	T	20021210	JP 2000-611914	20000412 <--
	JP 3989175	B2	20071010		
	HU 2002002708	A2	20021228	HU 2002-2708	20000412 <--
	HU 2002002708	A3	20041228		
	NZ 513639	A	20040227	NZ 2000-513639	20000412 <--
	RU 2260592	C2	20050920	RU 2001-130452	20000412
	RU 2312860	C2	20071220	RU 2005-107463	20000412
	ZA 2001007204	A	20021202	ZA 2001-7204	20010830 <--
	IN 2001MN01138	A	20050304	IN 2001-MN1138	20010919
	MX 2001PA10292	A	20021023	MX 2001-PA10292	20011011 <--
	NO 2001004970	A	20011210	NO 2001-4970	20011012 <--
	NO 322470	B1	20061009		
	US 20050261305	A1	20051124	US 2005-138793	20050526
	US 7189854	B2	20070313		
	US 20050288303	A1	20051229	US 2005-138942	20050526
	US 7153856	B2	20061226		
	US 20060079563	A1	20060413	US 2005-271626	20051110
	KR 2007020153	A	20070216	KR 2007-702337	20070130
PRAI	US 1999-129510P	P	19990415		
	RU 2000-130452	A	20000412		
	WO 2000-US9753	W	20000412		
	US 2000-548929	A1	20000413		
	KR 2001-713067	A3	20011013		
	US 2003-378373	A1	20030303		

OS MARPAT 133:321878
GI

L13 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. [I; Q = (un)substituted 5-6 membered heteroaryl, aryl; Z = a single bond, R15C:CH, (CH2)m (m = 1-2); X1, X2 = H; X1 and X2 together = O, S; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4, R5 = H, alkyl, alkenyl, etc.], useful in the treatment of protein tyrosine kinase-associated disorders such as immunol. and oncol. disorders (no data), were prepared E.g., a multi-step synthesis of thiazole II was given. Compds. I are effective at 0.1-100 mg/kg/day.

IT 302960-36-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic protein tyrosine kinase inhibitors)

RN 302960-36-7 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[[(4-chloro-1-naphthalenyl)amino]carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

PAGE 1-A



L13 ANSWER 45 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:688226 CAPLUS
DN 133:266866
TI Preparation of quinazolines as antitumor agents
IN Uckun, Fatih M.; Liu, Xing-ping; Narla, Rama K.
PA Parker Hughes Institute, USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056720	A1	20000928	WO 2000-US6902	20000316 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6258820	B1	20010710	US 1999-357404	19990720 <--
	CA 2367861	A1	20000928	CA 2000-2367861	20000316 <--
	EP 1163228	A1	20011219	EP 2000-921389	20000316 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002540103	T	20021126	JP 2000-606581	20000316 <--
	US 20010016588	A1	20010823	US 2001-779809	20010208 <--
	US 6358962	B2	20020319		
	US 20020137757	A1	20020926	US 2001-923903	20010807 <--
	US 6638939	B2	20031028		
	NO 2001004560	A	20010919	NO 2001-4560	20010919 <--
	MX 2001PA09453	A	20020614	MX 2001-PA9453	20010919 <--
	US 20040039002	A1	20040226	US 2003-454960	20030605 <--
	US 20050075353	A1	20050407	US 2004-852076	20040524
	US 7038049	B2	20060502		
PRAI	US 1999-125145P	P	19990319		
	US 1999-125177P	P	19990319		
	US 1999-125338P	P	19990319		
	US 1999-357404	A	19990720		
	WO 2000-US6902	W	20000316		
	US 2001-779809	A1	20010208		
	US 2001-923903	A1	20010807		
	US 2003-454960	B1	20030605		

OS MARPAT 133:266866
GI



I

L13 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AB The title compds. [I; Ra = I, hydroxyalkyl, methylenedioxy, etc.; n = 1-4; Rb = H, halo, OH, etc.; R1 = alkyl], useful for the treatment of cancer (e.g., leukemia and breast cancer) and for the treatment of allergic reactions, were prepared by reacting 4-chloro-6,7-dimethoxyquinazoline with the substituted aniline. Biol. data for compds. I were given.
IT 296234-50-9P 296234-97-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines as antitumor agents)
RN 296234-50-9 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-1-naphthalenyl)-6,7-dimethoxy- (CA INDEX NAME)



RN 296234-97-4 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-1-naphthalenyl)-6,7-dimethoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 47 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:688094 CAPLUS
DN 133:271682
TI Preparation of quinazolines for micellar pharmaceuticals for treatment of allergy and cancer
IN Yiv, Seang; Li, Mingshu; Uckun, Fatih M.
PA Parker Hughes Institute, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056338	A1	20000928	WO 2000-US7066	20000317 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366998	A1	20000928	CA 2000-2366998	20000317 <--
	EP 1162974	A1	20011219	EP 2000-914991	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539262	T	20021119	JP 2000-606242	20000317 <--
	US 20020111360	A1	20020815	US 2001-960464	20010919 <--
PRAI	US 1999-125147P	P	19990319		
	WO 2000-US7066	W	20000317		

OS MARPAT 133:271682
GI



I

AB Pharmaceutical compns. for parenteral administration of poorly soluble quinazoline compds. in the form of microemulsions or micellar solns. are described. The compns. are useful in treating patients suffering from cancer or having allergic reactions. E.g., I was prepared, its soly profile given, and micellar solns. containing PEGylated phosphatidylethanolamines were effective in enhancing the solubilization of I.
IT 296234-50-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolines for micellar pharmaceuticals for treatment of allergy and cancer)
RN 296234-50-9 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-1-naphthalenyl)-6,7-dimethoxy- (CA INDEX NAME)

L13 ANSWER 47 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 48 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:513688 CAPLUS
DN 133:120325
TI Preparation of aromatic heterocyclic ureas as antiinflammatory agents
IN Cirillo, Pier F.; Gilmore, Thomas A.; Hickey, Eugene R.; Regan, John R.; Zhang, Lin-Hua
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043384	A1	20000727	WO 1999-US29165	19991209 <--
	W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2352524	A1	20000727	CA 1999-2352524	19991209 <--
	EP 1147104	A1	20011024	EP 1999-960668	19991209 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916930	A	20011030	BR 1999-16930	19991209 <--
	HU 2002001406	A2	20020828	HU 2002-1406	19991209 <--
	HU 2002001406	A3	20031128		
	EE 200100376	A	20021015	EE 2001-376	19991209 <--
	EE 4527	B1	20050815		
	JP 2003535023	T	20031125	JP 2000-594800	19991209 <--
	JP 3793694	B2	20060705		
	RU 2230142	C2	20031227	RU 2001-122111	19991209 <--
	AU 770581	B2	20040226	AU 2000-17522	19991209 <--
	NZ 513525	A	20040528	NZ 1999-513525	19991209 <--
	TR 200102072	T2	20041221	TR 2001-2072	19991209 <--
	TW 546297	B	20030811	TW 2000-89100638	20000117 <--
	US 6333325	B1	20011225	US 2001-871559	20010531 <--
	IN 2001MN00642	A	20050304	IN 2001-MN642	20010604
	MX 2001PA05628	A	20020424	MX 2001-PA5628	20010605 <--
	ZA 2001004656	A	20030210	ZA 2001-4656	20010607 <--
	US 6329415	B1	20011211	US 2001-891579	20010626 <--
	US 20020065285	A1	20020530	US 2001-891820	20010626 <--
	US 6506748	B2	20030114		
	BG 105653	A	20020131	BG 2001-105653	20010627 <--
	BG 64971	B1	20061130		
	HR 2001000516	A1	20020831	HR 2001-516	20010710 <--
	NO 2001003559	A	20010718	NO 2001-3559	20010718 <--
PRAI	US 1999-116400P	P	19990119		
	WO 1999-US29165	W	19991209		
	US 2000-484638	A1	20000118		

OS MARPAT 133:120325
GI

L13 ANSWER 48 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. [I; Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, etc.; Ar2 = (un)substituted Ph, naphthyl, quinoline, etc.; L = (un)saturated (un)substituted carbon chain wherein one or more methylene groups are optionally replaced by O, N, or S; Q = (un)substituted Ph, naphthyl, pyridinyl, etc.], useful in pharmaceutic compns. for treating diseases or pathol. conditions involving inflammation such as chronic inflammatory diseases, were prepared E.g., a multi-step synthesis of the urea II was given. Representative compds. I were evaluated and showed IC50 of < 10 μM against TNF production in THP cells.
IT 285984-26-1P 285984-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic heterocyclic ureas as antiinflammatory agents)
RN 285984-26-1 CAPLUS
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



L13 ANSWER 48 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 285984-37-4 CAPLUS
CN 4-Pyridinecarboxamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:493535 CAPLUS
DN 133:120323
TI Preparation of 2-aryliminothiazolidines and related compounds progesterone receptor binding agents
IN Dixon, Brian R.; Bagi, Cedo M.; Brennan, Catherine R.; Brittelli, David R.; Bullock, William H.; Chen, Jinshan; Collibee, William L.; Dally, Robert; Johnson, Jeffrey S.; Kluender, Harold C. E.; Lathrop, William F.; Liu, Peiying; Mase, Carol Ann; Redman, Aniko M.; Scott, William J.; Urbahns, Klaus; Wolanin, John J.
PA Bayer Corporation, USA
SO PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042031	A2	20000720	WO 1999-US29601	19991214 <--
	WO 2000042031	A3	20001109		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359562	A1	20000720	CA 1999-2359562	19991214 <--
	EP 1144396	A2	20011017	EP 1999-968883	19991214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916999	A	20011030	BR 1999-16999	19991214 <--
	TR 200102041	T2	20011221	TR 2001-2041	19991214 <--
	HU 2001005134	A2	20020429	HU 2001-5134	19991214 <--
	JP 2002534517	T	20021015	JP 2000-593599	19991214 <--
	ZA 2001005253	A	20020905	ZA 2001-5253	20010626 <--
	MX 2001PA06675	A	20011203	MX 2001-PA6675	20010628 <--
	NO 2001003318	A	20010830	NO 2001-3318	20010704 <--
	IN 2001MN00824	A	20050304	IN 2001-MN824	20010713
	BG 105761	A	20020329	BG 2001-105761	20010801 <--
PRAI	US 1999-231906	A	19990114		
	WO 1999-US29601	W	19991214		

OS MARPAT 133:120323
GI



I

AB Title compds. (I; T = alkyl, alkoxy, aryl, CO2H, alkenyl, alkynyl, CHO, OH, NO2, cyano, halo, OCF3, etc.; R = aryl, heteroaryl; R1 = alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, alkynyl; R2-R4 = H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, halo, O, etc.; X = O, S, SO, SO2; G = halo, OH, O, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, etc.; m = 1-5; p, q = 0-4; Z = CnH2n-r; n = 2-5; r = sum of non-H substituents R2, R3, R4; with provisos), were prepared Thus, title compound (II), prepared from 2-chloroethylammonium chloride, 2-methyl-4-nitrophenyl isothiocyanate, and iso-Bu bromide, at 200 nM gave 80-100% inhibition of 3H-progesterone to

L13 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
the progesterone receptor.
IT 285125-10-2 285125-19-1 285125-59-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-aryliminothiazolidines and related compds. progesterone receptor binding agents)
RN 285125-10-2 CAPLUS
CN 2-Thiazolamine, 4,5-dihydro-4-(2-methylpropyl)-N-(4-nitro-1-naphthalenyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 285125-19-1 CAPLUS
CN 2-Thiazolamine, 4,5-dihydro-4-(1-methylpropyl)-N-(4-nitro-1-naphthalenyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 285125-59-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(3-thia-1-azaspiro[4.4]non-1-en-2-ylamino)- (CA INDEX NAME)



L13 ANSWER 49 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L13 ANSWER 50 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:420962 CAPLUS
DN 133:43443
TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035452	A1	20000622	WO 1999-US30334	19991217 <--
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2347770	A1	20000622	CA 1999-2347770	19991217 <--
	EP 1161240	A1	20011212	EP 1999-963107	19991217 <--
	EP 1161240	B1	20050817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6331541	B1	20011218	US 1999-465288	19991217 <--
	TR 200101859	T2	20011221	TR 2001-1859	19991217 <--
	BR 9917058	A	20020402	BR 1999-17058	19991217 <--
	JP 2002532427	T	20021002	JP 2000-587772	19991217 <--
	NZ 511394	A	20030725	NZ 1999-511394	19991217 <--
	AU 770042	B2	20040212	AU 2000-19406	19991217 <--
	AT 302005	T	20050915	AT 1999-963107	19991217
	IN 2001MN00521	A	20050304	IN 2001-MN521	20010501
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509 <--
	NO 2001002977	A	20010820	NO 2001-2977	20010615 <--
	MX 2001PA06148	A	20010911	MX 2001-PA6148	20010615 <--
	US 20030013741	A1	20030116	US 2001-7172	20011023 <--
	US 6521592	B2	20030218		
	US 20040002515	A1	20040101	US 2002-279416	20021024 <--
	US 6875776	B2	20050405		
	US 20040006107	A1	20040108	US 2002-279231	20021024 <--
	US 6780857	B2	20040824		
	US 20050096325	A1	20050505	US 2004-983367	20041108
	US 20050192291	A1	20050901	US 2004-21042	20041223
PRAI	US 1998-112717P	P	19981218		
	US 1999-161221P	P	19991022		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	US 1999-466442	A3	19991217		
	WO 1999-US30334	W	19991217		
	US 2002-180869	A1	20020626		
	US 2002-279416	A1	20021024		

OS MARPAT 133:43443
GI

L13 ANSWER 50 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).
IT 275813-60-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)
RN 275813-60-0 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 51 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:241135 CAPLUS
DN 132:279106
TI Non-peptide GnRH agents, methods and intermediates for their preparation
IN Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James
PA Agouron Pharmaceuticals, Inc., USA; et al.
SO PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020358	A2	20000413	WO 1999-US18790	19990820 <--
	WO 2000020358	A3	20001116		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341346	A1	20000413	CA 1999-2341346	19990820 <--
	BR 9913374	A	20010515	BR 1999-13374	19990820 <--
	EP 1105120	A2	20010613	EP 1999-968010	19990820 <--
	EP 1105120	B1	20050323		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 2001003622	A2	20020429	HU 2001-3622	19990820 <--
	HU 2001003622	A3	20030128		
	EE 200100102	A	20020617	EE 2001-102	19990820 <--
	SI 20746	A	20020630	SI 1999-20076	19990820 <--
	TR 200100631	T2	20020821	TR 2001-631	19990820 <--
	JP 2002535244	T	20021022	JP 2000-574479	19990820 <--
	AU 759310	B2	20030410	AU 2000-24709	19990820 <--
	NZ 509252	A	20040528	NZ 1999-509252	19990820 <--
	AT 291423	T	20050415	AT 1999-968010	19990820
	ES 2237966	T3	20050801	ES 1999-968010	19990820
	NO 2001000309	A	20010411	NO 2001-309	20010119 <--
	IN 2001DN00066	A	20070112	IN 2001-DN66	20010124
	ZA 2001000831	A	20020822	ZA 2001-831	20010130 <--
	MX 2001PA01834	A	20000821	MX 2001-PA1834	20010219 <--
	US 7101878	B1	20060905	US 2001-763216	20010220
	LV 12732	B	20020320	LV 2001-45	20010316 <--
	BG 105362	A	20011231	BG 2001-105362	20010319 <--
	LT 4904	B	20020425	LT 2001-24	20010319 <--
	US 20040010033	A1	20040115	US 2003-353160	20030708 <--
PRAI	US 1998-97520P	P	19980820		
	WO 1999-US18790	W	19990820		
	US 2001-763216	B3	20010220		

OS MARPAT 132:279106
GI



I



II

AB Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. The compds. and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compds. include those of formula I [X = C:O, C:S, S:O, or SO2; Het = 5-membered NOS-heterocycle; R1, R2 = H, alkyl; R3-R7 = H, halo, (un)substituted alkyl, aryl, heteroaryl, CH2OR, OR, CO2R; R = alkyl, aryl, etc.; adjacent rings positions such as R6R7 may form (un)substituted 5- or 6-membered ring with up to 4 heteroatoms; R8 = lipophilic moiety such as alkyl, aryl, CH2OR, OR, etc.; R9 = H, (un)substituted alkyl]. Methods and intermediates for synthesizing the compds. are also described. For instance, 4,4,7-trimethylchroman (preparation given) was alkylated in the 6- and 8-positions using Et 5-(chloromethyl)-2-furoate (46% total yield), and the resulting esters were hydrolyzed to a mixture of acids. This unsepd. mixture was treated with SOCl2 and amidated with 2,4,6-trimethoxyphenylamine-HCl to give the invention compound II and its chroman-6-position isomer, which were separated by HPLC. Several compds. exhibited high affinity (<100 nM) at human GnRH receptors. The compds. antagonized GnRH-stimulated inositol phosphate accumulation in cells with recombinant human GnRH receptors, and an example compound reduced plasma LH levels in castrated male rats. Various biol. data for several hundred compds. are given.

IT 263857-70-1P 263858-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of non-peptide GnRH agents for regulating gonadotropin secretion)

RN 263857-70-1 CAPLUS
CN 2-Furancarboxamide, N-(4-bromo-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (CA INDEX NAME)

L13 ANSWER 51 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 263858-24-8 CAPLUS
CN 2-Furancarboxamide, N-(4-cyano-1-naphthalenyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (CA INDEX NAME)



L13 ANSWER 52 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:227652 CAPLUS
DN 132:265101
TI Preparation of 3-cyanoquinolines as protein tyrosine kinase inhibitors
IN Wissner, Allan; Tsou, Hwei-Ru; Berger, Dan Maarten; Floyd, Middleton Brawner, Jr.; Hamann, Philip Ross; Zhang, Nan; Salvati, Mark Ernest; Frost, Philip
PA American Cyanamid Company, USA
SO PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018761	A1	20000406	WO 1999-US22054	19990922 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2344169	A1	20000406	CA 1999-2344169	19990922 <--
	AU 9961593	A	20000417	AU 1999-61593	19990922 <--
	AU 763669	B2	20030731		
	EP 1117659	A1	20010725	EP 1999-948410	19990922 <--
	EP 1117659	B1	20031203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 2001003520	A2	20020228	HU 2001-3520	19990922 <--
	HU 2001003520	A3	20030128		
	JP 2002525369	T	20020813	JP 2000-572221	19990922 <--
	NZ 510551	A	20030328	NZ 1999-510551	19990922 <--
	AT 255575	T	20031215	AT 1999-948410	19990922 <--
	PT 1117659	T	20040430	PT 1999-948410	19990922 <--
	ES 2211175	T3	20040701	ES 1999-948410	19990922 <--
	SK 284846	B6	20051201	SK 2001-413	19990922
	TW 233437	B	20050601	TW 1999-88116630	19990929
	NO 2001001575	A	20010528	NO 2001-1575	20010328 <--
	NO 324563	B1	20071119		
	MX 2001PA03230	A	20011011	MX 2001-PA3230	20010328 <--
	IN 2001KN00370	A	20060303	IN 2001-KN370	20010329
	ZA 2001002729	A	20020703	ZA 2001-2729	20010403 <--
	HK 1035188	A1	20040402	HK 2001-105823	20010817 <--
	IN 2007KN02342	A	20080801	IN 2007-KN2342	20070625
PRAI	US 1998-162802	A	19980929		
	WO 1999-US22054	W	19990922		
	IN 2001-370	A3	20010329		

OS MARPAT 132:265101
GI



II

L13 ANSWER 52 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB X(CH2)nZZ1CN [I; X = (un)substituted bicyclic (hetero)aryl or LTA; A = (un)substituted phenylene, -pyridinediyl, -pyrimidinediyl; T = O, S, (alkyl)imino(alkylene), oxyalkylene, etc.; Z = O, S, (alkyl or alkanoyl)imino; Z1 = 2-unsubstituted-5,6,7,8-(un)substituted quinoline-4,3-diyl; n = 0 or 1] were prepared Thus, Me 2-amino-4,5-diethoxybenzoate was N-condensed with HCNMe2/POCl3 and the product cyclocondensed with MeCN to give, after POCl3 treatment, 4-chloro-6,7-diethoxyquinoline-3-carbonitrile which was aminated by 6-aminoindoline to give title compd II. Data for biol. activity of I were given.

IT 263170-41-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-cyanoquinolines as protein tyrosine kinase inhibitors)

RN 263170-41-8 CAPLUS

CN 3-Quinolinecarbonitrile, 4-[(4-chloro-1-naphthalenyl)amino]-6,7-dimethoxy- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 53 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:34853 CAPLUS

DN 132:93655

TI Preparation of C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

IN Karanewsky, Donald S.; Ternansky, Robert J.

PA Idun Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001666	A1	20000113	WO 1999-US15074	19990701 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6197750	B1	20010306	US 1998-177549	19981022 <--
	CA 2336474	A1	20000113	CA 1999-2336474	19990701 <--
	CA 2336474	C	20080429		
	AU 9948569	A	20000124	AU 1999-48569	19990701 <--
	AU 752339	B2	20020919		
	EP 1091930	A1	20010418	EP 1999-932211	19990701 <--
	EP 1091930	B1	20061213		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	HU 2001002898	A2	20020128	HU 2001-2898	19990701 <--
	HU 2001002898	A3	20020930		
	BR 9911675	A	20020205	BR 1999-11675	19990701 <--
	JP 2002519406	T	20020702	JP 2000-558071	19990701 <--
	JP 3815968	B2	20060830		
	NZ 509025	A	20030530	NZ 1999-509025	19990701 <--
	AT 348096	T	20070115	AT 1999-932211	19990701
	EP 1754475	A1	20070221	EP 2006-125650	19990701
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	ES 2276520	T3	20070616	ES 1999-932211	19990701
	US 20020028774	A1	20020307	US 2000-745204	20001219 <--
	US 6544951	B2	20030408		
	MX 2000PA13014	A	20040402	MX 2000-PA13014	20001220 <--
	NO 2000006544	A	20010228	NO 2000-6544	20001221 <--
	IN 2000MN00792	A	20050318	IN 2000-MN792	20001229
	KR 804432	B1	20080220	KR 2000-715074	20001229
	ZA 2001000023	A	20020102	ZA 2001-23	20010102 <--
	US 20020042376	A1	20020411	US 2001-765105	20010116 <--
	US 7053056	B2	20060530		
	HK 1036616	A1	20070504	HK 2001-107291	20011018
	AU 2002311391	A1	20030320	AU 2002-311391	20021129 <--
	US 20050020504	A1	20050127	US 2004-926800	20040825
	US 7183260	B2	20070227		
PRAI	US 1998-91689P	P	19980702		
	US 1998-177549	A	19981022		
	AU 1999-48569	A3	19990701		
	EP 1999-932211	A3	19990701		
	WO 1999-US15074	W	19990701		

L13 ANSWER 53 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
US 2000-745204 A2 20001219
US 2001-765105 A1 20010116

OS MARPAT 132:93655

AB Oxamyl dipeptides R1NHCOCO-A-NHCH(CO-B)CH2CO2R2 [A is a natural or unnatural amino acid; B = H, D, cycloalkyl, (un)substituted Ph or naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, halomethyl, (CH2)ncycloalkyl, (CH2)nphenyl, (CH2)n(1- or 2-naphthyl), (CH2)nheteroaryl (n = 1-4), etc.; R1 = alkyl, cycloalkyl, cycloalkylalkyl, (un)substituted Ph, phenylalkyl, or naphthyl, etc.; R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, (un)substituted Ph, phenylalkyl, naphthyl, or naphthylalkyl] were prepared as inhibitors of the ICE/ced-3 family of cysteine protease (ICE = interleukin-1β converting enzyme). Thus, (3S)-3-[[N-(1-naphthyloxamyl)leucinyl]amino]-4-oxobutanoic acid, prepared via coupling of 1-naphthyloxamic acid with (3S)-3-(leucinylamino)-4-oxobutanoic acid tert-Bu ester semicarbazone, showed IC50 = 0.027 μM for mICE and IC50 = 0.010 μM for CPP32 enzyme assays.

IT 254749-63-8P 254750-51-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C-terminal modified oxamyl dipeptides as inhibitors of ICE/ced-3 family of cysteine proteases)

RN 254749-63-8 CAPLUS

CN Pentanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 254750-51-1 CAPLUS

CN Butanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 53 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 54 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:716157 CAPLUS
DN 131:322347
TI Preparation of pentanamides as pharmaceuticals for treatment of cancers, restenosis, and abnormal proliferation
IN Miyaji, Nobuhide; Suzuki, Mikio; Kitahara, Maki; Kanaki, Tatsuo
PA Nissan Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 41 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11310568	A	19991109	JP 1998-120943	19980430 <--
PRAI JP 1998-120943		19980430		

OS MARPAT 131:322347
AB R2NR3CR4(CH2XR1)CR5R6CR7R8CONR9R10 (R1 = H, (un)substituted C1-12 alkyl, (un)substituted C2-12 alkenyl, (un)substituted C2-10 aliphatic acyl, etc.; R2 = H, (un)substituted C1-6 alkyl, C2-3 aliphatic acyl, cyclopropylcarbonyl, cyclobutylcarbonyl, etc.; R3 = H, Me, Et, benzyl; R4 = H, Me, HOCH2, HSCH2; R5 = H, Me; R6 = H, Me; R6R8 may form bond; R7, R8 = H, Me, Et, Pr, Bu, pentyl, etc; R9 = H, (un)substituted C1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, etc.; R9R11 many form ring; R10 = (un)substituted C4-8 linear alkyl, etc.; X = S, O, etc.) or their salts, useful as pharmaceuticals for treatment and prevention of cancers, restenosis after PTCA, and abnormal proliferation of arteriosclerotic blood vessel intima smooth muscle cells, are prepared 4-(R)-tert-butoxycarbonylamino-5-triphenylmethylmercapto-2,3-E-pentenoic acid was reacted with 1-benzyl-4-aminopiperidine in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine, and diisopropylethylamine in dioxane at room temperature for 16 h to give 1-benzyl-4-[4-(R)-tert-butoxycarbonylamino-5-triphenylmethylmercapto-2,3-E-pentenoylamino]piperidine showing in vitro good inhibitory activity of proliferation of human leukemia cell (THP-1).
IT 249507-54-8P 249507-72-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pentanamides as pharmaceuticals for treatment of cancers, restenosis, and abnormal proliferation)
RN 249507-54-8 CAPLUS
CN Carbamic acid, [(1R,2Z)-4-[(4-nitro-1-naphthalenyl)amino]-4-oxo-1-[[(triphenylmethyl)thio]methyl]-2-butenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L13 ANSWER 54 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 249507-72-0 CAPLUS
CN Carbamic acid, [(1R)-4-[(4-cyano-1-naphthalenyl)amino]-4-oxo-1-[[(triphenylmethyl)thio]methyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 55 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:708594 CAPLUS
DN 131:310457
TI Preparation of aryl-substituted guanidines for treating mitochondria-associated diseases
IN Ghosh, Soumitra; Davis, Robert E.
PA Mitokor, USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9955321	A1	19991104	WO 1999-US8880	19990423 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2329709	A1	19991104	CA 1999-2329709	19990423 <--
AU 9939656	A	19991116	AU 1999-39656	19990423 <--
EP 1071414	A1	20010131	EP 1999-922721	19990423 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6268398	B1	20010731	US 1999-299044	19990423 <--
JP 2002512954	T	20020508	JP 2000-545520	19990423 <--
US 20020052409	A1	20020502	US 2001-875450	20010605 <--
PRAI US 1998-82998P	P	19980424		
US 1999-299044	A1	19990423		
WO 1999-US8880	W	19990423		

OS MARPAT 131:310457
AB The title compds. ArLNHC(:NH)NH2 [I; Ar = (un)substituted Ph or naphthyl; L = optional linker selected from (CH2)n, (CH2)nNH, etc.], useful for treating mitochondria-associated diseases, such as cancer, psoriasis, stroke, Alzheimer's disease and diabetes, were prepared E.g., 4-HOC6H4CH2CH2NHC(:NH)NH2 was prepared E.g., effect of I on ionomycin-induced apoptosis in cybrid cells was investigated.
IT 247234-22-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-substituted guanidines for treating mitochondria-associated diseases)
RN 247234-22-6 CAPLUS
CN Guanidine, N-(4-bromo-1-naphthalenyl)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 247234-21-5
CMF C11 H10 Br N3

L13 ANSWER 55 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-19-7
CMF C2 H4 O2

IT 247234-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl-substituted guanidines for treating mitochondria-associated diseases)
RN 247234-51-1 CAPLUS
CN Carbamic acid, [(4-bromo-1-naphthalenyl)carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 56 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:311199 CAPLUS
DN 130:325145
TI Preparation of aromatic heterocyclic compounds as antiinflammatory agents
IN Regan, John R.; Cirillo, Pier F.; Hickey, Eugene R.; Moss, Neil; Cywin, Charles L.; Pargellis, Christopher; Gilmore, Thomas A.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9923091	A1	19990514	WO 1998-US22907	19981029 <--
	W: AU, BG, BR, BY, CA, CN, CZ, HR, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, TR, UA, UZ, VN, YU				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2308428	A1	19990514	CA 1998-2308428	19981029 <--
	AU 9913675	A	19990524	AU 1999-13675	19981029 <--
	US 6080763	A	20000627	US 1998-181743	19981029 <--
	EP 1028953	A1	20000823	EP 1998-957405	19981029 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001521934	T	20011113	JP 2000-518962	19981029 <--
	EP 1473292	A1	20041103	EP 2004-8840	19981029 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6228881	B1	20010508	US 1999-461446	19991214 <--
	MX 200004102	A	20010131	MX 2000-4102	20000427 <--
	US 20010039290	A1	20011108	US 2001-808084	20010314 <--
PRAI	US 1997-64102P	P	19971103		
	EP 1998-957405	A3	19981029		
	US 1998-181743	A3	19981029		
	WO 1998-US22907	W	19981029		
	US 1999-461446	A3	19991214		

OS MARPAT 130:325145
GI



I



II

L13 ANSWER 56 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 223724-81-0 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 223725-08-4 CAPLUS
CN Urea, N-(4-cyano-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(3-pyridinyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



L13 ANSWER 56 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. I [A = C, N; B = C, N, O, etc.; D = C, N, S; E = C, N; G = C, S, N; X = S, O, etc.; Y = NH, etc.; R1 = (un)substituted, (partially or fully halogenated) alkyl, etc.; R2 is H, (partially or fully halogenated) alkyl, etc., when B is C or N; R3 is Ph, naphthyl, etc., when D is C or N; or R1R2 = fused Ph or pyridinyl ring; or R2R3 = fused Ph or pyridinyl ring; R4 is H, (partially or fully halogenated) alkyl when G is C or N; R5 is Ph, naphthyl, heteroaryl, etc.] are prepared I inhibit production of cytokines involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor. Pyrazole derivative II was prepared from phenylhydrazine and 4,4-dimethyl-3-oxopentanenitrile. Compds. of this invention had IC50 < 10 μM against TNF production in an in vitro assay using THP cells.
IT 223724-79-6P 223724-80-9P 223724-81-0P
223725-08-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic heterocyclic compds. as antiinflammatory agents)
RN 223724-79-6 CAPLUS
CN Urea, N-(4-cyano-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 223724-80-9 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

L13 ANSWER 56 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:166498 CAPLUS
DN 130:223295
TI Preparation of imidazoquinoxaline protein tyrosine kinase inhibitors
IN Barrish, Joel C.; Chen, Ping; Das, Jagabandhu; Iwanowicz, Edwin J.; Norris, Derek J.; Padmanabha, Ramesh; Roberge, Jacques Y.; Schieven, Gary L.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9909845	A1	19990304	WO 1998-US16027	19980803 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6235740	B1	20010522	US 1998-97338	19980615 <--
	AU 9886817	A	19990316	AU 1998-86817	19980803 <--
	ZA 9807649	A	20000224	ZA 1998-7649	19980824 <--
PRAI	US 1997-56770P	P	19970825		
	US 1997-69159P	P	19971209		
	WO 1998-US16027	W	19980803		

OS MARPAT 130:223295
GI





AB Novel imidazoquinoxalines I and salts thereof are disclosed [wherein: n = 0-4; R1, R2, R3 = H, R6, OH, OR6, SH, SR6, CO2H, SO3H, halo, cyano, NO2, etc.; R1-R3 may form ring(s); R4, R5 = H, R6, COR6; or NR4R5 forms (un)substituted 3- to 8-membered heterocyclic ring; R6 = (un)substituted alk(en/yn)yl, cycloalk(en)yl(alkyl), aryl, aralkyl, heterocyclo(alkyl)]. Also disclosed are pharmaceutical compns. containing the compds., and methods

L13 ANSWER 57 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
of their use in the treatment of various protein tyrosine kinase-assocd. disorders, such as immunol. disorders (no data). Over 500 synthetic examples are given. For instance, the nitroimidazoloquinoxalinone II (prepd. in 4 steps) was treated with POCl3 to give 78% of the corresponding chloro compd., which reacted with NaN(SiMe3)2 and 2-chloro-6-methylaniline in THF to give 86% title compd. III.
IT 221061-99-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of imidazoquinoxalines as protein tyrosine kinase inhibitors)
RN 221061-99-0 CAPLUS
CN Imidazo[1,5-a]quinoxalin-4-amine, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:64780 CAPLUS
DN 130:125095
TI Preparation of (hetero)aryl substituted benzenesulfonamides for the treatment of anxiety and/or depression
IN Bromidge, Steven Mark; Moss, Stephen Frederik
PA Smithkline Beecham Plc, UK
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902502	A2	19990121	WO 1998-EP4973	19980709 <--
	WO 9902502	A3	19990603		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2296033	A1	19990121	CA 1998-2296033	19980709 <--
	AU 9892578	A	19990208	AU 1998-92578	19980709 <--
	AU 736256	B2	20010726		
	EP 994862	A2	20000426	EP 1998-945162	19980709 <--
	EP 994862	B1	20050601		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	TR 200000073	T2	20000621	TR 2000-73	19980709 <--
	BR 9810991	A	20000808	BR 1998-10991	19980709 <--
	HU 2000003073	A2	20010129	HU 2000-3073	19980709 <--
	HU 2000003073	A3	20021028		
	JP 2002511097	T	20020409	JP 1999-508186	19980709 <--
	CN 1087294	C	20020710	CN 1998-806921	19980709 <--
	AT 296811	T	20050615	AT 1998-945162	19980709
	ES 2244082	T3	20051201	ES 1998-945162	19980709
	ZA 9806139	A	20000110	ZA 1998-6139	19980710 <--
	TW 470743	B	20020101	TW 1998-87111166	19980710 <--
	NO 2000000108	A	20000110	NO 2000-108	20000110 <--
	MX 200000414	A	20010629	MX 2000-414	20000110 <--
	US 6316450	B1	20011113	US 2000-462652	20000110 <--
PRAI	GB 1997-14530	A	19970711		
	GB 1997-24530	A	19971119		
	WO 1998-EP4973	W	19980709		

OS MARPAT 130:125095
GI

L13 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





AB The title compds. [I; P = Ph, naphthyl, 5-7 membered heterocyclyl containing 1-4 heteroatoms selected from O, N or S, etc.; A = a single bond, C1-6 alkylene, C1-6 alkenylene; B = SO2; R1 = halo, C1-6 alkyl optionally substituted by one or more fluorine atoms, C3-6 cycloalkyl, etc.; n = 0-6; R2 = H, C1-6 alkyl, aryl C1-6 alkyl, etc.; R3 = H, halo, C1-6 alkyl, etc.; R4 = X(CH2)pR6 (wherein X = a single bond, CH2, O, etc.; p = 0-6; R6 = (un)substituted 4-7 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, NR7R8; R7, R8 = H, C1-6 alkyl, aryl C1-6 alkyl); R5 = R3; R3R5 = (CH2)2O, (CH2)3O optionally substituted with 1 or more C1-6 alkyl groups], useful in the treatment of CNS disorders such as anxiety and depression, were prepared Thus, refluxing 1-[4-methoxy-3-(4-methylpiperazin-1-yl)benzenesulfonyl]-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline with 1-chloroethyl chloroformate in 1,2-dichloroethane for 18 h followed by addition of diisopropylethylamine afforded 52% II.HCl which showed pKi > 8.5 and selectivity > 100 against human cloned 5-HT6 receptors.
IT 219960-61-9P 219961-70-3P 219962-32-0P
219962-96-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)aryl substituted benzenesulfonamides for the treatment of anxiety and/or depression)
RN 219960-61-9 CAPLUS
CN Benzenesulfonamide, N-(4-chloro-1-naphthalenyl)-4-methoxy-3-(4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)

L13 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 219961-70-3 CAPLUS
CN Benzenesulfonamide, N-(4-chloro-1-naphthalenyl)-4-methoxy-3-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 219962-32-0 CAPLUS
CN Benzenesulfonamide, N-(4-chloro-1-naphthalenyl)-4-methoxy-3-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

L13 ANSWER 58 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 219962-96-6 CAPLUS
CN Benzenesulfonamide, N-(4-chloro-1-naphthalenyl)-4-methoxy-3-(1-piperazinyl)- (CA INDEX NAME)



L13 ANSWER 59 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:64675 CAPLUS
DN 130:148681
TI Combination antiinfective drug therapies comprising aminoglycoside antibiotics and N,N'-disubstituted guanidines
IN Gwynne, David I.; Durant, Graham J.
PA Cambridge Neuroscience, Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9902145	A1	19990121	WO 1998-US13640	19980706 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9882784	A	19990208	AU 1998-82784	19980706 <--
PRAI US 1997-51860P	P	19970707		
WO 1998-US13640	W	19980706		

OS MARPAT 130:148681
AB Methods and compns. are provided for treatment of infections, including Gram-neg. and Gram-pos. bacterial infections, comprising administering an aminoglycoside antibiotic in combination with a substituted guanidine or other compound as disclosed. Preferred methods and compns. of the invention will be effective against infections previously treated with aminoglycoside antibiotics, but with decreased occurrence of ototoxicity.
IT 137160-03-3 203196-18-3 203196-19-4
203196-21-8 203196-22-9 203196-29-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoglycoside antibiotic-disubstituted guanidine combination for antiinfective therapy)
RN 137160-03-3 CAPLUS
CN Guanidine, N-(3-ethylphenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



RN 203196-18-3 CAPLUS
CN Guanidine, N-(3-ethyl-2,6-difluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)

L13 ANSWER 59 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 203196-19-4 CAPLUS
CN Guanidine, N-(3-ethyl-2,4-difluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



RN 203196-21-8 CAPLUS
CN Guanidine, N-(3-ethyl-4-fluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



L13 ANSWER 59 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 203196-22-9 CAPLUS
CN Guanidine, N-(5-ethyl-2-fluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



RN 203196-29-6 CAPLUS
CN Guanidine, N'-(4-fluoro-1-naphthalenyl)-N-methyl-N-(3-methylphenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 60 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:788751 CAPLUS
DN 130:47495
TI Therapeutic acenaphthyl guanidines, and preparation thereof
IN Magar, Sharad; Durant, Graham J.; Hu, Lain-Yen; Goldin, Stanley M.; Reddy, N. Laxma; Fischer, James B.; Katragadda, Subbarao; Knapp, Andrew Gannett; Margolin, Lee David
PA Cambridge Neuroscience, Inc., USA
SO U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 155,930, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5847006	A	19981208	US 1995-454927	19950531 <--
	US 5403861	A	19950404	US 1992-833421	19920210 <--
	EP 940139	A2	19990908	EP 1999-107574	19920210 <--
	EP 940139	A3	20000119		
	EP 940139	B1	20050202		
	R: AT, CH, DE, FR, GB, IT, LI				
PRAI	US 1991-652104	B2	19910208		
	US 1992-833421	A2	19920210		
	US 1993-155930	B2	19931122		
	EP 1992-907382	A3	19920210		

OS MARPAT 130:47495
AB N,N'-diaryl substituted guanidines having therapeutic utility are provided. The compds. of the invention include Ar1N(R)C(NH)N(R1)Ar (R, R1 represent hydrogen, other group; Ar, Ar1 = selected aryl groups, ≥1 being acenaphthyl).
IT 167310-17-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(acenaphthyl guanidines, preparation, and therapeutic use)
RN 167310-17-0 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)-, hydrochloride (1:1) (CA INDEX NAME)



IT 167311-39-9 167311-40-2 167312-84-7
167312-85-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acenaphthyl guanidines, prepn., and therapeutic use)
RN 167311-39-9 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)- (CA INDEX NAME)



RN 167311-40-2 CAPLUS
CN Guanidine, N'-(4-chloro-1-naphthalenyl)-N-(1,2-dihydro-5-acenaphthylenyl)-N-methyl- (CA INDEX NAME)



RN 167312-84-7 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-3-acenaphthylenyl)- (CA INDEX NAME)

L13 ANSWER 60 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 167312-85-8 CAPLUS
CN Guanidine, N'-(4-chloro-1-naphthalenyl)-N-(1,2-dihydro-3-acenaphthylenyl)-N-methyl- (CA INDEX NAME)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 61 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:709065 CAPLUS
DN 129:330740
OREF 129:67459a,67462a
TI Preparation of bicyclic aryl or bicyclic heterocyclic ring containing (4-methylpiperazin-1-yl)phenyl compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
IN Gaster, Laramie Mary; Wyman, Paul Adrian
PA Smithkline Beecham PLC, UK
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847885	A1	19981029	WO 1998-EP2265	19980414 <--
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2288172	A1	19981029	CA 1998-2288172	19980414 <--
	EP 975614	A1	20000202	EP 1998-919278	19980414 <--
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001526643	T	20011218	JP 1998-544988	19980414 <--
	US 6159979	A	20001212	US 1999-403149	19991015 <--
PRAI	GB 1997-7876	A	19970418		
	GB 1998-1635	A	19980126		
	WO 1998-EP2265	W	19980414		

OS MARPAT 129:330740
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = II, III (P1 = bicyclic aryl, bicyclic heterocyclic ring containing 1-3 heteroatoms selected from O, N and S; P2, P3 = Ph, bicyclic aryl, 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from O, N and S, or bicyclic heterocyclic group containing 1-3 heteroatoms selected from O, N or S, providing that at least one of P2 and P3 = bicyclic aryl or bicyclic heterocyclic group; R11 = H, halo, C1-6 alkyl, etc.; R12, R13 = H, halo, C1-6 alkyl, etc.; a, b = 1-3; A = a bond, O, CH2, etc.); L = C(V)DG, DGC(V), YC(V)DG1; V = O, S; D = N, C, CH; G and G1 = H, C1-6 alkyl; Y = NH, NR5 (wherein R5 = C1-6 alkyl), CH2, O; X = N, C; R2, R3 = H, halo, OH, etc.; R4 = H, C1-6 alkyl], useful as CNS agents, were prepared Thus, treatment of 4-(pyridin-4-yl)naphth-1-ylamine with triphosgene in the presence of Et3N in CH2Cl2 followed by the addition of a solution of 4-chloro-3-(4-methylpiperazin-1-yl)aniline in CH2Cl2 afforded 27% IV which showed pKi of > 8.0 at 5-HT1A, 5-HT1B and 5HT1D receptors.
IT 215162-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic aryl or bicyclic heterocyclic ring containing (4-methylpiperazin-1-yl)phenyl compds. having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity)
RN 215162-52-0 CAPLUS
CN Urea, N-(4-bromo-1-naphthalenyl)-N'-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)

L13 ANSWER 61 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 62 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:509197 CAPLUS
DN 129:136345
OREF 129:27877a,27880a
TI Indolomorphinan derivatives as remedies or preventives for cerebral disorders
IN Nagase, Hiroshi; Imamura, Yoshifumi; Hirokawa, Junichi; Matsuda, Susumu; Miyauchi, Yasushi
PA Toray Industries, Inc., Japan
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9831684	A1	19980723	WO 1998-JP92	19980113 <--
	W: AU, CA, CN, JP, KR, NO, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2249240	A1	19980723	CA 1998-2249240	19980113 <--
	CA 2249240	C	20060919		
	AU 9853437	A	19980807	AU 1998-53437	19980113 <--
	AU 739367	B2	20011011		
	EP 894799	A1	19990203	EP 1998-900228	19980113 <--
	EP 894799	B1	20040407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	CN 1220668	A	19990623	CN 1998-800291	19980113 <--
	CN 1117754	C	20030813		
	NZ 331769	A	20000526	NZ 1998-331769	19980113 <--
	AT 263769	T	20040415	AT 1998-900228	19980113 <--
	ES 2217533	T3	20041101	ES 1998-900228	19980113 <--
	JP 4110579	B2	20080702	JP 1998-534101	19980113
	NO 9804263	A	19981113	NO 1998-4263	19980915 <--
	US 6156762	A	20001205	US 1998-142794	19980924 <--
PRAI	JP 1997-5829	A	19970116		
	WO 1998-JP92	W	19980113		

OS MARPAT 129:136345
GI



I



II

AB Indolomorphinan derivs. [I; R1 = H, alkyl, cycloalkylalkyl such as cyclopropylmethyl, etc.; R2, R3 = H, hydroxy, alkoxy, etc.; R4 = H, alkyl, aralkyl such as benzyl, etc.; R5 = substituent(s) on the benzene ring such as H, F, Cl, etc.; m = 0-4 integer; (R5)m may be benzo], their

L13 ANSWER 62 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
pharmaceutically acceptable salts, and remedies/preventives for cerebral disorders contg. them, are claimed. It has been clarified that the above compds. have excellent preventive effects on cranial nerve disorders. Thus, these compds. are useful as drugs for inhibiting various ischemic, hemorrhagic or traumatic cerebral disorders and cranial nerve disorders caused by various nerve degenerations, treating and preventing various cerebral diseases such as cerebral stroke, traumatic cerebral disease, cerebral edema and cranial nerve degeneration disease, ameliorating the after-troubles thereof, and preventing the recurrence thereof. In a prepn. example, naltrexone was reacted with 5-hydrazinoacenaphthene in ethanol contg. methanesulfonic acid to give the methanesulfonate salt of II. In an in vitro study, this had an ED50 of 0.053 μM for protecting nerve cells against the toxicity of glutamic acid.
IT 35158-78-2 101851-40-5 168169-05-9
210696-78-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(indolomorphinan derivs. as remedies or preventives for cerebral disorders)
RN 35158-78-2 CAPLUS
CN Hydrazine, (4-bromo-1-naphthalenyl)- (CA INDEX NAME)

RN 101851-40-5 CAPLUS
CN Hydrazine, (4-chloro-1-naphthalenyl)- (CA INDEX NAME)



RN 168169-05-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-hydrazinyl- (CA INDEX NAME)



RN 210696-78-9 CAPLUS
CN Hydrazine, (4-fluoro-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 62 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 63 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:180848 CAPLUS
DN 128:243960
OREF 128:48301a,48304a
TI 8-Hydroxy-7-substituted quinolines as anti-viral agents
IN Vaillancourt, Valerie A.; Romines, Karen R.; Romero, Arthur G.; Tucker, John A.; Strohbach, Joseph W.; Bezencon, Olivier; Thaisrivongs, Suvit; et al.
PA Pharmacia & Upjohn Co., USA
SO PCT Int. Appl., 280 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811073	A1	19980319	WO 1997-US15310	19970905 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2262786	A1	19980319	CA 1997-2262786	19970905 <--
	AU 9741721	A	19980402	AU 1997-41721	19970905 <--
	EP 927164	A1	19990707	EP 1997-939690	19970905 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6310211	B1	20011030	US 1997-924683	19970905 <--
	JP 2002505660	T	20020219	JP 1998-513685	19970905 <--
	US 6211376	B1	20010403	US 1999-425789	19991022 <--
	US 6252080	B1	20010626	US 1999-425564	19991022 <--
	US 6500842	B1	20021231	US 2001-14780	20011023 <--
PRAI	US 1996-25870P	P	19960910		
	US 1997-50720P	P	19970625		
	US 1997-924683	A3	19970905		
	WO 1997-US15310	W	19970905		

OS MARPAT 128:243960
GI



I

AB The present invention provides for 8-hydroxy-7-substituted quinoline compds. I (R = alkyl, alkylamino, alkoxyalkyl, etc.; R1 = H, F, Cl, Br, CF3, etc.; R2 = H, alkyl, OH, arylalkenyl, etc.; R3 = H, OH, CF3, C1-C3alkyl) are prepared as anti-viral agents. Specifically, these compds. have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compds. are also active against other herpes viruses, such

L13 ANSWER 63 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).
IT 205039-48-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-hydroxy-7-substituted quinolines as anti-viral agents)
RN 205039-48-1 CAPLUS
CN 7-Quinolinecarboxamide, N-(4-bromo-1-naphthalenyl)-8-hydroxy- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 64 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:94768 CAPLUS
DN 128:176172
OREF 128:34599a,34602a
TI Methods of treatment of eye trauma and disorders with substituted guanidines and other compounds
IN McBurney, Robert N.
PA Cambridge Neuroscience, Inc., USA; McBurney, Robert N.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804131	A1	19980205	WO 1997-US13203	19970725 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6242198	B1	20010605	US 1996-686494	19960725 <--
	CA 2261765	A1	19980205	CA 1997-2261765	19970725 <--
	AU 9739654	A	19980220	AU 1997-39654	19970725 <--
	AU 742404	B2	20020103		
	EP 918460	A1	19990602	EP 1997-937042	19970725 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000515895	T	20001128	JP 1998-509048	19970725 <--
	KR 2000029518	A	20000525	KR 1999-700559	19990123 <--
	US 6358696	B1	20020319	US 2000-635309	20000809 <--
	US 20030027801	A1	20030206	US 2002-60101	20020129 <--
	US 6673557	B2	20040106		
PRAI	US 1996-686494	A2	19960725		
	WO 1997-US13203	W	19970725		
	US 2000-635309	A3	20000809		

OS MARPAT 128:176172
AB Methods using substituted guanidines and other compds. are provided for treatment of eye disorders and injury, including methods for treatment of reduced flow of blood or other nutrients to retinal tissue and/or optic nerve, methods for treatment of retinal ischemia and trauma, and methods for treatment for optic nerve injury/damage.
IT 137160-03-3 203196-18-3 203196-19-4
203196-21-8 203196-22-9 203196-29-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted guanidines and other compds. for treatment of eye trauma and disorders)
RN 137160-03-3 CAPLUS
CN Guanidine, N-(3-ethylphenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)

L13 ANSWER 64 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 203196-18-3 CAPLUS
CN Guanidine, N-(3-ethyl-2,6-difluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



RN 203196-19-4 CAPLUS
CN Guanidine, N-(3-ethyl-2,4-difluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)

L13 ANSWER 64 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 203196-29-6 CAPLUS
CN Guanidine, N'-(4-fluoro-1-naphthalenyl)-N-methyl-N-(3-methylphenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 64 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 203196-21-8 CAPLUS
CN Guanidine, N-(3-ethyl-4-fluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



RN 203196-22-9 CAPLUS
CN Guanidine, N-(5-ethyl-2-fluorophenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)

L13 ANSWER 65 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:516250 CAPLUS
DN 127:121624
OREF 127:23457a,23460a
TI Preparation of epoxysuccinamide derivatives as cathepsin inhibitors
IN Yamashita, Tomohiro; Suda, Yoshimitsu; Tada, Yukio; Katsunuma, Nobuhiko; Asao, Tetsuji
PA Taiho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721694	A1	19970619	WO 1996-JP3603	19961210 <--
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2211128	A1	19970619	CA 1996-2211128	19961210 <--
	CA 2211128	C	20010206		
	AU 9710414	A	19970703	AU 1997-10414	19961210 <--
	AU 697565	B2	19981008		
	EP 808839	A1	19971126	EP 1996-941212	19961210 <--
	EP 808839	B1	20010523		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 3338452	B2	20021028	JP 1997-521927	19961210 <--
	US 5883121	A	19990316	US 1997-894050	19970812 <--
PRAI	JP 1996-322971	A	19961212		
	WO 1996-JP3603	W	19961210		

OS CASREACT 127:121624; MARPAT 127:121624
GI



I

AB The title compds. I [R1 and R2 are the same or different and each represents H or optionally substituted aromatic hydrocarbyl or aralkyl, or R1 and R2 may form a nitrogenous heterocycle together with the adjacent nitrogen atom; R3 represents H or acyl; R4 represents H or alkyl; and R5 represents optionally substituted aromatic hydrocarbyl or aralkyl or may form an optionally protected amino acid residue in cooperation with the adjacent nitrogen atom] are prepared These compds. have cathepsin inhibitory activity, in particular specific inhibitory activity against cathepsin L, and are hence effective in the prophylaxis and therapy of bone diseases such as osteoporosis. Compds. of this invention in vitro showed IC50 values of 4 x 10-11 M to 2.2 x 10-7 M against cathepsin L.
IT 192763-31-8P 192763-32-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of epoxysuccinamide derivs. as cathepsin inhibitors)
RN 192763-31-8 CAPLUS

L13 ANSWER 65 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2,3-Oxiranedicarboxamide, N-[5-amino-1-[[(4-chloro-1-naphthalenyl)amino]carbonyl]pentyl]-N'-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-, monohydrochloride, [2S-[2α(R*),3β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 192763-32-9 CAPLUS
CN 2,3-Oxiranedicarboxamide, N-[5-amino-1-[[(4-chloro-1-naphthalenyl)amino]carbonyl]pentyl]-N'-[2-oxo-2-[(2-phenylethyl)amino]-1-(phenylmethyl)ethyl]-, monohydrochloride, [2S-[2α(R*),3β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 192763-93-2P 192763-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of epoxysuccinamide derivs. as cathepsin inhibitors)
RN 192763-93-2 CAPLUS
CN Carbamic acid, [1-[[(4-chloro-1-naphthalenyl)amino]carbonyl]-5-[[(1,1-dimethylethoxy)carbonyl]amino]pentyl]-, phenylmethyl ester, (S)- (9CI)

L13 ANSWER 65 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 192763-94-3 CAPLUS
CN Carbamic acid, [5-amino-6-[(4-chloro-1-naphthalenyl)amino]-6-oxohexyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 66 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:377861 CAPLUS
DN 126:343579
OREF 126:66821a,66824a
TI Preparation of pyrimidinylpiperazines as lipid peroxidation inhibitors
IN Toldy, Lajos; Zubovics, Zoltan; Szilagyi, Katalin; Vida, Franciska; Andrasi, Ferenc; Sutka, Klara; Hodula, Eszter; Szekeres, Tibor; Feher, Gabor; Moravcsik, Imre; Matyus, Peter; Sebestyen, Laszlo; Szabo, Hilda; Zara, Erzsebet; Horvath, Edit
PA Gyogyszerkutato Intezet, Hung.; Toldy, Marta; Toldy, Andras; et al.
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9714685	A1	19970424	WO 1996-HU58	19961014 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	HU 76265	A2	19970728	HU 1995-3012	19951019 <--
	AU 9673259	A	19970507	AU 1996-73259	19961014 <--
	HU 9900088	A2	20000328	HU 1999-88	19961014 <--
PRAI	HU 1995-3012	A	19951019		
	WO 1996-HU58	W	19961014		

OS MARPAT 126:343579
GI



AB Title compds. [I; R = AX(CH2)r(CO)q(CH2)pR1; A = (un)substituted alkylene; R1 = (un)substituted aryl; R2,R3 = NH2 or N-attached heterocyclyl; X = bond, SO0-2, (un)substituted imino; Z = CH2 or CH2CH2; p,q,r = 0 or 1] were prepared Thus, 1-[2-hydroxy-3-(2-naphthylthio)propyl]piperazine (preparation given) was N-arylated by 2,6-diamino-4-chloropyrimidine to give I [R = R1SCH2CH(OH)CH2, R1 = 2-naphthyl, R2 = R3 = NH2, Z = CH2]. Data for biol. activity of I were given.
IT 190000-40-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinylpiperazines as lipid peroxidn. inhibitors)
RN 190000-40-9 CAPLUS
CN Ethanone, 1-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-2-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)

L13 ANSWER 66 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L13 ANSWER 67 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:335954 CAPLUS
DN 125:10631
OREF 125:2337a,2340a
TI Preparation of 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxyalkanoic acid amides as renin inhibitors
IN Rasetti, Vittorio; Rueeger, Heinrich; Maibaum, Juergen Klaus; Mah, Robert; Gruetter, Markus; Cohen, Nissim Claude
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 115 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 702004	A2	19960320	EP 1995-113964	19950906 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9530534	A	19960328	AU 1995-30534	19950908 <--
US 5719141	A	19980217	US 1995-525254	19950908 <--
FI 9504255	A	19960316	FI 1995-4255	19950911 <--
CA 2158227	A1	19960316	CA 1995-2158227	19950913 <--
ZA 9507726	A	19960315	ZA 1995-7726	19950914 <--
NO 9503629	A	19960318	NO 1995-3629	19950914 <--
HU 74453	A2	19961230	HU 1995-2684	19950914 <--
CN 1169986	A	19980114	CN 1995-118418	19950914 <--
JP 08176087	A	19960709	JP 1995-238779	19950918 <--
PRAI CH 1994-2816	A	19940915		

OS MARPAT 125:10631
AB R1XCH2CR2R3CH2CH(NHR4)CHR5CH2CR6R7CONHR8 [I; R1 = arylamino, N-aryl-N-aralkylamino, N-attached heterocyclyl, etc.; R3,R3,R7 = H or alkyl; R2R3 = alkylene; R4 = H, alkyl, alkanoyl, alkoxycarbonyl; R5 = OH, alkanoyloxy, alkoxycarbonyloxy; R6 = H, (ar)alkyl, alkenyl, etc.; R6R7 = alkylene; R8 = (cyclo)aliphatic group, heteroaliph. group; X = CO or CH2] were prepared Thus, quinoline-3-carboxylic acid was converted in 21 steps to N-butyl-(2R,4S,5S)-5-amino-4-hydroxy-2,7,7-trimethyl-8-(3RS-methoxycarbonyl-1,2,3,4-tetrahydroquinolin-1-carbonyl)octanamide. I gave inhibition of human renin at .apprx.10-6 to .apprx.10-10M in vitro.
IT 177196-85-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxyalkanoic acid amides as renin inhibitors)
RN 177196-85-9 CAPLUS
CN Nonanediamide, 5-amino-N9-(4-bromo-1-naphthalenyl)-N1-butyl-4-hydroxy-2,7,7-trimethyl-, [2R-(2R*,4S*,5S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 67 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 177198-48-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxyalkanoic acid amides as renin inhibitors)
RN 177198-48-0 CAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-[4-[(4-bromo-1-naphthalenyl)amino]-2,2-dimethyl-4-oxobutyl]-5-[3-(butylamino)-2-methyl-3-oxopropyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, [4S-[4α,5β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:332407 CAPLUS
DN 125:10627
OREF 125:2333a,2336a
TI [[(Naphthylamino)piperidino]alkyl] aryl ethers with antioxidant, antihypoxia, and antiamnesia activity
IN Gere, Aniko; Szabo, Sandor; Palosi, Eva; Karpati, Egon; Horvath, Csilla; Farkas, Sandor; Pellionisz Paroczai, Margit; Schon, Istvan; Lapis, Erzsebet; et al.
PA Richter Gedeon Vegyeszeti Gyar Rt., Hung.
SO Hung. Teljes, 27 pp.
CODEN: HUXXBU
DT Patent
LA Hungarian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI HU 71416	A2	19951128	HU 1994-2476	19940829 <--
HU 215397	B	19981228		
WO 9606828	A1	19960307	WO 1995-HU41	19950828 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI HU 1994-2476	A	19940829		

OS MARPAT 125:10627
GI



I

AB This invention provides title compds. I and their pharmaceutically acceptable salts, wherein: R = H, C1-4 alkyl; X = H, halo, C1-4 alkyl, C1-4 alkoxy, Ph, 2,3-(CH:CH)2, 3,4-(CH:CH)2, 3,4-(CH2)3CO; n is a whole number from 2-4; q is a whole number from 1-5; m is a whole number from 1-3; Y = halo, with antioxidant (lipid peroxidn. inhibiting), antihypoxia, and antiamnesia activity. Thus, e.g., alkylation of a 4-(naphthylamino)piperidine with a phenoxypropyl chloride in presence of triethylamine and KI afforded 1-[3-(4-chlorophenoxy)propyl]-4-[(2-naphthyl)amino]piperidine which exhibited IC50 = 1.1 and 6.4 μM for NADPH- and Fe2+-induced lipid peroxidn., resp., vs. 1.2 and 12.5 μM, resp., for idebenone, and 100% protection against histotoxic hypoxia at 50 mg/kg in mice. 1-(3-Phenoxypropyl)-4-[(1-naphthyl)amino]piperidine was prepared similarly, and exhibited 138% protection against CO2-induced retrograde amnesia at 0.1 mg/kg p.o. in mice, 45% protection against electroshock-induced amnesia at 0.1 mg/kg in mice, and 18% protection against hypoxia-induced memory loss in rats at 10.0 mg/kg.
IT 177178-30-2P 177178-32-4P 177178-41-5P
177178-49-3P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
([[(naphthylamino)piperidino]alkyl] aryl ethers with antioxidant, antihypoxia, and antiamnesia activity)
RN 177178-30-2 CAPLUS
CN 4-Piperidinamine, N-(4-chloro-1-naphthalenyl)-1-[3-(4-fluorophenoxy)propyl]- (CA INDEX NAME)

L13 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 177178-32-4 CAPLUS
CN 4-Piperidinamine, N-(4-chloro-1-naphthalenyl)-1-(3-phenoxypropyl)- (CA INDEX NAME)



RN 177178-41-5 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-[3-(4-fluorophenoxy)propyl]- (CA INDEX NAME)

L13 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 177178-49-3 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-(3-phenoxypropyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L13 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●HCl

L13 ANSWER 69 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:902779 CAPLUS
DN 123:306597
OREF 123:54671a,54674a
TI Substituted guanidines as blockers of voltage-activated sodium ion channel and calcium ion channel and uses
IN Goldin, Stanley M.; McBurney, Robert N.; Margolin, Lee D.; Reddy, N. Laxma; Katragadda, Subbarao; Knapp, Andrew G.; Hu, Lain-Yen; Durant, Graham J.; Fischer, James B.
PA Cambridge Neuroscience, Inc., USA
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9523132	A1	19950831	WO 1995-US2301	19950222 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9518823	A	19950911	AU 1995-18823	19950222 <--
PRAI	US 1994-200219	A	19940223		
	WO 1995-US2301	W	19950222		

AB This invention relates to methods of treatment of diseases and various other undesirable bodily states which involve the excessive, inappropriate, and/or prolonged activity of voltage-activated ion channels, and are ameliorated by administration of compds. which block said channels. The methods involve the administration to mammals of compds. which block one or more classes of voltage-activated sodium and/or calcium ion channels, in a manner operationally defined herein as "use-dependent". Specific examples of conditions treatable by compds. of the invention (i.e. substituted guanidine) include but not limited to ischemic brain disease, ischemic heart disease, epilepsy, and amyotrophic lateral sclerosis (LAS). Also epitopes (i.e. SS1/SS2) of sodium ion channel and calcium ion channel in brain, heart, smooth muscle, and skeletal muscle that blocked by the disclosed guanidine compds. were described.
IT 167310-17-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted guanidine compds. block voltage-activated sodium and calcium channels and are used for treatment of ischemic brain and/or heart)
RN 167310-17-0 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L13 ANSWER 70 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:812852 CAPLUS
DN 123:228178
OREF 123:40759a,40762a
TI Preparation of 1-naphthylpyrazole-3-carboxamides as neurotensin receptor ligands
IN Labeeuw, Bernard; Gully, Danielle; JeanJean, Francis; Molimard, Jean-claude; Boigegrain, Robert
PA SANOFI, Fr.
SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 647629	A1	19950412	EP 1994-402263	19941010 <--
	EP 647629	B1	19990707		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	FR 2711140	A1	19950421	FR 1993-12136	19931012 <--
	FR 2711140	B1	19960105		
	AT 181911	T	19990715	AT 1994-402263	19941010 <--
	CA 2117821	A1	19950413	CA 1994-2117821	19941011 <--
	FI 9404770	A	19950413	FI 1994-4770	19941011 <--
	NO 9403837	A	19950418	NO 1994-3837	19941011 <--
	HU 70048	A2	19950928	HU 1994-2933	19941011 <--
	US 5502059	A	19960326	US 1994-320270	19941011 <--
	RU 2140912	C1	19991110	RU 1994-36749	19941011 <--
	AU 9475753	A	19950504	AU 1994-75753	19941012 <--
	AU 685154	B2	19980115		
	ZA 9407957	A	19950522	ZA 1994-7957	19941012 <--
	CN 1108651	A	19950920	CN 1994-117090	19941012 <--
	JP 07278114	A	19951024	JP 1994-246609	19941012 <--
	US 5523455	A	19960604	US 1995-442106	19950516 <--
	US 5585497	A	19961217	US 1995-442105	19950516 <--
	AU 9741869	A	19980122	AU 1997-41869	19971016 <--
	AU 705008	B2	19990513		
PRAI	FR 1993-12136	A	19931012		
	US 1994-320270	A3	19941011		

OS MARPAT 123:228178
GI



I



II

AB Title compds. [I; R = cyano(methyl), CH2CO2H, SO2NH2, NHCHO, etc.; T = H, alkyl, allyl, CH2CH2OMe, etc.; X = H and X1 = H, alkyl, aliphatic carbocyclyl; XX1 = atoms to complete an aliphatic carbocyclic ring] were prepared Thus, 2,6-(MeO)C6H3C(ONa):CHCOCO2Me was cyclocondensed with 1-hydrazino-4-nitronaphthalene (preparation each given) and the saponified product amidated with 2-aminoadamantane-2-carboxylic acid to give, in 2 addnl. steps, title compound II (R = NHCHO, T = Me). I had IC50 of 1-50nM for binding at neurotensin receptors.

L13 ANSWER 70 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 168169-04-8P, 1-Hydrazino-4-nitronaphthalene hydrochloride
168169-05-9P, 4-Cyano-1-hydrazinonaphthalene
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-naphthylpyrazole-3-carboxamides as neurotensin receptor ligands)
RN 168169-04-8 CAPLUS
CN Hydrazine, (4-nitro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 168169-05-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-hydrazinyl- (CA INDEX NAME)

L13 ANSWER 71 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:797266 CAPLUS
DN 123:198613
OREF 123:35449a,35452a
TI Preparation of 5-(arylaminoalkyl)-1-azabicyclo[3.3.0]octanes as muscarinic agonists
IN Baba, Yutaka; Suzuki, Tomoo; Suzuki, Tsunemasa; Hirooka, Kiyotaka; Kurono, Masayasu; Sawai, Kiichi
PA Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 647642	A1	19950412	EP 1994-115611	19941004 <--
R: CH, DE, FR, GB, IT, LI				
JP 07149765	A	19950613	JP 1994-193116	19940817 <--
JP 2983141	B2	19991129		
US 5530138	A	19960625	US 1994-312638	19940927 <--
PRAI JP 1993-250343	A	19931006		
JP 1994-193116	A	19940817		

OS CASREACT 123:198613; MARPAT 123:198613
GI



AB Title compds. [I; R = 1-azabicyclo[3.3.0]oct-5-yl; R1 = H, alkyl, acyl; R2,R3 = H, halo, alkyl, Ph, etc.; Z = null, atoms to complete an addnl. ring; Z1 = (CH2)1-3] were prepared Thus, title compound II [R = 1-azabicyclo[3.3.0]oct-5-yl, R1 = Me, Z1 = CH2](preparation given) had IC50 of 0.01μM against pirenzipine binding at rat cerebellum preparation in vitro.
IT 776-37-4, 4-Fluoro-N-formyl-1-naphthylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 5-(arylaminoalkyl)-1-azabicyclo[3.3.0]octanes as muscarinic agonists)
RN 776-37-4 CAPLUS
CN Formamide, N-(4-fluoro-1-naphthalenyl)- (CA INDEX NAME)



L13 ANSWER 72 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:763860 CAPLUS
DN 123:160853
OREF 123:28383a,28386a
TI Therapeutic guanidines
IN Magar, Sharad; Durant, Graham J.; Hu, Lain-Yen; Goldin, Stanley M.; Reddy, N. Laxma; Fischer, James B.; Katragadda, Subbarao; Knapp, Andrew Gannett; Margolin, Lee David
PA Cambridge Neuroscience, Inc., USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9514467	A1	19950601	WO 1994-US13541	19941122 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2177084	A1	19950601	CA 1994-2177084	19941122 <--
AU 9512122	A	19950613	AU 1995-12122	19941122 <--
AU 703138	B2	19990318		
ZA 9409253	A	19960104	ZA 1994-9253	19941122 <--
EP 746316	A1	19961211	EP 1995-905152	19941122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09505600	T	19970603	JP 1994-515219	19941122 <--
PRAI US 1993-155930	A	19931122		
WO 1994-US13541	W	19941122		

OS MARPAT 123:160853
AB N,N'-diaryl substituted guanidines, Ar1NRC(:NH)NR1Ar, wherein R and R1 represent H or another group and Ar and Ar1 represent selected aryl groups, and at least one being acenaphthyl, are prepared and are used to modulate, i.e., inhibit or potentiate the release of neurotransmitters, or decrease or preferably lengthen the time course of action of neurotransmitters from neuronal tissue.
IT 167310-17-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(acenaphthyl guanidines for neurotransmitter modulation)
RN 167310-17-0 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L13 ANSWER 72 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

IT 167311-39-9 167311-40-2 167312-84-7
167312-85-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acenaphthyl guanidines for neurotransmitter modulation)
RN 167311-39-9 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)- (CA INDEX NAME)



RN 167311-40-2 CAPLUS
CN Guanidine, N'-(4-chloro-1-naphthalenyl)-N-(1,2-dihydro-5-acenaphthylenyl)-N-methyl- (CA INDEX NAME)

L13 ANSWER 72 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 167312-84-7 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,2-dihydro-3-acenaphthylenyl)-
(CA INDEX NAME)



RN 167312-85-8 CAPLUS
CN Guanidine, N'-(4-chloro-1-naphthalenyl)-N-(1,2-dihydro-3-acenaphthylenyl)-
N-methyl- (CA INDEX NAME)



L13 ANSWER 73 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:594440 CAPLUS
DN 123:132884
OREF 123:23345a,23348a
TI Substituted guanidines and their derivatives as modulators of neurotransmitter release and methodology for identifying neurotransmitter release blockers
IN Goldin, Stanley M.; Katragadda, Subbarao; Hu, Lain Yen; Reddy, N. Laxma; Fischer, James B.; Knapp, Andrew G.; Margolin, Lee D.
PA Cambridge NeuroScience, Inc., USA
SO U.S., 42 pp. Cont.-in-part of U.S. Ser. No. 652,104, abandoned.
CODEN: USXXAM
DT Patent
LA English
PAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5403861	A	19950404	US 1992-833421	19920210 <--
	CA 2099245	A1	19920809	CA 1992-2099245	19920210 <--
	ZA 9200944	A	19930810	ZA 1992-944	19920210 <--
	EP 940139	A2	19990908	EP 1999-107574	19920210 <--
	EP 940139	A3	20000119		
	EP 940139	B1	20050202		
	R: AT, CH, DE, FR, GB, IT, LI				
	AT 186047	T	19991115	AT 1992-907382	19920210 <--
	AT 288262	T	20050215	AT 1999-107574	19920210
	US 5672608	A	19970930	US 1994-343829	19941122 <--
	US 5847006	A	19981208	US 1995-454927	19950531 <--
	US 5614630	A	19970325	US 1995-463419	19950605 <--
	US 5622968	A	19970422	US 1995-464312	19950605 <--
	US 5652269	A	19970729	US 1995-464123	19950605 <--
	US 5670519	A	19970923	US 1995-463420	19950605 <--
	US 5677348	A	19971014	US 1995-462834	19950605 <--
	US 5741661	A	19980421	US 1995-463686	19950605 <--
	US 6071969	A	20000606	US 1995-461700	19950605 <--
	US 5637623	A	19970610	US 1995-468813	19950606 <--
	US 5681861	A	19971028	US 1995-466263	19950606 <--
	US 5686495	A	19971111	US 1995-466031	19950606 <--
	US 5837737	A	19981117	US 1995-485566	19950607 <--
	AU 9668130	A	19970109	AU 1996-68130	19961011 <--
	AU 709863	B2	19990909		
PRAI	US 1991-652104	B2	19910208		
	US 1991-652861	B1	19910208		
	US 1991-692104	B1	19910208		
	EP 1992-907382	A3	19920210		
	US 1992-833421	A3	19920210		
	US 1993-155930	B2	19931122		
	US 1994-343829	A1	19941122		

OS CASREACT 123:132884; MARPAT 123:132884
AB Modulators of neurotransmitter release, including substituted guanidines, N''-aminoguanidines, and N,N'N',N''-tetrasubstituted hydrazinedicarboximidamides, and pharmaceutical compns. thereof, are disclosed. Also disclosed are methods involving the use of such neurotransmitter release modulators for the treatment or prevention of pathophysiol. conditions characterized by the release of excessive or inappropriate levels of neurotransmitters. Also disclosed are screening assays for compds. which selectively inhibit glutamate release. Also disclosed are methods of blocking voltage sensitive sodium and calcium channels in mammalian nerve cells. Preparation of selected compds. of the invention is described. Ability of the compds. to inhibit glutamate release and to inhibit calcium uptake in synaptosomes was determined

L13 ANSWER 73 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 163805-17-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(substituted guanidines, their derivs., and their preparation for modulation of neurotransmitter release, and methodol. for identifying neurotransmitter release blockers)
RN 163805-17-2 CAPLUS
CN Guanidine, N-(1,2-dihydro-5-acenaphthylenyl)-N'-(4-fluoro-1-naphthalenyl)-
(CA INDEX NAME)



IT 438-26-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted guanidines, their derivs., and their preparation for modulation of neurotransmitter release, and methodol. for identifying neurotransmitter release blockers)
RN 438-26-6 CAPLUS
CN 1-Naphthalenamine, 4-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 163805-11-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted guanidines, their derivs., and their preparation for modulation of neurotransmitter release, and methodol. for identifying neurotransmitter release blockers)
RN 163805-11-6 CAPLUS
CN Guanidine, N-(1,2-dihydro-3-acenaphthylenyl)-N-(1,2-dihydro-5-acenaphthylenyl)-N'-(4-fluoro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L13 ANSWER 73 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

L13 ANSWER 74 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:591848 CAPLUS
DN 117:191848
OREF 117:33143a,33146a
TI Preparation of 5-naphthyltetrazole-1-acetates as aldose reductase inhibitors
IN Inukai, Sinji; Agata, Mitsuzi; Akiba, Kiyoshi; Ohmura, Takeo; Horio, Yoshihiro; Ootake, Yasuhiro; Sawaki, Shohei; Goto, Masayoshi
PA Wakamoto Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 495526	A1	19920722	EP 1992-100877	19920120 <--
R: DE, FR, GB, IT				
JP 04244070	A	19920901	JP 1991-16889	19910118 <--
US 5252592	A	19931012	US 1992-821456	19920116 <--
PRAI JP 1991-16889	A	19910118		

OS MARPAT 117:191848
GI



I

II

AB Title compds. [I; R1 = H, alkyl; R2-R4 = H, (halo)alkyl, halo, OH, alkoxy; 1 of R5, R6 = Q and the other = H] were prepared Thus, 5-(6-methoxy-2-naphthyl)tetrazole was condensed with BuCH2CO2Et to give, after saponification, title compound II which had IC50 of 1.9 + 10-3M against aldose reductase in vitro.
IT 143806-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of aldose reductase inhibitors)
RN 143806-44-4 CAPLUS
CN Glycine, N-(4-fluoro-1-naphthalenyl)-, methyl ester (CA INDEX NAME)

L13 ANSWER 74 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L13 ANSWER 75 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:99164 CAPLUS
DN 116:99164
OREF 116:16545a,16548a
TI Synthesis and pharmacological evaluation of some novel 13-[N,N-dialkylamino-alkyl]benzo[g][2]benzopyrano[4,3-b]indol-5[13H]ones
AU DeVito, Stephen C.; Stephani, Ralph A.
CS Coll. Pharm. Allied Health Prof., St. John's Univ., Jamaica, NY, 11439, USA
SO Medicinal Chemistry Research (1991), 1(1), 47-51
CODEN: MCREEB; ISSN: 1054-2523
DT Journal
LA English
GI



I

AB The synthesis and biol. evaluation of a series of novel 13-(N,N-dialkylaminoalkyl)benzo[g][2]benzopyrano[4,3-b]indol-5[13H]ones, or (N-alkylisochromenoindoles) [I, YNR1R2 = 3-piperidinopropyl, (CH2)3NMe2, (CH2)2NMe2, etc.] have led to the identification of this class of compds. as potential nonnarcotic analgesic agents.
IT 139191-49-4P 139191-50-7P 139191-53-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 139191-49-4 CAPLUS
CN 1-Piperidineethanamine, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



RN 139191-50-7 CAPLUS
CN 1-Pyrrolidineethanamine, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 75 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 139191-53-0 CAPLUS
CN 1-Piperidineethanamine, N-(4-chloro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L13 ANSWER 76 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:552066 CAPLUS
DN 113:152066
OREF 113:25835a,25838a
TI Naphthalenes as herbicide antidotes for use with 2-(4-aryloxy)phenoxyacetates or -propionates or with cyclohexenones
IN Hagen, Helmut; Pfister, Juergen; Eichenauer, Ulrich; Wuerzer, Bruno; Westphalen, Karl Otto; Helbig, Wilfried
PA BASF A.-G., Germany
SO Ger. Offen., 31 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3837926	A1	19900517	DE 1988-3837926	19881109 <--
CA 2001843	A1	19900509	CA 1989-2001843	19891031 <--
US 5035736	A	19910730	US 1989-429763	19891031 <--
JP 02237904	A	19900920	JP 1989-285079	19891102 <--
EP 368212	A2	19900516	EP 1989-120520	19891106 <--
EP 368212	A3	19920701		
EP 368212	B1	19950920		
R: CH, DE, FR, GB, IT, LI, NL				
PRAI DE 1988-3837926	A	19881109		

OS CASREACT 113:152066; MARPAT 113:152066
GI



I

AB The title compds. [I; R = alkyl, alkylthio, haloalkyl, alkoxy, halo, OH, NO2, PhCH2; R1 = CN, C(NH2):NOH, azolylcarbonyl, iminoxycarbonyl, 5-phenyl-1,2,4-oxadiazolyl, etc.; R2 = halo, amino, imino, sulfonylamino, OH, carboxy, alkoxycarbonyl, etc.; m = 0-3], were prepared Thus, 2-aminonaphthalene-1-carbonitrile in MeCN was added to a 65° mixture of CuCl2 and tert-Bu nitrite in MeCN to give 70% 2-chloronaphthalene-1-carbonitrile (II). II at 0.015 kg/ha reduced sethoxydim phytotoxicity in corn from 65% (controls) to 30%.
IT 129667-52-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide antidote)
RN 129667-52-3 CAPLUS
CN Acetamide, N-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 76 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L13 ANSWER 77 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:406599 CAPLUS
DN 113:6599
OREF 113:1279a,1282a
TI Preparation of (dialkoxyphosphinoylmethyl)benzamides as antihyperlipidemics
IN Tsutsumi, Kazuhiko; Uesaka, Eiji; Shinomiya, Kayoko; Tsuda, Yoshihiko; Shoji, Yasuo; Shima, Atsushi
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO Brit. UK Pat. Appl., 51 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2220206	A	19900104	GB 1989-14891	19890629 <--
GB 2220206	B	19920520		
JP 03109393	A	19910509	JP 1989-160171	19890621 <--
JP 07045508	B	19950517		
AU 8937078	A	19900104	AU 1989-37078	19890627 <--
AU 606808	B2	19910214		
SE 8902326	A	19891230	SE 1989-2326	19890628 <--
SE 469895	B	19931004		
SE 469895	C	19940203		
DE 3921188	A1	19900118	DE 1989-3921188	19890628 <--
DE 3921188	C2	19970814		
CA 1339370	C	19970826	CA 1989-604124	19890628 <--
FR 2633624	A1	19900105	FR 1989-8722	19890629 <--
FR 2633624	B1	19960705		
NL 8901652	A	19900116	NL 1989-1652	19890629 <--
NL 194239	B	20010601		
NL 194239	C	20011002		
CN 1040029	A	19900228	CN 1989-106420	19890629 <--
CN 1022632	C	19931103		
US 4971957	A	19901120	US 1989-373837	19890629 <--
ES 2017820	A6	19910301	ES 1989-2301	19890629 <--
CH 678530	A5	19910930	CH 1989-2429	19890629 <--
PRAI JP 1988-163082	A	19880629		
JP 1989-152784	A	19890615		
JP 1989-160171	A	19890621		

OS CASREACT 113:6599; MARPAT 113:6599
GI



I



II

AB The title compds [I; R1, R2 = H, alkyl (substituted) Ph, alkoxycarbonyl, pyridyl, phenylamino, naphthyl, pyrimidinyl, isoxazolyl, phthalazinylamino; R1R2N = indolin-1-yl, (halo-substituted) 1,2,3,4-tetrahydroquinolin-1-yl, phenothiazin-10-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, 2,3-dihydro-4H-1,4-benzoxazin-4-yl; R3 =

L13 ANSWER 77 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
alkyl; X = O, S], were prepd. Thus, (EtO)2P(O)CH2C6H4(CO2H)-4 and 3-amino-5-methylisozazole in DMF were treated with (PhO)2P(O)CN in DMF and then with Et3N in DMF at 0° to give isoxazolylbenzamide II. I at 300 mg/kg/daily orally in rats increased high d. lipoprotein cholesterol concns by 148-332% after 2 days. Tablet, capsule, and granule formulations are given.
IT 127432-07-9P 127432-08-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihyperlipidemic)
RN 127432-07-9 CAPLUS
CN Phosphonic acid, [[4-[[(4-bromo-1-naphthalenyl)amino]carbonyl]phenyl]methy 1]-, diethyl ester (9CI) (CA INDEX NAME)



RN 127432-08-0 CAPLUS
CN Phosphonic acid, [[4-[[(4-chloro-1-naphthalenyl)amino]carbonyl]phenyl]meth yl]-, diethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 78 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:508314 CAPLUS
DN 83:108314
OREF 83:16921a,16924a
TI Syntheses of amino acid derivatives and their biological activities. I. Antiinfluenza activity
AU Kanao, Seizo; Toyoda, Takeshi; Suyama, Tadashi; Toyoshima, Shigeshi
CS Cent. Res. Lab., Ajinomoto Co., Inc., Kawasaki, Japan
SO Yakugaku Zasshi (1975), 95(4), 397-401
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Japanese
GI For diagram(s), see printed CA Issue.
AB Among 325 amino acid derivs. tested for antiviral activity, 39 of them had some activity, while the following 5 had appreciable activity: N-benzyl-L-valine [15363-84-5], N-furfuryl-L-phenylalanine [38014-71-0], N-furfuryl-4-nitro-L-phenylalanine [40356-14-7], N-2-fluorenesulfonyl-β-alanine (I) [32869-90-2], and N-β-naphthylaminomethyl-L-alanine [32945-07-6]. These compds. were effective when administered to mice even 72 hr after viral infection. I had both antiviral and antiinflammatory activities. The synthesis of 7 amino acid derivs. are described.
IT 56211-89-3
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(antiviral activity and toxicity of)
RN 56211-89-3 CAPLUS
CN L-Leucine, N-[[(4-nitro-1-naphthalenyl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 79 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:103776 CAPLUS
DN 80:103776
OREF 80:16639a,16642a
TI Antimalarial drugs. 35. Synthesis and antimalarial effects of 1-(3,4-dichlorophenyl)-3-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-2-pyrimidinyl]guanidine and related substances
AU Elslager, Edward F.; Werbel, Leslie M.; Curry, Ann; Headen, Nancy; Johnson, Judith
CS Res. Dev. Div., Parke, Davis and Co., Ann Arbor, MI, USA
SO Journal of Medicinal Chemistry (1974), 17(1), 75-100
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Structure-antimalarial activity of 1-(3,4-dichlorophenyl)-3-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-2-pyrimidinyl]guanidine (I) [21062-28-2] and 120 analogs prepared by condensation of the aryl(4-chloro-6-methyl-2-pyrimidinyl)guanidine derivs. with the appropriate polyamines is given. Curative activity against Plasmodium berghei infection in mice was shown by 90 compds. in single s.c. doses of 20-640 mg/kg. While 62 compds showed suppressive activity after oral administration, 46 of them were 2-30 times as potent as quinine-HCl [130-89-2]. Strong suppressive activity against P. gallinaceum in chicks was shown by 59 compds.
IT 51387-75-8P 51387-78-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antimalarial activity of)
RN 51387-75-8 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-[4-[(1-ethyl-3-piperidinyl)amino]-6-methyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 51387-78-1 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-[4-[[3-[(diethylamino)methyl]-4-methoxyphenyl]amino]-6-methyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

L13 ANSWER 79 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 51388-17-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51388-17-1 CAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-(1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT 51387-88-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with polyamine)
RN 51387-88-3 CAPLUS
CN Guanidine, N-(4-chloro-6-methyl-2-pyrimidinyl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L13 ANSWER 79 OF 79 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



```
=> d his

     (FILE 'HOME' ENTERED AT 10:48:29 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:44 ON 07 OCT 2008
L1             STRUCTURE UPLOADED
L2              13 S L1
L3             875 S L1 FULL
L4             537 S L3 AND ED<06/09/2004
L5             587 S L3 AND REF.CAPLUS<=6
L6             288 S L3 NOT L5
L7             115 S L6 AND ED<06/09/2004

     FILE 'CAPLUS' ENTERED AT 10:57:25 ON 07 OCT 2008
L8             931 S L3
L9             765 S L8 AND PY<2004
L10            438 S L5
L11            369 S L10 AND PY<2005
L12            347 S L11 AND PY<2004
L13             79 S L12 AND THU/RL

=> s l11 not l12
L14            22 L11 NOT L12

=> d 1-22 bib abs hitstr
```

L14 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:497492 CAPLUS
DN 143:7727
TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes
IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, George; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice M.; Young, Erick Richard Roush
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 766,079.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050124640	A1	20050609	US 2004-933635	20040903
US 20040242613	A1	20041202	US 2004-766079	20040127 <--
PRAI US 2003-443700P	P	20030130		
US 2004-766079	A2	20040127		

OS CASREACT 143:7727; MARPAT 143:7727
GI



I



II

III

AB Title compds. I [wherein R1 = (un)substituted heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 = (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-NR4R5, -NH(CH2)p-X-R4, etc.; X = piperidinyl; n = 5-8; p = 1-3; q = 0-3; R4, R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo, CN, NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their tautomers, pharmaceutically acceptable salts, solvates, or amino-protected derivs., with certain compds. excluded] were prepared as inhibitors of protein kinase C (PKC)-theta useful for treating immunol. disorders and type II diabetes. For example, II was prepared in 5 steps via amination of 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine. Selected I inhibited PKC-theta with IC50 values ≤ 0.3 μM. Thus,

L14 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
I are useful for treating a disease or disorder assocd. with T cells activation.
IT 736052-41-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)
RN 736052-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-chloro-1-naphthalenyl)-5-nitro- (CA INDEX NAME)



L14 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:474930 CAPLUS
DN 143:26585
TI Preparation of fused succinimides as modulators of nuclear hormone receptor function
IN Salvati, Mark E.; Mitt, Toomas; Patel, Ramesh N.; Hanson, Ronald L.; Brzozowski, David; Goswami, Animesh; Chu, Linda Nga Hoong; Li, Wen-Sen; Simpson, James H.; Totleben, Michael J.; He, Weixuan
PA Bristol-Myers Squibb Company, USA
SO U.S. Pat. Appl. Publ., 281 pp., Cont.-in-part of U.S. Ser. No. 885,381.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050119228	A1	20050602	US 2001-24878	20011219
US 6953679	B2	20051011		
US 20040176324	A1	20040909	US 2001-885381	20010620 <--
CN 1995039	A	20070711	CN 2007-10006341	20010620
ZA 2003002963	A	20040715	ZA 2003-2963	20030415 <--
US 20050256048	A1	20051117	US 2005-130935	20050517
PRAI US 2000-233519P	P	20000919		
US 2001-885381	A2	20010620		
US 2000-214392P	P	20000628		
US 2001-284438P	P	20010418		
US 2001-284617P	P	20010418		
US 2001-284730P	P	20010418		
CN 2001-818955	A3	20010620		
US 2001-885827	A3	20010620		

OS MARPAT 143:26585
GI

L14 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
symbols are as defined above for II] with an enzyme or microorganism capable of catalyzing the hydroxylation of III to II is disclosed. Thus, hydroxylation of IV with Cunninghamella echinulata SC 16027 (ATCC 9244) afforded V. Also, prepn. of diol VI [the symbols are as defined above for I] by contacting the epoxide VII [the symbols are as defined above for I] with an enzyme or microorganism capable of catalyzing the opening of the epoxide ring, is claimed.
IT 573760-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused succinimides as modulators of nuclear hormone receptor function)
RN 573760-98-2 CAPLUS
CN Carbamic acid, (4-cyano-1-naphthalenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 265 THERE ARE 265 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; G = (substituted) aryl, heterocyclyl; Z1, Z2 = O, S, NH, NR6; A1, A2 = CR7, N; Y = JJ'J"; J, J" = (CR7R7')n; n = 0-3, J' = bond, O, S, SO, SO2, NH, NR7, CR7R7', R2PO, R2PS, R2OPO, R2NHPO, OPOOR2, OPONHR2, OSO2, NHNH, NHNR6, NR6NH, N:N, (substituted) cycloalk(en)yl, heterocyclo; W = CR7R7'CR7R7, CR7R7'CO, COCO, CR7R7'C:CH2, C:CH2C:CH2, CR7R7C:NR1, C:NR1C:NR1, NR9CR7R7, N:N, (substituted) cycloalk(en)yl, heterocyclo, aryl, etc.; Q1, Q2 = H, (substituted) alkyl, alkenyl, cycloalk(en)yl, heterocycloalkyl, aryl(alkyl), alkynyl, heterocyclo, halo, CN, R1O2C, R4CO, R5R6NCO, HOCR7R7', NO2, R1OCH2, R1O, NH2, COSR1, SO2R1, NR4R5; L = bond, (CR7R7')n, NH, NR5, NH(CR7R7')n, NR5(CR7R7')n; R1, R1' = H, R2; R2 = (substituted) alkyl, alkenyl, alkynyl, cycloalk(en)yl, heterocyclo, cycloalk(en)ylalkyl, heterocycloalkyl, aryl(alkyl); R3, R3' = R1, halo, CN, hydroxylamine, hydroxamide, (substituted) alkoxy, alkylthio, amino, NR1R2, SH; R4 = R1, R1CO, R1NHCO, SO2OR1, SO2NR1R1'; R5 = R2, R1CO, R1NHCO, SO2R1, SO2OR1, SO2NR1R1'; R6 = R5, CN, OH, OR1; R7, R7' = R4, halo, CN, OR4, NO2, hydroxylamine, hydroxylamide, amino, NHR4, NR2R5, NR5R5, NOR1, SH, (substituted) alkylthio, HO2C, R1CO2, NH2CO, SOR1, PO3R1R1', R1R1'NCO, COSR1; with provisos], were prepared for treating nuclear hormone receptor-associated conditions such as cancer and immune disorders (no data). Thus, 4-(tert-butyldimethylsiloxy)-2H-thiopyran (preparation given) and 1-(4-bromo-3-methylphenyl)-1H-pyrrole-2,5-dione (preparation given) were refluxed 5 h in PhMe to give an enol ether intermediate which was stirred with CF3CO2H in CH2Cl2 to give 22% (3aα,4α,7α,7aα)-2-(4-bromo-3-methylphenyl)tetrahydro-4,7-ethanothiopyrano[3,4-c]pyrrole-1,3,8(2H,4H)-trione. Preparation of compds. II [G = aryl, heterocyclyl; Z1, Z2 = O, S; A1, A2 = CR7; Y, Q1, Q2, L are as defined above for I] by contacting III [the

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1127314 CAPLUS
DN 142:74362
TI Preparation of substituted 1-naphthalenamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors
IN Cadilla, Rodolfo; Larkin, Andrew L.; Stewart, Eugene Lee; Trump, Ryan Paul; Turnbull, Philip Stewart
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110978	A2	20041223	WO 2004-US18456	20040609 <--
	WO 2004110978	A3	20050428		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1636167	A2	20060322	EP 2004-776434	20040609
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007505164	T	20070308	JP 2006-533682	20040609
	US 20060142387	A1	20060629	US 2005-560017	20051208
PRAI	US 2003-477256P	P	20030610		
	WO 2004-US18456	W	20040609		

OS MARPAT 142:74362
GI



AB The title compds. I [R1 = CN, NO2, halo, etc.; R2 = H, CN, NO2, etc.; R3, R4 = (CH2)xR5 (wherein x = 0-6; R5 = H, alkyl, OH, etc.); R9 = H, CN, NO2, halo, etc.] that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors (no data), were prepared Thus, reacting (cyclopropylmethyl)propylamine with 4-chloro-1-nitronaphthalene afforded 95% I [R1 = NO2; R2 = H; R3 = Pr; R4 = cyclopropymethyl; R9 = H]. The pharmaceutical composition comprising the compound I is disclosed.
IT 813430-11-4P 813430-16-9P 813430-18-1P

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted 1-naphthalenamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors)
RN 813430-11-4 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)amino]- (CA INDEX NAME)



RN 813430-16-9 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 813430-18-1 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



IT 813429-99-1P 813430-00-1P 813430-01-2P
813430-02-3P 813430-04-5P 813430-05-6P
813430-06-7P 813430-07-8P 813430-08-9P
813430-09-0P 813430-10-3P 813430-13-6P
813430-14-7P 813430-15-8P 813430-17-0P
813430-19-2P 813430-20-5P 813430-21-6P
813430-22-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 1-naphthalenamines as modulators of androgen,

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
glucocorticoid, mineralocorticoid, and progesterone receptors)
RN 813429-99-1 CAPLUS
CN 1-Naphthalenamine, N-(cyclopropylmethyl)-4-nitro-N-propyl- (CA INDEX NAME)



RN 813430-00-1 CAPLUS
CN 1-Naphthalenamine, N-cyclohexyl-N-methyl-4-nitro- (CA INDEX NAME)



RN 813430-01-2 CAPLUS
CN 1-Naphthalenamine, 4-nitro-N,N-dipropyl- (CA INDEX NAME)



RN 813430-02-3 CAPLUS
CN 1-Naphthalenamine, N-butyl-N-methyl-4-nitro- (CA INDEX NAME)



L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 813430-04-5 CAPLUS
CN 1-Naphthalenamine, N-butyl-N-ethyl-4-nitro- (CA INDEX NAME)



RN 813430-05-6 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(butylmethylamino)- (CA INDEX NAME)



RN 813430-06-7 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)



RN 813430-07-8 CAPLUS
CN 1,2-Ethanediamine, N1-ethyl-N2,N2-dimethyl-N1-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 813430-08-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(propylamino)- (CA INDEX NAME)

RN 813430-09-0 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(3-hydroxypropyl)amino]- (CA INDEX NAME)



RN 813430-10-3 CAPLUS
CN 1-Propanol, 3-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)



RN 813430-13-6 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)[3-(1-piperidinyl)propyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 813430-12-5
CMF C23 H29 N3

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 813430-14-7 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]- (CA INDEX NAME)



RN 813430-15-8 CAPLUS
CN 1-Naphthalenamine, 4-nitro-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 813430-17-0 CAPLUS

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1-Naphthalenamine, 4-bromo-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 813430-19-2 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[bis(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



RN 813430-20-5 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[propyl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



RN 813430-21-6 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[2-propen-1-yl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



RN 813430-22-7 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(2-hydroxyethyl)(2,2,2-trifluoroethyl)amino]-

L14 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



L14 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1015953 CAPLUS
DN 142:15152
TI Nanoscale probes for semiconductor device fabrication
IN Otomo, Akira; Furumi, Seiichi; Miki, Hideki; Suzuki, Hitoshi; Tanaka, Shukichi; Mashiko, Shinro
PA National Institute of Information and Communications Technology, Japan
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101429	A1	20041125	WO 2004-JP5882	20040423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1623953	A1	20060208	EP 2004-729206	20040423
	R: CH, DE, ES, FR, GB, LI, NL				
	US 20070114400	A1	20070524	US 2006-554203	20061103
PRAI	JP 2003-122630	A	20030425		
	WO 2004-JP5882	W	20040423		

AB The title proves comprise a Au substrate wire and an intermediate medium which is exited by an external energy to an excited triplet state and is fixed to the substrate wire, wherein transfer of excited triplet energy is effected from the intermediate excited medium toward a 1st mol. having a residue with bonding capability. The first mol. having been excited by the transfer of excited triplet energy is bonded with a second mol. having a residue with bonding capability as a bonding target to be bonded with the first mol.
IT 793696-72-7P
RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (excited intermediate medium; nanoscale probes for semiconductor device fabrication)
RN 793696-72-7 CAPLUS
CN Propanamide, 3-[[3,5-bis[[[3,5-bis[[[3,5-bis[[(4-mercaptophenyl)methyl]thio]phenyl]methyl]thio]phenyl]methyl]thio]phenyl]methoxy]-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 799280-04-9P
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(nanoscale probes for semiconductor device fabrication)
RN 799280-04-9 CAPLUS
CN Propanamide, 3-bromo-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



L14 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:965170 CAPLUS
DN 141:418915
TI Method and device for molecule bonding
IN Otomo, Akira; Furumi, Seiichi; Suzuki, Hitoshi; Miki, Hideki; Mashiko, Shinro
PA National Institute of Information and Communications Technology, Japan
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096698	A1	20041111	WO 2004-JP5877	20040423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1621517	A1	20060201	EP 2004-729214	20040423
	R: CH, DE, ES, FR, GB, LI, NL				
	US 20070172600	A1	20070726	US 2005-554059	20051024
PRAI	JP 2003-122629	A	20030425		
	WO 2004-JP5877	W	20040423		

AB External energy is fed to N-[3-[3,5-bis[3,5-bis[3,5-bis(4-mercaptobenzylthio)benzylthio]benzylthio)benzyloxy]-propionyl-4-nitro-1-naphthylamine, a mol. capable of photosensitization as an intermediate excitation medium fixed on a metal support, to a photosensitized mol. of excited triplet state, thereby inducing an excited triplet energy transfer from this photosensitized mol. to the first mol. having a residue capable of bonding. The first mol., excited by the excited triplet energy transfer, is bonded with second mol. having a residue capable of bonding with the first mol.
IT 793696-72-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(method and device for mol. bonding using mol. capable of photosensitization as intermediate excitation medium)
RN 793696-72-7 CAPLUS
CN Propanamide, 3-[[3,5-bis[[[3,5-bis[[[3,5-bis[[(4-mercaptophenyl)methyl]thio]phenyl]methyl]thio]phenyl]methyl]thio]phenyl]methoxy]-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)

L14 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



L14 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:964820 CAPLUS
DN 141:395584
TI Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Reddy, Velagala Venkira Rama Murali Krishna; Sridevi, Bhatlapenumarphy Shesha; Kumar, Potlapally Rajender; Reddy, Gaddam Om
PA Reddy Us Therapeutics, Inc., USA
SO U.S. Pat. Appl. Publ., 433 pp., Cont.-in-part of U.S. Ser. No. 390,485.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040224950	A1	20041111	US 2003-400140	20030326 <--
	US 7132423	B2	20061107		
	US 20040077648	A1	20040422	US 2003-390485	20030317 <--
	US 7173032	B2	20070206		
	JP 2006188533	A	20060720	JP 2006-79816	20060322
	US 20060258641	A1	20061116	US 2006-441326	20060525
	US 7332490	B2	20080219		
	US 20070122444	A1	20070531	US 2006-512863	20060830
	US 7335656	B2	20080226		
	US 20070043051	A1	20070222	US 2006-543969	20061005
PRAI	US 2001-324147P	P	20010921		
	US 2002-253288	B1	20020923		
	US 2003-390485	A2	20030317		
	JP 2004-538153	A3	20030326		
	US 2003-400140	A1	20030326		

OS CASREACT 141:395584; MARPAT 141:395584
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to methods and compns. comprising compds. I or II [R1 = H, alkyl, cycloalkyl, etc.; G = NR1, O; J = CH, N; n = 0-3; X1 = o-R1, m-R1, m-OR1, m-OCF3, etc.; X2 = o-R1, p-R1, p-OR1, p-OCF3, etc.; X3 = o-R1, m-R1, p-R1, o-OR1, p-OR1; or X2 and X3 together is a fused benzene, pyridine, dioxane, tetrahydropyran ring; AY, DY = OR1, F, Cl, Br, I, tetrahydroquinolin-1-yl, etc.; or A, B = O, NR1; and Y = R1, (CHR1)qR1, (CHR1)qCF3, etc.; q = 0-3] that treat pathophysiol. conditions arising from inflammatory responses. Over 100 synthetic examples described synthesis of compds. I and II and their intermediates. E.g., a multi-step synthesis of the triazine III, starting from cyanuric chloride, is given. In particular, the present invention is directed to compds. that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to comds. that inhibit smooth muscle cell (SMC) proliferation. Many of the compds. I and II inhibited SMC proliferation by greater than 70%. Also, the most effective compds. I and II showed an 80% decrease in IL-6 secretion in test for AGE-induced inflammatory response determination In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

IT 502766-18-9P 502766-20-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel triazine compds. for inhibiting smooth muscle cell proliferation)

L14 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 502766-18-9 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 502766-20-3 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-chloro-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:878168 CAPLUS
DN 141:360665
TI Synergistic methods and compositions using insulin-like growth factor 1 receptor (IGF1R) inhibitors with additional kinase inhibitors for treating cancer
IN Carboni, Joan M.; Hurlburt, Warren W.; Gottardis, Marco M.; Lee, Francis Y.
PA USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 676,214.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040209930	A1	20041021	US 2004-814199	20040331 <--
	CA 2500714	A1	20040415	CA 2003-2500714	20031001 <--
	US 20040072760	A1	20040415	US 2003-677067	20031001 <--
	AU 2003275364	A1	20040423	AU 2003-275364	20031001 <--
	US 20040106605	A1	20040603	US 2003-676214	20031001 <--
	EP 1551411	A2	20050713	EP 2003-759640	20031001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503867	T	20060202	JP 2004-541997	20031001
	WO 2005094376	A2	20051013	WO 2005-US10820	20050330
	WO 2005094376	A3	20070222		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1758564	A2	20070307	EP 2005-762085	20050330
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRAI	US 2002-415416P	P	20021002		
	US 2003-676214	A2	20031001		
	US 2003-677067	A2	20031001		
	WO 2003-US31091	W	20031001		
	US 2004-814199	A	20040331		
	WO 2005-US10820	W	20050330		

OS MARPAT 141:360665
AB Combination therapies using IGF1R inhibitors in combination with addnl. kinase inhibitors are described for the synergistic treatment of cancer.
IT 302960-36-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IGF1 receptor inhibitors with addnl. kinase inhibitors for synergistic treatment of cancer)
RN 302960-36-7 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[[(4-chloro-1-naphthalenyl)amino]carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

L14 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
PAGE 1-A



PAGE 2-A

L14 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:878154 CAPLUS
DN 141:366254
TI Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Krishna, Reddy Velagala Venkata Rama Murali; Sesila, Sridevi Bhatlapenumarthy; Kumar, Potlapally Rajender; Reddy, Gaddam Om
PA USA
SO U.S. Pat. Appl. Publ., 422 pp., Cont.-in-part of U.S. Ser. No. 253,388.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040209882	A1	20041021	US 2003-400169	20030326 <--
	US 7169785	B2	20070130		
	US 20040077648	A1	20040422	US 2003-390485	20030317 <--
	US 7173032	B2	20070206		
	US 20050124619	A1	20050609	US 2004-951120	20040927
	US 7238692	B2	20070703		
	JP 2006188533	A	20060720	JP 2006-79816	20060322
	US 20070117795	A1	20070524	US 2006-511129	20060828
	US 7332488	B2	20080219		
	US 20070043051	A1	20070222	US 2006-543969	20061005
PRAI	US 2001-324147P	P	20010921		
	US 2002-253388	A2	20020923		
	US 2003-390485	A2	20030317		
	JP 2004-538153	A3	20030326		
	US 2003-400169	A3	20030326		

OS MARPAT 141:366254
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to methods and compns. comprising compds. I or II [R1 = H, alkyl, cycloalkyl, etc.; G = NR1, O; J = CH, N; n = 0-3; X1 = o-R1, m-R1, m-OR1, m-OCF3, etc.; X2 = o-R1, p-R1, p-OR1, p-OCF3, etc.; X3 = o-R1, m-R1, p-R1, o-OR1, p-OR1; or X2 and X3 together is a fused benzene, pyridine, dioxane, tetrahydropyran ring; AY, DY = OR1, F, Cl, Br, I, tetrahydroquinolin-1-yl, etc.; or A, B = O, NR1; and Y = R1, (CHR1)qR1, (CHR1)qCF3, etc.; q = 0-3] that treat pathophysiol. conditions arising from inflammatory responses. Over 100 synthetic examples described synthesis of compds. I and II and their intermediates. E.g., a multi-step synthesis of the triazine III, starting from cyanuric chloride, is given. In particular, the present invention is directed to compds. that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to comds. that inhibit smooth muscle cell (SMC) proliferation. Many of the compds. I and II inhibited SMC proliferation by greater than 70%. Also, the most effective compds. I and II showed an 80% decrease in IL-6 secretion in test for AGE-induced inflammatory response determination In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
IT 502766-18-9P 502766-20-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L14 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(prepn. of novel triazine compds. for inhibiting smooth muscle cell proliferation)
RN 502766-18-9 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 502766-20-3 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-chloro-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:878152 CAPLUS
DN 141:366252
TI Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Krishna, Reddy Velagala Venkata Rama Murali; Sridevi, Bhatlapenumarthy Sesha; Kumar, Potlapally Rajender; Reddy, Gaddam Om
PA USA
SO U.S. Pat. Appl. Publ., 359 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040209880	A1	20041021	US 2003-397968	20030326 <--
	US 7163943	B2	20070116		
	US 20040077648	A1	20040422	US 2003-390485	20030317 <--
	US 7173032	B2	20070206		
	US 20050137196	A1	20050623	US 2004-951316	20040927
	US 7169784	B2	20070130		
	JP 2006188533	A	20060720	JP 2006-79816	20060322
	US 20070004729	A1	20070104	US 2006-471099	20060620
	US 20070043051	A1	20070222	US 2006-543969	20061005
PRAI	US 2001-324147P	P	20010921		
	US 2002-253388	B1	20020923		
	US 2003-390485	A2	20030317		
	JP 2004-538153	A3	20030326		
	US 2003-397968	A3	20030326		

OS MARPAT 141:366252
GI



AB The present invention relates to methods and compns. comprising compds. I [G = NH, O; Z = H, substituted Ph; A = NR1, O; Y1 = R1, cycloheptyl, cyclohexylmethyl; B = NR1, O; Y2 = II (wherein q = 0-1; E = O, NR2; R2 = R1, OR1, C(O)OR1, CONH2, CH2NH2), III (R3 = R1, C(O)R1, C(O)OR1, CONH2); R1 = H, alkyl] that treat pathophysiol. conditions arising from inflammatory responses. Over 100 synthetic examples described synthesis of compds. I and their intermediates. E.g., a multi-step synthesis of the triazine IV, starting from cyanuric chloride, is given. In particular, the present invention is directed to compds. that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compds. that inhibit smooth muscle cell (SMC) proliferation. Many of the compds. I inhibited SMC proliferation by greater than 70%. Also, the most effective compds. I showed an 80% decrease in IL-6 secretion in test for AGE-induced inflammatory response determination. In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
IT 502766-18-9P 502766-20-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)
RN 502766-18-9 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 502766-20-3 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-chloro-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)





RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:648512 CAPLUS
DN 141:190795
TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes
IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, Georg; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice M.; Young, Erick Richard Roush
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma GmbH & Co. KG
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067516	A1	20040812	WO 2004-US2240	20040127 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514612	A1	20040812	CA 2004-2514612	20040127 <--
	EP 1590334	A1	20051102	EP 2004-705675	20040127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006515014	T	20060518	JP 2005-518568	20040127
PRAI	US 2003-443700P	P	20030130		
	WO 2004-US2240	W	20040127		

OS MARPAT 141:190795
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted heteroaryl/aryl/cyclo/cycloalkyl/alkyl, naphthyl, quinolinyl, etc.; R2 = (un)substituted -NH-CH2-(CH2)n-CH2-NR4R5, -NH-(CH2)p-phenylene-(CH2)q-NR4R5, -NH(CH2)p-X-R4, etc.; X = pyridinyl; n = 3-8; p = 1-3; q = 0-3; R4, R5 = independently H, amidino, (un)substituted aryl/alkyl; R3 = halo, CN, NO2, aminocarbonyl, (un)substituted alkyl, alkyloxycarbonyl; their tautomers, pharmaceutically acceptable salts, solvates, or amino-protected derivs., with certain compds. excluded] were prepared as inhibitors of protein kinase C (PKC)-theta useful for treating immunol. disorders and type II diabetes. For example, II was prepared in 5 steps via amination of 2,4-dichloro-5-fluoropyrimidine with amine III and 2-chlorobenzylamine. Selected I inhibited PKC-theta with IC50 values ≤ 0.3 μM. Thus, I are useful for treating a disease or disorder associated with T cells activation.
IT 736052-41-8P, N'-[[4-(Aminomethyl)cyclohexyl]methyl]-N-(4-chloro-1-naphthyl)-5-nitropyrimidine-2,4-diamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)
RN 736052-41-8 CAPLUS
CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-chloro-1-naphthalenyl)-5-nitro- (CA INDEX NAME)

L14 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L14 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:565188 CAPLUS

DN 141:106268

TI Preparation of salicylic acid derivatives as ligands of adenine nucleotide translocase

IN Ghosh, Soumitra S.; Pei, Yazhong; Tang, Xiao-qing

PA Mitokor, Inc., USA

SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058683	A2	20040715	WO 2003-US41213	20031219 <--
	WO 2004058683	A3	20040930		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003300360	A1	20040722	AU 2003-300360	20031219 <--
	US 20040198777	A1	20041007	US 2003-741823	20031219 <--
PRAI	US 2002-435394P	P	20021220		
	WO 2003-US41213	W	20031219		

OS MARPAT 141:106268

GI



I

AB Salicylic acids I [X = CH2Y, NHC(:Z)NH, CH:NH, NHCO; Y = NH, S, (un)substituted N(SO2H); Z = O, S; R1 = H, halogen, NO2, CN, (un)substituted alkyl, OH, aryl, NHCHO, heteroaryl; R2, R3, R5, R6 = H, halogen, NO2, CN, (un)substituted alkyl, OH, aryl, heteroaryl; R4 = H, halogen, NO2, CN, (un)substituted alkyl, OH, aryl, heteroaryl, acyl, CO2H, CONH2, NHCHO] were prepared for use as ligands of adenine nucleotide translocase in the treatment of conditions associated with altered mitochondrial function. Thus, 3-aminosalicylic acid was treated with 4-MeC6H4NCO to give I [X = NHCONH, R1-R3, R5, R6 = H, R4 = Me].

IT 721423-51-4
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of salicylic acid derivs. as ligands of adenine nucleotide

L14 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
translocase)

RN 721423-51-4 CAPLUS

CN Benzoic acid, 3-[[(4-bromo-1-naphthalenyl)amino]methyl]-2-hydroxy- (CA INDEX NAME)



L14 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:546480 CAPLUS

DN 141:89019

TI Substituted biphenyl-4-carboxylic acid arylamide analogues as VR1 receptors modulators

IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Darrow, James W.; De Lombaert, Stephane; Yoon, Taeyoung; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056774	A2	20040708	WO 2003-US40878	20031219 <--
	WO 2004056774	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2510471	A1	20040708	CA 2003-2510471	20031219 <--
	AU 2003299797	A1	20040714	AU 2003-299797	20031219 <--
	EP 1575918	A2	20050921	EP 2003-800070	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060100245	A1	20060511	US 2006-539860	20060103
PRAI	US 2002-435118P	P	20021219		
	WO 2003-US40878	W	20031219		

OS MARPAT 141:89019

GI



I



II

L14 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. [such as I; A, B, D, E, W, X, Y, Z = CR1, N; T, U, V = CR8, N; R1 = halo, CN, NO2, etc.; R2 = NO2, CN, NHOH, etc.; R3, R4 = H, halo, alkyl, etc.; R8 = H, halo, OH, etc.] which are capable of modulating capsaicin receptor activity (biol. data given), are provided. E.g., the nicotinamide II was prepared starting from 3-isopropylphenylboronic acid, Me 6-chloronicotinate and 2,3-dihydrobenzo[1,4]dioxin-6-ylamine. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.

IT 717115-27-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted biphenyl-4-carboxylic acid arylamide analogs as VR1 receptors modulators for treating pain associated with various conditions)

RN 717115-27-0 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-chloro-1-naphthalenyl)-6-(2-methylphenyl)- (CA INDEX NAME)



L14 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kinase inhibitor; prepn. of triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis)

RN 333731-13-8 CAPLUS

CN 1,3,5-Triazine-2,4-diamine, N2-(4-bromo-1-naphthalenyl)-N4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 333735-74-3 CAPLUS

CN 1,3,5-Triazine-2,4-diamine, N2-(4-chloro-1-naphthalenyl)-N4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:493561 CAPLUS

DN 141:54365

TI Preparation of 1,3,5-triazines as kinase inhibitors for treatment of angiogenesis or vasculogenesis

IN Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian

PA Amgen Inc., USA

SO U.S. Pat. Appl. Publ., 300 pp., Cont. of U.S. Ser. No. 85,053, abandoned.
CODEN: USXXCO

DT Patent

LA English

PAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20040116388	A1	20040617	US 2003-699518	20031031 <--
US 7074789	B2	20060711		
PRAI US 1999-158176P	P	19991007		
US 1999-166978P	P	19991123		
US 1999-170378P	P	19991213		
US 2000-183263P	P	20000217		
US 2000-215576P	P	20000630		
US 2000-219801P	P	20000720		
US 2000-685053	B1	20001006		

OS MARPAT 141:54365

GI



AB Title compds. I [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, (un)substituted heterocyclyl, alkyl; R3 = independently aryl, (un)substituted Ph, heteroaryl; R5 = independently H, alkynyl, cycloalkenyl, aryl, R9, (un)substituted (cyclo)alkyl, alkenyl; R6 = independently COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, SO1-2R5; R8 = independently (un)substituted (hetero)monocyclyl, (hetero)bicyclyl, (hetero)tricyclyl] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. Examples include a number of general synthetic methods, specific exptl. details for the preparation of selected invention compds., and phys. and bioassay data. For instance, 2,4-dichloro-1,3,5-triazine was coupled with 3,4,5-trimethoxyaniline in the presence of diisopropylethylamine in DMF to give the triazinamine (37%). Subsequent reaction with 4-aminoveratrole using diisopropylethylamine in EtOH provided II (66%). The latter was one of over 960 invention compds. tested for activity against the EGFR-1, IGFR-1, Akt3-1, Met-1, KDR-1, Zap-1, Lck-1, Itk-1, PDGFRB-1, Tek-1, ErbB2-2, EPHB4-1, ErbB4-1, FGFR1-1, Flt-1, Fyn-1, Hck-1, Lyn-1, Ret-1, and/or Src-1 receptors with IC50 values in ranges from <0.4 μg/mL to >4.5 μg/mL. Thus, I and their compns. are useful for the treatment of diseases or conditions involving angiogenesis or vasculogenesis (no data).

IT 333731-13-8P 333735-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L14 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:485042 CAPLUS

DN 141:242926

TI Linear Free Energy Relationships in SNAr Reactions of Aryl and Diaryl N-Anions with Aryl Halides

AU Vlasov, V. M.; Os'kina, I. A.

CS Vorozhtsov Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, Novosibirsk, Russia

SO Russian Journal of General Chemistry (Translation of Zhurnal Obshchei Khimii) (2004), 74(4), 600-605
CODEN: RJGCEK; ISSN: 1070-3632

PB MAIK Nauka/Interperiodica Publishing

DT Journal

LA English

AB A good correlation has been established between the Bronsted coeffs. βNuc and βox for reactions of aryl-containing N-anions with various aryl halides. This correlation reflects the dependence of the internal barrier of aromatic nucleophilic substitution on the oxidation potentials of nucleophiles.

IT 92943-60-7
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(oxidation potential; linear free energy relationships in aromatic nucleophilic reactions of aryl and diaryl N-anions with aryl halides)

RN 92943-60-7 CAPLUS

CN 1-Naphthalenamine, 4-nitro-, monosodium salt (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:452960 CAPLUS
DN 141:28605
TI Open chain prolyl urea-related modulators of androgen receptor function therapeutic use for nuclear hormone receptor-associated conditions
IN Hamann, Lawrence G.; Augeri, David J.; Manfredi, Mark C.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045518	A2	20040603	WO 2003-US36331	20031113 <--
	WO 2004045518	A3	20041007		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003302084	A1	20040615	AU 2003-302084	20031113 <--
	US 20050059652	A1	20050317	US 2003-712456	20031113
	EP 1567487	A2	20050831	EP 2003-808410	20031113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20080108691	A1	20080508	US 2007-931498	20071031
PRAI	US 2002-426694P	P	20021115		
	US 2003-712456	A3	20031113		
	WO 2003-US36331	W	20031113		

OS MARPAT 141:28605
GI



AB The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula (I), wherein R1, R2 and R3 are groups consisting of hydrogen (H), alkyl, or substituted alkyl etc; G is a mono- or polycyclic ring system; X is a linking group selected from the group consisting of NR4 and CHR4; Y is selected from the group consisting of oxygen (O), NR4, NOR4 and sulfur (S); Z is oxygen (=O) or NR4. Further provided are methods of using such compds. for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compns. containing such compds.
IT 496841-10-2P

L14 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(open chain prolyl urea-related modulators of androgen receptor function therapeutic use for nuclear hormone receptor-assocd. conditions)
RN 496841-10-2 CAPLUS
CN L-Proline, 1-[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:451671 CAPLUS
DN 141:23307
TI Preparation of aryl intermediates such as arylboronic acids
IN Song, Jinhua J.; Tan, Zhulin; Yee, Nathan K.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040106807	A1	20040603	US 2003-715029	20031117 <--
	US 7022883	B2	20060404		
	CA 2506913	A1	20040610	CA 2003-2506913	20031117 <--
	WO 2004048389	A1	20040610	WO 2003-US36685	20031117 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003291006	A1	20040618	AU 2003-291006	20031117 <--
	EP 1565477	A1	20050824	EP 2003-783591	20031117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006507346	T	20060302	JP 2004-555469	20031117
PRAI	US 2002-428618P	P	20021122		
	WO 2003-US36685	W	20031117		

OS CASREACT 141:23307
GI

AB Disclosed are methods of making aryl intermediate compds. I [P = N-protecting group chemical suitable for Grignard reagents; Y = B(OH)2, CHR1OH, C(R1)2OH, etc.; R1 = alkyl, aryl; Ph ring is optionally benzofused to form naphthyl] which are useful in the production of heteroaryl ureas. The compds. I are prepared in a one pot reaction comprising (1) reacting II [X = Br, I; the remaining substituents defined as above] with 2 equiv of RSMgLi (wherein R = alkyl) in a aprotic solvent at a temperature between -40° to 40° C;and (2) adding an electrophile such as B(Oalkyl)3, R1CHO; (R1)2CO, etc. to produce the compound I. Thus, treating BuMgCl with BuLi in THF followed by addition of N-Boc-4-bromo-1-aminonaphtalene, and subsequently adding B(OMe2)3 afforded 65% N-Boc-4-amino-1-naphthaleneboronic acid.
IT 698370-68-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-Boc-4-amino-1-naphthaleneboronic acid from N-Boc-1-amino-4-bromonaphthalene)
RN 698370-68-2 CAPLUS
CN Formic acid, 1,1-dimethylethyl ester compd. with 1,1-dimethylethyl N-(4-bromo-1-naphthalenyl)carbamate (1:1) (CA INDEX NAME)

CM 1

L14 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CRN 168169-11-7
CMF C15 H16 Br N O2



CM 2

CRN 762-75-4
CMF C5 H10 O2

L14 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:346289 CAPLUS
DN 141:81696
TI Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke
AU Linton, Steven D.; Aja, Teresa; Allegrini, Peter R.; Deckwerth, Thomas L.; Diaz, Jose-Luis; Hengerer, Bastian; Herrmann, Julia; Jahangiri, Kathy G.; Kallen, Joerg; Karanewsky, Donald S.; Meduna, Steven P.; Nalley, Kip; Robinson, Edward D.; Roggo, Silvio; Rovelli, Giorgio; Sauter, Andre; Sayers, Robert O.; Schmitz, Albert; Smidt, Robert; Ternansky, Robert J.; Tomaselli, Kevin J.; Ullman, Brett R.; Wiessner, Christoph; Wu, Joe C.
CS Idun Pharmaceuticals, Inc., San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2685-2691
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:81696
AB Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.
IT 254749-63-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(oxamyl dipeptide caspase inhibitors developed for the treatment of stroke)
RN 254749-63-8 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-[[2-[(4-chloro-1-naphthalenyl)amino]-2-oxoacetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:267312 CAPLUS
DN 140:303704
TI Preparation of aminotriazines for treatment of unwanted cell proliferation, inflammation, hyperproliferation, and as glycosidase modulators.
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Reddy, Velagala Venkata Rama Murali Krishna; Sridevi, Bhatlapenumarthy Sesha; Kumar, Potlapally Rajender; Reddy, Gaddam Om
PA Reddy US Therapeutics, Inc., USA
SO PCT Int. Appl., 840 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026844	A1	20040401	WO 2003-US9356	20030326 <--
	WO 2004026844	A9	20041111		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20040077648	A1	20040422	US 2003-390485	20030317 <--
	US 7173032	B2	20070206		
	CA 2499964	A1	20040401	CA 2003-2499964	20030326 <--
	AU 2003231975	A1	20040408	AU 2003-231975	20030326 <--
	BR 2003014670	A	20050809	BR 2003-14670	20030326
	EP 1560817	A1	20050810	EP 2003-797788	20030326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1697831	A	20051116	CN 2003-822602	20030326
	JP 2006511476	T	20060406	JP 2004-538153	20030326
	IN 2005CN00486	A	20070601	IN 2005-CN486	20050324
	JP 2006188533	A	20060720	JP 2006-79816	20060322
	US 20070099874	A1	20070503	US 2007-528724	20070104
	US 7332489	B2	20080219		
PRAI	US 2002-253388	A	20020923		
	US 2003-390485	A	20030317		
	US 2001-324147P	P	20010921		
	JP 2004-538153	A3	20030326		
	WO 2003-US9356	W	20030326		

OS MARPAT 140:303704
GI



L14 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Title compds. e.g. [I; R1 = substituted Ph, PhCH2, PhCH2CH2, pyridyl; R2 = (substituted) amino, piperazinyl, piperidinyl, thiomorpholinyl, piperidinylamino, hydroxymethylpyrrolidinyl; R6 = H, Me; R7 = hexamethyleneimino, cycloheptylimino, bicyclo[2.2.1]heptyloxy, substituted amino], were prepared Thus, N2-(3-chloro-4-methoxyphenyl)-N4-cycloheptyl-N6-methyl-N6-piperidin-4-yl-1,3,5-triazine-2,4,6-triamine in an antiproliferation assay (perlican) showed IC50 = 2.2 μM.
IT 502766-18-9P 502766-20-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminotriazines for treatment of unwanted cell proliferation, inflammation, hyperproliferation, and as glycosidase modulators)
RN 502766-18-9 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-bromo-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 502766-20-3 CAPLUS
CN 1,3,5-Triazine-2,4,6-triamine, N2-(4-chloro-1-naphthalenyl)-N4-cycloheptyl-N6-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182832 CAPLUS
DN 140:235497
TI Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents
IN Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 359 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018414	A2	20040304	WO 2003-US24797	20030822 <--
	WO 2004018414	A3	20040617		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050113450	A1	20050526	US 2003-645732	20030820
	AU 2003282779	A1	20040311	AU 2003-282779	20030822 <--
PRAI	US 2002-405464P	P	20020823		
	WO 2003-US24797	W	20030822		

OS MARPAT 140:235497
GI



AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R1 = CO2H; R2 = electron withdrawing group; R4 = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by conversion of 4-(chlorosulfonyl)benzoic acid to the acid chloride then amidated with Me 2-amino-5-bromobenzoate with subsequent reaction with di-Et amine and hydrolysis to give the benzoic acid moiety. In assays, the min. inhibitory concentration values (μg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antisepsis, and disinfection. Claims for therapeutic use of I as an antibacterial agent are made.
IT 668265-36-9P 668266-05-5P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)

L14 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 668265-36-9 CAPLUS
CN Benzoic acid, 5-bromo-2-[[3-[[(4-chloro-1-naphthalenyl)amino]sulfonyl]-4-methylbenzoyl]amino]- (CA INDEX NAME)



RN 668266-05-5 CAPLUS
CN Benzoic acid, 5-bromo-2-[[3-[[(4-chloro-1-naphthalenyl)amino]sulfonyl]-4-methoxybenzoyl]amino]- (CA INDEX NAME)



L14 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
benzene ring; X1 represents carbon; X2 represents carbon, oxygen, etc.; W represents nitrogen, etc.; Y11 represents a group represented by the formula CR2R3' (wherein R2 represents hydrogen, cyano, nitro, etc. and R3' represents hydrogen, cyano, nitro, etc.); Y21 represents a group represented by the formula CR4R5' (wherein R4 represents hydrogen, cyano, nitro, etc. and R5' represents hydrogen, cyano, nitro, etc.), etc.; R1 represents an electron-attracting group; and the dotted line represents a single bond or double bond] are prepd. The bioactivities of the title compds. were demonstrated. Formulations are given.
IT 168169-05-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic moiety-containing fused benzene derivs. as androgen receptor modulators)
RN 168169-05-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-hydrazinyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:162658 CAPLUS
DN 140:217648
TI Preparation of heterocyclic moiety-containing fused benzene derivatives as androgen receptor modulators
IN Shiraishi, Mitsuru; Hara, Takahito; Kusaka, Masami; Kanzaki, Naoyuki; Yamamoto, Satoshi; Miyawaki, Toshio
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016576	A1	20040226	WO 2003-JP10228	20030811 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495383	A1	20040226	CA 2003-2495383	20030811 <--
	AU 2003254993	A1	20040303	AU 2003-254993	20030811 <--
	JP 2004091486	A	20040325	JP 2003-291584	20030811 <--
	BR 2003013405	A	20050712	BR 2003-13405	20030811
	EP 1553074	A1	20050713	EP 2003-788076	20030811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688527	A	20051026	CN 2003-824131	20030811
	NZ 538713	A	20070126	NZ 2003-538713	20030811
	MX 2005PA01631	A	20050819	MX 2005-PA1631	20050210
	IN 2005KN00384	A	20060224	IN 2005-KN384	20050310
	NO 2005001270	A	20050509	NO 2005-1270	20050311
	US 20060106067	A1	20060518	US 2005-524452	20050829
PRAI	JP 2002-235275	A	20020812		
	WO 2003-JP10228	W	20030811		

OS MARPAT 140:217648
GI



AB The title compds. I [ring A represents an optionally substituted 5- to 8-membered ring; ring B represents a further optionally substituted 4- to 10-membered ring; ring C represents a further optionally substituted

L14 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:120821 CAPLUS
DN 140:163886
TI Preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases
IN Gazit, Aviv; Levitzki, Alexander
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013091	A2	20040212	WO 2003-IL632	20030731 <--
	WO 2004013091	A3	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003247141	A1	20040223	AU 2003-247141	20030731 <--
PRAI	US 2002-399736P	P	20020801		
	WO 2003-IL632	W	20030731		

OS MARPAT 140:163886
GI



AB Title compds. I [R1 = (un)substituted Ph, naphthyl, etc.; R2 = H, halo, phenylamino, etc.; R3 = H, alkoxy, NO2, etc.; n = 1-3] are prepared For instance, 4-chloro-6-methylquinazoline is reacted with 2-aminophenol (EtOH, reflux, 1 h) to give II. I are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity. I are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.
IT 655248-47-8P 655248-48-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases)
RN 655248-47-8 CAPLUS
CN 4-Quinazolinamine, 6-methyl-N-(4-nitro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L14 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 655248-48-9 CAPLUS
CN 4-Quinazolinamine, 6-methyl-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



L14 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:102259 CAPLUS
DN 140:296873
TI Interaction of substituted hexose analogues with the Trypanosoma brucei hexose transporter
AU Azema, Laurent; Claustre, Samantha; Alric, Isabelle; Blonski, Casimir; Willson, Michele; Perie, Jacques; Baltz, Theo; Tetaud, Emmanuel; Bringaud, Frederic; Cottem, Dominique; Opperdoes, Frederik R.; Barrett, Michael P.
CS Groupe de Chimie Organique Biologique, Laboratoire de Synthese et Physico Chimie de Molecules d'Interet Biologique, UMR-5068-CNRS, Bat IIR1, Universite Paul Sabatier, UMR-5068-CNRS, Bat IIR1, Toulouse, 31062, Fr.
SO Biochemical Pharmacology (2004), 67(3), 459-467
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science B.V.
DT Journal
LA English
AB Glucose metabolism is essential for survival of bloodstream form Trypanosoma brucei subspecies which cause human African trypanosomiasis (sleeping sickness). Hexose analogs may represent good compds. to inhibit glucose metabolism in these cells. Delivery of such compds. to the parasite is a major consideration in drug development. A series of D-glucose and D-fructose analogs were developed to explore the limits of the structure-activity relationship of the THT1 hexose transporter of bloodstream form African trypanosomes, a portal that might be exploited for drug uptake. D-Glucose analogs with substituents at the C2 and C6 position continued to interact with the exofacial hexose binding site of the transporter. There was a limit to the size at C6 which still permitted recognition, although compds. carrying large groups at position C2 were still recognized. However, radiolabeled N-acetyl-D-[1-14C] glucosamine was not internalized by trypanosomes, in spite of the ability of this compound to inhibit glucose uptake, indicating that there is a limit to the size of C2 substituent that allows translocation. Addition of an alkylating group (bromoacetyl) at position C2 in the D-glucose series and at position 6 in the D-fructose set, created two analogs which interact with the transporter and kill trypanosomes in vitro. This indicates that inhibition of the transporter may be a good means of killing trypanosomes.
IT 229971-54-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship and interaction of hexose analogs with the Trypanosoma brucei hexose transporter)
RN 229971-54-4 CAPLUS
CN D-Mannitol, 2,5-anhydro-1-deoxy-1-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L14 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l12 not l13
L15         268 L12 NOT L13

=> s l15 and patent/dt
       6386785 PATENT/DT
L16         105 L15 AND PATENT/DT

=> d 1-105 bib abs hitstr
```

L16 ANSWER 1 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:490974 CAPLUS
DN 139:69296
TI Preparation of benzodiazepinones and a benzodiazepinone combinatorial library as potential bradykinin receptor antagonists
IN Leung, Carmen; Santhakumar, Vijayaratnam; Tomaszewski, Miroslaw; Woo, Simon
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051274	A2	20030626	WO 2002-SE2306	20021211 <--
	WO 2003051274	A3	20031030		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2468448	A1	20030626	CA 2002-2468448	20021211 <--
	AU 2002359123	A1	20030630	AU 2002-359123	20021211 <--
	EP 1458691	A2	20040922	EP 2002-793634	20021211 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005516918	T	20050609	JP 2003-552208	20021211
	US 2005076699	A1	20050811	US 2004-497565	20040603
	US 7375101	B2	20080520		
PRAI	SE 2001-4250	A	20011214		
	WO 2002-SE2306	W	20021211		

OS MARPAT 139:69296
GI



I



II

AB Benzodiazepines I [R1 = alkyl, cycloalkyl, heteroalkyl, aryl, heterocyclyl, aralkyl, heteroarylalkyl, acyl, alkoxycarbonyl; R3 = alkyl, cycloalkyl, aryl, heteroaryl; R4 = H, halogen, alkyl, heteroalkyl, O2N, cyano, HO, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyl, alkylthiocarbonyl, amino, aminocarbonyl, aminosulfonyl, alkylsulfonylamino, alkoxycarbonyl; R5 = h, (un)substituted C1-6 alkyl; X = (un)substituted aminomethylamino or aminoethenylamino; R1 and X may form a ring; R1, R5, R4, X may all be substituted with alkyl groups] are prepared both by classic synthetic techniques and as members of a combinatorial library; I are human B2 bradykinin receptor antagonists with Ki values between 43 and 3110 nM. Thus, treatment of 6-chloro-1-methyl-2H-3,1-benzoxazinone with glycine, chlorination with POCl3, Pd-catalyzed coupling of the resultant chloroimine with 2,4-dimethoxy-5-pyrimidineboronic acid, azidation with trisyl azide, Staudinger reaction of the azide with resin-bound triphenylphosphine, acylation of the free amine with thiophosgene, and addition of 4-(diethylamino)-2-methylaniline to the isothiocyanate yields the benzodiazepine II. Methods for the synthesis of combinatorial libraries of I by alkylation of the N1 site of benzodiazepin-2-ones followed by deprotection, acylation of the free amine with either phosgene or thiophosgene, and addition of amines to the isocyanates or isothiocyanates formed in the previous step are claimed. Methods for the synthesis of I by palladium-mediated coupling of boronic acids with 5-halobenzo-1,4-diazepin-2-ones followed by regioselective azidation at the 3-position of the benzodiazepinone and Staudinger reaction of the azide with triphenylphosphine are also claimed. I may be useful as potential analgesics (no data).
IT 548747-01-9P 548747-25-7P 548747-97-3P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(preparation of a combinatorial library of benzodiazepinones as potential human B2 bradykinin receptor antagonists)
RN 548747-01-9 CAPLUS
CN Thiourea, N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 1 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 548747-25-7 CAPLUS
CN Thiourea, N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)



RN 548747-97-3 CAPLUS
CN Thiourea, N-[7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 2 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:332167 CAPLUS
DN 136:355244
TI Preparation processes and herbicidal uses of 2-pyrimidinyloxy-N-aryl-benzylamine derivatives
IN Lu, Long; Chen, Jie; Wu, Jun; Ling, Wen; Mao, Lisheng; Li, Mingzhi; Cai, Xian; Peng, Weili; Wu, Yong; Wu, Shenggan; Wang, Hongjun; Wang, Guochao; Cui, Hu; Han, Shidong; Qiu, Weilian; Wang, Yonghua
PA Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Peop. Rep. China; Zhejiang Chemical Industry Research Institute
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034724	A1	20020502	WO 2001-CN1395	20010913 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1348690	A	20020515	CN 2000-130735	20001016 <--
	CN 1127295	C	20031112		
	CN 1347876	A	20020508	CN 2001-112689	20010420 <--
	CN 1323788	A	20011128	CN 2001-113199	20010629 <--
	AU 2002020458	A	20020506	AU 2002-20458	20010913 <--
	CA 2425984	A1	20030411	CA 2001-2425984	20010913 <--
	EP 1327629	A1	20030716	EP 2001-988710	20010913 <--
	EP 1327629	B1	20071114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001014812	A	20030930	BR 2001-14812	20010913 <--
	JP 2004512326	T	20040422	JP 2002-537715	20010913 <--
	JP 4052942	B2	20080227		
	MX 2003PA01972	A	20040910	MX 2003-PA1972	20030306 <--
	US 20030220198	A1	20031127	US 2003-380865	20030409 <--
	US 6800590	B2	20041005		
PRAI	CN 2000-130735	A	20001016		
	CN 2001-112689	A	20010420		
	CN 2001-113199	A	20010629		
	WO 2001-CN1395	W	20010913		

OS CASREACT 136:355244; MARPAT 136:355244
GI



I

L16 ANSWER 2 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AB Title compds. [I; R1 = H, 6-Cl, 5-F, 5-OCH2, 5-Cl, 3-OCH3, 5-(CH2)8CH3; R3 = H, COCH2OCH3, COCH2Cl, COCH2CH3, COCH3; Q = C6H5, 2-FC6H4, 3-FC6H4, 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2-BrC6H4, 4-BrC6H4, 2-IC6H4, 3-IC6H4, 4-IC6H4, 2-CH3C6H4, 4-CH3C6H4, 2-F3CC6H4, 4-F3CC6H4, 4-CH3OC6H4, 3,4-F2C6H3, 2,5-Cl2C6H3, 3,4-Cl2C6H3, 2,4-Cl2C6H3, 2,4-Cl2-3-FC6H2, 4-CH3CONHC6H4, 4-bromo-1-naphthyl, 2-naphthyl, 2-pyridyl, 6-methyl-2-pyridyl, 5-methyl-2-pyridyl, 4-methyl-2-pyridyl, 5-chloro-2-pyridyl, 3-(4,6-dimethyl-2-pyrimidinyl)oxy-2-pyridyl] are prepared and are useful as chemical herbicide in agriculture. Thus, the title compound I (R1 = H; R3 = H; Q = 4-CH3(CH2)2OC6H4) was prepared from 4-CH3NHC6H4COO(CH2)2CH3, 2-HOC6H4CHO, and 4,6-dimethoxy-2-(methylsulfonyl)-pyrimidine in three steps and was tested for herbicidal activities.
IT 420138-72-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation processes and herbicidal uses of 2-pyrimidinyloxy-N-aryl-benzylamine derivs.)
RN 420138-72-3 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[[2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]phenyl]methyl]- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:182134 CAPLUS
DN 136:231936
TI Attached tags for use in combinatorial chemistry synthesis
IN Hochlowski, Jill Edie; Sowin, Thomas J.; Norbeck, Daniel W.; Grillot, Anne-Laure Marie; Swenson, Rolf E.
PA USA
SO U.S., 36 pp., Cont.-in-part of U.S. Ser. No. 713,710, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6355490	B1	20020312	US 1997-923206	19970904 <--
CA 2237298	A1	19980319	CA 1997-2237298	19970910 <--
WO 9811036	A1	19980319	WO 1997-US15975	19970910 <--
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 879219	A1	19981125	EP 1997-941492	19970910 <--
EP 879219	B1	20000301		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
AT 190049	T	20000315	AT 1997-941492	19970910 <--
ES 2146116	T3	20000716	ES 1997-941492	19970910 <--
JP 2002501474	T	20020115	JP 1998-513801	19970910 <--
US 6274385	B1	20010814	US 1999-370437	19990809 <--
PRAI US 1996-713710	B2	19960913		
US 1997-923206	A	19970904		
WO 1997-US15975	W	19970910		

AB The present invention relates to a process of coding and identifying individual members of a chemical combinatorial library synthesized on a plurality of solid supports which undergo mix and split synthesis. The process provides for tagging the solid supports with a coding identifier (nitrile derivs.) that is attached to the solid support and which can be decoded by IR or raman spectroscopy when directly attached to the support.
IT 204919-73-3
RL: CUS (Combinatorial use); CMBI (Combinatorial study); USES (Uses)
(tag/coding identifier compound; nitrile tags for coding and identifying individual members of a combinatorial library via IR and/or raman spectroscopy)
RN 204919-73-3 CAPLUS
CN Butanoic acid, 4-[(4-cyano-1-naphthalenyl)amino]-4-oxo- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:171600 CAPLUS
DN 136:228356
TI Preparation of disubstituted benzenes as insecticides
IN Theodoridis, George; Qi, Hongyan; Rowley, Elizabeth; Ali, Syed F.; Crawford, Ellen M.; Cullen, Thomas G.; Yeager, Walter H.; Duggan, Christina B.; Barron, Edward; Cohen, Daniel H.
PA FMC Corporation, USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002017712	A2	20020307	WO 2001-US26962	20010829 <--
WO 2002017712	A3	20030612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086909	A	20020313	AU 2001-86909	20010829 <--
US 20021835342	A1	20021205	US 2001-941812	20010829 <--
US 6753429	B2	20040622		
EP 1334083	A2	20030813	EP 2001-966389	20010829 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524266	T	20040812	JP 2002-522697	20010829 <--
CN 1543452	A	20041103	CN 2001-814832	20010829 <--
BR 2001013445	A	20050412	BR 2001-13445	20010829
HU 2005000470	A2	20050829	HU 2005-470	20010829
HU 2005000470	A3	20051128		
AU 2001286909	B2	20060209	AU 2001-286909	20010829
US 20030207894	A1	20031106	US 2003-353471	20030129 <--
US 7247756	B2	20070724		
ZA 2003001173	A	20040816	ZA 2003-1173	20030212 <--
IN 2003MN00233	A	20050304	IN 2003-MN233	20030217
MX 2003PA01537	A	20030606	MX 2003-PA1537	20030220 <--
IN 2007MN00073	A	20070810	IN 2007-MN73	20070117
PRAI US 2000-229701P	P	20000901		
US 2001-277203P	P	20010320		
US 2001-941812	A3	20010829		
WO 2001-US26962	W	20010829		
IN 2003-MN233	A3	20030217		

OS MARPAT 136:228356
GI

AB The disubstituted benzenes I [A = H, aryl, alkylheterocyclyl, etc.; B, D = H, halo, alkyl, haloalkyl alkoxy, etc.; R = (un)substituted amine or heterocyclyl, etc.] are prepared as insecticides.

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 402741-40-6P 402741-42-8P 402741-80-4P
402741-81-5P 402741-82-6P 402741-83-7P
402741-85-9P 402741-89-3P 402742-06-7P
402742-10-3P 402742-11-4P 402742-12-5P
402742-13-6P 402742-19-2P 402742-25-0P
402742-26-1P 402742-27-2P 402742-28-3P
402742-29-4P 402742-30-7P 402742-31-8P
402742-32-9P 402742-33-0P 402742-35-2P
402742-36-3P 402742-37-4P 402742-38-5P
402742-39-6P 402742-40-9P 402742-41-0P
402742-42-1P 402742-43-2P 402742-44-3P
402742-45-4P 402744-05-2P 402744-06-3P
402744-07-4P 402744-08-5P 402744-09-6P
402744-10-9P 402744-11-0P 402744-12-1P
402744-13-2P 402744-14-3P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as insecticide)
RN 402741-40-6 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[3-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402741-42-8 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[2-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402741-80-4 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-(diethylamino)phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402741-81-5 CAPLUS
CN Acetamide, N-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenyl]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)



RN 402741-82-6 CAPLUS
CN Carbamic acid, [4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenyl][2-(diethylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402741-89-3 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-[4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 402742-06-7 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-(2-ethoxyethoxy)phenyl]methyl]- (CA INDEX NAME)



L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402741-83-7 CAPLUS
CN 1,2-Ethanediamine, N2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenyl]-N1,N1-diethyl- (CA INDEX NAME)



RN 402741-85-9 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-(4-methoxyphenyl)- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 402742-10-3 CAPLUS
CN Acetic acid, 2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 402742-11-4 CAPLUS
CN Acetamide, 2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenoxy]-N,N-diethyl- (CA INDEX NAME)



RN 402742-12-5 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[(4-ethoxyphenyl)methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402742-13-6 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-(2-fluoroethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 402742-19-2 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[[2-(diethylamino)ethyl]thio]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402742-27-2 CAPLUS
CN 1-Naphthalenamine, N-[[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]methyl]-4-bromo- (CA INDEX NAME)



RN 402742-28-3 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402742-25-0 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-26-1 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[[4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 402742-29-4 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 402742-30-7 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(ethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-31-8 CAPLUS

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 402742-35-2 CAPLUS
CN 1-Naphthalenamine, N-[[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]methyl]-4-chloro- (CA INDEX NAME)



RN 402742-36-3 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(dibutylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-32-9 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-33-0 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 402742-37-4 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 402742-38-5 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 402742-39-6 CAPLUS
CN Carbamic acid, [2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenoxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

RN 402742-42-1 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-43-2 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[3-(dibutylamino)propoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402742-44-3 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[3-(4-morpholinyl)propoxy]phenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 402742-40-9 CAPLUS
CN Carbamic acid, [2-[4-[[(4-chloro-1-naphthalenyl)amino]methyl]phenoxy]ethyl]ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 402742-41-0 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A



L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 402742-45-4 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[4-(dibutylamino)butoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402744-05-2 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]-2-fluorophenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402744-06-3 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]-2-methoxyphenyl]methyl]- (CA INDEX NAME)



RN 402744-07-4 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]methyl]- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402744-08-5 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[4-[2-(diethylamino)ethoxy]-3,5-dimethoxyphenyl]methyl]- (CA INDEX NAME)



RN 402744-09-6 CAPLUS
CN 1-Naphthalenamine, N-[[3,4-bis[2-(diethylamino)ethoxy]phenyl]methyl]-4-chloro- (CA INDEX NAME)

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 402744-10-9 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[2-chloro-4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402744-11-0 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[3-chloro-4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402744-12-1 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[2,3-dichloro-4-[2-

L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402744-13-2 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[2,6-dichloro-4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 402744-14-3 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[[3,5-dichloro-4-[2-(diethylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)



L16 ANSWER 4 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 5 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:47554 CAPLUS
DN 136:104222
TI Manufacture of N-acylnitroaniline derivatives
IN Yoshida, Tomoyasu
PA Sumitomo Chemical Company, Limited, Japan
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1172356	A1	20020116	EP 2001-117046	20010712 <--
	EP 1172356	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002088048	A	20020327	JP 2001-205902	20010706 <--
	CA 2352937	A1	20020113	CA 2001-2352937	20010712 <--
	US 20020016506	A1	20020207	US 2001-903489	20010712 <--
	US 6630598	B2	20031007		
PRAI	JP 2000-212693	A	20000713		

OS MARPAT 136:104222
AB N-Acylnitroanilines O2N(Xn)C6H4-nNHCOR1 [I; R1 = alk(en)yl, haloalkyl, alkoxy, phenylalkyl, phenylalkoxy; X = H, halo, alk(en)yl, (halo)alkyl, alkoxy, Ph, PhCH2, CHO, N,N-dialkylamino, etc.; n = 0-4] were manufactured by N-acylation of nitroanilines O2N(Xn)C6H4-nNH2 (X, n as above) with acid anhydrides O(COR1)2 (R1 as above) or acid chlorides R1COZ (R1 as above, Z = halo) in the presence of an alkali metal compound or an alkaline earth metal compound N-substituted derivs. of I O2N(Xn)C6H4-nNR2COR1 [R2 = alk(en)yl, alkynyl; R1, X, n as above] were manufactured by N-alkylation of N-acylnitroanilines I with compds. R2Y (Y = leaving group, R2 as above). For example, adding 22.10 g THF solution containing 2.00 g 2-nitroaniline to ice-cooled suspension of 1.50 g of 60% NaH in 20.24 g THF, stirring for 10 min, allowing to stand at ambient temperature and stirring for 30 min, adding 6.92 g THF solution containing 3.41 g O(CO2CMe3) at ambient temperature and stirring for 2 h gave 96% 2-O2NC6H4NHCO2CMe3.
IT 388571-32-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of N-acylnitroaniline derivs.)
RN 388571-32-2 CAPLUS
CN Carbamic acid, (4-nitro-1-naphthalenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:819160 CAPLUS
DN 133:350252
TI Preparation of 6-haloalkyl-3-(substituted amino)-1,2,4-triazin-5-ones, their intermediates, and their use as microbicides, insecticides, and herbicides
IN Kishida, Masashi; Ohta, Chikako; Natsume, Fumitsugu; Fukuchi, Toshiki; Kawaguchi, Shinji; Kikutake, Kazuhiko
PA Mitsubishi Chemical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000319268	A	20001121	JP 1999-129857	19990511 <--
PRAI	JP 1999-129857		19990511		

OS MARPAT 133:350252
GI



AB Title compds. I (R1 = C1-4 haloalkyl; R2 = H, C1-10 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, etc.; R3 = H, C1-6 alkyl, C2-6 alkenyl, C1-6 haloalkyl, C2-6 haloalkenyl, etc.; Q = (un)substituted Ph, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc.) are prepared 2-Nitro-4-trifluoromethylaniline (1.00 g) was reacted with 1.05 g 4-methyl-3-methylthio-6-trifluoromethyl-1,2,4-triazine-5(4H)-one in DMF in the presence of NaH at room temperature for 30 min to give 1.70 g I (R1 = CF3, R2 = Me, R3 = H, Q = 2-nitro-4-trifluoromethylphenyl) showing good insecticidal activity.
IT 305795-35-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of haloalkyl(substituted amino)triazinones for microbicides, insecticides, and herbicides)
RN 305795-35-1 CAPLUS
CN 1,2,4-Triazin-5(4H)-one, 4-methyl-3-[(4-nitro-1-naphthalenyl)amino]-6-(trifluoromethyl)- (CA INDEX NAME)

L16 ANSWER 6 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 7 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:278055 CAPLUS
DN 132:309702
TI Amide group-containing azo compounds with good resistance to heat, light, moisture and solvent and dicarboxynaphthol compounds for their manufacture
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Wakamori, Hiroyuki
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023525	A1	20000427	WO 1999-JP5656	19991014 <--
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2314117	A1	20000427	CA 1999-2314117	19991014 <--
	EP 1048694	A1	20001102	EP 1999-947885	19991014 <--
	EP 1048694	B1	20060607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	CN 1125144	C	20031022	CN 1999-802977	19991014 <--
	CN 1515547	A	20040728	CN 2002-2002143238	19991014 <--
	JP 3672823	B2	20050720	JP 2000-577242	19991014
	AT 328965	T	20060615	AT 1999-947885	19991014
	TW 562840	B	20031121	TW 1999-88117836	19991015 <--
	US 6409812	B1	20020625	US 2000-581704	20000616 <--
PRAI	JP 1998-296215	A	19981016		
	JP 1999-105206	A	19990413		
	JP 1999-176626	A	19990623		
	WO 1999-JP5656	W	19991014		

OS MARPAT 132:309702
AB The azo compds. are prepared by coupling of diazotized amino compds. with couplers which are amidated 2-hydroxynaphthalene-3,6-dicarboxylic acid provided that at least one of the amides in the amidated compound is aliphatic Various uses of the compds. are also provided, e.g., dyes, pigments, inks and coatings. Thus, adding DMF 0.2 and thionyl chloride (I) 16.0 to a slurry of 2-hydroxy-3-hydroxycarbonyl-6-methoxycarbonylnaphthalene (II) 36.9 in THF 300, reacting at 50° for 2 h, removing the remaining I with solvent, adding a solution of α-naphthylamine 23.2 in THF 100, and 1,8-diazabicyclo[5·4·0]undec-7-ene (III) 25.2, and heating at reflux for 15 h gave 2-hydroxy-6-methoxycarbonyl-3-(naphth-1'-yl)aminocarbonylnaphthalene which was converted to a 6-carbonyl chloride using I, then amidated with propylamine in the presence of III to give a diamide of II. Coupling of diazotized 2-methoxy-5-phenylaminocarbonylaniline with the diamide gave a redish purple dye.
IT 265332-45-4P
RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(dyes; manufacture of amide group-containing azo compds. for colorants with good resistance to heat, light, moisture and solvent)
RN 265332-45-4 CAPLUS
CN 2,7-Naphthalenedicarboxamide, N7-dodecyl-3-hydroxy-4-[2-[2-methoxy-5-[(phenylamino)carbonyl]phenyl]diazenyl]-N2-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 7 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 265331-81-5P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; reaction in manufacture of azo compds. for colorants with good resistance to heat, light, moisture and solvent)
RN 265331-81-5 CAPLUS
CN 2,7-Naphthalenedicarboxamide, N7-dodecyl-3-hydroxy-N2-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:180819 CAPLUS
DN 128:243589
OREF 128:48229a,48232a
TI Attached IR- and Raman-detectable tags for use in combinatorial chemistry synthesis
IN Hochlowski, Jill Edie; Sowin, Thomas J.; Norbeck, Daniel W.; Grillot, Anne-Laure Marie; Swenson, Rolf E.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811036	A1	19980319	WO 1997-US15975	19970910 <--
	W: CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6355490	B1	20020312	US 1997-923206	19970904 <--
	EP 879219	A1	19981125	EP 1997-941492	19970910 <--
	EP 879219	B1	20000301		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
	AT 190049	T	20000315	AT 1997-941492	19970910 <--
	JP 2002501474	T	20020115	JP 1998-513801	19970910 <--
PRAI	US 1996-713710	A	19960913		
	US 1997-923206	A	19970904		
	WO 1997-US15975	W	19970910		

AB The invention relates to a process of coding and identifying individual members of a chemical combinatorial library, which are synthesized on a plurality of solid supports which undergo mix-and-split synthesis. The process provides for tagging the solid supports with a coding identifier that is attached to the solid support, and which can be decoded by IR or Raman spectroscopy while directly attached to the support. The tags employed in the examples are nitriles and/or acetylenes. For instance, polystyrene beads were partially iodinated and partially chloromethylated in the para position, and the chloromethyl groups were etherified with 4-hydroxybenzyl alc. (linker) to give [(4-hydroxymethyl)phenoxy]methyl groups. This iodinated Wang resin was then tagged by coupling at the iodide with 5-cyano-1-pentyne (IR peak at 2247 cm-1) and varying amts. of either (2-methoxy-5-cyanophenyl)acetylene (IR peak at 2226 cm-1) or 6-methoxy-6-(p-cyanophenyl)-6-methyl-1-hexyne (IR peak at 2229 cm-1). Four such tagged resins were then used to support 4 different acids, and the resin beads were mixed and the acids then cleaved with CF3CO2H. The FTIR spectra of two random beads clearly identified them as belonging to two of the four library members. A variety of schemes and IR and Raman spectra are attached as figures.
IT 204919-73-3, 4-[(4-Cyano-1-naphthyl)amino]-4-oxobutanoic acid
RL: ANT (Analyte); NUU (Other use, unclassified); PRP (Properties); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent); USES (Uses)
(tag; attached IR- and Raman-detectable tags as coding identifiers for combinatorial chemical)
RN 204919-73-3 CAPLUS
CN Butanoic acid, 4-[(4-cyano-1-naphthalenyl)amino]-4-oxo- (CA INDEX NAME)

L16 ANSWER 8 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:618545 CAPLUS
DN 127:313111
OREF 127:61137a,61140a
TI Recording medium with reversible hydrophilicity-hydrophobicity, recording method, and apparatus for it
IN Minami, Masato; Taguchi, Nobuyoshi
PA Matsushita Electric Industrial Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09240148	A	19970916	JP 1996-54616	19960312 <--
PRAI JP 1996-54616		19960312		

OS MARPAT 127:313111
AB The method involves the following steps; heating a polymer recording medium containing heat-light-sensitive groups to change hydrophobicity on the medium based on reverse photochromism of the groups into hydrophilicity, developing the medium with a liquid ink, transferring the ink to a receptor, and irradiating the medium with light to change the hydrophilicity based on reverse isomerization into hydrophobicity. The apparatus for it is also claimed. The medium is obtained by dispersing or introducing heat-light-sensitive groups with reverse photochromism into a polymer. A medium using a spirobenzopyran derivative dispersed in polystyrene showed controlled reversibility between hydrophilicity and hydrophobicity.
IT 197511-46-9P, 4-Bromonaphthylhydrazine hydrochloride
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(photothermog. recording medium using photochromic compound with reversible hydrophilicity-hydrophobicity)
RN 197511-46-9 CAPLUS
CN Hydrazine, (4-bromo-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

L16 ANSWER 10 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:546596 CAPLUS
DN 125:211381
OREF 125:39237a,39240a
TI Test swab and method of using same
IN Stone, Marcia J.
PA Hybrivet Systems, Inc., USA
SO U.S., 16 pp., Cont.-in-part of U.S. 5,364,792.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5550061	A	19960827	US 1994-325149	19941020 <--
US 5330917	A	19940719	US 1991-750312	19910827 <--
US 5364792	A	19941115	US 1993-156623	19931124 <--
PRAI US 1989-305221	B2	19890202		
US 1990-499488	A1	19900507		
US 1991-709981	B2	19910604		
US 1991-750312	A2	19910827		
US 1993-156623	A2	19931124		

AB A swab is impregnated with a test reagent such that a test for a specific substance can be effected by rubbing the impregnated swab over the surface to be tested and then viewing the swab for a reagent reaction. The swab may have a hollow stem, and within the hollow stem is a cartridge within another cartridge. An activator solution is in one of the cartridges and a reagent is in another of the cartridges. A method for testing for a substance includes impregnating a swab, and rubbing the swab over a surface suspected of containing the substance. If the substance is present in the surface, a reaction with the substance produces an easily detectable color on the swab tip.
IT 52005-37-5, 4-Nitronaphthalenediazoaminoazobenzene
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(metal determination in surfaces by colorimetry using fibrous swabs containing dyes)
RN 52005-37-5 CAPLUS
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]- (9CI) (CA INDEX NAME)

D1—N═N—Ph



L16 ANSWER 11 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:584202 CAPLUS
DN 123:127690
OREF 123:22447a,22450a
TI Thermal recording sheets for durable high-density image
IN Minami, Toshiaki; Nagai, Tomoaki; Hamada, Kaoru; Sekine, Akio
PA Nippon Seishi KK, Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07061130	A	19950307	JP 1993-213856	19930830 <--
JP 3424214	B2	20030707		
PRAI JP 1993-213856		19930830		

GI



I

AB The title recording sheets comprise a support coated with a heat-sensitive layer containing a basic dye, a color developer, and, as a stabilizer, a thiourea dimer derivative I [R1-8 = H, lower alkyl, cycloalkyl, lower alkoxy, halo, nitro, cyano; A = (substituted) C1-18 alkyl, aryl, aralkyl, acyl, phenoxycarbonyl; X = S, SO2]. A thermal recording paper containing 3-(N-ethyl-N-isoamylamino)-6-methyl-7-anilinofluoran, 4-hydroxy-4'-isopropoxydiphenylsulfone, and I (R1-8 = H, A = Ph, X = S) showed high thermal sensitivity and gave high d. images with good resistance to heat, water, and oils.
IT 166096-92-0
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(thermal recording materials containing thiourea dimers as stabilizers with good heat-, water-, and oil-resistance)
RN 166096-92-0 CAPLUS
CN Thiourea, N,N''-[thiobis(2-cyclohexyl-4,1-phenylene)]bis[N'-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L16 ANSWER 12 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:397134 CAPLUS
DN 122:174476
OREF 122:31785a,31788a
TI Thermosensitive recording material.
IN Takahashi, Yoshiyuki
PA New Oji Paper Co., Ltd., Japan
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 615859	A1	19940921	EP 1994-103305	19940304 <--
EP 615859	B1	19980603		
R: DE, GB				
JP 06262856	A	19940920	JP 1993-55886	19930316 <--
JP 3196404	B2	20010806		
US 5449657	A	19950912	US 1994-206154	19940307 <--
PRAI JP 1993-55886	A	19930316		

OS MARPAT 122:174476
AB A thermosensitive recording is provided with a thermosensitive colored image-forming layer formed on a substrate sheet and comprising a substantially colorless dye precursor and a color developing agent comprising ≥1 aromatic compound selected from R1-SO2NHC(:X)NH-R2 and R3-SO2NHC(:Y)NH-R4 [X and Y = O or S; R1 = alkyl, cycloalkyl, alkenyl or alkynyl group or a hetero atom-containing alkyl, cycloalkyl or alkenyl group having ≥1 hetero atom included in a backbone group thereof; R2 = aryl or aralkyl group or a substituted aralkyl group having ≥1 hetero atom substituent; R3 = unsubstituted aralkyl group or substituted aralkyl group having ≥1 hetero atom substituted in an aliphatic hydrocarbon group thereof; and R4 = alkyl, unsubstituted aralkyl group, aryl group, substituted alkyl group, or substituted aralkyl group having ≥1 hetero atom substituted in an aliphatic hydrocarbon group thereof, an aromatic hydrocarbon ring group included in each of the groups represented by R1 to R4 optionally having ≥1 substituent]. The material has an enhanced color-developing property and a high persistency of the resultant colored images.
IT 161359-06-4 161359-08-6
RL: TEM (Technical or engineered material use); USES (Uses)
(leuco dye developer)
RN 161359-06-4 CAPLUS
CN Methanesulfonamide, N-[[(4-chloro-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)



RN 161359-08-6 CAPLUS
CN 2-Propanesulfonamide, N-[[(4-chloro-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)

L16 ANSWER 12 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 13 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:569250 CAPLUS
DN 121:169250
OREF 121:30437a,30440a
TI Test swab device and method of detecting lead, mercury, arsenic, and bismuth
IN Stone, Marcia J.
PA HybriVet Systems, Inc., USA
SO U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 709,981, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5330917	A	19940719	US 1991-750312	19910827 <--
	US 5278075	A	19940111	US 1993-15827	19930210 <--
	US 5364792	A	19941115	US 1993-156623	19931124 <--
	US 5550061	A	19960827	US 1994-325149	19941020 <--
PRAI	US 1989-305221	B2	19890202		
	US 1990-499488	A1	19900507		
	US 1991-709981	B2	19910604		
	US 1991-750312	A3	19910827		
	US 1993-156623	A2	19931124		

AB A swab is impregnated with a test reagent such that a test for a sp. substance can be effected by rubbing the impregnated swab over the surface to be tested and then viewing the swab for a reagent reaction. A method for testing for a substance includes impregnating a swab with a reagent, and rubbing the swab over a surface suspected of containing the substance. If the substance is present in the surface, a reaction with the substance produces an easily detectable color on the swab tip.
IT 52006-37-5
RL: ANST (Analytical study)
(reagent containing, in test swabs for metal detection)
RN 52006-37-5 CAPLUS
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 14 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:508817 CAPLUS
DN 121:108817
OREF 121:19655a,19658a
TI Preparation of 2-(arylamino)pyrimidinone derivatives as herbicides and plant growth regulators
IN Kawamura, Yasuo; Satow, Jun; Oya, Biichi; Itoh, Kaoru; Kita, Hiroshi; Nakata, Hisashi; Fukuda, Kenzou; Nawamaki, Tsutomu; Fuji, Seiichi; et al.
PA Nissan Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9321162	A1	19931028	WO 1993-JP482	19930415 <--
	W: AU, BG, BR, CA, CZ, FI, HU, KR, NO, NZ, PL, RO, RU, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 06321913	A	19941122	JP 1993-87462	19930414 <--
	AU 9339051	A	19931118	AU 1993-39051	19930415 <--
	AU 666721	B2	19960222		
	CN 1079736	A	19931222	CN 1993-105949	19930415 <--
	CN 1041724	C	19990120		
	EP 636615	A1	19950201	EP 1993-908093	19930415 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5518994	A	19960521	US 1994-318680	19941206 <--
PRAI	JP 1992-95441	A	19920415		
	JP 1992-222657	A	19920821		
	JP 1992-324141	A	19921203		
	JP 1993-60336	A	19930319		
	WO 1993-JP482	A	19930415		

OS CASREACT 121:108817; MARPAT 121:108817
GI



AB Title compds. [I; R1 = haloalkyl, alkyl, cycloalkyl, alkenyl, haloalkenyloxy, etc.; R2 = H, halo, alkyl, haloalkyl, nitro; R3 = alkyl, alkenyl, alkynyl, cycloalkyl, amino; R4 = H, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, etc.; X = O, S; Q = (un)substituted Ph, (un)substituted naphthyl] are prepared E.g., a mixture of 3-methyl-2-(methylthio)-6-(trifluoromethyl)-4-(3H)-pyrimidinone and 4-chloro-2-fluoroformanilide in DMF containing NaH was heated at 100° for 5 h and and allowed to react at room temperature overnight to give I [R1 = CF3, R2 = R4 = H, R3 = Me, X = O, Q = 2-fluoro-4-chlorophenyl]. This at 2.5 kg/ha effected 100% kill against crabgrass.
IT 156111-26-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide and plant growth regulator)
RN 156111-26-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(4-chloro-1-naphthalenyl)amino]-3-methyl-6-

L16 ANSWER 14 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(trifluoromethyl)- (CA INDEX NAME)



L16 ANSWER 15 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:271418 CAPLUS
DN 120:271418
OREF 120:48107a,48110a
TI Photosensitive monomer and polymer bearing nitronaphthylaminocarbonyl group and their preparation
IN Sastre Munoz, Roberto; Catalina Lapuente, Fernando; Bosch Sarobe, Paula; Mateo Lopez, Jose Luis; Diaz Alzamora, Fernando; Tagle Dominguez, L. H.
PA Consejo Superior de Investigaciones Cientificas, Spain
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9311096	A1	19930610	WO 1992-ES78	19921201 <--
W: US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ES 2037611	A1	19930616	ES 1991-2725	19911204 <--
ES 2037611	B1	19940401		
PRAI ES 1991-2725	A	19911204		

AB The title monomer and polymer are useful for polymerization initiator for coating materials and inks. Thus, 4-nitro-1-naphthylacrylamide prepared from 4-nitro-1-naphthylamine and acryloyl chloride was polymerized with Me methacrylate in vacuo to give a copolymer useful as an initiator for polymerization of Bu acrylate.
IT 131482-30-9P, 4-Nitro-1-naphthylacrylamide 131482-32-1P, p-Vinyl-(4-nitro-1-naphthyl)benzamide
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and polymerization of, for photopolymn. initiators)
RN 131482-30-9 CAPLUS
CN 2-Propenamide, N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 131482-32-1 CAPLUS
CN Benzamide, 4-ethenyl-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 15 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 154806-42-5P
RL: PREP (Preparation)
(preparation of, for photopolymn. initiators)
RN 154806-42-5 CAPLUS
CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with N-(4-nitro-1-naphthalenyl)-2-propenamide (9CI) (CA INDEX NAME)

CM 1

CRN 131482-30-9
CMF C13 H10 N2 O3



CM 2

CRN 80-62-6
CMF C5 H8 O2

L16 ANSWER 16 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:560149 CAPLUS
DN 119:160149
OREF 119:28697a
TI Nootropic agents containing a 1-azabicyclo[3.3.0]octan-5-yl moiety
IN Kurono, Masayasu; Baba, Yutaka; Suzuki, Tomoo; Suzuki, Tsunemasa; Hirooka, Kiyotaka; Sawai, Kiichi
PA Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 543307	A2	19930526	EP 1992-119554	19921116 <--
EP 543307	A3	19930630		
EP 543307	B1	19980506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06184152	A	19940705	JP 1992-253546	19920831 <--
US 5434165	A	19950718	US 1992-976499	19921113 <--
AT 165829	T	19980515	AT 1992-119554	19921116 <--
PRAI JP 1991-302070	A	19911118		

OS CASREACT 119:160149; MARPAT 119:160149
GI



I

AB The title compds. I [A = CH, N, NO; R1 = NO2, NH2; R2 = H, lower alkyl, acyl group; R3 = (CO)m(CH2)nC(R4)R5N(R6)R7; R4, R5 = H, lower alkyl; R6, R7 = H, (un)branched lower alkyl; R4R6, R5R7, R6,R7 = alkylene chain forming a heterocyclic ring; m = 0, 1; n = 0-3], useful in the treatment of Alzheimer's disease (no data), dementia (no data), memory retention defect, aphasia (no data), apraxia (no data), psychosis (no data), or cerebral disorders caused by cerebral infarct and cerebrosclerosis (no data), are prepared, and pharmaceutical formulations containing I are presented. Thus, 1-[N-(1-azabicyclo[3.3.0]octan-5-yl)methyl-N-methylamino]-4-nitronaphthalene (II) was prepared by the condensation of 1-chloro-4-nitronaphthalene with 5-(methylamino)methyl-1-azabicyclo[3.3.0]octane. II demonstrated 50% inhibitory concentration for inhibition of tritiated pirenzepine bonding with rat brain homogenate of 0.04 μM.
IT 149947-97-7P 149948-00-5P 149948-02-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and nootropic activity of)
RN 149947-97-7 CAPLUS
CN 1H-Pyrrolizine-7a(5H)-methanamine, tetrahydro-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 16 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 149948-00-5 CAPLUS
CN 1,2-Ethanediamine, N1,N1-bis(1-methylethyl)-N2-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 149948-02-7 CAPLUS
CN 1H-Pyrrolizine-7a(5H)-ethanamine, tetrahydro-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 17 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:208996 CAPLUS
DN 118:208996
OREF 118:35880h,35881a
TI 1,8-naphthosultam derivatives and aromatic amines for enzyme immunostaining
IN Yamazaki, Masahiko
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05002020	A	19930108	JP 1991-152029	19910624 <--
PRAI	JP 1991-152029		19910624		

OS MARPAT 118:208996
AB Naphthosultam derivs. and aromatic amines are used in enzyme immunostaining to provide safety (low carcinogenic risk), brightness, and high sensitivity for accurate diagnosis. The color image generated with the title compds. is treated with metal ions to become organic solvent-resistant. For diagnosis of cancer of the large intestine, two chromogenic solns. containing a naphthosultam analog and N-ethyl-N-β-methanesulfonamidoethyl-3-methyl-4-aminoaniline (3/2 hydrogensulfate) were tested using rabbit anti-CEA antibody and peroxidase-labeled goat anti-rabbit IgG antibody. The stain was treated with ferric chloride and hexaamminecobalt chloride solns. to generate a long-lasting image.
IT 147241-46-1
RL: ANST (Analytical study)
(aromatic amines and metal ion and, for enzyme immunostaining)
RN 147241-46-1 CAPLUS
CN Benzenesulfonamide, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 18 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:80645 CAPLUS
DN 118:80645
OREF 118:14177a,14180a
TI Preparation of substituted guanidines and derivatives as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
IN Goldin, Stanley M.; Katragadda, Subbarao; Hu, Lain Yen; Reddy, N. Laxma; Fischer, James B.; Knapp, Andrew Gannett; Margolin, Lee David
PA Cambridge Neuroscience, Inc., USA
SO PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9214697	A1	19920903	WO 1992-US1050	19920210 <--
	W: AU, BB, BG, BR, CA, CH, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	CA 2099245	A1	19920809	CA 1992-2099245	19920210 <--
	AU 9214496	A	19920915	AU 1992-14496	19920210 <--
	AU 670232	B2	19960711		
	ZA 9200944	A	19930810	ZA 1992-944	19920210 <--
	EP 584088	A1	19940302	EP 1992-907382	19920210 <--
	EP 584088	B1	19991027		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 06506455	T	19940721	JP 1992-507274	19920210 <--
	EP 940139	A2	19990908	EP 1999-107574	19920210 <--
	EP 940139	A3	20000119		
	EP 940139	B1	20050202		
	R: AT, CH, DE, FR, GB, IT, LI				
	AT 186047	T	19991115	AT 1992-907382	19920210 <--
	AT 288262	T	20050215	AT 1999-107574	19920210
	AU 9668130	A	19970109	AU 1996-68130	19961011 <--
	AU 709863	B2	19990909		
PRAI	US 1991-652104	A	19910208		
	EP 1992-907382	A3	19920210		
	WO 1992-US1050	A	19920210		

OS MARPAT 118:80645
GI



II

AB (RNH)(R1NH)C:NN:C(R4NH)(R5NH) (I; (substituted) R, R1, R4, R5 = C3-12 cycloalkyl, aryl, alkaryl, aralkyl, heterocyclyl, tolyl, alkylphenyl, naphthyl, indanyl, etc.) and tautomers are prepared To 5-aminoacenaphthene in EtOH was added BrCN in EtOH and the solution refluxed for 6 h and kept 48 h to give the title guanidine II. II at 10 μM showed 43% uptake of Ca into synaptosomes.

L16 ANSWER 18 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 144682-53-1 144682-54-2 144682-59-7
144682-60-0 144682-61-1 144682-64-4
144682-65-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(neurotransmitter modulator)
RN 144682-53-1 CAPLUS
CN Guanidine, N-3-acenaphthylenyl-N'-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 144682-54-2 CAPLUS
CN Guanidine, N-(1,2-dihydro-5-acenaphthylenyl)-N'-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 144682-59-7 CAPLUS
CN Guanidine, N-(4-bromo-1-naphthalenyl)-N'-(1,2-dihydro-3-acenaphthylenyl)- (CA INDEX NAME)



RN 144682-60-0 CAPLUS
CN Guanidine, N-(4-cyano-1-naphthalenyl)-N'-(1,2-dihydro-3-acenaphthylenyl)-

L16 ANSWER 18 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RN 144682-61-1 CAPLUS
CN Guanidine, N-(4-cyano-1-naphthalenyl)-N'-(1,2-dihydro-5-acenaphthylenyl)- (CA INDEX NAME)



RN 144682-64-4 CAPLUS
CN Guanidine, N-(1,2-dihydro-3-acenaphthylenyl)-N'-(4-iodo-1-naphthalenyl)- (CA INDEX NAME)



RN 144682-65-5 CAPLUS
CN Guanidine, N-(1,2-dihydro-5-acenaphthylenyl)-N'-(4-iodo-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 18 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 438-26-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with fluoronaphthylamine)
RN 438-26-6 CAPLUS
CN 1-Naphthalenamine, 4-fluoro-, hydrochloride (9CI) (CA INDEX NAME)

● HCl

IT 145040-65-9P 145040-66-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as neurotransmitter modulator)
RN 145040-65-9 CAPLUS
CN Guanidine, N-(1,2-dihydro-3-acenaphthylenyl)-N'-(4-fluoro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)

L16 ANSWER 18 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 145040-66-0 CAPLUS
CN Guanidine, N-(1,2-dihydro-5-acenaphthylenyl)-N'-(4-fluoro-1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



L16 ANSWER 19 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:458774 CAPLUS
DN 117:58774
OREF 117:10221a,10224a
TI Silver halide color photographic material
IN Toyoda, Masayoshi
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03242644	A	19911029	JP 1990-39298	19900220 <--
PRAI	JP 1990-39298		19900220		

GI



I

AB In a Ag halide photog. material with a support having ≥1 Ag halide emulsion layer(s), the emulsion layer(s) contains ≥2 couplers I (R1 = aliphatic group, aromatic group, heterocyclic group; Ar = aromatic group; X = H or group releasable upon the reaction with an aromatic primary amine developer; R1 and/or Ar being different for different couplers), and a high-b.p. organic solvent ≤0.2 weight ratio with respect to the couplers. The material has an improved color-image stability.
IT 142315-04-6
RL: USES (Uses)
(cyan photog. couplers)
RN 142315-04-6 CAPLUS
CN Butanamide, N-[4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-3-hydroxyphenyl]-2-(3-pentadecylphenoxy)- (CA INDEX NAME)

L16 ANSWER 19 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 20 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:210723 CAPLUS
DN 116:210723
OREF 116:35606h,35607a
TI Spectrophotometric analysis using peroxidase as label
IN Kamiyama, Mikio; Kawakatsu, Satoru; Kita, Hiroshi; Kaneko, Yutaka
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03254699	A	19911113	JP 1990-51710	19900305 <--
PRAI JP 1990-51710		19900305		

OS MARPAT 116:210723
GI



AB A sensitive spectrophotometric method using peroxidase as a label and a chromogenic reagent comprised of primary aromatic amines and I or II [R = substitutes; m = 0-4; Y = substitutes having 1.5>σp (Hammett's constant)>0.3; X = H, departing groups] are described. H2O2 from the peroxidase-catalyzed reaction oxidizes the primary aromatic amines and the oxidation products subsequently couple-react with I or II to generate dyes that are detectable in the 500.apprx.700 nM range. Determination of glucose using a chromogenic composition containing N,N-diEt-3-Me-4-aminoaniline and II (R = H; Y = CN; X = H) was shown. The sensitivity was significantly higher than that of prior art.
IT 140175-07-1
RL: ANST (Analytical study)
(substrate in peroxidase-mediated spectrophotometric anal.)
RN 140175-07-1 CAPLUS
CN Acetamide, N-[1-chloro-4-(cyanoamino)naphthalenyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:193941 CAPLUS
DN 116:193941
OREF 116:32849a,32852a
TI Preparation of (oximinomethyl)cyclohexanedione herbicides and naphthalene antidotes and mixtures thereof
IN Saupe, Thomas; Kast, Juergen; Misslitz, Ulf; Hagen, Helmut; Nilz, Gerhard; Pfister, Juergen; Walter, Helmut; Landes, Andreas
PA BASF A.-G., Germany
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 456090	A2	19911113	EP 1991-106993	19910430 <--
EP 456090	A3	19920708		
EP 456090	B1	19940713		
R: AT, CH, DE, ES, FR, GB, IT, LI, NL				
DE 4014985	A1	19911114	DE 1990-4014985	19900509 <--
JP 05078210	A	19930330	JP 1991-96846	19910426 <--
ES 2056517	T3	19941001	ES 1991-106993	19910430 <--
CA 2042111	A1	19911110	CA 1991-2042111	19910508 <--
HU 56999	A2	19911128	HU 1991-1541	19910508 <--
HU 212702	B	19961028		
PRAI DE 1990-4014985	A	19900509		

OS MARPAT 116:193941
GI







AB Herbicidal mixts. containing herbicide antidotes [I; R = alkyl, alkylthio, haloalkyl, alkoxy, halo, OH, NO2, PhCH2; R3 = cyano, C(NH2)NOH, azolylcarbonyl, R4 = halo, amino, imino, OH, etc.; m = 0-3], and herbicides [II R1 = alkyl; R2 = (substituted)alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, Ph; X = H, NO2, cyano, halo, alkyl, alkoxy, alkylthio, CO2H, (substituted) benzyloxycarbonyl, Ph,

L16 ANSWER 21 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
etc.; A = (halo- or alkyl-substituted) alkylene, alkenylene; n = 1-5] were prepd. Thus, aq. diazotized aniline was added to a mixt. of butadiene, CuCl2, and CaO in acetone/H2O at -15° to give a mixt. of 1-chloro-4-phenylbut-2-ene and 3-chloro-4-phenylbut-1-ene. The mixt. was stirred with N-hydroxyphthalimide and K2CO3 in N-methylpyrrolidone at 60° to give (E)-N-(4-phenyl-2-butenyloxy)phthalimide. The latter was deprotected with ethanolamine to give (E)-4-phenyl-2-butenyloxyamine, isolated as the oxalate. The latter was stirred with 2-propionyl-5-(3-tetrahydrothiopyranyl)cyclohexane-1,3-dione and NaHCO3 in MeOH to give 3-hydroxy-2-[1-(4-phenylbut-2-enyloximino)propyl]-5-(3-tetrahydrothiopyranyl)cyclohex-2-en-1-one. A mixt. of herbicide III 0.25 kg/ha and antidote IV 0.75 kg/ha postemergent gave 98% damage to Setacia viridis and only 10% damage to Zea mays, vs. 85% damage to the latter without IV.
IT 129667-52-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as herbicide antidote for cyclohexenone herbicide)
RN 129667-52-3 CAPLUS
CN Acetamide, N-(4-cyano-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 22 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:72187 CAPLUS
DN 116:72187
OREF 116:12145a,12148a
TI Silver halide color photographic material containing ureidophenol cyan coupler
IN Tsukahara, Jiro; Yamazaki, Shigeru
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03220554	A	19910927	JP 1990-15791	19900125 <--
PRAI JP 1990-15791		19900125		

GI



AB The title photog. material having ≥1 Ag halide emulsion layer on a support contains ≥1 cyan coupler I (R, R1 = H, aryl, aralkyl, alkenyl, cycloalkyl; R2 = aryl; R3 = H, leaving group in coupling with the oxidized developing agent). A monocolor film containing cyan coupler I (R = R1 = C18H37, R2 = 4-NCPh, R3 = H) in an emulsion layer showed high spectral absorption of cyan dye and good developability.
IT 138763-47-0
RL: TEM (Technical or engineered material use); USES (Uses)
(cyan photog. coupler, for good developability)
RN 138763-47-0 CAPLUS
CN Acetic acid, 2-[2-[[2-cyano-4-(dodecyloxy)-1-oxobutyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, methyl ester (CA INDEX NAME)



L16 ANSWER 22 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 23 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:6403 CAPLUS
DN 116:6403
OREF 116:1267a,1270a
TI Process for the preparation of aromatic amines
IN Makosza, Mieczyslaw; Bialecki, Maciej
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 453885	A2	19911030	EP 1991-105749	19910411 <--
	EP 453885	A3	19920304		
	EP 453885	B1	19940316		
	R: CH, DE, FR, GB, IT, LI				
	PL 163080	B1	19940228	PL 1990-284896	19900423 <--
	US 5262539	A	19931116	US 1991-682820	19910409 <--
	JP 04225939	A	19920814	JP 1991-110752	19910417 <--
PRAI	PL 1990-284896	A	19900423		

OS CASREACT 116:6403; MARPAT 116:6403
AB A process for the preparation of aromatic amines comprises the treatment of substituted nitroarenes with organic sulfenamides. A sulfenamide anion is formed in the presence of base and forms an adduct with the nitroarene which then undergoes an elimination reaction. The amination is regioselective. Thus, 3-chloro-4-nitrobenzenamine, 5-nitro-N-phenylthiophenamine, 4-ethoxy-5-nitro-2-pyridinamine are prepared Addition of 1-nitronaphthalene (3.5 g) and N,N-tetramethylenethiocarbamoylsulfenamide (3.3 g) in DMF (15 mL) to a suspension of KOH (6 g) in DMSO (50 mL) gave 4-nitro-1-naphthalenamine in 77% yield and 1-nitro-2-naphthalenamine in 2% yield. Treatment of 1-nitronaphthalene with 2-benzothiazolesulfenamide gave 8% 4-nitro-1-naphthalenamine and 72% 1-nitro-2-naphthalenamine.
IT 137807-36-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 137807-36-4 CAPLUS
CN 1-Naphthalenamine, 4-nitro-N-phenyl- (CA INDEX NAME)



L16 ANSWER 24 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:679833 CAPLUS
DN 115:279833
OREF 115:47550h,47551a
TI Preparation of bis[(quinolylamino)ethylamine and analogs as N-methyl-D-aspartic acid (NMDA) receptor antagonists
IN Antoku, Fujio; Saji, Ikutaro; Ohashi, Naohito; Nagata, Ryu
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 443862	A1	19910828	EP 1991-301417	19910222 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 04211040	A	19920803	JP 1991-48974	19910220 <--
	CA 2036781	A1	19910823	CA 1991-2036781	19910221 <--
PRAI	JP 1990-43638	A	19900222		

OS MARPAT 115:279833
GI



II

AB Ar1NR1A1NR2A2NR3Ar2 [I; Ar1 = (un)substituted aryl, 6-membered heterocyclyl containing 1-3 N, bicyclic heterocyclyl having a 5-membered hetero ring fused to a benzene ring, etc.; Ar2 = (un)substituted naphthyl, bicyclic heterocyclyl having a 5-membered hetero ring with 1-3 N atoms fused to a benzene ring, etc.; A1, A2 = (oxo-substituted) alkylene; R1-R3 = H, alkyl, aryl, arylalkyl, arylalkoxycarbonyl, alkylalkoxycarbonyl, acyl] and salts, useful in the prevention or treatment of symptoms associated with cerebral apoplexy or cerebral infarction, were prepared A stirred mixture of 8-aminoquinoline 0.1, HCl.NH(CH2CH2Cl)2 0.1, and Na2CO3 0.2 mol in 100 mL BuOH was refluxed for 35.5 h to give 3.9% title triamine which was converted to its HCl salt (II). II in mice inhibited NMDA-induced convulsions with ED50 = 16.4 mg/kg i.p., and in an in vitro competitive binding test with [3H]MK 801, II had IC50 of 1.3 μM. Approx. 22 I were prepared
IT 137582-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of methylaspartate receptor antagonist)
RN 137582-97-9 CAPLUS
CN 1,2-Ethanediamine, N-(4-chloro-1-naphthalenyl)-N'-[2-[(4-chloro-1-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 24 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

IT 137582-59-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as methylaspartate receptor antagonist)
RN 137582-59-3 CAPLUS
CN 1,2-Ethanediamine, N-(4-chloro-1-naphthalenyl)-N'-[2-[(4-chloro-1-naphthalenyl)amino]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L16 ANSWER 24 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

●3 HCl

L16 ANSWER 25 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of, as excitatory amino acid antagonist)
RN 137160-03-3 CAPLUS
CN Guanidine, N-(3-ethylphenyl)-N'-(4-fluoro-1-naphthalenyl)-N-methyl- (CA INDEX NAME)



L16 ANSWER 25 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:679620 CAPLUS
DN 115:279620
OREF 115:47499a,47502a
TI Preparation of N-(1-naphthyl)guanidines and analogs
IN Weber, Eckard; Keana, John F. W.
PA Oregon State Board of Higher Education, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9112797	A1	19910905	WO 1991-US1447	19910304 <--
	W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2076664	A1	19910909	CA 1991-2076664	19910304 <--
	CA 2076664	C	20040113		
	AU 9175796	A	19910918	AU 1991-75796	19910304 <--
	AU 655176	B2	19941208		
	ZA 9101553	A	19911224	ZA 1991-1553	19910304 <--
	EP 517852	A1	19921216	EP 1991-906702	19910304 <--
	EP 517852	B1	20020710		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05507062	T	19931014	JP 1991-507163	19910304 <--
	JP 3298875	B2	20020708		
	US 5262568	A	19931116	US 1991-663134	19910304 <--
	SG 73414	A1	20000620	SG 1996-7226	19910304 <--
	AT 220320	T	20020715	AT 1991-906702	19910304 <--
	ES 2181668	T3	20030301	ES 1991-906702	19910304 <--
	US 5336689	A	19940809	US 1993-105458	19930811 <--
	US 5559154	A	19960924	US 1993-105456	19930811 <--
	US 5943082	A	19990824	US 1995-382181	19950201 <--
	US 5637622	A	19970610	US 1995-446229	19950522 <--
	US 5798390	A	19980825	US 1995-446451	19950522 <--
	US 5767162	A	19980616	US 1995-470345	19950606 <--
	US 6251948	B1	20010626	US 1995-468028	19950606 <--
	JP 2002020361	A	20020123	JP 2001-154124	20010523 <--
	JP 3341000	B2	20021105		
PRAI	US 1990-487036	A	19900302		
	JP 1989-339406	A	19891227		
	JP 1990-51359	A	19900301		
	JP 1990-74757	A	19900323		
	US 1990-633134	B1	19901224		
	JP 1991-507163	A3	19910304		
	US 1991-663134	A3	19910304		
	WO 1991-US1447	A	19910304		
	US 1993-105456	A3	19930811		
	US 1994-252625	A3	19940601		

OS MARPAT 115:279620
AB RR1NC(:NH)NR2R3 [I; R-R3 = alkynyl, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, (hetero)aryl, heterocyclyl; R2 may addnl. = H] were prepared Thus, 3-EtC6H4NHCN was N-methylated and the product condensed with 1-naphthylamine hydrochloride to give 3-EtC6H4NMeC(:NH)NHR3.HCl (R3 = 1-naphthyl) which had IC50 of 35.4 (units not given) for rat brain PCP receptor affinity.
IT 137160-03-3P
RL: SPN (Synthetic preparation); PREP (Preparation)

L16 ANSWER 26 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:631877 CAPLUS
DN 115:231877
OREF 115:39501a,39504a
TI Preparation of polyfluoroanilides as arachnicides and insecticides
IN Gajewski, Robert Peter
PA Eli Lilly and Co., USA
SO Rom., 15 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RO 95050	B1	19880815	RO 1986-122856	19860402 <--
PRAI	RO 1986-122856		19860402		

OS MARPAT 115:231877
GI



I

AB Title compds. RCONR3R4 [R = (CF3)3C, (CF3)2CMe, R1R2R5C; R1 = CF3, C2F5, C3F7, m-C4F9, etc., R2 = CF3, C2F5, C3F7, NC, perfluoro-C1-3-alkoxy, bis(perfluoro-C1-3-alkyl)amino, perfluoropyrrolidine, etc.; R3 = H, Me; R4 = substituted Ph, substituted naphthyl, 5-nitro-2-pyridyl; R5 = Br, Cl, F] and their salts are prepared by reaction of HNR3R4 with RCOX (X = halo) in an organic solvent in presence of HF acceptor such as e.g. Et3N at 10-110°, preferably 20-70°. Et3N was added to 2,4-Br(O2N)C6H3NH2 in Et2O followed by a mixture of F3CCF2CF2COF and F3CCHFCOF and HF, to the reactants was added a mixture of dry ice/Me2CO, to give after a workup the title anilide I. I at 0.85-3.4 g/row controlled worms at corn root. Title compds. were very active against Spodoptera eridanis, Tetranychus witica, and Aphis gossypii larvae and others.
IT 105923-67-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as arachnicides and insecticides)
RN 105923-67-9 CAPLUS
CN Propanamide, 2,3,3,3-tetrafluoro-N-(4-nitro-1-naphthalenyl)-2-(trifluoromethyl)- (CA INDEX NAME)



L16 ANSWER 27 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:471647 CAPLUS
DN 115:71647
OREF 115:12395a,12398a
TI Preparation of quinoxaline derivatives as neuroleptics
IN Honore, Tage; Jacobsen, Poul; Nielsen, Flemming Elmelund; Naerum, Lars
PA Aktieselskabet Ferrosan, Den.
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 374534	A1	19900627	EP 1989-121912	19891128 <--
	EP 374534	B1	19940706		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 92464	A	19950731	IL 1989-92464	19891127 <--
	CA 2004077	A1	19900622	CA 1989-2004077	19891128 <--
	ES 2057076	T3	19941016	ES 1989-121912	19891128 <--
	ZA 8909470	A	19900926	ZA 1989-9470	19891212 <--
	US 5081123	A	19920114	US 1989-451382	19891215 <--
	DK 8906397	A	19900623	DK 1989-6397	19891218 <--
	DK 165293	B	19921102		
	DK 165293	C	19931108		
	AU 8946874	A	19900628	AU 1989-46874	19891219 <--
	AU 624885	B2	19920625		
	NO 8905196	A	19900625	NO 1989-5196	19891221 <--
	NO 178662	B	19960129		
	NO 178662	C	19960508		
	JP 02221264	A	19900904	JP 1989-329779	19891221 <--
	US 5153195	A	19921006	US 1991-794262	19911115 <--
	US 5306845	A	19940503	US 1992-914274	19920715 <--
PRAI	DK 1988-7161	A	19881222		
	US 1989-451382	A2	19891215		
	US 1991-794262	A3	19911115		

OS MARPAT 115:71647
GI



I

AB Quinoxalinedione derivs. I [R1 = OH, alkoxy, aryloxy, aralkoxy, cycloalkylalkoxy, cycloalkoxy, acyloxy; R5R6 or R7R18 forms fused ring substituted by halo or cyano; remaining 2 of R5-R8 = H, NO2, halo, cyano, SO2NR'R", SO2R', CF3, OR'; R' = H, C1-4 alkyl], which are quisqualate neurotransmitter receptor antagonists, were prepared as neuroleptics. For example, amidation of 4-bromo-2-nitro-1-naphthylamine with Et02CCOCl in THF containing Et3N gave 82% ethoxalylamino derivative, which was cyclized and debrominated by hydrogenation over Pd/C in THF-DMF containing aqueous NH3 to give 65% I (R1 = OH, R5R6 = CH:CHCH:CH, R7 = R8 = H) (II). The IC50 of II for

L16 ANSWER 27 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
antagonism of quisqualate-stimulated efflux of 3H-GABA from rat cortical neurons in vitro was 0.61 μg/mL. Nine addnl. syntheses and several IC50 (0.23-0.61 μg/mL) and Ki (0.1-0.16 μg/mL) values were reported.
IT 135220-84-7P, 4-Cyano-1-ethoxalylaminonaphthalene
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of fused quinoxalinedione neuroleptics)
RN 135220-84-7 CAPLUS
CN Acetic acid, 2-[(4-cyano-1-naphthalenyl)amino]-2-oxo-, ethyl ester (CA INDEX NAME)



L16 ANSWER 28 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:468290 CAPLUS
DN 113:68290
OREF 113:11369a,11372a
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Ishii, Fumio; Uchida, Taku; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01253742	A	19891011	JP 1988-81769	19880401 <--
PRAI	JP 1988-81769		19880401		

OS MARPAT 113:68290
GI



I



II

AB The claimed photog. material having >1 Ag halide emulsion layer on the support contains in >1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = aryl; R1 = alkyl, aryl; R2 = H, alkyl, aryl; R3 = H, alkyl; R4 = substituent other than hydrocarbon residue). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical 3-step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128362-55-0
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128362-55-0 CAPLUS
CN Acetic acid, 2-[5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-2-[[2-[3-(1,1-dimethylethyl)-4-hydroxyphenoxy]-1-oxotetradecyl]amino]-4-hydroxyphenoxy]-, 1-methyl-1-(methylthio)ethyl ester (CA INDEX NAME)

L16 ANSWER 28 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 29 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:468289 CAPLUS
DN 113:68289
OREF 113:11369a,11372a
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01253741	A	19891011	JP 1988-81768	19880401 <--
PRAI JP 1988-81768		19880401		

OS MARPAT 113:68289
GI



I



II

AB The claimed photog. material having ≥1 Ag halide emulsion layer on the support contains in ≥1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = CR3R4R5; R2-5 = alkyl, aryl; R1 = aryl). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128313-91-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128313-91-7 CAPLUS
CN Acetic acid, 2-[2-[[2-[2,4-bis(1-methylpropyl)phenoxy]-1-oxooctyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L16 ANSWER 29 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 30 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:468288 CAPLUS
DN 113:68288
OREF 113:11369a,11372a
TI Silver halide color photographic material containing an ureido type cyan coupler capable of providing high developed density and little leuco cyan dye
IN Ishii, Fumio; Uchida, Taku; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01253740	A	19891011	JP 1988-81767	19880401 <--
PRAI JP 1988-81767		19880401		

OS MARPAT 113:68288
GI



I



II

AB The claimed photog. material having >1 Ag halide emulsion layer on the support contains in >1 of the emulsion layer a cyan dye-forming coupler of the formula I (R = aryl; R1 = alkyl, aryl; R2 = H, alkyl; R3 = substituent). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process comprising color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.
IT 128314-24-9
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)
RN 128314-24-9 CAPLUS
CN Propanoic acid, 3-[[2-[5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxy-2-[[1-oxo-2-(phenylthio)dodecyl]amino]phenoxy]acetyl]oxy]- (CA INDEX NAME)

L16 ANSWER 30 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 31 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:468287 CAPLUS
DN 113:68287
OREF 113:11369a,11372a
TI Silver halide color photographic material containing an ureido type cyan coupler with high developed density and little leuco cyan dye
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01253738	A	19891011	JP 1988-81351	19880404 <--
PRAI	JP 1988-81351		19880404		

GI



I



II

AB The claimed photog. material having ≥1 Ag halide emulsion layer on the support contains in ≥1 of the emulsion layers a cyan dye-forming coupler of the formula I (R = (Z0)l(Z1O)mR3; Z, Z1 = alkylene; R3 = H, alkyl, aryl, alkylcarbonyl, arylcarbonyl, heterocyclic ring; l, m are integer; R1 = aryl; R2 = alkyl, aryl). It has high speed and high developed d., and has less tendency to leave leuco cyan dye in the image layer even when processed by an exhausted bleach or bleach-fix. Thus, an exptl. monocolor film was prepared by adding a dispersion of coupler II to a Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process consisting of color development, simulated exhausted bleach-fix and washing, it showed the mentioned advantages.

IT 128314-32-9
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for high developed d.)

RN 128314-32-9 CAPLUS
CN Acetic acid, 2-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, 2-(2-ethoxy-1-methylethoxy)ethyl ester (CA INDEX NAME)

L16 ANSWER 31 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 32 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:188916 CAPLUS
DN 112:188916
OREF 112:31753a,31756a
TI Silver halide color photographic materials with phenolic cyan couplers
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi
PA Koncia Co., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01253739	A	19891011	JP 1988-81766	19880401 <--
PRAI	JP 1988-81766		19880401		

GI



I



II

AB Cyan couplers I are contained in the title materials [X = -CHR1R2; R1 = H, (cyclo)alkyl; R2 = (cyclo)alkyl, alkenyl, aryl, heterocyclyl; R1-2 are not substituted when both are Me; sum of number of C atoms in R1-2 is ≥2 when these are either alkyls or an alkyl and H; R1-2 may jointly form a ring with a :CH group; A = (substituted) alkyl; B = (substituted) alkyl or aryl]. These couplers provide cyan image with high sensitivity and d., with small loss of dye when exhausted bleach-fix is used in processing. Thus, polyester base was coated with a red-sensitive Ag(I,Br) emulsion mixed with coupler II and other reagents, exposed, and processed using fresh bleach-fix containing Fe EDTA ammonium salts or using that simulating exhausted condition. Cyan image d. was 1.00 and 0.95, resp., for these bleach-fix solns.

IT 126391-62-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler, for high sensitivity and low dye loss by exhausted bleach-fix)

RN 126391-62-6 CAPLUS
CN Acetic acid, 2-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-, 3-[(methylsulfonyl)amino]propyl ester (CA INDEX NAME)

L16 ANSWER 32 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 33 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:148989 CAPLUS
DN 112:148989
OREF 112:24983a,24986a
TI Silver halide color photographic material containing a 2-ureide-5-amido-phenol (cyan coupler) to improve developability and reduce leuco cyan dye
IN Miura, Akio; Ishii, Fumio; Uchida, Taku; Tsuruta, Mayumi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01172952	A	19890707	JP 1987-330274	19871228 <--
PRAI JP 1987-330274		19871228		

GI



I



II

AB The claimed photog. material having ≥1 Ag halide emulsion layer on the support contains in ≥1 of the emulsion layer a cyan coupler I [R = alkyl, aryl; R1 = aryl; R2 = O(CR3R4)nP:O(OR5)(OR6); R3-6 = H, alkyl, aryl; n = integer]. It provides a cyan image with high developed d. and also remains less leuco cyan dye after processing. Thus, an exptl. monocolor film was prepared by adding cyan coupler II to a red-sensitive Ag(Br,I) emulsion (AgI 7 mol%) and coating it on a film base. Upon development by a typical three step process comprising color development, bleach-fix and washing, it showed the mentioned advantages.
IT 126051-41-0
RL: USES (Uses)
(cyan coupler, in photog. material)
RN 126051-41-0 CAPLUS
CN Phosphonic acid, [5-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]propyl]-, hexyl methyl ester (9CI) (CA INDEX NAME)

L16 ANSWER 33 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 34 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:28047 CAPLUS
DN 112:28047
OREF 112:4733a,4736a
TI Silver halide photographic materials containing cyan couplers
IN Uchida, Taku; Ishii, Fumio; Miura, Akio; Tsuruta, Mayumi; Kida, Shuji
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01172954	A	19890707	JP 1987-330276	19871228 <--
PRAI JP 1987-330276		19871228		

GI



I



II

AB Cyan couplers I (R = alkyl, aryl; R1 = aryl; X = alkyl, aryl, alkylamino, arylamino, alkoxy, aryloxy; Y = alkyl, aryl, heterocyclyl) are contained in Ag halide photog. materials. These couplers give high photosensitivity and high image d., with stability in processing even when exhausted bleaching solns. or bleach-and-fixing solns. are uses. Thus, a red-sensitive Ag(I,Br) emulsion was mixed with an emulsion containing II 0.1 mol/mol Ag and other agents, and applied on a polyester base. The obtained film showed high sensitivity and image d., which was only slightly affected by using a model exhausted fixer.
IT 124451-20-3
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 124451-20-3 CAPLUS
CN Benzenepentanamide, α-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]-N-(2-chlorophenyl)-γ,γ-dimethyl-β-oxo- (CA INDEX NAME)

L16 ANSWER 34 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 35 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:487309 CAPLUS
DN 111:87309
OREF 111:14527a,14530a
TI Reduction sensitization of silver halide photographic emulsion
IN Szucs, Miklos; Frigyik Szemjonova, Olga; Csaplaros Sule, Judit; Palotas Toth, Agata
PA Forte Fotokemiai Ipar, Hung.
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3820592	A1	19881229	DE 1988-3820592	19880616 <--
	HU 47752	A2	19890328	HU 1987-2723	19870616 <--
	HU 203120	B	19910528		
	GB 2205966	A	19881221	GB 1988-14328	19880616 <--
	GB 2205966	B	19900418		
	JP 01015731	A	19890119	JP 1988-149222	19880616 <--
PRAI	HU 1987-2723	A	19870616		

AB Ag halide photog. emulsions are reduction-sensitized without increasing the fog by using an inclusion complex of a hydrazine derivative with a substituted cyclodextrin or a water-soluble cyclodextrin polymer. The molar ratio of the cyclodextrin derivative to the hydrazine derivative in the inclusion complex is 4:1 to 80:1, preferably 10:1 to 50:1. The complex is added to the emulsion before the precipitation of the Ag halide crystals, or during the period of crystal growth or thereafter. The addition of a tris(carboxymethoxy)cyclodextrin/PhNHNH2 complex (molar ratio 40) to a gelatin-Ag(Br,Cl) emulsion showed improved during crystal growth sensitivity with no increase in fog even a control containing only the cyclodextrin derivative
IT 101851-40-5D, inclusion complexes with β-cyclodextrin carboxymethyl polyether derivs.
RL: USES (Uses)
(photog. reduction sensitizer)
RN 101851-40-5 CAPLUS
CN Hydrazine, (4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 36 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:415284 CAPLUS
DN 111:15284
OREF 111:2605a,2608a
TI Electrophotographic photoreceptor containing bisazo compound
IN Oseto, Hiroki; Matsura, Kazuo
PA Toray Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63049762	A	19880302	JP 1986-192848	19860820 <--
PRAI	JP 1986-192848		19860820		

OS MARPAT 111:15284
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB In the electrophotog. photoreceptor containing a conductive layer and a photosensitive layer, the photosensitive layer has a charge-generating composition and a charge-transporting composition, and the charge-generating composition contains a bisazo compound of the formula I (R,R1 = H, halo, alkyl, alkoxy, nitro). This shows high sensitivity, stability and durability. Thus, Metalumy #75 (Al-deposited polyester film) was coated with a composition containing II and Vylon 200 (polyester resin), and overcoated with a compn containing Panlite L-1225 and a hydrazone compound. When the photoreceptor was corona-discharged (-6 KV), retained 5 s in the dark, and exposed to a 5 lx source for 20 s, the residual potential, dark decay, and exposure required to halve the potential were -880 V, 11.4%, and 1.3 lx-s, resp.
IT 120298-08-0 120298-09-1
RL: USES (Uses)
(charge generator, electrophotog photoreceptor using)
RN 120298-08-0 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(4-chloro-1-naphthalenyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L16 ANSWER 36 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120298-09-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

L16 ANSWER 36 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 37 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:192446 CAPLUS
DN 110:192446
OREF 110:31933a,31936a
TI Process for the preparation of N-aryl- and N-heteroarylacetoacetamides
IN Papenfuhs, Theodor; Daub, Wolfgang
PA Hoechst A.-G., Fed. Rep. Ger.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 280156	A2	19880831	EP 1988-102229	19880216 <--
	EP 280156	A3	19891011		
	EP 280156	B1	19921111		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	DE 3731912	A1	19880908	DE 1987-3731912	19870923 <--
	IN 168510	A1	19910413	IN 1988-CA123	19880211 <--
	AT 82253	T	19921115	AT 1988-102229	19880216 <--
	ES 2052618	T3	19940716	ES 1988-102229	19880216 <--
	DK 8800955	A	19880826	DK 1988-955	19880224 <--
	JP 63233960	A	19880929	JP 1988-39754	19880224 <--
	BR 8800784	A	19881004	BR 1988-784	19880224 <--
	CA 1340980	C	20000502	CA 1988-559637	19880224 <--
PRAI	DE 1987-3706009	A	19870225		
	DE 1987-3731912	A	19870923		
	EP 1988-102229	A	19880216		

OS CASREACT 110:192446; MARPAT 110:192446
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R = H, C1-6 alkyl, HOCH2CH2, alkyl-(un)substituted C5-6 cycloalkyl, (un)substituted Ph, PhCH2; R1 = MeCOCH2CO (Q); T = H, C1-6 alkyl, C1-6 alkoxy, HOCH2CH2, alkyl-(un)substituted C5-6 cycloalkyl, (dialkyl)amino, Z; X = Y = CH; 1 of X, Y = N, the other = CH; Z = H, Br, Cl, F, iodo, R2O, R2CO2, R2O2C, R2SO3, R2R3NSO2, R2CONH, QNH, (un)substituted alkyl, Ph, etc.; R2, R3 = R] were prepared in high yield and purity by acylation of I (R1 = H) with diketene in the presence of a basic catalyst. I are intermediates for agrochems. and pharmaceuticals and as coupling agents for azo dyes. A mixture of 4-O2NC6H4NH2 69.1, Bu3N 10, and HOAc 500 g was stirred at 70° while 46.5 g diketene was added dropwise, followed by stirring 2 h at 70-80° to give 98.0 g 4-O2NC6H4NHQ of 96% purity (88.2% yield).
IT 118352-90-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for agrochems. and pharmaceuticals)
RN 118352-90-2 CAPLUS
CN Butanamide, N-(4-nitro-1-naphthalenyl)-3-oxo- (CA INDEX NAME)



L16 ANSWER 37 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 38 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:66645 CAPLUS
DN 110:66645
OREF 110:10841a,10844a
TI Second harmonic generation by carbamic acid derivatives
IN Tiers, George V. D.
PA Minnesota Mining and Manufacturing Co., USA
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 271251	A1	19880615	EP 1987-310372	19871125 <--
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	AU 8780678	A	19880609	AU 1987-80678	19871104 <--
	AU 620796	B2	19920227		
	JP 63163828	A	19880707	JP 1987-305533	19871202 <--
PRAI	US 1986-937234	A	19861203		

OS MARPAT 110:66645
AB Second harmonic generators are described which employ chiral N-aryl carbamyl compds. (e.g., urea and urethane derivs.) which crystallize in noncentrosym. configurations and which are transparent to radiation at both the fundamental and 2nd harmonic frequencies. N-(4-Nitrophenyl)-N'-(R-α-Me-benzyl)urea was prepared and exhibited a 2nd harmonic generation efficiency 37+ that of urea. X-ray powder patterns were obtained for this and other compds. which were prepared
IT 117368-98-6P
RL: PREP (Preparation)
(preparation of, as optical nonlinear material for second harmonic generation)
RN 117368-98-6 CAPLUS
CN Urea, N-(4-nitro-1-naphthalenyl)-N'-(1-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 39 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1987:524533 CAPLUS
DN 107:124533
OREF 107:19983a,19986a
TI Electrophotographic charge-generating disazo compound for semiconductor laser printer
IN Matsumoto, Masakazu; Miyazaki, Hajime; Umehara, Masashige; Takiguchi, Takao; Yamashita, Masataka; Ishikawa, Shozo
PA Canon K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62043649	A	19870225	JP 1985-182835	19850820 <--
PRAI	JP 1985-182835		19850820		

GI



I

AB The title compound has the formula I (R = electron-donating group such as OMe; A = aryl or heterocyclyl having ≥1 substituent of NO2, CN, and CF3 such as 3-NO2Ph). A support may be coated with a charge-generating layer containing the disazo compound and a poly(vinyl butyral) and a charge-transporting layer cong. a hydrazone and PMMA to give a composite photoconductor. It shows improved sensitivity and constant sensitivity in the wavelength range 760-800 nm.
IT 110308-32-2
RL: USES (Uses)
(electrophotog. charge-generating photoconductor, for improved sensitivity and constant sensitivity to semiconductor lasers with varied wavelengths)
RN 110308-32-2 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2-hydroxy-N-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

L16 ANSWER 39 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 40 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1987:487296 CAPLUS
DN 107:87296
OREF 107:14147a,14150a
TI Optical recording material
IN Ozawa, Tetsuo; Maeda, Shuichi; Kurose, Yutaka
PA Mitsubishi Chemical Industries Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62018290	A	19870127	JP 1985-156596	19850716 <--
PRAI	JP 1985-156596		19850716		

GI



AB The title material is composed of a support bearing a recording layer containing a light-absorbing compound I [R = Ph or naphthalene ring substituted by 1 or 2 groups selected from halo, alkylthio, hydroxylalkyl, aralkyloxyl]. The material has high sensitivity for laser beam recording and high storage stability. Thus, 5-amino-2,3-dicyano-1,4-naphthoquinone was reacted with p-hydroxyethylaniline in EtOH and recrystd. to yield I (R = P-C6H4C2H4OH) (II). II was vacuum-sublimated on a methacrylate resin support to form a recording dye layer with a thickness of 2010 Å and a broad absorption peaked at 790 nm. The dye layer was exposed to a semiconductor laser beam (power 4 m W; diameter 1 μm) operated at 830 nm to give a recoded pit (1 + 2 μm in size) with a clear outline and a high carrier-to-noise (C/N) ratio of 52 dB.
IT 109793-21-7
RL: USES (Uses)
(optical recording layer from)
RN 109793-21-7 CAPLUS
CN 2,3-Naphthalenedicarbonitrile, 5-amino-8-[(4-chloro-1-naphthalenyl)amino]-1,4-dihydro-1,4-dioxo- (CA INDEX NAME)

L16 ANSWER 40 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 41 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1987:175957 CAPLUS
DN 106:175957
OREF 106:28545a,28548a
TI Carboxanilide derivatives
PA Air Products and Chemicals, Inc., USA
SO Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61236756	A	19861022	JP 1986-79064	19860404 <--
	IL 78393	A	19901223	IL 1986-78393	19860331 <--
	AU 8655525	A	19861009	AU 1986-55525	19860401 <--
	AU 588296	B2	19890914		
	EP 201193	A2	19861217	EP 1986-302434	19860402 <--
	EP 201193	A3	19880518		
	EP 201193	B1	19901024		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	RO 95059	B3	19880815	RO 1986-122858	19860402 <--
	AT 57681	T	19901115	AT 1986-302434	19860402 <--
	CN 86102271	A	19861203	CN 1986-102271	19860403 <--
	CN 1012576	B	19910508		
	ZA 8602480	A	19870225	ZA 1986-2480	19860403 <--
	DD 248952	A5	19870826	DD 1986-288740	19860403 <--
	HU 42750	A2	19870828	HU 1986-1425	19860403 <--
	ES 553704	A1	19870901	ES 1986-553704	19860403 <--
	CN 1050536	A	19910410	CN 1990-107985	19860403 <--
	CA 1283918	C	19910507	CA 1986-505802	19860403 <--
	DK 8601544	A	19861006	DK 1986-1544	19860404 <--
	BR 8601566	A	19861209	BR 1986-1566	19860404 <--
	PL 149721	B1	19900331	PL 1986-258779	19860404 <--
	PL 149800	B1	19900331	PL 1986-267525	19860404 <--
	SU 1561822	A3	19900430	SU 1986-4027246	19860404 <--
PRAI	US 1985-720212	A	19850405		
	EP 1986-302434	A	19860402		
	CN 1986-102271	A	19860403		

OS MARPAT 106:175957
GI



AB R1CONR2R3 (R1 = perfluorocycloalkyl; R2 = H, Me; R3 = aryl), effective insecticides at 0.112 kg/ha, herbicides at 0.05-8 lb/acre, and agrochem. fungicides at 0.5-5.0 lb/acre, are prepared Thus, 0.02 mol 2,4-Br(O2N)C6H3NH2 was added to a solution of 0.02 mol acid fluoride I (R4 = F) and 0.02 mol Et3N in Et2O at 25° with stirring to give 57% anilide I [R4 = 2,4-Br(O2N)C6H3NH].
IT 107350-95-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide, herbicide, and fungicide)
RN 107350-95-8 CAPLUS
CN Cyclohexanecarboxamide, 1,2,2,3,3,4,4,5,5,6,6-undecafluoro-N-(4-nitro-1-

L16 ANSWER 41 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 42 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1987:18140 CAPLUS
DN 106:18140
OREF 106:3101a,3104a
TI Fluorinated alkanoyl anilides with biocidal activities
IN Gajewski, Robert Peter
PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 197756	A2	19861015	EP 1986-302435	19860402 <--
	EP 197756	A3	19880824		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4826841	A	19890502	US 1986-836658	19860305 <--
	IL 78394	A	19891215	IL 1986-78394	19860331 <--
	AU 8655527	A	19861009	AU 1986-55527	19860401 <--
	AU 588297	B2	19890914		
	CN 86102262	A	19861119	CN 1986-102262	19860403 <--
	CN 1012575	B	19910508		
	DD 244550	A5	19870408	DD 1986-288741	19860403 <--
	ZA 8602474	A	19870624	ZA 1986-2474	19860403 <--
	HU 42679	A2	19870828	HU 1986-1413	19860403 <--
	HU 198606	B	19891128		
	DK 8601545	A	19861006	DK 1986-1545	19860404 <--
	JP 61236755	A	19861022	JP 1986-79062	19860404 <--
	BR 8601567	A	19861209	BR 1986-1567	19860404 <--
	PL 146891	B1	19890331	PL 1986-258778	19860404 <--
	SU 1528343	A3	19891207	SU 1986-4027304	19860404 <--
	US 4962284	A	19901009	US 1989-319453	19890306 <--
PRAI	US 1985-720236	A	19850405		
	US 1986-836658	A3	19860305		

OS CASREACT 106:18140; MARPAT 106:18140
GI



IV

AB Title compds. RR1R2CCONR3R4 (I), (F3C)3CCONR3R4 (II), and Me(F3C)2CCONR3R4 (III) [R = Br, Cl, F; R1 = CF3, C2F5, C3F7, n-, iso-, or sec-C4F9; R2 = CF3, C2F5, C3F7, cyano, OR5, NR5R6, CF2OR5, CF2NR5R6; R3 = H, Me; R4 = 5-nitro-2-pyridyl, substituted Ph, naphthyl; R5, R6 = perfluoroalkyl; R5R6 = (CF2)n, (CF2)2O(CF2)2, (CF2)2N(CF3)(CF2)2; n = 4, 5] and their Na, K, and R7R8R9R10N+ salts [R7 - R9 = alkyl, PhCH2, CH2CH2OH, CH2CHMeOH, (CH2)3OH; R10 = H, as given for R7] are prepared as agrochems., especially as insecticides and arachnicides. Acylation of 2,4-Br(O2N)C6H3NH2 with (F3C)2CFCOF (isomer mixture containing some F3CCF2CF2COF) in THF containing Et3N gave, after hydrolysis of straight-chain product with 1N NaOH, 86.0% propionanilide IV having 99.5% purity. A granular formulation containing 10% IV was prepared by drying a 12% CH2Cl2 solution of IV on a Florex carrier. At 0.85-3.4 g/100 row ft, IV controlled corn rootworm (no numerical data),

L16 ANSWER 42 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
showing no phytotoxicity at most test locations.
IT 105923-67-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide and arachnicide)
RN 105923-67-9 CAPLUS
CN Propanamide, 2,3,3,3-tetrafluoro-N-(4-nitro-1-naphthalenyl)-2-(trifluoromethyl)- (CA INDEX NAME)



L16 ANSWER 43 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1987:1846 CAPLUS
DN 106:1846
OREF 106:371a,374a
TI Use of acylurea compounds for controlling endoparasites and ectoparasites of warm-blooded animals
IN Potter, Michael Fred; Rotramel, George Lorton; Caruso, Andrew James; Chou, David Teh Wei; Cain, Paul Alfred
PA Union Carbide Corp., USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8603941	A1	19860717	WO 1985-US2545	19851227 <--
	W: AU, BR, DK, FI, HU, JP, KR, LK, MW, NO, SD, SU				
	RW: AT, BE, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	US 5135953	A	19920804	US 1985-804638	19851209 <--
	AU 8653006	A	19860729	AU 1986-53006	19851227 <--
	AU 599313	B2	19900719		
	EP 211004	A1	19870225	EP 1986-900553	19851227 <--
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	BR 8507149	A	19870331	BR 1985-7149	19851227 <--
	JP 62501418	T	19870611	JP 1986-500537	19851227 <--
	HU 43033	A2	19870928	HU 1986-555	19851227 <--
	CN 85109721	A	19870715	CN 1985-109721	19851228 <--
	ZA 8509897	A	19860827	ZA 1985-9897	19851230 <--
	DK 8604082	A	19861017	DK 1986-4082	19860827 <--
	FI 8603490	A	19860828	FI 1986-3490	19860828 <--
	NO 8603463	A	19861027	NO 1986-3463	19860828 <--
	US 5420163	A	19950530	US 1992-924089	19920803 <--
	US 5776981	A	19980707	US 1995-426092	19950421 <--
	US 5776982	A	19980707	US 1995-455097	19950531 <--
PRAI	US 1984-687249	A	19841228		
	US 1985-723588	A	19850415		
	US 1985-804638	A	19851209		
	WO 1985-US2545	A	19851227		
	US 1992-924089	A3	19920803		

OS CASREACT 106:1846; MARPAT 106:1846
AB The urea derivs. R1CONR2C(Y)NR3R4 [R1 = (un)substituted carbocyclic or heterocyclic ring, etc.; R2, R3 = H, (un)substituted alkyl -benzyl, PhSO2, PhS, etc., R4 = H, R1; Y = O, S] are prepared as endo- and ectoparasiticides. Thus, 3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylaniline (preparation given) was reacted with 2,6-difluorobenzoyl isocyanate in MePh at 50° , to give 1-[3-chloro-4-(4-chloro-1-naphthoxy)-2,5-dimethylphenyl]-3-(2,6-difluorobenzoyl)urea (I). Addition of 25 ppm I to the feed of chicken, totally controlled lice (Menacanthus stramineus).
IT 105621-72-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as endo- and ectoparasiticide)
RN 105621-72-5 CAPLUS
CN Benzamide, N-[[(4-chloro-1-naphthalenyl)amino]carbonyl]-2,6-difluoro- (CA INDEX NAME)

L16 ANSWER 43 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 44 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1986:197089 CAPLUS
DN 104:197089
OREF 104:31025a,31028a
TI Photochromic compounds
IN Kondo, Hirofumi; Arakawa, Seiichi; Seto, Nobuyoshi
PA Sony Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60177089	A	19850911	JP 1984-31828	19840222 <--
JP 05049717	B	19930727		
PRAI JP 1984-31828		19840222		

OS CASREACT 104:197089
GI



I



II

AB Photochromic compds. of the formulas I and II (R = C1-20 alkyl; R1, R2 = H, C1-5 alkyl, C1-5 alkoxy, C2-10 alkoxyalkyl, halo, NO2, CN) are claimed. The photochromic compds. are especially useful in semiconductor laser recording materials. Thus, reaction of 1-naphthylhydrazine with 3-methyl-2-butanone gave 2,3,3-trimethylbenz[g]indolenine whose subsequent reaction with MeI gave 1,2,3,-tetramethylbenz[g]indolenium iodide (III). Sep., 2-chloro-5-nitrobenzaldehyde was made to react with Na2S2 and the reaction product was treated with HCl to give 5-nitrothisalicylaldehyde (IV). The reaction of III with IV gave I (R = Me; R1 = R2 = H), whose λmax, absorbance at λmax and at 780 nm were 690 nm, 0.32 and 0.19, resp.
IT 101851-40-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of photochromic spiro compds.)
RN 101851-40-5 CAPLUS
CN Hydrazine, (4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 44 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 45 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1985:513259 CAPLUS
DN 103:113259
OREF 103:18005a,18008a
TI Silver halide color photographic material
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60050533	A	19850320	JP 1983-158470	19830830 <--
JP 03016012	B	19910304		
PRAI JP 1983-158470		19830830		

GI For diagram(s), see printed CA Issue.
AB The claimed color photog. material contains a cyan dye-forming coupler expressed by the formula I or II (R = alkyl, aryl, heterocyclic group; R1 = alkyl, aryl, alkenyl, cycloalkyl, heterocyclic group; R2 = halo, alkyl, aryl, OH, alkoxy, acyloxy, aryloxy, acyl, sulfonyl, alkylthio, NO2; A = 5- or 6-membered condensed ring consisting of nonmetallic atom group; m = 1-4; n = 0-2; R2 may be A). Coupler I and II provide cyan dyes stable at high temperature and at lighted conditions, and in contrast to other 2-ureido-5-acylaminophenol couplers, they keep low stain level and have good solubility in coupler solvent. The couplers also have a good dye developability even in weak and/or exhausted bleaching baths. Thus, a Ag(Br,I) emulsion containing coupler I (R = butyl(2,5-di-tert-amylphenoxy)methylene; R1 = p-octyloxycarbonylphenyl; R2 = 2-chloro-4-cyanophenyl) was processed to give a stable cyan dye image with an excellent maximum d. and low stain level.
IT 97459-13-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 97459-13-7 CAPLUS
CN Hexanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxy-2-[(4-nitrophenyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A



L16 ANSWER 45 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



IT 97459-10-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of photog. cyan coupler)
RN 97459-10-4 CAPLUS
CN Carbamic acid, (4-cyano-1-naphthalenyl)-, phenyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 46 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:479410 CAPLUS
DN 103:79410
OREF 103:12651a,12654a
TI Silver halide color photographic material
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60049336	A	19850318	JP 1983-157424	19830829 <--
JP 05083897	B	19931130		
PRAI JP 1983-157424		19830829		

GI For diagram(s), see printed CA Issue.
AB Claimed color photog. material contains a cyan dye-forming coupler expressed by the formula I or II (R = alkyl, aryl, heterocyclic group; R1 = alkyl, aryl, alkenyl, cycloalkyl, heterocyclic group; R2 = halo, alkyl, aryl, OH, alkoxyl, acyloxy, aryloxy, acyl, sulfonyl, alkylthio, NO2; A = 5- or 6-membered condensed ring consisting of non-metallic atoms; m = 1-4; n = 0-2; R2 may be A). Couples I and II provide stable cyan dyes stable at high temperature or at lighted condition, and in contrast to other 2-ureido-5-acylaminophenol couplers, they have low stain level and good solubility to coupler solvent. The couplers have also a good dye developability even in weak and/or exhausted bleach baths. Thus, a Ag(Br,I) emulsion containing coupler I (R = butyl(2,5-di-tert-amylphenoxy)methylene; R1 = 4-methoxyphenyl; R2 = 2-chloro-4-cyanophenyl) was processed to give a stable cyan dye image with excellent maximum d. and low strain level.
IT 97639-12-8P
RL: PREP (Preparation)
(preparation of, as photog. cyan coupler)
RN 97639-12-8 CAPLUS
CN Acetic acid, 2-[[2-[2-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxohexyl]amino]-5-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-4-hydroxyphenoxy]ethyl]thio]- (CA INDEX NAME)

L16 ANSWER 46 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



IT 97459-10-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of photog. cyan coupler)
RN 97459-10-4 CAPLUS
CN Carbamic acid, (4-cyano-1-naphthalenyl)-, phenyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 47 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:463588 CAPLUS
DN 101:63588
OREF 101:9703a,9706a
TI Silver halide photosensitive materials for color photography
IN Sato, Ryosuke; Sasaki, Takashi; Kato, Katsunori; Sugita, Hiroshi
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 105991	A1	19840425	EP 1982-305544	19821018 <--
R: AT, BE, CH, IT, LI, NL, SE				
EP 199164	A1	19861029	EP 1986-104642	19821018 <--
R: AT, BE, CH, IT, LI, NL, SE				
CA 1292137	C	19911119	CA 1982-413879	19821021 <--
PRAI EP 1982-305544	P	19821018		

OS CASREACT 101:63588; MARPAT 101:63588
GI For diagram(s), see printed CA Issue.
AB A phenol-type cyan photog. coupler which has a high color development even in the absence of benzyl alc. comprises I (R = H or a group removable upon coupling with an oxidized developer; R1 = CN, CO2R4, COR4, SO2OR4, SO2R4, SO2NR4R5, CONR4R5, NO2, or CF3 where R4 = alkyl or aryl and R5 = H, alkyl, or aryl; R2 = H, OH, halo, NO2, or a monovalent org group; Z = (optional) a nonmetallic group which forms a 5- or 6-membered ring; R3 = ballast group; n = 0-4 and when n >2 each R2 may be the same or different). Thus, II 0.03 mol was added to a mixture of the same weight of di-Bu phthalate and 3 times the volume of BtOAc, heated to 60°, mixed with Alkanol B and gelatin, emulsified, added to a Ag(Cl,Br) (20 mol% AgBr) emulsion containing 0.1 mol Ag, and the obtained mixture was coated on a polyethylene-laminated paper support. The obtained element was imagewise exposed, color developed in a composition containing 4-amino-3-methyl-N-ethyl-N-(β-methanesulfonamidoethyl)aniline sulfate 5 g, benzyl alc. 15 mL, Na hexametaphosphate 2.5, Na2SO3 1.85, NaBr 1.4, KBr 0.5, borax 39.1 g, and H2O to 1 L (pH adjusted to 10.3), bleached, and fixed to give an image with a relative sensitivity of 98 and a Dmax of 71 vs. 71 and 1.8 for a sample developed in a developer free of benzyl alc.
IT 84953-90-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 84953-90-2 CAPLUS
CN Butanamide, 4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX NAME)

L16 ANSWER 47 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 48 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

D1-CH_2-Cl

D1-CH=CH_2

L16 ANSWER 49 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:148450 CAPLUS
DN 100:148450
OREF 100:22517a,22520a
TI Color-forming carboxamidonaphthalene dye precursor compounds, photographic materials containing them and corresponding carboximide dyes
IN Klijanowicz, James Edward; Kovacs, Csaba Andras
PA Eastman Kodak Co., USA
SO Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 95899	A2	19831207	EP 1983-303041	19830526 <--
	EP 95899	A3	19840229		
	EP 95899	B1	19860820		
	R: DE, FR, GB				
	US 4423126	A	19831227	US 1982-382546	19820527 <--
	CA 1206972	A1	19860701	CA 1982-413214	19821012 <--
	US 4536598	A	19850820	US 1983-473925	19830310 <--
	JP 58215460	A	19831214	JP 1983-91632	19830526 <--
PRAI	US 1982-382546	A	19820527		

OS MARPAT 100:148450
GI



I

AB Photog. useful 4-(4'-secondary or tertiary-aminoanilino)-1-carboxamidonaphthalene dye precursors provide a dye image (which enhances a Ag image) by cross-oxidation during development, with no need for a coupling reaction. Thus, a subbed poly(ethylene terephthalate) support was coated with a composition containing a S-Au sensitized Ag(Br,I) emulsion 9.7, I (dispersed in a solvent at a 1:1 ratio) 3, and a gelatin binder hardened by bis(vinylsulfonylmethyl) ether (2 weight parts in 200 parts water) 0.43 mg/dm2, imagewise exposed, processed in a developer composition containing Na3PO4 47.5, 4-hydroxymethyl-4-methyl-1-phenyl-3-pyrazolidone 1 g, benzyl alc. 10 mL, KBr 1 g, and H2O to 1L for 30 s, washed with H2O, fixed, washed, and dried, to give an image which was exposed to 5400 lx irradiation for 1, 3, and 7 days to show a % of dye fade equal to 0.28, 0.62, and 1.86, resp. (the dye fade % was calculated as [D initial-D faded/D initial] + 100%, where d. D was measured at the maximum absorption wavelength for the dye equaled λ = 576 nm).

IT 88878-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 88878-07-3 CAPLUS
CN Methanesulfonamide, N-[2-[ethyl[3-methyl-4-[(4-nitro-1-naphthalenyl)amino]phenyl]amino]ethyl]- (CA INDEX NAME)

L16 ANSWER 48 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:211003 CAPLUS
DN 100:211003
OREF 100:32059a,32062a
TI Preparation of self-sensitizing photopolymer
PA Nishikubo, Tadatomi, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58164603	A	19830929	JP 1982-46567	19820324 <--
PRAI	JP 1982-46567		19820324		

AB The title photopolymers are prepared from a copolymer containing both a haloalkyl group and a photosensitizer unit in the side chain and a compound containing a light-sensitive group which is reactive with the haloalkyl group. The polymers have excellent properties with respect to photocuring, reproducibility, and prevention of pollution in the working environment. Thus, chloromethylstyrene 43.49, 2-methacryloyloxy-N-(4-nitro-1-naphthyl)acetamide 3.96, and AIBN 0.477 g were mixed to give 28.74 g copolymer (yield 50.03%). The copolymer 3.815, Bu4NBr 0.665, and K cinnamate 4.652 g were mixed to give 4.91 g photopolymer (I) (yield 78.3%). I coated on a Cu plate showed excellent light sensitivity.

IT 87133-95-7D, reaction products with potassium cinnamate or sodium azide
RL: USES (Uses)
(photopolymers, self-sensitizing)

RN 87133-95-7 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[(4-nitro-1-naphthalenyl)amino]-2-oxoethyl ester, polymer with (chloromethyl)ethenylbenzene (9CI) (CA INDEX NAME)

CM 1

CRN 86830-99-1
CMF C16 H14 N2 O5



CM 2

CRN 30030-25-2
CMF C9 H9 Cl
CCI IDS

L16 ANSWER 49 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 88878-08-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
RN 88878-08-4 CAPLUS
CN 1,4-Benzenediamine, N4,N4-diethyl-2-methyl-N1-(4-nitro-1-naphthalenyl)-
(CA INDEX NAME)



L16 ANSWER 50 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:129806 CAPLUS
DN 100:129806
OREF 100:19649a,19652a
TI Cyan coupler
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58189633	A	19831105	JP 1983-43686	19830315 <--
	JP 02047736	B	19901022		
PRAI	JP 1983-43686		19830315		

GI



AB The couplers have (1) a substituted or condensed 4-cyanophenylureido group at position 2, (2) H, or a group detachable by coupling reaction at position 4, and (3) a ballasted acylamino group at position 5. Such couplers reduce the loss of cyan dye during processing, even when the processes are speeded up and the solns. are exhausted by running. Thus, cyan coupler I dispersed in a mixture containing di-Bu phthalate, AcOEt, Alkanol B, and gelatin was added to a Ag(Cl,Br) emulsion, coated on a laminated paper, imagewise exposed, and developed with a solution containing 4-amino-3-methyl-N-ethyl-N-(β-methanesulfonamidoethyl)aniline sulfate, with or without benzyl alc., followed by bleach-fixing using Fe/NH4 EDTA complex to give an image with satisfactory sensitivity, optical d., and color purity, in both cases.
IT 84953-90-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 84953-90-2 CAPLUS
CN Butanamide, 4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX NAME)

L16 ANSWER 50 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 51 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:129805 CAPLUS
DN 100:129805
OREF 100:19649a,19652a
TI Cyan coupler
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58189634	A	19831105	JP 1983-43687	19830315 <--
	JP 01053774	B	19891115		
PRAI	JP 1983-43687		19830315		

GI



AB The cyan couplers carry (1) a substituted or condensed 4-cyanophenylureido group at position 2, (2) H, or a group detachable by coupling reaction at position 4, and (3) a ballasted acylamino group at position 5. The couplers eliminate the use of benzyl alc. in the developer and yet provide high cyan optical d. Thus, a dispersion containing cyan coupler I and additives was added to a Ag(Cl,Br) emulsion, coated on a laminated paper, imagewise exposed, developed using a developer containing 4-amino-3-methyl-N-ethyl-N-(β-methanesulfonamidoethyl)aniline sulfate with or without benzyl alc. Bleach-fixer contained Fe/NH4 EDTA complex. Satisfactory sensitivity, cyan optical d., and color purity were obtained with both developers.
IT 84953-90-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)
RN 84953-90-2 CAPLUS
CN Butanamide, 4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX NAME)

L16 ANSWER 51 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 52 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:112176 CAPLUS
DN 100:112176
OREF 100:16929a,16932a
TI Photographic cyan couplers
PA Konishiroku Photo Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58189635	A	19831105	JP 1983-43688	19830315 <--
	JP 01053775	B	19891115		
PRAI	JP 1983-43688		19830315		

GI



I

AB Phenol derivative cyan couplers having a substituted or condensed 4-cyanophenylureido moiety at position 2, H or a moiety which can be eliminated by coupling with an oxidation product of color developers at position 4 and a ballasted aminoacyl moiety at position 5 provide high coloring sensitivity and d. and improved stability of the final cyan dye image. Thus, a Ag(Cl,Br) photog. emulsion containing coupler I was wedge exposed and color developed to give a cyan image with high sensitivity and d., and the final image showed high stability against light, heat, and humidity.

IT 84953-90-2
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. cyan coupler)

RN 84953-90-2 CAPLUS
CN Butanamide, 4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX NAME)

L16 ANSWER 52 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 53 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:102982 CAPLUS
DN 100:102982
OREF 100:15633a,15636a
TI Insecticidal naphthalenamine derivatives
IN Clinton, Albert James; O'Doherty, George Oliver Plunkett
PA Eli Lilly and Co., USA
SO Brit. UK Pat. Appl., 14 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2119380	A	19831116	GB 1983-12033	19830503 <--
	GB 2119380	B	19860702		
	US 4423065	A	19831227	US 1982-374802	19820504 <--
	IL 68500	A	19860731	IL 1983-68500	19830427 <--
	FI 8301500	A	19831105	FI 1983-1500	19830502 <--
	AU 8314143	A	19831110	AU 1983-14143	19830502 <--
	AU 557503	B2	19861224		
	JP 58203949	A	19831128	JP 1983-78844	19830502 <--
	ZA 8303104	A	19840125	ZA 1983-3104	19830502 <--
	HU 31911	A2	19840628	HU 1983-1501	19830502 <--
	HU 190627	B	19860929		
	CA 1198123	A1	19851217	CA 1983-427229	19830502 <--
	DK 8301967	A	19831105	DK 1983-1967	19830503 <--
	BR 8302284	A	19840103	BR 1983-2284	19830503 <--
	EP 102680	A1	19840314	EP 1983-302481	19830503 <--
	EP 102680	B1	19860305		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DD 210255	A5	19840606	DD 1983-250551	19830503 <--
	AT 18393	T	19860315	AT 1983-302481	19830503 <--
	SU 1346041	A3	19871015	SU 1983-3591651	19830503 <--
	US 4764534	A	19880816	US 1984-631665	19840717 <--
	CA 1200481	A2	19860211	CA 1984-470465	19841218 <--
PRAI	US 1982-374801	A	19820504		
	US 1982-374802	A	19820504		
	CA 1983-427229	A3	19830502		
	EP 1983-302481	A	19830503		

OS CASREACT 100:102982; MARPAT 100:102982

GI



I

AB N-Phenylnaphthylamines I (R = H, alkyl; R1 = H, halo; R2 = halo, Ph, NO2, cyano, fluoroalkyl, fluoroalkoxy, fluoroalkylthio; R3 = H, halo) were prepared, and they showed insecticidal and coccidiostatic activity. 1-Nitro-2-naphthylamine was N-arylated by 2-chloro-3,5-dinitrobenzotrifluoride and NaH in DMF to give the appropriate I (2-anilino, R = R1 = R3 = H, R2 = 1-NO2).

IT 88965-48-4P 88965-49-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except

L16 ANSWER 53 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and insecticidal activity of)
RN 88965-48-4 CAPLUS
CN 1-Naphthalenamine, N-[2,4-dinitro-6-(trifluoromethyl)phenyl]-4-nitro- (CA INDEX NAME)



RN 88965-49-5 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[[2,4-dinitro-6-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



IT 88965-44-0P 88965-46-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and insecticidal and coccidiostatic activity of)
RN 88965-44-0 CAPLUS
CN 1-Naphthalenamine, 4-chloro-N-[2,4-dinitro-6-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L16 ANSWER 53 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 88965-46-2 CAPLUS
CN 1-Naphthalenamine, 4-bromo-N-[2,4-dinitro-6-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L16 ANSWER 54 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:612522 CAPLUS
DN 99:212522
OREF 99:32710h,32711a
TI Anthelmintics
IN Webster, Richard Andrew Bentley; Dorgan, Roderick John
PA Beecham Group PLC, UK
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 76622	A1	19830413	EP 1982-305126	19820929 <--
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	ZA 8207294	A	19830831	ZA 1982-7294	19821005 <--
	JP 58072593	A	19830430	JP 1982-176016	19821006 <--
	AU 8289191	A	19830414	AU 1982-89191	19821007 <--
	ES 516336	A1	19831201	ES 1982-516336	19821007 <--
	DK 8300498	A	19831209	DK 1983-498	19830204 <--
	ES 524072	A1	19841201	ES 1983-524072	19830712 <--
PRAI	GB 1981-30241	A	19811007		
	GB 1982-16624	A	19820608		

OS MARPAT 99:212522
GI



AB Tetramisole derivs. I [R = N:C(XR1) NR2R3, NR4C(XR1):NR3, NR4CXNR2R3; R1 = alkyl, aralkyl; R2-R4 = H, alkyl, aryl, aralkyl; NR2R3 = heterocyclic; X = O, S] and their 2,3-didehydro analogs were prepared Thus, I (R = NH2) was treated with PhNCS to give I (R = NHCSNHPh) which was S-methylated to give I [R = N:C(SMe)NHPh (II)]. At 200 mg/kg orally in mice II gave 99% control of Nematospiroides dubius. dubries.
IT 87023-39-0P 87023-40-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of)
RN 87023-39-0 CAPLUS
CN Thiourea, N-(4-nitro-1-naphthalenyl)-N'-[3-(2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl)phenyl]- (CA INDEX NAME)



RN 87023-40-3 CAPLUS
CN Thiourea, N-(4-cyano-1-naphthalenyl)-N'-[3-(2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl)phenyl]- (CA INDEX NAME)

L16 ANSWER 54 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 87023-46-9P 87023-47-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87023-46-9 CAPLUS
CN Carbamimidothioic acid, N-(4-nitro-1-naphthalenyl)-N'-[3-(2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl)phenyl]-, methyl ester (CA INDEX NAME)



RN 87023-47-0 CAPLUS
CN Carbamimidothioic acid, N-(4-cyano-1-naphthalenyl)-N'-[3-(2,3,5,6-tetrahydroimidazo[2,1-b]thiazol-6-yl)phenyl]-, methyl ester (CA INDEX NAME)



L16 ANSWER 55 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:446002 CAPLUS
DN 99:46002
OREF 99:7097a,7100a
TI A phenol cyan coupler for silver halide color photographic material
IN Tsuda, Yasuo; Sato, Ryosuke
PA Konishiroku Photo Industry Co., Ltd. , Japan
SO Eur. Pat. Appl., 62 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 73145	A1	19830302	EP 1982-304385	19820819 <--
	R: DE, FR, GB				
	JP 58033251	A	19830226	JP 1981-131313	19810820 <--
	JP 63010817	B	19880309		
	JP 58033252	A	19830226	JP 1981-131314	19810820 <--
	JP 63035971	B	19880718		
PRAI	JP 1981-131313	A	19810820		
	JP 1981-131314	A	19810820		

OS MARPAT 99:46002
GI



(Z)p I



II

AB A photog. cyan coupler comprises a phenol nucleus substituted at the 2-position with a NHCOHNR (R = heterocyclic or a condensed heterocyclic group) group or with I (Z = monovalent group; p = 0, 1-5), and by acylamino group at the 5-position. Thus, a polyethylene-laminated paper support was coated with a mixture containing a Ag(Br,Cl) emulsion (20 mol.% AgBr) and a gelatin solution containing an EtOAc-di-Bu phthalate solution of 0.03 mol II, dried, imagewise exposed, developed at 30° for 3.5 min in a solution containing 4-amino-3-methyl-N-ethyl-N-(β-methanesulfonamidoethyl)aniline sulfate 5, Na hexametaphosphate 2.5, Na2SO3 1.85, NaBr 1.4, KBr 0.5, borax 39.1 g, and H2O to 1 L (pH = 10.3), bleached, and fixed at 30° for 1.5 min in a solution containing ferric ammonium ethylenediaminetetraacetate 50 g, 40% (NH4)2SO3 50, 70% (NH4)2S2O3 140, 20% NH3 20 mL, EDTA 4 g, and H2O to 1 L to give an image with a Dmax. of 1.8 and relative sensitivity of 74.

L16 ANSWER 55 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 85915-48-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aminochloronitrophenol)
RN 85915-48-6 CAPLUS
CN Urea, N-(4-chloro-1-naphthalenyl)-N'-phenyl- (CA INDEX NAME)



L16 ANSWER 55 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 85929-27-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and photog. applications of)
RN 85929-27-7 CAPLUS
CN Hexanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-chloro-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 85915-47-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of)
RN 85915-47-5 CAPLUS
CN Urea, N-(5-chloro-2-hydroxy-4-nitrophenyl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 56 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:135179 CAPLUS
DN 98:135179
OREF 98:20447a,20450a
TI Silver halide photosensitive materials for color photography
IN Sato, Ryosuke; Kato, Katsunori; Sasaki, Takashi; Sugita, Hiroshi
PA Konishiroku Photo Industry Co., Ltd. , Japan
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 67689	A1	19821222	EP 1982-303047	19820611 <--
	EP 67689	B1	19860910		
	R: DE, FR, GB				
	JP 57204543	A	19821215	JP 1981-90334	19810611 <--
	JP 59041181	B	19841005		
	JP 57204544	A	19821215	JP 1981-90335	19810611 <--
	JP 59041182	B	19841005		
	JP 57204545	A	19821215	JP 1981-90336	19810611 <--
	JP 61038464	B	19860829		
	EP 148536	A2	19850717	EP 1984-201945	19820611 <--
	EP 148536	A3	19850918		
	EP 148536	B1	19890906		
	R: DE, FR, GB				
	BR 8206597	A	19840619	BR 1982-6597	19821112 <--
	US 4451559	A	19840529	US 1983-522818	19830812 <--
	US 4465766	A	19840814	US 1983-540719	19831011 <--
	US 4772543	A	19880920	US 1983-540720	19831011 <--
	US 4554244	A	19851119	US 1984-616652	19840604 <--
	US 4929539	A	19900529	US 1988-191224	19880506 <--
PRAI	JP 1981-90334	A	19810611		
	JP 1981-90335	A	19810611		
	JP 1981-90336	A	19810611		
	US 1982-385096	A1	19820604		
	EP 1982-303047	P	19820611		
	US 1983-522818	A3	19830812		
	US 1983-540719	A1	19831011		
	US 1983-540720	A3	19831011		

OS CASREACT 98:135179; MARPAT 98:135179
GI For diagram(s), see printed CA Issue.
AB A cyan coupler for color photog. comprises I (R = CN, CO2R1, COR1, SO2OR1, SO2R1, SO2NR1R2, CONR2R2, NO2, CF3 where R1 = alkyl, aryl and R2 = H, alkyl, aryl; R3 = H, halogen, OH, NO2, monovalent organic group; R4 = H, or a removable group upon coupling reaction of a color developing agent with an oxidized product, Y = non-metallic atom groups capable of forming a 5- or 6-member ring; X = ballast group; n = 0-4). Thus, a polyethylene-laminated paper support was coated with a Ag(Cl, Br) (20 mol% AgBr) emulsion containing II, imagewise exposed, developed 3 min 30 s at 30° in a composition containing 4-amino-3-methyl-N-ethyl-N-(β-methanesulfonamidoethyl)aniline sulfate 5, Na hexametaphosphate 2.5, Na2SO3 1.85, NaBr 1.4, KBr 0.5, borax 39.1 g, benzyl alc. 15 mL, H2O to 1 L (pH 10.3 adjusted with NaOH), bleach-fixed 1 min 3 s in a solution containing ethylenediaminetetraacetate Fe ammonium complex 50 g, (NH4)2SO3 (40% aq) 50, (NH4)2S2O3 (40% aq) 140, 28% aqueous NH3 20 mL, EDTA 4 g, H2O to 1 L, and washed with H2O 2 min to give an image with maximum d. 2.24 and relative sensitivity 100.
IT 84953-90-2
RL: USES (Uses)
(photog. element containing)
RN 84953-90-2 CAPLUS
CN Butanamide, 4-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]amino]-5-hydroxyphenyl]- (CA INDEX

L16 ANSWER 56 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)

PAGE 1-A



PAGE 2-A



L16 ANSWER 57 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:44222 CAPLUS
DN 98:44222
OREF 98:6679a,6682a
TI Self-sensitized photosensitive resins
PA Nishikubo, Chuji, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 57064229	A	19820419	JP 1980-139523	19801006 <--
PRAI JP 1980-139523		19801006		

AB Copolymers having cinnamate ester groups and N-substituted amide groups as photosensitive and sensitiizing groups, resp., are used as self-sensitiizing type photosensitive imaging materials. Thus, 2-cinnamoyloxyethyl methacrylate and N-(4-nitrophenyl)methacrylamide were copolymd. to give a self-sensitized photosensitive polymer, which was useful as a photoresist for printed circuit preparation
IT 77901-88-3 82601-04-5 84135-67-1
84135-76-2
RL: USES (Uses)
(self-sensitized, as photoresists)
RN 77901-88-3 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-[(1-oxo-3-phenyl-2-propenyl)oxy]ethyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide (9CI) (CA INDEX NAME)

CM 1

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 2

CRN 41261-99-8
CMF C15 H16 O4



RN 82601-04-5 CAPLUS
CN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester, polymer with

L16 ANSWER 57 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide, 3-phenyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 621-82-9
CMF C9 H8 O2

CM 2

CRN 219861-20-8
CMF (C14 H12 N2 O3 . C6 H10 O3)x
CCI PMS

CM 3

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 4

CRN 868-77-9
CMF C6 H10 O3



RN 84135-67-1 CAPLUS
CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide and oxiranylmethyl 2-methyl-2-propenoate, 3-phenyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 621-82-9
CMF C9 H8 O2

CM 2

L16 ANSWER 57 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 205041-25-4
CMF (C14 H12 N2 O3 . C7 H10 O3 . C5 H8 O2)x
CCI PMS

CM 3

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 4

CRN 106-91-2
CMF C7 H10 O3



CM 5

CRN 80-62-6
CMF C5 H8 O2



RN 84135-76-2 CAPLUS
CN 2-Propenoic acid, 2-hydroxyethyl ester, polymer with 2-methyl-N-(4-nitro-1-naphthalenyl)-2-propenamide, 3-phenyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 621-82-9
CMF C9 H8 O2

CM 2

CRN 212889-76-4
CMF (C14 H12 N2 O3 . C5 H8 O3)x

L16 ANSWER 57 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CCI PMS

CM 3

CRN 77901-87-2
CMF C14 H12 N2 O3



CM 4

CRN 818-61-1
CMF C5 H8 O3



L16 ANSWER 58 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1981:578682 CAPLUS
DN 95:178682
OREF 95:29689a,29692a
TI Photoresist compositions
IN Kamoshida, Yoichi; Yoshihara, Toshiaki; Harita, Yoshiyuki; Harada, Kunihiro
PA Japan Synthetic Rubber Co., Ltd., Japan
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 26088	A2	19810401	EP 1980-303280	19800918 <--
	EP 26088	A3	19810708		
	EP 26088	B1	19831123		
	R: DE, FR, GB, NL				
	JP 56043635	A	19810422	JP 1979-120406	19790919 <--
	JP 56069624	A	19810611	JP 1979-145051	19791109 <--
	JP 62002304	B	19870119		
	JP 56153338	A	19811127	JP 1980-56682	19800428 <--
	JP 57035850	A	19820226	JP 1980-111386	19800813 <--
	JP 63015571	B	19880405		
	US 4349619	A	19820914	US 1980-185771	19800910 <--
PRAI	JP 1979-120406	A	19790919		
	JP 1979-145051	A	19791109		
	JP 1980-56682	A	19800428		
	JP 1980-111386	A	19800813		

OS MARPAT 95:178682
GI



AB A photoresist for elec. circuit fabrication providing a high resolution and only a small number of pinholes even with a support board having a high reflectance surface comprises cyclized product of conjugated diene polymer or copolymer, photocrosslinking agent soluble in an organic solvent and ≥1 of amino- or diaminoazobenzene, amino- or diaminostilbene, alkylamino- or dialkylaminostilbene, I, or II (R, R1, R2, R3, R5, R6 = H, alkyl, alkenyl, aryl, aralkyl; R4 = H, amino; R7 = H, aryl). Thus, a Si wafer having vacuum deposited Al layer was coated with a photoresist composition containing 2,6-bis(4'-azidobenzal)cyclohexanone 0.22, 2,2'-methylenebis(4-methyl-6-t-butylphenol) 0.11, 4,4'-thiobis(2,6-di-t-butylphenol) 0.11, cyclized product of cis-1,4-polyisoprene 11, xylene 87.8, 4-amino-4'-(N,N-dimethylamino)stilbene 0.66 g, dried at 80° for 15 min, imagewise exposed (Hg lamp, 50 W/m2) 3 s, developed with Kodak Microresist developer 1 min, and rinsed with Bu acetate 1 min to give an image with 2.2 μm resolution
IT 78369-86-5
RL: USES (Uses)
(photoresist for elec. circuit fabrication containing cyclized conjugated

L16 ANSWER 58 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
diene polymer and photocrosslinking agent and)
RN 78369-86-5 CAPLUS
CN 1-Triazene, 1-(1-naphthalenyl)-3-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 59 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:84763 CAPLUS
DN 86:84763
OREF 86:13369a,13372a
TI 3-Pyridylmethyl aryl urea rodenticides
IN Kilbourn, Edward E.; Peardon, David L.; Ware, J. Edgar
PA Rohm and Haas Co., USA
SO U.S., 7 pp. Division of U.S. 3,931,203.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3994905	A	19761130	US 1975-622914	19751016 <--
	US 3931203	A	19760106	US 1974-460264	19740411 <--
	IN 140450	A1	19761113	IN 1974-CA1697	19740730 <--
	NO 7500051	A	19740920	NO 1975-51	19750108 <--
	NO 141589	B	19800102		
	NO 141589	C	19800416		
PRAI	US 1973-342334	A2	19730319		
	US 1974-460264	A3	19740411		
	GB 1973-41440	A	19730904		
	NO 1974-926	A	19740315		

GI



AB The title compds. I (Ar = 4-substituted phenyl or -naphthyl) and their acid addition salts are rodenticides. Thus, 1-(3-pyridylmethyl)-3-(4-nitrophenyl)urea [53558-25-1] prepared from p-nitrophenyl isocyanate [100-28-7] and 3-(aminomethyl)pyridine [3731-52-0] given orally to albino rate at 50 mg/kg was 100% effective; addnl. 28 I were prepared and tested.
IT 54528-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and rodenticidal activity of)
RN 54528-32-4 CAPLUS
CN Urea, N-(4-nitro-1-naphthalenyl)-N'-(3-pyridinylmethyl)- (CA INDEX NAME)



L16 ANSWER 59 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 60 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:7544 CAPLUS
DN 86:7544
OREF 86:1257a,1260a
TI Concentrating cadmium in a solution
IN Ichiki, Minoru; Nakade, Kazuhiko; Narabe, Hiroshi
PA Mitsui Mining and Smelting Co., Ltd., Japan
SO Jpn. Tokkyo Koho, 2 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51022445	B	19760709	JP 1971-38476	19710602 <--
PRAI	JP 1971-38476	A	19710602		

AB Cd is concentrated in a solution and separated therefrom by formation of a chelate compound. The chelate is formed by adding p-nitrodiazoaminoazobenzene [60999-15-7] or 4-nitronaphthyldiazoaminoazobenzene [52005-37-5], and floated by a bubbling activator.
IT 52005-37-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(cadmium chelation by, for concentration and removal from solution)
RN 52005-37-5 CAPLUS
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 61 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1976:137221 CAPLUS
DN 84:137221
OREF 84:22319a,22322a
TI Dye former
IN Ozutsumi, Minoru; Miyazawa, Yoshihide; Yamaguchi, Masahiko
PA Hodogaya Chemical Co., Ltd., Japan
SO Ger. Offen., 38 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2530463	A1	19760129	DE 1975-2530463	19750708 <--
	DE 2530463	B2	19771110		
	JP 51007027	A	19760121	JP 1974-77348	19740708 <--
	JP 51041139	B	19761108		
	US 4073614	A	19780214	US 1975-594173	19750708 <--
	US 4074050	A	19780214	US 1977-778280	19770316 <--
PRAI	JP 1974-77348	A	19740708		
	US 1975-594173	A3	19750708		

GI For diagram(s), see printed CA Issue.
AB Mixts. of color formers I (R = H, Me, Et, PhCH2, 4-MeC6H4; R1 = PhCH2, Ph; R2 = Me, Ph, substituted Ph, Et, Bu, cyclohexyl, allyl, C10H7, C10H7CH2, PhCH2CH2, Me2CHCH2; R3 = Et2N, H, (PhCH2)2N, MeO, Me2N, Me, Cl, EtO; R4 = H, Me, Cl) and II (R, R1, R2, R3, R4 defined as in I) were prepared and gave intense greenish blue to purple shades on acid clay after several hr of contact. Thus, bis[4-(dimethylamino)phenyl]-[2-N-methylcarbamoyloxy-4-(diethylamino)phenyl]methane [58709-51-2] was oxidized with chloranil to give a mixture of I (R = R1 = R2 = Me, R3 = Me2N, R4 = H) [58710-12-6] and II (R = R1 = R2 = Me, R3 = Me2N, R4 = H) [58710-13-7]. The other I-II mixts. were similarly prepared
IT 58709-56-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 58709-56-1 CAPLUS
CN Carbamic acid, (4-chloro-1-naphthalenyl)-, 2-[bis[4-(dimethylamino)phenyl]methyl]-5-ethoxyphenyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 62 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1976:90018 CAPLUS
DN 84:90018
OREF 84:14685a,14688a
TI 3-Pyridylmethyl aryl urea rodenticides
IN Kilbourn, Edward E.; Peardon, David L.; Ware, J. Edgar
PA Rohm and Haas Co., USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3931203	A	19760106	US 1974-460264	19740411 <--
	RO 68859	A2	19781030	RO 1973-74978	19730531 <--
	JP 49125370	A	19741130	JP 1973-119783	19731024 <--
	JP 56010283	B	19810306		
	FR 2222371	A1	19741018	FR 1974-1260	19740115 <--
	BE 809868	A1	19740717	BE 1974-139919	19740117 <--
	GB 1456269	A	19761124	GB 1974-6594	19740213 <--
	AU 7466206	A	19750904	AU 1974-66206	19740301 <--
	RO 68859	A1	19801230	RO 1974-77906	19740305 <--
	SU 589888	A3	19780125	SU 1974-2001552	19740306 <--
	BR 7401670	D0	19741029	BR 1974-1670	19740307 <--
	HU 168295	B	19760328	HU 1974-R0772	19740307 <--
	CS 181263	B2	19780331	CS 1974-1706	19740308 <--
	NL 7403398	A	19740923	NL 1974-3398	19740313 <--
	CH 582674	A5	19761215	CH 1974-3520	19740313 <--
	CH 582472	A5	19761215	CH 1974-3521	19740313 <--
	FI 55653	B	19790531	FI 1974-799	19740315 <--
	FI 55653	C	19790910		
	SE 409859	B	19790910	SE 1974-3542	19740315 <--
	NO 143742	B	19801229	NO 1974-926	19740315 <--
	NO 143742	C	19810408		
	DK 141049	B	19791231	DK 1974-1482	19740318 <--
	DK 141049	C	19800623		
	DD 110266	A5	19741212	DD 1974-177279	19740319 <--
	DD 110163	A5	19741212	DD 1974-177280	19740319 <--
	AT 7402256	A	19761115	AT 1974-2256	19740319 <--
	AT 338035	B	19770725		
	IT 1007622	B	19761030	IT 1974-20566	19740408 <--
	IN 140450	A1	19761113	IN 1974-CA1697	19740730 <--
	NO 7500051	A	19740920	NO 1975-51	19750108 <--
	NO 141589	B	19800102		
	NO 141589	C	19800416		
	US 3994905	A	19761130	US 1975-622914	19751016 <--
	SU 659090	A3	19790425	SU 1976-2194152	19761202 <--
PRAI	US 1973-342334	A2	19730319		
	GB 1973-41440	A	19730904		
	NO 1974-926	A	19740315		
	US 1974-460264	A3	19740411		

GI For diagram(s), see printed CA Issue.
AB Eighteen ureas I [R = 4-substituted phenyl (e.g., 4-O2NC6H4, 4-HSC6H4, 4-NCC6H4, 4-MeSC6H4), or 4-nitro-1-naphthyl], with rodenticidal activity (tests on rats and mice given), were prepared, 17 of them by reaction of 3-(aminomethyl)pyridine with RNCO in C6H6 or PhMe; I (R = 4-NCC6H4) was prepared by reaction of Ph (3-pyridylmethyl)carbamate and 4-H2NC6H4CN in EtOH at reflux. Salts (e.g., hydrobromide, hydrochloride, oxalate) of some I were also prepared
IT 54528-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and rodenticidal activity of)
RN 54528-32-4 CAPLUS
CN Urea, N-(4-nitro-1-naphthalenyl)-N'-(3-pyridinylmethyl)- (CA INDEX NAME)

L16 ANSWER 62 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 63 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:59220 CAPLUS
DN 84:59220
OREF 84:9734h,9735a
TI 3-Pyridylmethyl aryl ureas
IN Ware, James E.; Kilbourn, Edward E.; Peardon, David L.
PA Rohm and Haas Co., USA
SO S. African, 31 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	ZA 7400954	A	19750430	ZA 1974-954	19740213	<--
	RO 68859	A2	19781030	RO 1973-74978	19730531	<--
	JP 49125370	A	19741130	JP 1973-119783	19731024	<--
	JP 56010283	B	19810306			
	FR 2222371	A1	19741018	FR 1974-1260	19740115	<--
	BE 809868	A1	19740717	BE 1974-139919	19740117	<--
	GB 1456269	A	19761124	GB 1974-6594	19740213	<--
	AU 7466206	A	19750904	AU 1974-66206	19740301	<--
	RO 68859	A1	19801230	RO 1974-77906	19740305	<--
	SU 589888	A3	19780125	SU 1974-2001552	19740306	<--
	BR 7401670	D0	19741029	BR 1974-1670	19740307	<--
	HU 168295	B	19760328	HU 1974-R0772	19740307	<--
	CS 181263	B2	19780331	CS 1974-1706	19740308	<--
	NL 7403398	A	19740923	NL 1974-3398	19740313	<--
	CH 582674	A5	19761215	CH 1974-3520	19740313	<--
	CH 582472	A5	19761215	CH 1974-3521	19740313	<--
	FI 55653	B	19790531	FI 1974-799	19740315	<--
	FI 55653	C	19790910			
	SE 409859	B	19790910	SE 1974-3542	19740315	<--
	NO 143742	B	19801229	NO 1974-926	19740315	<--
	NO 143742	C	19810408			
	DK 141049	B	19791231	DK 1974-1482	19740318	<--
	DK 141049	C	19800623			
	DD 110266	A5	19741212	DD 1974-177279	19740319	<--
	DD 110163	A5	19741212	DD 1974-177280	19740319	<--
	AT 7402256	A	19761115	AT 1974-2256	19740319	<--
	AT 338035	B	19770725			
	IT 1007622	B	19761030	IT 1974-20566	19740408	<--
	IN 140450	A1	19761113	IN 1974-CA1697	19740730	<--
	NO 7500051	A	19740920	NO 1975-51	19750108	<--
	NO 141589	B	19800102			
	NO 141589	C	19800416			
	SU 659090	A3	19790425	SU 1976-2194152	19761202	<--
PRAI	US 1973-342334	A	19730319			
	GB 1973-41440	A	19730904			
	NO 1974-926	A	19740315			

GI For diagram(s), see printed CA Issue.
AB Sixteen ureas I (R = p-O2NC6H4, p-MeSC6H4, p-F3CC6H4, 4-nitronaphthyl, etc.) were prepared by treating 3-(aminomethyl)pyridine with RNCO, which were prepared from RNH2 and C12CO. I (R = p-NCC6H4) was prepared from Ph N-(3-pyridylmethyl)carbamate and p-H2NC6H4CN. The rodenticidal activity of I was determined with albino mice and rats.
IT 54528-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and rodenticidal activity of)
RN 54528-32-4 CAPLUS
CN Urea, N-(4-nitro-1-naphthalenyl)-N'-(3-pyridinylmethyl)- (CA INDEX NAME)

L16 ANSWER 63 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 64 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:13499 CAPLUS
DN 84:13499
OREF 84:2199a,2202a
TI N-Naphthyl tetrachlorophalamides as bactericides and fungicides
IN Nakagami, Kazuto; Yamazaki, Toshiharu; Yoshitake, Hiroto; Honda, Takeo
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	JP 50116640	A	19750912	JP 1974-20122	19740220	<--
	JP 57020924	B	19820504			
PRAI	JP 1974-20122	A	19740220			

GI For diagram(s), see printed CA Issue.
AB The title compds. I (R1 = lower alkyl- and halonaphthyl or 5,6,7,8-tetrahydronaphthyl, and R2 = H or lower alkyl) and their salts are bactericides and fungicides, especially effective against Xanthomonas oryzae. Thus, 84.2% of rice leaves were infected when a suspension of X. oryzae was sprayed on rice, but pretreatment of the rice with 100 ppm N-(2-methyl-α-naphthyl)tetrachlorophthalic acid monoamide [57462-14-3] decreased the infection rate to 2.0%.
IT 57462-15-4
RL: BIOL (Biological study)
(bactericide and fungicide)
RN 57462-15-4 CAPLUS
CN Benzoic acid, 2,3,4,5-tetrachloro-6-[[(4-chloro-1-naphthalenyl)amino]carbonyl]- (CA INDEX NAME)



L16 ANSWER 65 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:592932 CAPLUS
DN 83:192932
OREF 83:30329a,30332a
TI Naphthylanthranilic acid derivatives
IN Nohara, Fujio; Sugino, Toshiya
PA Ikeda Mohando Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50077352	A	19750624	JP 1973-126976	19731112 <--
PRAI	JP 1973-126976	A	19731112		

GI For diagram(s), see printed CA Issue.
AB N-naphthylanthranilic acids (I; R, R1 = H, Cl, iodo, lower alkyl; R R1 ≠ H) were prepared from benzimidates by Chapman rearrangement followed by hydrolysis of cyano, carbalkoxy, or carboxamido groups. I had analgesic and antiinflammatory activities (no data given). Thus, 2 g the benzimidate II (R2 = o-cyanophenyl) was heated with 10 g Ph2CO 2 hr at 290-300° under N to give 41% the naphthylamine III. The latter (1.8 g) was refluxed in EtOH containing 8 g 50% aqueous NaOH 2 hr to give 92.3% I (R = Cl, R1 = 4-Cl). Other I prepared were (R, R1 given): Bu, H; Cl, H; Me3C, H; Bu, 4-Cl; H, 4-Cl; H, 3-iodo).
IT 51671-14-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51671-14-8 CAPLUS
CN Benzoic acid, 2-[(4-chloro-1-naphthalenyl)amino]- (CA INDEX NAME)



L16 ANSWER 66 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:4130 CAPLUS
DN 82:4130
OREF 82:711a,714a
TI Rodenticidal 1-phenyl-3-(3-pyridylmethyl)ureas
IN Ware, James E.; Peardon, David L.; Kilbourn, Edward E.
PA Rohm and Haas Co.
SO Ger. Offen., 23 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2409686	A1	19741010	DE 1974-2409686	19740228 <--
	RO 68859	A2	19781030	RO 1973-74978	19730531 <--
	JP 49125370	A	19741130	JP 1973-119783	19731024 <--
	JP 56010283	B	19810306		
	FR 2222371	A1	19741018	FR 1974-1260	19740115 <--
	BE 809868	A1	19740717	BE 1974-139919	19740117 <--
	GB 1456269	A	19761124	GB 1974-6594	19740213 <--
	AU 7466206	A	19750904	AU 1974-66206	19740301 <--
	RO 68859	A1	19801230	RO 1974-77906	19740305 <--
	SU 589888	A3	19780125	SU 1974-2001552	19740306 <--
	BR 7401670	D0	19741029	BR 1974-1670	19740307 <--
	HU 168295	B	19760328	HU 1974-R0772	19740307 <--
	CS 181263	B2	19780331	CS 1974-1706	19740308 <--
	NL 7403398	A	19740923	NL 1974-3398	19740313 <--
	CH 582674	A5	19761215	CH 1974-3520	19740313 <--
	CH 582472	A5	19761215	CH 1974-3521	19740313 <--
	FI 55653	B	19790531	FI 1974-799	19740315 <--
	FI 55653	C	19790910		
	SE 409859	B	19790910	SE 1974-3542	19740315 <--
	NO 143742	B	19801229	NO 1974-926	19740315 <--
	NO 143742	C	19810408		
	DK 141049	B	19791231	DK 1974-1482	19740318 <--
	DK 141049	C	19800623		
	DD 110266	A5	19741212	DD 1974-177279	19740319 <--
	DD 110163	A5	19741212	DD 1974-177280	19740319 <--
	AT 7402256	A	19761115	AT 1974-2256	19740319 <--
	AT 338035	B	19770725		
	IT 1007622	B	19761030	IT 1974-20566	19740408 <--
	IN 140450	A1	19761113	IN 1974-CA1697	19740730 <--
	NO 7500051	A	19740920	NO 1975-51	19750108 <--
	NO 141589	B	19800102		
	NO 141589	C	19800416		
	SU 659090	A3	19790425	SU 1976-2194152	19761202 <--
PRAI	US 1973-342334	A	19730319		
	GB 1973-41440	A	19730904		
	NO 1974-926	A	19740315		

GI For diagram(s), see printed CA Issue.
AB Sixteen ureas I [R = e.g. NO2 (II), CN (III), CF3, SH, C1-6 alkylthio, COEt, COPr, SO2Ph, SO2NEt2] and 1-(4-nitronaphthyl)-3-(3-pyridylmethyl)urea, used for mouse and rat control, were prepared in most part by reaction of 3-(aminomethyl)pyridine (IV) with isocyanates. Thus, 4-O2NC6H4NCO reacted with IV in PhMe at ≤40° to give 98% II. IV reacted with ClCO2Ph in Et2O containing Et3N to give 89% Ph (3-pyridylmethyl)carbamate, which on refluxing with 4-NCC6H4NH2 in EtOH gave 43% III.
IT 54528-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)

L16 ANSWER 66 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. and rodenticidal activity of)
RN 54528-32-4 CAPLUS
CN Urea, N-(4-nitro-1-naphthalenyl)-N'-(3-pyridinylmethyl)- (CA INDEX NAME)



L16 ANSWER 67 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:133461 CAPLUS
DN 80:133461
OREF 80:21529a,21532a
TI Antibacterial and antimalarial 2,4-diamino-6-[(arylamino)methyl]quinazolines
IN Elslager, Edward F.; Werbel, Leslie M.
PA Parke, Davis and Co.
SO Brit., 8 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1345502	A	19740130	GB 1972-31827	19720706 <--
PRAI	GB 1972-31827	A	19720706		

GI For diagram(s), see printed CA Issue.
AB 2,4-Diamino-6-[(arylamino)methyl]quinazolines (I, R = H, Me, Cl; R1 = e.g. 3,4-Cl2C6H4, m-BrC6H4, 4-chloro-1-naphthyl), which have antimalarial and antibacterial activity, were prepared by reaction of the corresponding 2,4-diamino-5-quinazolinecarbonitriles with R1NH2 in AcOH under H in the presence of Raney Ni catalyst. I were converted into N-nitroso derivs. (II), N-Ac derivs. (III), and N-formyl derivs. (IV).
IT 52128-14-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52128-14-0 CAPLUS
CN 2,4-Quinazolinediamine, 6-[[(4-chloro-1-naphthalenyl)amino]methyl]-, acetate (2:3) (CA INDEX NAME)

CM 1

CRN 52128-13-9
CMF C19 H16 Cl N5



CM 2

CRN 64-19-7
CMF C2 H4 O2

L16 ANSWER 67 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 68 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:78131 CAPLUS
DN 80:78131
OREF 80:12537a,12540a
TI Colormetric determination of cadmium
IN Ichiki, Minoru; Ogawa, Naoaki
PA Mitsui Mining and Smelting Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48081586	A	19731031	JP 1972-11574	19720131 <--
	JP 51029840	B	19760827		
PRAI	JP 1972-11574	A	19720131		

AB Cd is extracted from aqueous solution with a solution of p-(nitrodiazoamino)azobenzene (I) or 4-nitronaphthalenediazoaminoazobenzene (II) in trichloroethane, dichloroethane, or dichlorobenzene or their mixts. as a stable Cd complex with I or II and Cd was determined by measuring absorbance of the organic phase. Thus, 10 ml aqueous Cd solution was shaken with 3 ml 0.007% I solution in C2H4Cl2 and 2 ml 2N KOH, and the absorbance of the organic phase was measured at 500 mm by using the 0.007% I solution as a reference The results agreed well with those of the atomic absorption spectrometric determination or the dithizone method.
IT 52005-37-5
RL: ANST (Analytical study)
(in determination of cadmium, photometric)
RN 52005-37-5 CAPLUS
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]- (9CI) (CA INDEX NAME)

D1—N═N—Ph



IT 52005-37-5D, 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]-, cadmium complexes
RL: PRP (Properties)
(spectra of)
RN 52005-37-5 CAPLUS
CN 1-Triazene, 1-(4-nitro-1-naphthalenyl)-3-[(phenylazo)phenyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 68 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

D1—N═N—Ph



L16 ANSWER 69 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:59782 CAPLUS
DN 80:59782
OREF 80:9693a,9696a
TI N-Naphthylanthranilic acids
IN Nohara, Fujio; Fujinawa, Tomoaki N.
PA Ikeda Mohando Co., Ltd.
SO Ger. Offen., 61 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2323956	A1	19731206	DE 1973-2323956	19730511 <--
	JP 49005954	A	19740119	JP 1972-46665	19720511 <--
	JP 52030511	B	19770809		
	US 3989746	A	19761102	US 1973-358291	19730508 <--
	GB 1391584	A	19750423	GB 1973-22452	19730510 <--
	NL 7306611	A	19730725	NL 1973-6611	19730511 <--
	FR 2184101	A1	19731221	FR 1973-17062	19730511 <--
	CA 1000727	A1	19761130	CA 1973-171328	19730511 <--
	CH 583178	A5	19761231	CH 1973-6700	19730511 <--
PRAI	JP 1972-46665	A	19720511		

GI For diagram(s), see printed CA Issue.
AB About 45 naphthylanthranilic acids (I, R = e.g. H, 2-Me, 2-F, 2-Cl, or 3-Me; R1 = e.g. H, Cl, Br, or alkyl) with analgesic and antiinflammatory activities were prepared by reaction of the naphthalene derivative II (Y = NH2 or halogen) with 2-XC6H4CO2H (X = H, NH2, or halo) in the presence of a Cu catalyst. Thus, II (Y = NH2, R = H, R1 = Me) 11.5, 2-ClC6H4CO2K 12.0, K2CO3 11.0, and Cu powder 1.0 g were refluxed 10 hr in 100 ml BuOH to give 5.3 g I (R = H, R1 = Me) which was also prepared by reaction of II (Y = Br, R = H, R1 = Me), o-H2NC6H4CO2H, K2CO3, and Cu powder 1 hr at 190-5°.
IT 51670-32-7P 51671-14-8P 51671-20-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51670-32-7 CAPLUS
CN Benzoic acid, 2-[(4-bromo-1-naphthalenyl)amino]- (CA INDEX NAME)



RN 51671-14-8 CAPLUS
CN Benzoic acid, 2-[(4-chloro-1-naphthalenyl)amino]- (CA INDEX NAME)

L16 ANSWER 69 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 51671-20-6 CAPLUS
CN Benzoic acid, 2-[(4-fluoro-1-naphthalenyl)amino]- (CA INDEX NAME)



L16 ANSWER 70 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:48403 CAPLUS
DN 80:48403
OREF 80:7898a
TI Tripeptide amides as substrates for proteolytic enzymes
IN Claeson, Karl G.; Karlsson, Birgitta G.; Svendsen, Lars G.
PA Aktiebolag Bofors
SO Ger. Offen., 57 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2322115	A1	19731122	DE 1973-2322115	19730502 <--
	DE 2322115	B2	19800110		
	SE 380258	B	19751103	SE 1972-5758	19720502 <--
	SE 380258	C	19760226		
	US 3886136	A	19750527	US 1973-354038	19730424 <--
	FI 56829	B	19791231	FI 1973-1308	19730425 <--
	FI 56829	C	19800410		
	BE 798917	A1	19730816	BE 1973-130584	19730430 <--
	AT 324558	B	19750910	AT 1973-3812	19730430 <--
	NO 135362	B	19761220	NO 1973-1791	19730430 <--
	CA 1019724	A1	19771025	CA 1973-169885	19730430 <--
	JP 49042396	A	19740420	JP 1973-48994	19730501 <--
	AU 7355039	A	19741107	AU 1973-55039	19730501 <--
	GB 1426385	A	19760225	GB 1973-20694	19730501 <--
	NL 7306088	A	19731106	NL 1973-6088	19730502 <--
	FR 2183170	A1	19731214	FR 1973-15736	19730502 <--
	ZA 7302975	A	19740424	ZA 1973-2975	19730502 <--
	DD 108282	A5	19740912	DD 1973-170659	19730502 <--
	PL 89227	B1	19761130	PL 1973-162269	19730502 <--
	CS 172974	B2	19770128	CS 1973-5129	19730502 <--
	CH 590475	A5	19770815	CH 1973-6266	19730502 <--
	HU 170669	B	19770828	HU 1976-B01429	19761102 <--
PRAI	SE 1972-5758	A	19720502		
	HU 1973-B01429	A	19730428		

AB Tripeptide amide derivs. R-X-Y-Z-NHR1.n HCl (I, R = H, Bz; X = Leu, Ala, β-Ala, Val, Ile; Y = Leu, Val, Ile; Z = Arg, Lys; R1 = C6H4NO2-4, 2-naphthyl, 1-nitro-2-naphthyl, 4-nitro-1-naphthyl, n = 1 or 2) (17 compds.) were prepared by standard coupling methods. I had a higher sensitivity against trypsin, thrombin, and(or) plasmin than Nα-benzoyl-DL-arginine p-nitroanilide.HCl and were useful in the determination of the enzymes.
IT 51078-28-5P 51078-29-6P 51078-30-9P
51168-67-3P 51211-48-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51078-28-5 CAPLUS
CN Carbamic acid, [4-[[imino(nitroamino)methyl]amino]1-[[(4-nitro-1-naphthalenyl)amino]carbonyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 70 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 51078-29-6 CAPLUS
CN L-Ornithinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucyl-N5-[imino(nitroamino)methyl]-N-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 51078-30-9 CAPLUS
CN L-Argininamide, N-benzoyl-L-leucyl-L-leucyl-N-(4-nitro-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 70 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● HCl

RN 51168-67-3 CAPLUS
CN L-Ornithinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N5-[imino(nitroamino)methyl]-N-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51211-48-4 CAPLUS
CN L-Ornithinamide, N-benzoyl-L-leucyl-L-leucyl-N5-[imino(nitroamino)methyl]-N-(4-nitro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 70 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L16 ANSWER 71 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1973:442359 CAPLUS
DN 79:42359
OREF 79:6885a,6888a
TI N-Phenethylpiperidinederivatives
IN Schenker, Erhard
PA Sandoz Ltd.
SO Patentschrift (Switz.), 8 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 535767	A	19730630	CH 1970-6177	19700425 <--
PRAI CH 1970-6177	A	19700425		

GI For diagram(s), see printed CA Issue.

AB Analgesic phenethylpiperidines I (R = H, 4-Br, 7-MeO, 4-O2N, 4- Cl; R1 = H, EtCO; R2 = H, 2-Cl, 3-Cl, 4-Cl, 4-MeO) and tetrahydronaphthylamino and 5-indanylamine analogs were prepared Thus I (R-R2 = H) was obtained by treating 1-naphthylamine with 1- ethoxycarbonyl-4-piperidone, reducing with LiAlH4, to give 1-ethoxy- carbonyl-4-(1-naphthylamino)piperidine, which was decarboxylated and treated with BrCH2CH2Ph.

IT 39742-69-3P 39742-87-5P 39742-89-7P
42466-11-5P 42466-14-8P 42466-15-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 39742-69-3 CAPLUS
CN 4-Piperidinamine, N-(4-chloro-1-naphthalenyl)-1-[2-(4-chlorophenyl)ethyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47544-87-6
CMF C23 H24 Cl2 N2

PAGE 1-A



L16 ANSWER 71 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 39742-87-5 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-(2-phenylethyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47491-37-2
CMF C23 H25 Br N2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 39742-89-7 CAPLUS
CN 4-Piperidinamine, N-(4-nitro-1-naphthalenyl)-1-(2-phenylethyl)- (CA INDEX NAME)

L16 ANSWER 71 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 42466-11-5 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 42466-15-9
CMF C15 H17 Br N2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 42466-14-8 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-(phenylmethyl)- (CA INDEX NAME)

L16 ANSWER 71 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 42466-15-9 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 72 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:84270 CAPLUS
DN 78:84270
OREF 78:13445a,13448a
TI N-Aryl-2-pyridones
IN Bayer, Horst O.; Nulty, Patrick J.
PA Rohm and Haas Co.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3711488	A	19730116	US 1970-44862	19700609 <--
PRAI US 1970-44862	A	19700609		

GI For diagram(s), see printed CA Issue.
AB 3-Carboxy-2-pyridones I (R = p-ClC6H4, p-BrC6H4, p-MeC6H4, 4-Cl10H6-1) (II), possessing plant-growth-inhibitory activity, were prepared by condensing the corresponding RNH2 with Me2C:C(CO2Et)2 to give Me2C:C(CO2Et)CONHR; the latter underwent ring closure with (MeO)2CHNMe2 and were then hydrolyzed by NaOH to give II.
IT 39818-88-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39818-88-7 CAPLUS
CN 2-Butenoic acid, 2-[[(4-chloro-1-naphthalenyl)amino]carbonyl]-3-methyl-, ethyl ester (CA INDEX NAME)



L16 ANSWER 73 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:58251 CAPLUS
DN 78:58251
OREF 78:9239a,9242a
TI 1-Phenethylpiperidine derivatives
IN Schenker, Erhard
PA Sandoz Ltd.
SO Patentschrift (Switz.), 6 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 528507	A	19720930	CH 1970-528507	19700428 <--
PRAI CH 1970-6354	A	19700428		

GI For diagram(s), see printed CA Issue.
AB The 4-naphthylamino-1-phenethylpiperidines I (R = H, 2-Cl, 3-Cl, 4-Cl, 4-OMe; R1 = H, 4-Br, 4-NO2, 7-OMe) and some related compds. were prepared by treating the 1-phenethyl-4-piperidone with the 1-naphthylamine and reducing the naphthyliminopiperidine with NaBH4. The phenethylpiperidones were prepared by treating 1,4-dioxa-8-azaspiro-[4.5]decane with RC6H4CH2CH2Br, followed by acid hydrolysis.
IT 39742-69-3P 39742-87-5P 39742-89-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39742-69-3 CAPLUS
CN 4-Piperidinamine, N-(4-chloro-1-naphthalenyl)-1-[2-(4-chlorophenyl)ethyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47544-87-6
CMF C23 H24 Cl2 N2

PAGE 1-A



L16 ANSWER 73 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 110-16-7
CMF C4 H4 04

Double bond geometry as shown.

RN 39742-87-5 CAPLUS
CN 4-Piperidinamine, N-(4-bromo-1-naphthalenyl)-1-(2-phenylethyl)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47491-37-2
CMF C23 H25 Br N2



CM 2

CRN 110-16-7
CMF C4 H4 04

Double bond geometry as shown.

RN 39742-89-7 CAPLUS
CN 4-Piperidinamine, N-(4-nitro-1-naphthalenyl)-1-(2-phenylethyl)- (CA INDEX NAME)

L16 ANSWER 73 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 74 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:17623 CAPLUS
DN 78:17623
OREF 78:2805a,2808a
TI Amine derivatives of 1,2-dihydrobenz[cd]indoles
IN Padmanathan, Thurairajah
PA American Cyanamid Co.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3687972	A	19720829	US 1970-69115	19700902 <--
PRAI US 1970-69115	A	19700902		

AB Seventeen benzindoles (I, R = H or Me; R1 = 4,1-C1C10H6, substituted Ph including azo substitution) and two bisbenzindoles (II, R2 = p-C6H4S02C6H4-p, 5,5'-dichloro-2,2'-dimethoxy-4,4'-biphenylylene) were prepared by reaction of 2-(methylthio)-1,2-dihydrobenz[cd]indole-HI (III) with R1NH2 or R2(NH2)2, resp., and optional methylation. I and II dyed nylon 66, cellulose acetate and triacetate, polyester, polyacrylonitrile, and polypropylene fast yellow to orange shades from an aqueous dispersion. For example, III was condensed with 4,1-C1C10H6NH2 and methylated with MeI to give 2-(4-chloro-1-naphthylimino)-1,2-dihydro-1-methylbenz[cd]indole (I, R = Me, R1 = 4,1-C1C10H6) [37697-60-2], lightfast yellow on polypropylene.
IT 40496-10-4P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 40496-10-4 CAPLUS
CN Benz[cd]indol-2-amine, N-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 75 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1973:5411 CAPLUS
DN 78:5411
OREF 78:885a,888a
TI N-Carbamoylethyl aromatic amine compounds useful in the synthesis of dyes
IN Loffelman, Frank Fred
PA American Cyanamid Co.
SO Brit., 18 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1287343		19720831	GB 1970-37677	19700804 <--

AB Thirty-seven direct and oxidation hair dyes (I, Ar = benzene, naphthalene, biphenyl nucleus, R = H, CH2CH2CONH2, R1 = H2N, HO; R2 = H, H2N, O2N, MeO, Cl; n = 1 or 2) were prepared. For example, a mixture of p-O2NC6H4NH2 and CH2:CHCONH2 was heated in AcOH at 80.deg. for 10 hr to give 3-(p-nitroanilino)propionamide (II) [35210-96-9] which dyed albino, bleached or permanently waved hair a bright yellow shade. Reduction of II gave 3-(p-aminoanilino)propionamide (III) [35210-97-0] which, with H2O2, dyed yellowish gray hair a deep brown-black shade. The other I were similarly prepared. A reddish brown dye for cotton was prepared by coupling diazotized p-H2NC6H4N(CH2CH2CONH2)2 with 2,6-HOC10H6SO3Na.
IT 37182-38-0P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 37182-38-0 CAPLUS
CN Propanamide, 3-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)



L16 ANSWER 76 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:514260 CAPLUS
DN 77:114260
OREF 77:18825a,18828a
TI 1-(γ-Piperidinopropylamino)naphthalene
IN Foldeak, Sandor; Kovacz, Kalman; Porszasz, Janos
PA Richter, Gedeon, Vegyeszeti Gyar R. t.
SO Ger., 4 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 1695632	C2	19730208	DE 1967-R45804	19670419 <--
CH 482643	A	19691215	CH 1967-482643	19670418 <--
DK 119409	B	19701228	DK 1967-2110	19670419 <--
NL 6705680	A	19671023	NL 1967-5680	19670421 <--
FR 6201	M	19680722	FR 1967-6201	19670421 <--
SE 323079	B	19700427	SE 1967-5647	19670421 <--
PRAI HU 1966-RI298	A	19660422		

OS MARPAT 77:114260
GI For diagram(s), see printed CA Issue.
AB Piperidino-propylaminonaphthalenes (I, R = F, Br, R1 = H; R = H, R1 = Br) were prepared by condensing the 1-naphthylamine with γ-chloropropylpiperidine. I are spasmolytics, especially for petit mal type spasms. The oral ED50 of I (R = Br, R1 = H) in rats was 47 mg/kg and the LD50 382 mg/kg. I (R = F, R1 = H) was obtained in 92% yield by treating 4-fluoro-1-naphthylamine with γ-chloropropylpiperidine.
IT 18975-11-6P 19209-11-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 18975-11-6 CAPLUS
CN 1-Piperidinepropanamine, N-(4-fluoro-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 19209-11-1 CAPLUS
CN 1-Piperidinepropanamine, N-(4-bromo-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L16 ANSWER 76 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

L16 ANSWER 77 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:503336 CAPLUS
DN 77:103336
OREF 77:17033a,17036a
TI N-(β-Cyanoethyl) arylamines
IN Schladetsch, Hans Jakob
PA Farbwerke Hoechst A.-G.
SO Ger. Offen., 18 pp. Addn. to Ger. Offen. 1,963,010 (CA 75:88296h).
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2056215	A	19720518	DE 1970-2056215	19701116 <--
	NL 7018125	A	19710618	NL 1970-18125	19701211 <--
	CH 552563	A	19740815	CH 1970-18436	19701211 <--
	US 3829454	A	19740813	US 1970-98126	19701214 <--
	GB 1307279	A	19730214	GB 1970-59589	19701215 <--
	CA 940922	A1	19740129	CA 1970-100635	19701215 <--
	JP 49017249	B	19740427	JP 1970-111341	19701215 <--
PRAI	DE 1969-1963010	A	19691216		
	DE 1970-2056215	A	19701116		
	DE 1970-2056216	A	19701116		

AB Six title compds. of structure RNHCH2CH2CN (I; R = 1- or 2-C10H7, 4,1-O2NC10H6, 1- or 2-anthryl, or anthraquinon-2-yl), useful as azo coupling components, were prepared by treatment of the appropriate RN(CHO)CH2CH2CN with aqueous HCl in EtOH at .sim.80.deg.. Coupling 1-[N-(β-cyanoethyl)amino]anthracene (II) [35994-06-0] with diazotized aniline gave a red disperse dye for polyester fibers.
IT 38266-47-6P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 38266-47-6 CAPLUS
CN Propanenitrile, 3-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)



L16 ANSWER 78 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:450157 CAPLUS
DN 77:50157
OREF 77:8317a,8320a
TI N-(Carbamoylethyl) aromatic amine hair dyes
IN Paul, Albert P.
PA American Cyanamid Co.
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3658454	A	19720425	US 1969-825428	19690516 <--
PRAI	US 1969-825428	A	19690516		

AB The title compds. (I, Ar = benzene, naphthalene, biphenyl nucleus; X = H2NCOCH2CH2NH, (H2NCOCH2CH2)2N; Y = H2N, NO2, OH, X; Z = H2N, NO2, OH, Cl, Me, MeO, X), useful for direct or oxidative dyeing of hair, were prepared Thus, reaction of p-nitroaniline with acrylamide in HOAc gave crystalline 3-(p-nitroanilino)propionamide (II, R = NO2)(III) [35210-96-9], a direct yellow dye. Catalytic reduction of III gave 3-(p-aminoanilino)propionamide (II, R = NH2) [35210-97-0] which was used both as a direct and oxidative dye. Similarly, 39 other I and(or) their hydrochlorides were prepared Hair dyeing comprns. containing I are described.
IT 37182-38-0P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 37182-38-0 CAPLUS
CN Propanamide, 3-[(4-nitro-1-naphthalenyl)amino]- (CA INDEX NAME)



L16 ANSWER 79 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:99994 CAPLUS
DN 76:99994
OREF 76:16095a,16098a
TI Adenosine derivatives having dilative action on the coronary arteries
IN Yoshioka, Yoshio; Marumoto, Ryuji; Honjo, Mikio; Kikuchi, Kenzo
PA Takeda Chemical Industries, Ltd.
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2131938	A	19720105	DE 1971-2131938	19710626 <--
	BE 768925	A1	19711103	BE 1971-104987	19710623 <--
	US 3796700	A	19740312	US 1971-156138	19710623 <--
	NL 7108858	A	19720103	NL 1971-8858	19710625 <--
	GB 1351501	A	19740501	GB 1971-30123	19710628 <--
	FR 2100839	A1	19720324	FR 1971-23583	19710629 <--
	FR 2100839	A5	19720324		
	HU 163640	B	19730927	HU 1971-TA1126	19710629 <--
	CA 954856	A1	19740917	CA 1971-117084	19710630 <--
PRAI	JP 1970-57507	A	19700630		

GI For diagram(s), see printed CA Issue.
AB The adenosine derivs. I (R = Ph, naphthyl, or a nitrogen-containing heterocycle, R1 = H; R = 1-naphthyl, R1 = NH2) are prepared by treating a 6-adenosyl halide with RNHNH2. They are coronary dilators as effective as and longer-lasting than adenosine. Treatment of 1 part 6-chloronebularin with 1.5 parts PhNHNH2 gave 0.5 parts I (R = Ph, R1 = H).
IT 35908-37-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35908-37-3 CAPLUS
CN Inosine, (4-bromo-1-naphthalenyl)hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 80 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:449107 CAPLUS
DN 75:49107
OREF 75:7757a,7760a
TI Synthetic cephalosporin derivatives
IN Atarashi, Sueo; Omori, Satoko
PA Fujisawa Pharmaceutical Co., Ltd.
SO Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 46014659	B4	19710420	JP	19670607 <--

GI For diagram(s), see printed CA Issue.
AB Antibacterial I are prepared by aminolysis of II. Thus, 1.75 g II and 4-nitro-1-naphthylamine heated in aqueous EtOHMe2CO at 60° 4.5 hr gave 70 mg I (R = 4,1-O2NC10H7), m. 170-5° . Also prepared were I (R = 1-naphthyl, p-O2NC6H4, p-HO2CC6H4, p-HO3SC6H4).
IT 32912-08-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32912-08-6 CAPLUS
CN Sydnone, 3-[[[2-carboxy-3-[[(4-nitro-1-naphthyl)amino]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]carbamoyl]methyl]- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 81 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1970:31465 CAPLUS
DN 72:31465
OREF 72:5732h,5733a
TI N-1-naphthylsalicylamides
PA N. V. Philips' Gloeilampenfabrieken
SO Neth. Appl., 10 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6802364		19690821	NL 1968-2364	19680219 <--
DE 1768435			DE	
FR 1584534			FR	
FR 7945			FR	
GB 1212111			GB	
US 3549704		19701222	US	19680513 <--
ZA 6802040		19680000	ZA	<--

GI For diagram(s), see printed CA Issue.
AB Title compds. (I) which are useful in treatment of tapeworm disease, schi stosomiasis, and show strong antibacteriological action, were prepared Thus, a solution of 0.065 mole 3,5-dibromosalicyloyl chloride in 125 ml MeC N was added to a solution of 0.060 mole 1-amino-3,4-dichloronaphthalene in 300 ml MeCN, the mixture stirred and refluxed for 6 hr, 200 ml MeCN added, and the hot mixture filtered giving N-(3,4-dichloro-1-naphthyl)-3,5-dibromosalicylamide, m. 237.5-39° . Similarly prepared was N-(4-chloro-1-naphthyl)-3,5-diiodosalicylamide, m. 221-24° . The compds. are used in pharmaceutical and veterinarian prepns. Schistosomiasis is treated with 25-100 mg/kg/day for 5-15 days. For tapeworm in humans the amts. are 0.5-2 g/day for 1-3 days, for animals 50-200 mg/kg/day.
IT 26037-15-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26037-15-0 CAPLUS
CN Salicylamide, N-(4-chloro-1-naphthyl)-3,5-diiodo- (8CI) (CA INDEX NAME)



L16 ANSWER 82 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1970:21616 CAPLUS
DN 72:21616
OREF 72:3949a,3952a
TI N-Aryl-2-pyridones
IN Seidel, Michael C.; Viste, Kenneth L.; Yih, Roy Y.
PA Rohm and Haas Co.
SO Ger. Offen., 52 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 1900947	A	19690911	DE 1969-1900947	19690109 <--
DE 1900947	C3	19790913		
DE 1900947	B2	19790104		
US 3503986	A	19700331	US 1968-698106	19680116 <--
FR 1599535	A	19700715	FR 1968-1599535	19681230 <--
GB 1253293	A	19711110	GB 1969-1253293	19690113 <--
ES 362532	A1	19701116	ES 1969-362532	19690115 <--
SE 351428	B	19721127	SE 1969-513	19690115 <--
NO 127446	B	19730625	NO 1969-162	19690115 <--
BE 726971	A	19690716	BE 1969-726971	19690116 <--
NL 6900775	A	19690718	NL 1969-775	19690116 <--
CH 506943	A	19710615	CH 1969-506943	19690116 <--
AT 306428	B	19730410	AT 1969-473	19690116 <--
SU 416917	A3	19740225	SU 1969-1298317	19690116 <--
DK 136860	B	19771205	DK 1969-225	19690116 <--
US 3576814	A	19710427	US 1970-7256	19700130 <--
US 3761240	A	19730925	US 1971-114377	19710210 <--
PRAI US 1968-698106	A	19680116		
US 1968-779198	A	19681121		
US 1970-7256	A2	19700130		

GI For diagram(s), see printed CA Issue.
AB Ia were prepared by condensing II with 2,4-diketones in presence of a basic catalyst. The compds. were useful for plant growth control. A mixture of 19.4 g II (R = 4-Cl), 10 g 2,4-pentanedione, 5 ml. piperidine and 200 ml. EtOH was refluxed 3 hr to give 22 g Ia (R1 = 4-Cl, R2 = 4,6-Me2) (III), m. 314-16° . III (40 g) was hydrolyzed with 100 ml concentrated H2SO4 and 60 ml H2O to give Ib (R1 = 4-Cl, R2 = 4,6-Me2) (IV) m. 215-17° . Hydrolysis of 777 g III with 1940 g concentrated H2SO4 and 1164 ml H2O gave 326 g IV and 257 g Ic (R1 = 4-Cl, R2 = 4,6-Me2) m. 222-6° . III was esterified with MeOH and a trace of HCl to give Id (R1 = 4-Cl, R2 = 4,6-Me2, R4 = Me), m. 188-9° . The compds. (R2 = 4,6-Me2) prepared are given in the table. Also prepared were Id (R1 = 4-Cl, R2 = 4,6-Me2, R4 = iso-Pr), m. 130- 5° ;I (R1 = 4-Cl, R2 = 4,6-Me2, R3 = COCl), m. 130-6° ;I (R1 = 4-Cl) (R2, R3, and m.p. given): 4,5,6-Me3, CO2H, 168-75° ;4,5,6-Me3, CONH2, 213-15° ;4,5,6-Me3, CN, 197-200° ;4,6-Et2, CO2H, 126-7° ;4,6-Et2, CN, 161-2° ; 4,6,5-Me2(Cl), CO2H, 176-8° ;4,6,5-Me2(Cl), CN, 168-70° . N-(4-Chloronaphthyl)-2-cyanoacetanilide, m. 279-80° ; 1-(4-chloronaphthyl)-3-cyano-4,6-dimethyl-2-pyridone, m. 275° ; 1-(4-chloronaphthyl)-3-carboxy-4,6-dimethyl-2-pyridone, 221-3° . Na, Cu (m. 205-10°)and Me2NH salts of IV and the Na and Me2NH salt of Ib (R1 = 3,4-Cl2, R2 = 4,6-Me2) were prepared
IT 24522-47-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24522-47-2 CAPLUS
CN Acetamide, N-(4-chloro-1-naphthalenyl)-2-cyano- (CA INDEX NAME)

L16 ANSWER 82 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 83 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1969:451245 CAPLUS
DN 71:51245
OREF 71:9467a,9470a
TI N-(1-Naphthyl)-1-hydroxy-4-[o-(carboalkoxy)phenylazo]-2-naphthamide color couplers
PA Fuji Photo Film Co., Ltd.
SO Brit., 7 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1146368		19690326	GB 1967-34086	19670725 <--
DE 1643988			DE	
FR 1544009			FR	
US 3583971		19710608	US	19670725 <--
PRAI JP		19660725		

GI For diagram(s), see printed CA Issue.
AB Colored cyan couplers(I) are prepared and used to obtain good masking effects. 2-H2NC6H4CO2CH2CH-BuEt (II) (15 g.) is diazotized and coupled with 15 g. 1,2-H-OC10H6CONHC10H6R1-1,4 (III, R1 = H) to give 69% I (R = BuEtCH, R1 = H) (IV), m. 139-41°. Similarly prepared are the following I (R, R1, and m.p. given): 1-hexylnonyl, H, 11-13°; Me, 2,4-(sec-C5H11)2C6H3OCH2CONH (Q), 198-9°. Also prepared, according to known methods, are II and the following III(R1 and m.p. given): H, 160-1°; NO2, 204-2° (decomposition); NH2, 225-6°; Q, 178-80°. Film coated with Ag(I,Br) emulsion containing IV and a red-sensitive dye, exposed to red light, and developed with p-Et2NC6H4NH2 gave a pos. magenta image, λmaximum 520 mμ.
IT 23681-54-1P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 23681-54-1 CAPLUS
CN 2-Naphthamide, 1-hydroxy-N-(4-nitro-1-naphthyl)- (8CI) (CA INDEX NAME)



L16 ANSWER 84 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1969:106259 CAPLUS
DN 70:106259
OREF 70:19823a,19826a
TI Salicylamides anthelmintics
PA N. V. Philips' Gloeilampenfabrieken
SO Neth. Appl., 10 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6706931		19681120	NL 1967-6931	19670519 <--
FR 1584534			FR	
GB 1212111			GB	
US 3549704		19701222	US	19680513 <--
ZA 6802040		19680000	ZA	<--

AB Halonaphthyldihalosalicyl-amides have anthelmintic activity against liver flukes, schistosomes, and tapeworms. Thus, 12.73 g. 3,5-dibromosalicylic acid, 7.63 g. 1-amino-4-chloronaphthalene, 5.93 g. PCl3, 150 ml. PhCl, and a crystal of AlCl3 was refluxed 3.5 hrs. to yield 10.9 g. N-(4-chloro-1-naphthyl)-3,5-dibromosalicylamide, m. 204-6° (alc.).
IT 22346-41-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22346-41-4 CAPLUS
CN Salicylamide, 3,5-dibromo-N-(4-chloro-1-naphthyl)- (8CI) (CA INDEX NAME)



L16 ANSWER 85 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1968:419029 CAPLUS
DN 69:19029
OREF 69:3579a,3582a
TI N-(γ-Piperidinopropyl)-α-naphthylamine derivatives with antiepileptic effects
IN Foldeak, Sandor; Kovacs, Kalman; Porszasz, Janos
PA Richter, Gedeon, Vegyeszeti Gyar R. T.
SO Hung., 9 pp.
CODEN: HUXXAT
DT Patent
LA Hungarian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI HU 154604		19680330	HU	19660422 <--

AB A mixture of 1.47 g. 4-fluoro-1-aminonaphthalene (m. 56°, obtained by hydrolysis of the N-Ac derivative, CA 49: 15765a), 1.47 g. γ-chloropropylpiperidine, and 1.5 mole absolute PhMe was refluxed 30 min. to give 92% 4-fluoro-1-(γ-piperidinopropylamino)naphthalene-HCl, m. 208.5° (EtOH-Et2O). 4-Bromo-1-(γ-piperidinopropylamino)naphthalene-HCl, m. 224°, and 5-bromo-1-(γ-piperidinopropylamino)naphthalene-HCl, m. 260° (H2O), were similarly prepared
IT 18975-11-6 19209-11-1
RL: PRP (Properties)
(antiepileptic effect of)
RN 18975-11-6 CAPLUS
CN 1-Piperidinepropanamine, N-(4-fluoro-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 19209-11-1 CAPLUS
CN 1-Piperidinepropanamine, N-(4-bromo-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L16 ANSWER 85 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

L16 ANSWER 86 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1968:43165 CAPLUS
DN 68:43165
OREF 68:8419a, 8422a
TI Germicidal compositions
IN Stecker, Herbert C.
PA Stecker International S.p.A.
SO Brit., 5 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1088498		19671025	GB 1965-6694	19650216 <--

GI For diagram(s), see printed CA Issue.
AB Germicidal properties are imparted to compns. comprising soaps, detergents, plastics, rubber, and fibrous materials, such as sanitary and medicated dressings, by incorporating 50-1000 ppm. of an amide or halogenated amide of a S-containing phenol carboxylic acid of general formula, I, II, ArCONHAr' (III), or ArCSNHAr' (IV). In antibacterial tests against Staphylococcus aureus it was apparent that the introduction of halogen substituents did not appreciably increase inhibition activity. The compds. examined were I (R, R', X, Y, and Z given): Cl, H, SH, H, H; Cl, Cl, SH, Cl, Cl; Br, H, SH, H, Br; H, H, SH, H, H. II (R, R1, X, Y, and Z given): iodine, H, H, OH, H; Cl, Cl, H, OH, Br; Br, H, OH, H, H; H, H, OH, H, H; iodine, H, SH, H, iodine; H, H, SH, H, H. III (Ar and Ar' given): 3,5,2,-Br2(HS)C6H2, 2,4-F2C6H3; 3,5,2-Br2(HS)C6H2, 1,3-C1C10H6; 1,2,3-C1(HS)C10H5, m-FC6H4; 2,3-HSC10H6, p-C1C6H4. IV (Ar and Ar' given): 1,2,4-C1(HS)C10H5, 2,4,5-C13C6H2; 1,2,3-C1(HS)C10H5, 1,4-C1C10H6; 2,4-HSC10H6, p-C1C6H4; 1,2,3-C1(HO)C10H5, 1,3-C1C10H6; 2,1-HOC10H6, Ph.
IT 18378-57-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(as bactericide)
RN 18378-57-9 CAPLUS
CN 2-Naphthamide, 4-chloro-N-(4-chloro-1-naphthyl)-3-mercaptothio- (8CI) (CA INDEX NAME)



L16 ANSWER 87 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1967:421731 CAPLUS
DN 67:21731
OREF 67:4118h, 4119a
TI N-(Dialkylaminoalkyl)-1,4-naphthalenediamines
IN Elslager, Edward F.; Worth, Donald F.
PA Parke, Davis and Co.
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3291808		19661213	US 1964-420450	19610814 <--

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are prepared by reduction of 4-substituted-1-naphthylamines (II) in which X is NO2, an aromatic carbocyclic azo group, or a heterocyclic azo group. I have antiparasitic properties and for this use are employed in the form of their addition salts with an organic or inorg. acid. In a preparation of II, a mixture of 570 g. 1-naphthylamine, 690 g. 2-chlorotriethylamine.HCl, 1250 g. anhydrous K2CO3, 3 l. C6H6, and 20 g. Cu-bronze was stirred and heated at reflux 18 hrs. to give N,N-diethyl-N'-(1-naphthyl)ethylenediamine (III), bl.5 170-2°, n20D 1.5903. A solution of 93.1 g. PhNH2 in 2 l. H2O containing 250 ml. HCl was cooled to 0° and the amine diazotized by dropwise addition of a solution of 69 g. NaNO2 in 300 ml. H2O. The diazonium salt solution was added at 5° to a solution of 242 g. III in 4 l. H2O containing 170 ml. HCl and an addnl. 4 l. H2O added toward the end of the addition Work-up gave N,N-diethyl-N'-(4-phenyl-azo-1-naphthyl)ethylenediamine (IV), m. 62°; 2HCl salt m. 155°. For preparation of the corresponding I, 5 g. Raney Ni was added to a solution of 100 g. IV in 600 ml. BtOH, the mixture shaken under H at initial pressure 55 psig. until H uptake was completed to give N-(2-diethylaminoethyl)-1,4-naphthalenediamine.-2HCl, hemihydrate (V), m. 220-5° (decomposition). Alternately, IV was reduced to V by SnCl2.2H2O in concentrated HCl. In another method for the preparation of V, N,N-diethyl-N'-(4-nitro-1-naphthyl)-ethylenediamine, prepared by the reaction of 1-chloro-4-nitronaphthalene with N,N-diethylethylenediamine was reduced with Raney Ni. In a manner similar to the preparation of IV, 5-[4-(2-diethylaminoethylamino)-1-naphthylazo]uracil (VI) was prepared by diazotization of 5-aminouracil with subsequent addition of this diazonium salt to a solution of III; the crude VI was crystallized from BtOH to give a product m. 210-11° (decomposition). Raney Ni reduction of VI gave V. Similarly, the diazonium salt of N-(2-diethylaminoethyl)-N-(4-amino-1-naphthyl) trifluoroacetamide-HCl (VII) was added to III to give 4,4'-bis[N',N'-diethylaminoethyleneamino)-1,1'-azonaphthalene (VIII), m. 163-5°. Reduction of VIII with Raney Ni gave V. For the preparation of VII, IV in HCONMe2 was treated with trifluoroacetic anhydride to give N-(2-diethylaminoethyl)-N-(4-phenylazo-1-naphthyl)-2,2,2-trifluoroacetamide.HCl, m. 206-8°, which was reduced with Raney Ni to give VII, m. 216-18°. Raney Ni reduction of p-[4-(2-diethylaminoethylamino)-1-naphthylazo]benzenesulfonic acid, prepared from the reaction of III which with sulfanilic acid, also gave V. Reduction of IV with (NH4)2S also yielded V. The following salts of V were prepared: [TABLE OMITTED] The following 1,4-naphthalenediamines were prepared by Raney Ni redns. (N substituent, salt, and m.p. of salt given): 3-diethylaminopropyl, 2HCl, 200-10°; 3-dimethylaminopropyl, 3HCl, 243-60°; 2-diisobutylaminoethyl, 2HCl, 240-2°; 3-diethylamino-2,2-dimethylpropyl, 3HCl.0.5H2O, 192-4°; 2-(2-diethylaminoethoxy)ethyl, 2HCl, -; 2-(2-diethylaminoethylthio)-ethyl, 2HCl, -; 4-dimethylaminocyclohexyl, 3HCl, -; 4-diethylamino-1-methylbutyl,

L16 ANSWER 87 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
2.5HCl.0.75 H2O, 182°; 2-dimethylamino-1-methylethyl, 3HCl, 181-3°; 3-dimethylamino-2-methylpropyl, 3HCl.H2O, -; 2-(allylethylamino)ethyl, 2.5HCl, 216-18°; 2-[bis(2-ethoxyethyl)amino]ethyl, 2HCl, -; 2-(cyclohexylmethylamino)ethyl, 3HCl.1.33H2O, 250-5°; 5-diethylaminopentyl, 3HCl.H2O, 169-71°; 6-chloro-N1-(2-diethylaminoethyl), 2HCl, -; 2-(isopropylmethylamino) ethyl, 2HCl, 230° (decompn.); 2-(butylmethylamino)ethyl, 2HCl, 220-50°; 2-(ethylmethylamino)ethyl, 2HCl, 245-55°; N1-(3-diethylamino-2-methoxypropyl)-6-methyl, 2HCl, -. Other I similarly prepd. are (compd., salt, and m.p. of salt given): 4-[3-(4-amino-1-naphthylamino)propyl]morpholine, 2HCl.H2O, 206-8°; 4-[2-(4-amino-1-naphthylamino)ethyl]morpholine, 2HCl, 195-200°; 1,1-diisopropyl-4-methyl-7-(4-amino-1-naphthyl)diethylenetriamine, 3HCl, -; 7-(4-amino-1-naphthyl)-1,1,4-triethyldiethylenetriamine, 3HCl.H2O, 174-8°; 1-[2-(4-amino-1-naphthylamino)ethyl]-1,4-ethylenedipiperidine, 3HCl, -; 1-[2-(4-amino-1-naphthylamino)ethyl]-4-methylpiperazine, 3HCl, 237-9° (decompn.); 1-[2-(4-amino-1-naphthylamino)ethyl]piperazine, 3HCl, 283-5°; 1-[2-(4-amino-1-naphthylamino)ethyl]-4-piperidinol, 3HCl, 227-30°; N2-(4-amino-1-naphthyl)-N1,N1,N3,N3-tetramethyl-1,2,3-propanetriamine, 3HCl, -; 1-[2-(4-amino-1-naphthylamino) ethyl]pyrrolidine, 2HCl, 293-6°; 1-(4-amino-1-naphthylamino)-3-diethylamino-2-propanol, 3HCl, -; 3-(4-amino-1-naphthylamino)-N-ethylpiperidine, 3HCl, -; 2-[[2-(4-amino-1-naphthylamino)ethyl]methylamino] ethanol, 3HCl.1/3H2O, 213-14°; 1-[3-(4-amino-1-naphthylamino)propyl]piperidine, 3HCl, 198-210°; 1-(4-amino-1-naphthyl)-4-(2-diethylaminoethyl)-7,7-diethyldiethylenetriamine, 4HCl, -; 1-[2-(4-amino-1-naphthylamino)ethyl]piperidine, 2HCl, 275-80°; 1-[2-(4-amino-1-naphthylamino)ethyl]-4-pipecoline, 2HCl.0.25H2O, 289-91°; 4-[2-(4-amino-1-naphthylamino)ethyl]-1-homopiperazinethanol, 3HCl, -; 1-[2-(4-amino-1-naphthylamino)ethyl] hexamethyleneimine, 2HCl, 280°; 1'-[2-(4-amino-1-naphthylamino)-ethyl]-1,4'-bipiperidine, 3HCl, -.
IT 5235-99-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 5235-99-4 CAPLUS
CN Ethylenediamine, N,N-diethyl-N'-(4-nitro-1-naphthyl)- (7CI, 8CI) (CA INDEX NAME)



L16 ANSWER 88 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1967:28577 CAPLUS
DN 66:28577
OREF 66:5415a, 5418a
TI Insecticides derived from N-(fluoroacetyl)naphthylamine
IN Kageyama, Ikuzo; Watanabe, Shiro
PA Daikin Kogyo Co., Ltd.
SO Fr., 7 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1440634		19660603	FR 1964-993148	19641029 <--
PRAI JP		19631029		

GI For diagram(s), see printed CA Issue.
AB I are prepared by reaction of substituted napthylamine with fluoroacetyl chloride in the presence of pyridine. Thus, 188 g. 4-nitro-1-aminonaphthalene and 93 g. pyridine at 5-10° was treated dropwise with a mixture of 96 g. monofluoroacetyl chloride and 400 g. MeCl over 3 hrs. and the mixture kept 0.5 hr. to give 73% N-(fluoracetyl)-4-nitro-1-naphthylamine, m. 181°. The following I are tabulated [position of acetamido group, X, and LD50 (mg./kg.) on mouse are given]: 1, 2,4-C12, 85; 1, 2,4-Br2, 113; 1, 2-Cl, 74; 1, 4-Br, 98; 1, 5-Cl, 94; 1, 4-NO2, 88; 1, 5-NO2, 93; 1, 8-NO2, 105; 1, 2,4-(NO2)2, 92; 2, 1,3,4-Cl3, 97; 2, 1-Cl-4-Br, 103; 2, 1,4-Br2, 137; 1, 5-NH2, 88; 1, 4,8-(SO3Na)2, 130; 1, 5-OH, 90; 2, 1-Me, 68; 2, 1,4-Me2, 72; 1, 1-NO2-2-I, 118. These compds. have insecticidal and acaricidal activity against bugs, aphids, and mites.
IT 14200-98-7P 14201-01-5P 14201-16-2P,
Acetamide, N-(4-chloro-1-naphthyl)-2-fluoro-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 14200-98-7 CAPLUS
CN Acetamide, 2-fluoro-N-(4-nitro-1-naphthalenyl)- (CA INDEX NAME)



RN 14201-01-5 CAPLUS
CN Acetamide, N-(4-bromo-1-naphthyl)-2-fluoro- (8CI) (CA INDEX NAME)



RN 14201-16-2 CAPLUS
CN Acetamide, N-(4-chloro-1-naphthalenyl)-2-fluoro- (CA INDEX NAME)

L16 ANSWER 88 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 89 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1966:429336 CAPLUS
DN 65:29336
OREF 65:5425d-f
TI N-(α-Naphthyl)-3-aminopropionic acid derivatives
PA N. V. Philips' Gloeilampenfabrieken
SO 9 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6410579		19660314	NL 1964-10579	19640911 <--
BE 669420			BE	
PRAI NL		19640911		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), where R = H, alkyl, or alkoxy and R' = H or alkyl (preferably C1-4 alkyl), and their acid addition salts are depressants of the central nervous system. They potentiate the depressive effect of hexobarbital in mice (results of expts. given). They can be used for the treatment of psychic disorders, e.g. anxiety, psychoses, and neuroses. They are applied in the usual formulations (examples of tablets and injectable solns. given) in daily dosages of 5-1000 mg. Their preparation is given. Thus, a mixture of 36 g. α-naphthylamine, Et acrylate 175 g. (II) and 50 ml. AcOH is refluxed 8 hrs. After the excess II is distilled, EtOHHCl (400 ml.) is added to yield the HCl salt of I (R = H, R' = Et) (Ia), m. 137-9° (EtOH). Similarly, the following I are prepared (R, R', and m.p. given): 6-MeO, Et, 124-6° and 6-MeO, Me, 149-51° . In a 2nd method, a solution of I (R = H, R' = H) (10 g.) in 50 ml. EtOH and 1 ml. concentrated H2SO4 is refluxed 1 hr. to yield after the usual work up the HCl salt of Ia, m. 137-9° (EtOH). In a 3rd method, a mixture of 72 g. β-propiolacetone, 175 g. 6-methoxy-α-naphthylamine and 500 ml. anhydrous MeCN is refluxed 24 hrs. to yield after the usual work up I (R = 6-MeO, R' = H), m. 156-8° (Me2CO-benzene 1:25). Similarly, the following I (R' = H) are prepared (R and m.p. given): 2-Me, 200-1° ;2-EtO, 190-2° ; 4-Cl, 162-3° ;and 5-MeO, 159-60° .
IT 6662-63-1P, β-Alanine, N-(4-chloro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)
RN 6662-63-1 CAPLUS
CN β-Alanine, N-(4-chloro-1-naphthyl)- (7CI, 8CI) (CA INDEX NAME)



L16 ANSWER 90 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1966:75659 CAPLUS
DN 64:75659
OREF 64:14148f-h,14149a-h,14150a-h,14151a-g,14152a-g
TI Azo compounds
IN Elslager, Edward F.; Worth, Donald F.; Short, Franklin W.
PA Parke, Davis & Co.
SO 24 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3218309		19651116	US 1961-131110	19610814 <--
PRAI US		19610814		

AB N,N-Dialkyl-N'-(1-arylazo-4-naphthyl)alkylenediamines, useful as antiparasitics, insecticides, and fungicides, are prepared by coupling aryldiazonium salts and 1-dialkylaminoalkylaminonaphthalenes (I). A mixture of 86.4 g. α-C10H7OH, 102.8 g. II (R = NH2), 93.6 g. NaHSO3, and 600 ml. H2O is stirred 8 hrs. at 150° in a pressure vessel, made alkaline with NaOH and filtered, and the precipitate recrystd. from aqueous EtOH to give II (R = 1-C10H7NH), m. 82-3.5° . Other I similarly prepared are: 1-C10H7NH(CH2)3NMe2, b2.5 184-5° , n25D 1.6054; 1-C10H7NHCH2CH(OH)CH2NEt2, b0.5 175-8° ;1-C10H7NHCH(CH2NMe2)2, b0.3 137-8° , n25D 1.5836. To a suspension of 36 g. 50% NaH in oil is added a solution of 72 g. α-C10H7NH2 in 300 ml. C6H4Me2, the mixture refluxed 2 hrs. and cooled, a C6H4Me2 solution of the free base from 100 g. ClCH2CHMeCH2NMe2.HCl added slowly, and the mixture refluxed 20 hrs. to give 1-C10H7NHCH2CHMeCH2NMe2, b0.15 117-18° . Other I similarly prepared are: 1-C10H7NH(CH2)2O(CH2)2NEt2, b0.3 160-1° , n20D 1.5533; 1-C10H7NH(CH2)2NEt2, b1.5 170-2° ;1-C10H7NHCHMeCH2NMe2, b0.2 118-20° ;1-C10H7NH(CH2)5NEt2, b1.8 198-200° , n25D 1.5740; 7,1-MeOC10H6NH(CH2)2NEt2, b0.7 170-3° , n25D 1.5875. A mixture of 166 g. 1-C10H7NH(CH2)2Br.HBr, 79 g. iso-Pr2N(CH2)2NHMe, 138 g. K2CO3, and 500 ml. HCONMe2 is heated 30 hrs. at 100° to give 1-C10H7NH(CH2)2NMe(CH2)2NPr2-iso, b0.3 153-7° , n25D 1.5619. Other I similarly prepared are III, m 70-2° ;IV, b0.2 208-9° , n25D 1.5795; 1-C10H7NH(CH2)2NEtCH2CH2OH, b0.2 170-2° , n25D 1.6109; 1-C10H7NH(CH2)2NEtCH2CH:CH2, b0.07 147-8° , n25D 1.5941; V, b0.2 163-5° , m. 58-60° ;VI.HCl, m. 252-4° ;VII.3HCl, m. 207-11° . A mixture of 157 g. Et2NCH2CMe2CH0, 143 g. α-C10H7NH2, 1 g. p-MeC6H4SO3H, and 400 ml. C6H6 is refluxed 8 hrs. under a H2O trap, the solvent removed in vacuo, and the residue dissolved in MeOH and hydrogenated over 5 g 20% Pd-C at room temperature and 52 psig. to give 1-C10H7NHCH2CMe2CH2NEt2, b1.0 161° , n25D 1.5790. Other similarly prepared I are: 1-C10H7NHCH2CMe2CH2NMe2, b0.75 142-3° , n25D 1.5855; VIII, m. 76-7° ;IX, m. 57-8° ;1-C10H7NHCHMe(CH2)3NEt2, b0.2 149-51° , n25D 1.5730; X, b0.2 144-6° . A toluene solution of the free bases from 33.9 g. HS(CH2)2NEt2.HCl and 66.2 g. 1-C10H7NH(CH2)2Br.HBr is refluxed 18 hrs. to give 1-C10H7NH(CH2)2S(CH2)2NEt2, b0.1 164-5° , n25D 1.6015. A mixture of 226 g. tetrahydrobenzaldehyde, 185 g. Et2NH.HCl, 78 g. paraformaldehyde (XI), and 125 ml. EtOH is refluxed 2 hrs., 78 g. more XI is added, and refluxing is continued 6 hrs. to give XII (R = CHO), b0.1 59-60° , n25D 1.4708. Condensation of XII (R = CHO) and α-C10H7NH2, followed by hydrogenation yields XII (R = 1-C10H7NHCH2), b0.07 161-2° . A mixture of 46 g. 1,4-Cl(O2N)C10H6 and 77 g. H2N(CH2)2NEt2 is heated on a steam bath until an exothermic reaction ensues and then heated 2 hrs. after the reaction subsides to give 4,1-(O2N)-[Et2N(CH2)2NH]C10H6 (XIII), m. 80-1° . Addition of a solution of 13.5 g. (F3CCO)2O in 40 ml. HCONMe2 to 14.4 g. XIII in HCONMe2 during 30 min., stirring 1 hr., pouring the solution into 1 l. ice H2O containing 150 ml. M NaHCO3, extracting the precipitate into ether, washing, drying and evaporating the ether solution, and hydrogenating the residue in 250 ml. MeOH and 40 ml. N methanolic HCl over 1 g. Raney Ni at 25-35° /25-55psig. gives 4,1-C10H6(NH2)N(COCF3)(CH2)2NEt2.HCl, m.

L16 ANSWER 90 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
216-18° . In the table are listed various arylazo compds. (XIV) prepd. by diazotization of the appropriate aromatic amine and coupling with the appropriate I.
IT 5235-99-4P, Ethylenediamine, N,N-diethyl-N'-(4-nitro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)
RN 5235-99-4 CAPLUS
CN Ethylenediamine, N,N-diethyl-N'-(4-nitro-1-naphthyl)- (7CI, 8CI) (CA INDEX NAME)



L16 ANSWER 91 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1965:403140 CAPLUS
DN 63:3140
OREF 63:537h,538a-f
TI Preparation of N-(2-carboxyphenyl)-N'-arylureas
PA Imperial Chemical Industries Ltd.
SO 14 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 6407857		19650113	NL 1964-7857	19640710 <--
PRAI GB		19630712		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are useful in the treatment of allergic phenomena and the healing of wounds. Anthranilic acid 13.7 parts is dissolved in 200 parts 0.5N NaOH, then 250 parts Me2CO and 19.94 parts 4-ClC6H4NCO are added, and the mixture is stirred 30 min. After filtration, the filtrate is acidified to pH 1 (concentrated HCl) and the precipitate worked up to give I (R = R' = H, Ar = 4-ClC6H4), m. 170-2° (H2O, EtOH). The tabulated I (R = H) are obtained in an analogous way. To a solution of 2.5 parts 3,6-Br(MeO)C6H3NH2 in 35 parts anhydrous C6H6 is added under reflux a solution of 2 parts 2-MeO2CC6H4NCO in 5 parts anhydrous C6H6. R', Ar, m.p., R', Ar, m.p.; H, 4-MeOC6H4, 179-81°; H, C6F5, 206-8°; 5-CO2H, 4-BrC6H4, 296°; H, 4-PhC6H4, 197°; H, 2-MeOC6H4, 170-1°; H, 2-ClC6H4, 176°; H, 4-BrC6H4 (III), 203-5°; H, 4-MeC6H4, 179-80°; H, 3-BrC6H4, 188°; H, 2,5-Cl2C6H3, 196-7°; H, 2-BrC6H4, 183°; H, 2,4-Cl2C6H3: (IV), 196-7°; H, 4-O2NC6H4, 202-4°; H, 4-FC6H4, 179-80°; H, 3-F3CC6H4, 169-71°; H, 2,4,6-Cl3C6H2, 208-9°; H, 4,2-BrMeC6H3, 198-204°; H, 2,4,6-Br3C6H2, 200-2°; H, 4,3-BrMeC6H3, 192°; H, 4-IC6H4, 192-3°; H, NCC6H4, 162-5°; H, 2,3-Me2C6H3, 196°; H, 4-MeSO2C6H4, 189-90°; H, 4-bromonaphthyl, 203-4° The mixture is refluxed 20 min., cooled, and filtered to give I (R' = H, R = Me, Ar = 3,6-BrMeC6H3), m. 205-6°. In the same way are obtained the tabulated I (R' = H).
The starting isocyanates can be obtained by treating over 30 min. a solution of 75 parts Me anthranilate in 25 parts EtOAc with a saturated solution of COCl2 in 200 parts EtOAc. R, Ar, m.p., R, Ar, m.p.; Me, 2,3-Me2C6H3, 198-200°, Me, 3-F3CC6H4, 165-6°; PhCH2, 3-MeC6H4, 150-1°, Me, 4-Et2OC6H4, 152-4°; Me, 4-BrC6H4, 172-4°, Me, 3,4-Cl2C6H3, 168-70°; PhCH2, 3-BrC6H4, 162-5°, PhCH2, 4-BrC6H4, 172-4°; Me, 2-ClC6H4, 180-2°, PhCH2, 2,4-Cl2C6H3 (V) 178°; Me, 3,5-Br2C6H3, 202-5°, , , ; COCl2 is bubbled through the mixture during the addition and for a further 30 min. The mixture is refluxed 10.5 hrs., cooled, filtered, the filtrate evaporated, and the residue distilled in vacuo to give 2-MeO2CC6H4NCO, b10 125°. In this way are obtained the following isocyanates: 2-PhCH2O2CC6H4-, b0.15 120-5°; 4-FC6H4-, b1669°; 2-BrC6H4-, b0.05 56-8°; 2,3-Me2C6H3-, b9.5 88-90°; 4,2-BrMeC6H3-, b1 78°; 4,3-BrMeC6H3-, b20 125°; 4-bromo-1-naphthyl-, b0.35 124-8°, m. 55-6°; Ph-, b25 58-9°. To a solution of 4.7 parts Me 4-chloroanthranilate in 56 parts anhydrous C6H6 is added at reflux a solution of 5 parts 4-BrC6H4NCO in 56 parts anhydrous C6H6. The mixture is refluxed 15 min., cooled, and filtered to give I (R' = 5-Cl, R = Me, Ar = 4-BrC6H4), m. 214-16°. In this way are obtained the tabulated I (Ar = 4-BrC6H4) and N-2-(3-carboxynaphthyl)-N'-4-bromophenylurea, m. 208°. R', R, m.p., R', R, m.p.; 5-CO2Me, Me, 222-4°, H, allyl, 158-61°; H, Bu, 163-5°, H, 2,4-Cl2C6H3, 172-3°; H, Ph, 318-20°, H, 4-MeOC5H4, 165-7°; 4-Me, H, 215-17°, 4-I, H, 212-14°; 4-NO2, H, 206°, 4,6-Cl2, H, 199-200°; 5-NO2, H, 206-8°, 4,6-Br2, H, 225-30°; 3,4,5,6-Cl4, H, 266-7°, 5-Cl, H, 208-9°; 5-SO2NH2, H, 219-21°, , , ; A soln. of 0.33 parts V in 20 parts dry dioxane is stirred 20 hrs. under a H atm. with a Pd-C catalyst. Sepn. of the catalyst and diln. with 100 parts H2O yields IV. Over 15 min., 13 parts PhNCO is added to 13.7 parts anthranilic acid in 90 parts dry EtOAc. To the slurry, Br 16 parts is added over 15 min. with violent agitation and the stirring is continued 45 min. After filtration, the ppt. gives III. II (Ar = 4-BrC6H4) 1 part is added to a boiling mixt. of 20 parts H2O and 1 part 11N NaOH. The soln. is boiled 15 min., quenched with ice, and acidified to pH 1 with 2N HCl. After filtration, the solid residue is extd. with a mixt. of 12 parts MeOH, 15 parts H2O, and 1 part HOCH2CH2NH2; 2N HCl is added to pH 1 to give III. A mixt. of 1 part PhO2CNHC6H4Br-p and 0.47 parts anthranilic acid is heated 15 min. at 150°. After cooling, the mixt. is extd. with aq. HOCH2CH2NH2 and 2N HCl is added to pH 2 to ppt. III.
IT 1767-67-5P, Anthranilic acid, N-[(4-bromo-1-naphthyl)carbamoyl]-
RL: PREP (Preparation)
(preparation of)
RN 1767-67-5 CAPLUS
CN Benzoic acid, 2-[[[(4-bromo-1-naphthalenyl)amino]carbonyl]amino]- (CA INDEX NAME)



L16 ANSWER 92 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1964:440289 CAPLUS
DN 61:40289
OREF 61:6971h,6972a-h,6973a-f
TI Azonaphthalenes
IN Elslager, Edward F.; Worth, Donald F.; Capps, David B.; Werbel, Leslie M.
PA Parke, Davis & Co.
SO 34 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3139421		19640630	US 1960-14523	19600314 <--
GB 981952			GB	
PRAI US		19600314		

GI For diagram(s), see printed CA Issue.
AB Compds. of the general formula I used as antiparasitic agents, where Ar is a heterocyclic group and Q is an alkylene group, are prepared Thus, a mixture of 572 g. 1-C10H7NH2. 690 g. Et2NCH2CH2Cl.HCl, 1250 g. anhydrous K2CO3, 3 l. C6H6, and 20 g. Cu-bronze powder is refluxed 18 hrs. to give 1-C10H7-NHCH2CH2NEt2 (II), b1.5 170-2°, n25D 1.5903. 5-Aminouracil (41.2 g.) is diazotized and coupled with 78.7 g. II in 95% EtOH to give 5-[4-(2-diethylaminoethylamino)-1-naphthylazo]uracil (III), red crystals, m. 210-11° (decomposition) (EtOH); di-HCl salt m. 200-3°. III (0.5 mole) is treated with 0.25 mole [2,3-H0-(H02C)C10H5]2CH2 to give red addition salt, m. 210-15°. Similarly prepared are the following I (X = H, R1 = R2) [n, Ar, Q, R1[or NR1R2], appearance, and m.p. given]: 1, 2,6-diamino-3-pyridyl, CH2CH2, Et, black crystals, 234° (decomposition)(HCONMe2-iso-PrOH); 0, 5-indazolyl, CH2CH2NMeCH2CH2, iso-Pr, orange crystals, 107-9°; 3 (1.5 moles H2O), 5,6-dimethoxy-8-quinolyl, CH2CMe2CH2, Et, -, 166-70° (iso-PrOH); 0, 3-dibenzofuryl, CH2CH2, piperidino, red crystals, 164-5° (Me2CO); 3 (monohydrate), 3-pyridyl, CH2CH(OH)CH2, Et, red-brown solid, 154-7°; 0, 5-benzimidazolyl, (CH2)3, morpholino, -, 220-3°; 0, 5-isoquinolyl, (CH2)3, Me, -, 158-60°; 0, 8-hydroxy-5-quinolyl, CH2CH2, Et, reddish brown crystals, 161-3° (HCONMe2-H2O); 0, 2,3-dimethylquinoxalin-6-yl, CH2CH2-SCH2CH2, Et, red, -; 0, 2-thiazolyl, CH2CH2, piperidino, emerald green crystals, 135-7° (EtOH-H2O); 0, 3-quinolyl, CH2CH2, Et, red crystals, 124-5° (iso-PrOH); 0, 6-methoxy-8-[(2-diisobutylaminoethyl)amino]-5-quinolyl, CH2CH2, Et, -, 92-4° (decomposition)(95% EtOH); 0, 6-hydroxyuracil-5-yl, CH2CH2, Et, reddish-black crystals, 209-13° (EtOH-HCONMe2); 0, 2H-1,4-benzothiazin-3(4H)-on-6-yl, CH2CH2, Et, red luminous crystals, 213-14° (iso-PrOH); 0, 2,6-dihydroxy-5-pyrimidyl, (CH2)5, Et, deep red crystals, 170° (decomposition)(HCONMe2-H2O); 3 (containing 3.5 moles H2O), 3-pyridyl, CH2CH2, Et, maroon solid, 139-41°; 3, 2,6-dihydroxy-5-pyrimidyl, CH2CH2-NEtCH2CH2, Et, dark blue crystals, 164-7° (MeOH-iso-PrOH); 0, 1,4-dihydroxyphthalazin-6-yl, CH2CH2, Et, greenish-black crystals, 211-13° (AcNH-iso-PrOH); 3, 8-methyl-5-quinolyl, CH2CH2, 4-(2-diethylaminoethyl)piperidino, deep purple solid, 145-7° (iso-PrOH-MeOH); 0, 3-pyridyl, (CH2)3, piperidino, maroon crystals, 130-3° (iso-PrOH); 0, 1H-benzotriazol-6-yl, (QNR1R2=)CHMeCH2NMe2, orange-red crystals, 197-9° (EtOH); 0, 2,6-dimethoxy-5-pyrimidyl, CH2CH2, iso-Pr, red-needles, 157-8° (Me2CO); 0, 3-methyl-1-phenyl-2-pyrazolin-5-on-4-yl, CH2CH2, Et, brown iridescent needles, 154-5° (iso-PrOH); 2, 1-(2-diethylaminoethyl)-1,2,3,4-tetrahydroquinolin-6-yl, CH2CH2, Et, -, 195-8.5° (MeOH-EtOAc); 3, 10-ethylphenothiazin-3-yl 5,5-dioxide (QNR1R2=)CH(CH2NMe2)CH2NMe2, purple-brown hydrated solid, 195-7°; 0, 2-butoxy-5-pyridyl, CH2CH2, Et, orange-red crystals, 92-4° (EtOH); 0, 8-quinolyl, CH2CH2, 4-hydroxypiperidino, red crystals, 168.5° (decomposition) (MeCN); 0, 2-benzothiazolyl, CH2CH2, azepino, blue-green crystals, 150-3° (MeCN-H2O); 0, 9-ethylcarbazol-3-yl, (QNR1R5=)CHMe(CH2)3NEt2, maroon, -; 2, 8-quinolyl, CH2CH2, Et, purple-green solid, 156-8° (contg. 3.5 moles H2O) (iso-PrOH contg. HCl-iso-PrOH mixt.); 0, 2,6-dihydroxy-5-pyrimidyl, 1,1-cyclohexylidenedimethyl, Et, red crystals, 219° (decompn.)(EtOH contg. NH3); 0, 2-methoxy-1,2-dihydro-5-pyridyl, CH2CH2, decahydro-1-quinolyl, yellow-orange crystals, 193.5-6° 2CMe2CH2, piperidino, deep maroon crystals, 80° (decompn.)(AcNMe2-H2O); 0, 2,3-dimethyl-1-phenyl-3-pyrazolin-5-on-4-yl, CH2CH2, 4-(2-hydroxyethyl)piperazino, yellow-orange crystals, 180.5-1.5° (iso-PrOH); 0, 2,1,3-benzothiadiazol-5-yl, CH2CH2, Et, red crystals, -; 0, 3-pyridyl, (QNR1R2=) 1-methyl-4-piperidyl, orange-red crystals, 169.5-71° (iso-PrOH); 5, 3-quinolyl, CH2CH2, Et2NCH2CH2, reddish-purple hydrated solid, 155-63° (decompn.)(MeOH-iso-PrOH contg. HCl-EtOH); 0, 1,2-benzoisothiazol-5-yl, CH2CH2, pyrrolidinyl, orange-red crystals, -; 0, pyridin-2-yl 1-oxide, CH2CHMeCH2, Me, green crystals, 185-6° (decompn.)(MeOH-MeCN); 0, 5-nitro-1,3,4-thiadiazol-2-yl, CH2CH2, Et, -, -; 0, 3-methyl-1-2,4-thiadiazol-5-yl, CH2CH2, CH2CH20Et, -, -; 0, 4-methyl-10-thiaxanthenon1-yl, CH2CH2, Et, red crystals, -; 3, 3-pyridyl, (QNR1R2=) 2-(1-methyl-2-piperidyl)ethyl, reddish-purple solid, -; 0, 2-thiazolyl, CH2CH2, 4-methylhomopiperazino, brilliant green crystals, -; 0, 6-indazolyl, CH2CH2, 2-(2-dimethylaminoethyl)piperidino, orange-red crystals, -; 3, 8-quinolyl, CH2CH2, piperazino, hydrated deep maroon cryst. solid, 210° (decompn.) (iso-PrOH); 0, 3-dibenzofuranyl, CH2CH2, 1-azaspiro[4.5]decan-1-yl, red crystals, -. The following I (X = H) were prepd. (n, Ar, Q, R1, R2, appearance, and m.p. given): 2, 8-hydroxy-5-quinolyl, CH2CH2, Et, CH2CH2OH, brown hydrated solid, 190-2°; 0, dibenzothiophen-2-yl, CH2CH2, Me, Bu, -, 120-1° (iso-PrOH); 0, benzo[f]quinoline-7-yl, CH2CH2, Me, Et, maroon crystals, 182-4° (iso-PrOH); 0, 3-acridinyl, CH2CH2, Me, cyclohexyl, orange-red crystals, -; 0, 7-cinnolinyl, CH2CH2, Et, allyl, red crystals, -; 0, 3-nitro-5-acetyl-2-thienyl, CH2CH2, Me, iso-Pr, -, -. The following comps. are prepd. (appearance and m.p. given): I [n = 2 (hydrated), X = MeO, Ar = 2,3-dimethyl-1-phenyl-5-oxo-3-pyrazolin-4-yl, Q = CH2CH2, R1 = R2 = Et], blue crystals, 200-2° (iso-PrOH-MeOH); reaction product, -, 215° (decompn.), of 2-(4,6-disulfo-1,3,2-benzodioxastibiol-2-yloxy)-1-phenol-3,5-disulfonic acid penta-Na salt-7H2O (IV) and 3-[4-(2-diethylaminoethylamino)-1-naphthylazo]pyridine (V), V-IV molar ratio .apprx.5:4. Also prepd. are the following VI (Y = H, R' = CH2CH2NEt2) (X, R, and m.p. given): NO2, H, 80-1° (iso-PrOH); NO2, F3CCO, -; NH2, F3CCO, -[HCl salt m. 216-18° (EtOH)]; 2,6-diamino-3-pyridylazo, F3CCO, -; NO2, HCO, -; NH2, HCO, - [di-HCl salt-1.5 hydrate m. 130-40° (decompn.)(iso-PrOH contg. HCl)]; 2,6-diamino-3-pyridylazo, HCO, -; 8-hydroxyquinolin-5-yl, F3CCO, 158-60° (iso - PrOH); 6 - methoxy - 8 - (2 - diisobutylaminoethylamino)-5-quinolylazo, F3CCO, 50-70°; 3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo, F3CCO, 154-5° (Me2CO). The following VI (Y = H) were prepd. (X, R, R', m.p., b.p./mm., and n25D given): H, H, (iso-Pr)2NCH2CH2NMeCHCH2, -, 153-7° /3, 1.5619; H, H, Et2NCH2CMe2CH2, -, 161° /1.0, 1.5790; 5-dibenzofurylazo, H, CH2CH2Br, 157-8° (CHCl3), -, -; 3-pyridylazo, H, Et2NCH2CH(OH)CH2, -, -, -[tri-HC salt monohydrate m. 153-5°]; 3-pyridylazo, H, H, 185-7°, -, -; H, (CH2)3NMe2, -, 184-5° /2.5, 1.6054; H, H, Et2NCH2CH2-SCH2CH2, -, 164-5° /0.1, 1.6014; H, H, 2-piperidinoethyl, -, 168-70° /0.5, 1.6088; 3-quinolylazo, H, H, 238-9°, -, -; H, H, CH2CH2NEtCH2CH2OH, -, 170-2° /0.2, 1.6109; H, H, (CH2)5-NEt2, -, 198-200° /1.8, n24.5D 1.5740; H, H, CH2CH2NBuMe, -, 142-4° /0.1, 1.5800; H, H, Et2NCH2CH2NEtCH2CH2, -, 145-8° /0.1, 1.5715; H, H, 2-[4-(2-diethylaminoethyl)piperidino]-ethyl, -, 208-9° /0.2, 1.5795; H, H, 3-piperidinopropyl, 70-2°, -, -; H, H, CHMeCH2NMe2, -, 118-20° /0.2, -; H, H, (iso-Pr)2NCH2CH2, -, 178-9° /0.9, 1.5782; H, H, CH2CH2NEtMe, -, 146-7° /6.4, 1.5990; H, H, CH(CH2NMe2)2, -, 137-8° /0.3, 1.5836; H, H, 2-(hexahydroazepino)ethyl, -, 164-6° /0.1, 1.6062; H, H, CHMe(CH2)3NEt2, -, 149-51° /0.2, 1.5730; H H, decahydro-1-quinolyl, (HCl salt m. 252-4°), -, -; H, H, 3-piperidino-2,2-dimethylpropyl,

L16 ANSWER 92 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
76-7° , -, -; H, H, 2-[4-(2-hydroxyethyl)piperazino]ethyl-(tri-HCl salt m. 207-11°), -, -; H, H, 1-methyl-4-piperidyl, -, 144-6° /0.2, -; H, H, CH2CH2-N(CH2CH2NEt2)2, -, 176-7° /0.1, 1.5563; H, H, 2-pyrrolidinylethyl, -, 142-3° /0.1, 1.6183; H, H, CH2CHMeCH2NEt2, -, 117-18° /0.15, -; H, H, 2-(N-methyl-N-cyclohexylamino)ethyl, -, 167-8° /0.2, 1.5984; H, H, CH2CH2N(CH2CH2OEt)2, -; 157-8° /0.07, 1.5598; H, H, CH2CH2N(CH2CH:CH2)Et, -, 147-8° /0.07, 1.5941; H, H, Me(iso-Pr)HCH2CH2, -, 131-2° /0.1, 1.5909; H, H, 2-(1-methyl-2-piperidyl)ethyl, -, 198-9° /1.3, -; H, H, 2-(2-dimethylaminoethyl)piperidino, -, 170-1° /0.07, 1.5875; H, H, 2-piperazinoethyl, -, 170-3° /0.25, 1.7023. Also prepd. were (b.p./mm. and n25D given): VI (X = R = H, Y = MeO, R' = CH2CH2NEt2), 195-6° /2, 1.5904; 1,2,3,6-tetrahydro-1-(diethylaminomethyl)benzaldehyde, 59-60° /10.1, 1.4780; N,N-diethyl-N'-(1-naphthyl)-1,1-cyclohexanebis(meth-ylamine), 161-2° /0.07, -.

IT 5235-99-4P, Ethylenediamine, N,N-diethyl-N'-(4-nitro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)

RN 5235-99-4 CAPLUS

CN Ethylenediamine, N,N-diethyl-N'-(4-nitro-1-naphthyl)- (7CI, 8CI) (CA INDEX NAME)



L16 ANSWER 93 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1964:3030 CAPLUS

DN 60:3030

OREF 60:481c-e

TI 1-Arylamino(nitro)anthraquinones

IN Fuchs, Otto; Wagner, Dieter

PA Farbwerke Hoechst A.-G.

SO 3 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1150996		19630704	DE 1962-F36426	19620330 <--
	BE 630423			BE	
PRAI	DE		19620330		

GI For diagram(s), see printed CA Issue.

AB 1-Amino-4-nitroanthraquinone 134, 1,2-dichlorobenzene 294, Cu powder 5, anhydrous Na2CO3 33, and nitrobenzene 160 parts by weight is kept 4 hrs. at 180° , the mixture cooled to 100° , MeOH 1000 parts by volume added, the mixture filtered, the precipitate washed with MeOH, heated with dilute aqueous HCl, filtered, and washed to give 78% I (R = 2-chlorophenyl), m. 190-3° (MeNO2). Similarly prepared are the following I (R and m.p. given): 2,5-Cl2C6H3, 222-5° ; 3,5-Br2 C6H3, 227-31° ; 5-chloro-1-naphthyl, 264-6° ; 1,5,6,8,10-penta chloro-3-pyrenyl, 345-52° . Also prepared are the 5-nitro analogs (same data): pentachlorophenyl, 338-9° (MeNO2) (86% yield); 4-BrC6H4, 226-7° ; 2,4-dichloro-5-tolyl, 230-2° ; 2,4,5-Cl3C6H2, 244-6° . Also prepared are the 8-nitro analogs (same data): 4chloro-1-naphthyl, 230-1° (MeNO2) (80% yield); 4-ClC6H4, 197-200° ; 3,5-Cl2C6H3, 275-80° .

IT 96943-31-0P, Anthraquinone, 1-[(4-chloro-1-naphthyl)amino]-8-nitro-
RL: PREP (Preparation)
(preparation of)

RN 96943-31-0 CAPLUS

CN 9,10-Anthracenedione, 1-[(4-chloro-1-naphthalenyl)amino]-8-nitro- (CA INDEX NAME)



L16 ANSWER 94 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1963:441728 CAPLUS

DN 59:41728

OREF 59:7533c-g

TI N-Substituted 2-aminooxazolines

PA Laboratoires Dausse S.A.

SO 14 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1313055		19621228	FR 1958-771767	19580801 <--
PRAI	FR		19580801		

GI For diagram(s), see printed CA Issue.

AB The title compds. were prepared from the corresponding substituted ureas. β-Chloroethyl isocyanate (10.55 g.) in 50 cc. Et20 was treated with 12.1 g. -phenylethylamine in 50 cc. Et20. After standing 24 hrs., the resulting precipitate was filtered off, washed with Et20, dried, triturated with 50 cc. H20, filtered, washed with H20, and dried to give 15.5 g. N1-phenylethyl-N3-chloroethylurea, m. 102. N1-Substituted N3-chloroethylureas similarly prepared were (N1-substituent, m.p., % yield given): C5H11, 68, 61; C7H15, 82, 69; C8H17, 82, 68; C12H25, 86, 81; PhCH2 (I), 108 9, 62; PhCH2 CHM2, 101-2, 57; Ph, 126, 78; pClC6H4, 175, 47; 2,6-Me2C6H3, 159 61, 41; p-AcC6H4, 166, 65; p-(EtCO)C6H4, 125, 72; 4-chloronaphthyl, 211 12, 81; Ph2CH, 163-5, 61; -(p-chlorophenyl)benzyl, 138-9, 40; α-(m-chlorophenyl)benzyl, 144-6, 38; cyclohexyl, 130-2, 40; α-naphthylmethyl, 152-4, 68; α-naphthyl, 147-9, 86. I (15.6 g.) and 130 cc. H20 was refluxed 10 min., the hot solution filtered, left overnight in the refrigerator, filtered again with Norite, then made alkaline to pH 9-10 with 30 cc. 2.5% NH4OH. The resultant oil solidified to give 7.2 g. 2-benzylaminooxazoline (II), m. 72. N-Substituted 2-aminooxazolines similarly prepared were (N-substituent, m.p., % yield given): phenethyl, 87,174; n-C5H11, -(b0.2 94), 55; n-C7H15, 47-8; 73; n-C8H17, 50, 93; n-C12H25, 55, 34, PhCH2CHMe, 64-5, 44; H, 121, 56; p-ClC6H4, 163, 48; 2,6-Me2C6H3, 81, 49; p-MeOC6H4, 120, 78; p-AcC6H4, 123-5, 74, p-(EtCO)C6H4, 155, 34; Ph2CH, 155-6, 57; -(p-chlorophenyl)benzyl, 167; 57; α-(p-chlorophenyl)benzyl, 114-15, 23; cyclohexyl, 131, 42; α-naphthylmethyl, 104-5, 74; α-naphthyl (II), 125, 31. II was a vasoconstrictor and was 2-3 times as active as Naphazoline (III) (2-α-naphthylmethylimidazoline) and only slightly less active than adrenaline, according to several types of assay. II was less toxic than both III and adrenaline. II was preferably administered as its HCl salt in aqueous solution

IT 97027-10-6P, Urea, 1-(2-chloroethyl)-3-(4-chloro-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)

RN 97027-10-6 CAPLUS

CN Urea, N-(2-chloroethyl)-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 95 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1962:476598 CAPLUS

DN 57:76598

OREF 57:15287e-g

TI Water-insoluble disazo dyes

IN Ribka, Joachim

PA Farbwerke Hoechst A.-G.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3025287		19620313	US 1960-30101	19600519 <--
	DE 1153844			DE	
	GB 913604			GB	
PRAI	DE		19600408		

AB Disazo compds. formed by coupling tetrazotized tetrachlorobenzidine with aromatic acetoacetylamino compds. are insol. yellow pigments suitable for coloring plastic masses and pigment printing. Thus, 32.2 parts [4,2,5-H2N(Cl)2C6H2]2 (I) was tetrazotized and stirred into a suspension of 46 parts 1-AcCH2CONHC10H7 (II) (prepared by solution in dilute NaOH and precipitation with AcOH in the presence of 20 mols. of ethylene oxide and 1 mol. of oleyl alc.) with simultaneous addition of NaOAc solution The mixture was boiled for 1 hr. and filtered to yield 80 parts of a yellow powder. A mixture of 0.2 part dye and 1 part TiO2 was incorporated within 10 min. on the roller mill into a mixture of 66 parts of poly(vinyl chloride), 17 parts of dioctyl phthalate, and 17 parts of di-Bu phthalate, and the dyeing pressed for 5 min. at 100° to obtain films. The greenish yellow dyeing was fast to light and bleeding. An ink containing 5 parts of dye, 35 parts Al(OH)3, and 60 parts linseed oil varnish, gave prints on art paper of high transparency. Lacquers colored with the dye possessed good heat resistance. The color was developed on cotton fabric by impregnating the material with a solution containing II, and treating the dried fabric with a solution of tetrazotized I.

IT 106216-34-6P, Acetoacetamide, 2,2'-[(2,2',5,5'-tetrachloro-4,4'-biphenylylene)bis(azo)]bis[N-(4-cyano-1-naphthyl)-
RL: PREP (Preparation)
(preparation of)

RN 106216-34-6 CAPLUS

CN Acetoacetamide, 2,2'-[(2,2',5,5'-tetrachloro-4,4'-biphenylylene)bis(azo)]bis[N-(4-cyano-1-naphthyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 96 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1960:868 CAPLUS
DN 54:868
OREF 54:137d-i,138a
TI Color developer
IN Anon.
PA Kodak Soc.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI BE 570978		19580930	BE	<--

AB A new developer for reducing the colored fogging and yielding maximum color d. is of the aromatic primary amine type (substituted by OH or another NH2 group) and contains a heterocyclic compound RCH2SM or RSM with R = tetraazaindenyl or pentaazaindenyl radical and M = H or cation (Belg. 530,062). Maximum d. and fogging values are given for emulsions sensitized by polyethylene glycol oleic ester: with 4,7-dihydroxy-2-mercapto-1-phenyl-1,3,5,6-tetraazaindene (I), 3.50 and 0.10; with 4,7-dihydroxy-2-mercapto-1,3,5,6-tetraazaindene (II), 3.00 and 0.14; with 6-hydroxy-3-mercapto-4-methyl-1,2,3a,7-tetraazaindene (III), 3.50 and 0.12; with 4-hydroxy-2-mercaptomethyl-6-methyl-1,3,3a,7-tetraazaindene (IV), 3.30 and 0.09; with 7-mercapto-1,3,4,6-tetraazaindene (V), 3.90 and 0.23; with 7-amino-5-mercapto-1,2,3,4,6-pentaazaindene (VI), 3.20 and 0.14; blank values are 3.30 and 0.31. The following compds. have also been used: 3-(2-formamidoethyl)-5-mercapto-1,2,4-triazole (VII), 5-formamido-1,3,4-triazaindene (VIII), tartaric bis[2-(4-hydroxy-6-methylpyrimid-2-yl)hydrazide] (IX), tetrachlorobenzo-1,2,3-triazole (X), α-amino-β-mercaptoisovaleric acid (XI), 2-(4-hydroxy-3-methoxyphenyl)-4-carboxythiazolidine (XII), 2-(4-hydroxyphenyl)-4-carboxythiazolidine (XIII). III is prepared by adding 7 g. phenyl isothiocyanate to a solution of 7 g. 2-hydrazino-4-hydroxy-6-methylpyrimidine in 2 l. hot EtOH and keeping reaction mixture at room temperature for 24 hrs. Crystallization from H2O yields 5 g. III, m. 278° . Treatment of 2-formamidinothiomethyl-4-hydroxy-6-methyl-1,3,3a,7-tetraazaindene in boiling dilute aqueous NaOH followed by acidification and crystallization from H2O yield
IV, m. 255-9° . VI, is obtained from 16 g. 2-mercapto-4,5,6-triaminopyrimidine sulfate dissolved in 200 cc. H2O by NaOH addition; 7 g. NaNO3 is added to the filtered solution which is then acidified and heated for 1/2 hr. on steam-bath. After cooling (0°), the precipitated solid is dissolved in NaOH solution and treated with active C; after AcOH addition, solid is washed with H2O and dried; yield of VI, m. 300° is 8 g. VII is prepared by refluxing for 5 hrs. 5 g. 3-(2-aminoethyl)-5-mercapto-1,2,4-triazole in 25 cc. HCOOH 98%; evaporation to dryness under reduced pressure (steam bath), trituration of residue with a little EtOH, and recrystn. from aqueous EtOH yield 2 g. VII-hydrate, m. 202-3° . VIII, m. 257-8° is similarly obtained from 2,3,6-triaminopyridine-HCl, HCOONa and HCOOH. IX is obtained by heating, for 20 hrs. on a steam bath, a mixture of 178 g. tartaric hydrazide, 340 g. 2-ethylthio-4-hydroxy-6-methylpyrimidine in 1 l. H2O; precipitate digestion in 2 l. boiling H2O yields, after cooling, 219 g. IX, m. 281-5° (decompose) with infrared absorption at 7270 A. Preparation of XII and XIII are given in Belg. 559,754 (cf. following abstract).

IT 35158-78-2, Hydrazine, (4-bromo-1-naphthyl)-
(in color photography)

RN 35158-78-2 CAPLUS
CN Hydrazine, (4-bromo-1-naphthalenyl)- (CA INDEX NAME)

L16 ANSWER 96 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 97 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1960:867 CAPLUS
DN 54:867
OREF 54:137c-d
TI Antifoggant for photographic developers and solubilizing agents for hydrazines
IN Hunsberger, Isaac M.
PA Antioch College
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2892715		19590630	US 1955-546958	19551115 <--

AB Two surfactants, Na xylenesulfonate (I) and octylphenoxypolyoxyethyleneeth anol (II), in combination, act both as solubilizing agents for N2H4 derivs. incorporated in photographic developers and as antifogging agents. The present invention overcomes the disadvantages of higher fog d. and increased γ normally accompanying the advantage of speed increase when certain N2H4 derivs. are added to conventional developers. The range of the utility of the less-soluble hydrazines is also increased. The optimum concns. of I and II depend on the developer used. A typical formulation consists of 10 drops II and 50 ml. of a 40% solution of I in 4 l. of Eastman Kodak developer D-19 containing 4-bromo-1-naphthylhydrazine in 10-6M concentration

IT 35158-78-2, Hydrazine, (4-bromo-1-naphthyl)-
(in color photography)

RN 35158-78-2 CAPLUS
CN Hydrazine, (4-bromo-1-naphthalenyl)- (CA INDEX NAME)



L16 ANSWER 98 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1956:42184 CAPLUS
DN 50:42184
OREF 50:8127e-g
TI Herbicidal products
IN Todd, Charles W.
PA E. I. du Pont de Nemours & Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2723193		19551108	US 1954-412046	19540223 <--

AB Compds. useful as herbicides have the general formula AN-(R)C(:X)NR'R'', where A is a univalent binuclear aromatic radical (I), X is O or S, and R, R', and R'' are H or univalent aliphatic radicals, at least one of the latter being an aliphatic radical. The I include substituted or unsubstituted naphthyl and biphenylyl radicals. Standard reactions are used to prepare these ureas. Thus, a slight excess of Me2NH was slowly added with stirring to a solution of 25.4 parts 2-naphthyl isocyanate in 125 parts Et2O. After refluxing 30 min., the mixture was cooled and essentially pure 3-(2-naphthyl)-1,1-dimethylurea, m. 210.5-10.8° , precipitated out. Application as a 1% solution killed tomato plants in 4 weeks and quack grass in 3 months. Formulations are given for water-dispersible powders, dusts, oil-water dispersible powders, water-dispersible liquid compns., and granular compns.

IT 859734-10-4, Urea, 3-(4-chloro-1-naphthyl)-1,1-dimethyl-
(for weed control)

RN 859734-10-4 CAPLUS
CN Urea, N'-(4-chloro-1-naphthalenyl)-N,N-dimethyl- (CA INDEX NAME)



L16 ANSWER 99 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1955:53668 CAPLUS
DN 49:53668
OREF 49:10362i,10363a-d
TI Hydantoin compounds
PA Cassella Farbwerke Mainkur Akt.-Ges.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 704978		19540303	GB 1951-5469	19510306 <--

AB Hydantoins having antiepileptic and hypnoticactivity may be obtained from an alkali-metal cyanide with 2- or 4-RC6H4C(:O)Y (in which R is HO, alkoxy containing halogen, dialkylamino, a double bond or PhO and Y is H, alkyl, aralkyl, or haloalkyl) and an amine or NH3 in the presence of an acid. Thus, 204 g. o-HOC6H4Ac, 120 g. KCN, 240 g. NH4HCO3, 500 cc. EtOH, and 600 cc. H2O stirred 12 hrs. under a CO2 pressure of 15-17 atmospheric and the product recrystd. from MeOH gives 5-o-hydroxyphenyl-5-phenylhydantoin (I), m. 229-30.5°. Similarly are prepared the following hydantoins: 5-p-allyloxyphenyl-3-methyl (II), m. 171°; 5-o-(2-diethylaminoethoxy)phenyl-5-propyl, m. 156°; 5-o-hydroxyphenyl-1-butyl, m. 191°; and 5-p-phenoxyphenyl-5-methyl, m. 182°. Other hydantoins can be prepared by adding 8 g. Br in 100 cc. dry CHCl3 to 12.3 g. II in 1200 cc. CHCl3, stirring several hrs., evaporating the solvent, and recrystg. the residue from MeOH and Norit to yield 5-p-(2,3-dibromopropoxy)phenyl-5-methylhydantoin, m. 180-3°. Also, 165 g. Me2SO4 added to 123 g. II in 525 cc. N NaOH and 300 cc. H2O with cooling, and the precipitate filtered off and recrystd. from MeOH gives 3,5-dimethyl-5-p-allyloxyphenylhydantoin, m. 137-8°. Also prepared in addition to compds. reported in U.S. 2,615,897 (C.A. 48, 7633d) are the following substituted 5-phenylhydantoins (III) (substituents, when other than H, and m.p. given): 4'-HO, 5-Me, 244-6°; 4'-HO, 5-Et, 258-61°; 4'-HO, 5-Pr, 245-6°; 2'-HO, 5-Et, 213-14°; 2'-HO, 5-Pr, 218.5°; 2'-allyloxy, 5-Me, 151°; 2'-allyloxy, 5-Pr, 179°; 2'-allyloxy, 5-Me, 181-2.5°; 2'-allyloxy, 5-Et, 164-6°; 2'-allyloxy, 5-Pr, 158-9°; 2'-BrCH2CHBrCH2O, 5-Me, 199-201°; 4'-BrCH2-CHBrCH2O, 5-Et, 180-3°; 4'-BrCH2CHBrCH2O, 5-Pr, 159-61°; 2'-HO, 1-Me, 273°; 2'-HO, 1-Et, 203°; 2'-HO, 1-Pr, 216-17°; 2'-HO, 1-allyl, 184-5°; 2'-HO, 5-Me, 3-PhCH2, 114-15°; 2'-allyloxy, 3,5-di-Me, m. 193-4°; 2'-HO, 1-BrCH2CHBrCH2, 172-80°; 2'-HO, 1-PhCH2CH2, 234-5°.

IT 874517-58-5P, Urea, 3-(4-chloro-1-naphthyl)-1,1-bis-(2-hydroxyethyl)-
RL: PREP (Preparation)
(preparation of)

RN 874517-58-5 CAPLUS
CN Urea, N'-(4-chloro-1-naphthalenyl)-N,N-bis(2-hydroxyethyl)- (CA INDEX NAME)

L16 ANSWER 99 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 100 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1955:53667 CAPLUS
DN 49:53667
OREF 49:10362g-i
TI (Haloaryl) (hydroxyalkyl)ureas
IN Searle, Norman E.; Todd, Charles M.
PA E. I. du Pont de Nemours & Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2663729		19531222	US 1952-318728	19521104 <--

AB The ureas are prepared from substituted aryl thiocyanates and N,N-dialkylamines in which 1 or both of the alkyl groups may be HO-substituted. The products are herbicidal and H2O-soluble To a stirred solution of 15.3 g. p-ClC6H4NCO in 160 g. C6H6 was rapidly added at 15° 12.6 g. diethanolamine (I), the temperature maintained 4 min. at 15-18°, then permitted to rise to 25° over 1.1 hrs., the mixture refluxed 15 min., and the C6H6 decanted off; the remaining oil crystallized in several hrs., and removal of the I with water and drying of the crystals yielded 87% RNHCON(CH2CH2OH)2 (R = p-ClC6H4) (II), m. 88-9.1°. Similarly were prepared the following analogs of II (R, % yield, and m.p. given): p-BrC6H4, 84, 105°, from 27 g. I and 50 g. RNCO in 310 g. dioxane (III); p-IC6H4, 73, 112.5-13° (from H2O), from 61.5 g. RNCO and 29 g. I in 309 g. dry III; m-FC6H4, 76.5, 84-5°, from 18 g. I in 51.5 g. III; and 21.5 g. RNCO in 67 g. III; 2,4,6-Cl3C6H2, 82.5, 121-2°, from 25.6 g. I in 103 g. III and 48.5 g. RNCO in 103 g. III; 4,1-ClC10H6, 90.5, 127-8°, from 21.4 g. I in 206 g. III and 57.5 g. RNCO in 51.5 g. III.

IT 874517-58-5P, Urea, 3-(4-chloro-1-naphthyl)-1,1-bis-(2-hydroxyethyl)-
RL: PREP (Preparation)
(preparation of)

RN 874517-58-5 CAPLUS
CN Urea, N'-(4-chloro-1-naphthalenyl)-N,N-bis(2-hydroxyethyl)- (CA INDEX NAME)



L16 ANSWER 101 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1948:34449 CAPLUS
DN 42:34449
OREF 42:7346e-f
TI Pyrimidine derivatives
IN Curd, Francis H. Swinden; Hall, Margaret I.; Owen, Edmund C.; Rose, Francis L.; Tuey, George A. P.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2443305		19480615	US	<--

AB See Brit. 587,550 (C.A. 42, 2627c). Not included in this abstract is 4-p-chloroanilino - 2 - (3 - dibutylaminopropylamino) - 6-methylpyrimidine(di-HCl salt, m. 171-3°).

IT 878777-67-4P, Pyrimidine, 2-(4-chloro-1-naphthylamino)-4-(2-diethylaminoethylamino)-6-methyl-, dihydrochloride
RL: PREP (Preparation)
(preparation of)

RN 878777-67-4 CAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chloro-1-naphthalenyl)-N4-[2-(diethylamino)ethyl]-6-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L16 ANSWER 102 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1948:12017 CAPLUS
DN 42:12017
OREF 42:2627c-i,2628a-i,2629a-c
TI Condensation of pyrimidine derivatives with arylamines
IN Curd, Francis H. S.; Davis, Margaret I.; Owen, Edmund C.; Rose, Francis L.; Tuey, Geo. A. P.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 587550		19470429	GB	<--

AB Parasiticidal or antimalarial drugs are prepared by the condensation of an arylamine with a pyrimidine derivative having a halogen atom in the 2- or 4-position. 4-Chloro-2-(3-diethylaminopropylamino)-6-methylpyrimidine 5.2, p-ClC6H4NH2 7.68, and p-ClC6H4NH2.·HCl 3.3 g. are heated at 170-5° 2 hrs., cooled, and stirred with 50 g. C6H6. The undissolved residue is filtered off and dissolved in a solution containing AcOH 1 and NaOAc 1 to H2O 40 g. This solution is decolorized with activated C and filtered hot, and NaCl is added to precipitate 4-p-chloroanilino-2-(3-diethylaminopropylamino)-6-methylpyrimidine-2HCl, m. 268-70° (from MeOH); monohydrochloride monopicrate m. 236-8° ;dipicrate m. 212-14° . The following compds. are similarly prepared from the corresponding starting materials; in some instances the crude product is first recovered as the free base, and the purification procedure is modified accordingly. 4-Substituted 2-(2-diethylaminoethylamino)-6-methylpyrimidine-2HCl: p-chloroanilino, m. 266-8° ;p-toluidino, m. 236-8° ;(6-bromo-2-naphthylamino), m. 266-8° (dipicrate m. 224-5°);p-methoxyanilino, m. 216-18° (dipicrate m. 180°);(3,4-dichloroanilino), m. 260-1° (dipicrate m. 218-19°);anilino, m. 238° (addition of alc. picric acid to the alc. solution of the di-HCl salt prts. the monohydrochloride monopicrate, m. 228°). p-Nitroanilino, m. 293° . 2-Substituted 4-p-chloroanilino-6-methylpyrimidine-2HCl: (4-diethylaminobutylamino), m. 197-8° (from aqueous MeOH) (dipicrate, m. 226-7° (from 2-ethoxyethanol)); (3-dimethylaminopropylamino), m. 270° ; (3-dibutylaminopropylamino), m. 171-3° (dipicrate m. 220-2°);[3-(1-piperidyl) propylamino] , m. 277-9° ; (3-butylaminopropylamino), m. 301-3° ;(3-diethylaminopropylamino), m. 268-70° ;[(2-diethylaminoethyl)methylamino], m. 244-6° (freebase, m. 83-5°). 4-p-Chloroanilino-2-(3-diethylaminopropylamino)-5-ethyl-6-methylpyrimidine-2HCl m. 245-6° ; the 2-(3-dibutylaminopropylamino) analog m. 215-16° . 2-p-Chloroanilino-4-(2-diethylaminoethylamino)-6-methylpyrimidine b0.2 204-8° (picrate, m. 218-19° (from 2-ethoxyethanol); di-HCl salt m. 270-1° (from alc.)). 2-Substituted 4-(2-diethylaminoethylamino)-6-methylpyrimidine-2HCl: p-methoxyanilino, m. 231-2° ;p-toluidino, m. 216-18° ;(p-methylmercaptoanilino), m. 232-4° ;(2-naphthylamino), m. 252-4° (decomposition); (6-bromo-2-naphthylamino), m. 290° (decomposition); (6-methoxy-2-naphthylamino), m. 228-30° (decomposition); o-chloroanilino, m. 251-3° ;anilino, m. 264° (decomposition); o-methoxyanilino, m. 272-3° ;o-toluidino, m. 237-8° ;m-toluidino, m. 272-4° ;p-ethoxyanilino, m. 211-13° ;(1-naphthylamino), m. 275-6° ;(4-chloro-1-naphthylamino), m. 294-5° . 2-Substituted 4-(6-bromo-2-naphthylamino)-6-methylpyrimidine-2HCl: (3-dibutylaminopropylamino), m. 250-2° (from EtOH-AcOEt); (3-diethylaminopropylamino), m. 259-61° ;(2-diethylaminoethylamino), m. 266-8° . 4-p-Bromoanilino-2-(3-

L16 ANSWER 102 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
dibutylaminopropylamino)-6-methylpyrimidine-2HCl m. 160-1° . 6-Methyl-4-m-nitroanilino-2-[3-(1-piperidyl)propylamino]pyrimidine-2HCl m. 262-4° . 4-(6-Bromo-2-naphthylamino)-6-methyl-2-[3-(1-piperidyl)propylamino] pyrimidine-2HCl m. 288-9° . 6-Methyl-4-p-nitroanilino-2-[3-(1-piperidyl) propylamino] pyrimidine m. 174-5° (di-HCl salt, m. 277-9°). 2-Substituted p-(6-methyl-4-pyrimidylamino)benzonitriles: (3-dibutylaminopropylamino)-2HCl, m. 224-6° ;(2-diethylaminoethylamino)-2HCl, m. 307-8° ; (3-diethylaminopropylamino) (di-HCl salt, m. 274-5°)and its S-ethyl deriv., 151-2° (from aq. EtOH and C6H6, successively); [3-(1-piperidyl)propylamino]-2HCl, m. 280-2° ;(4-diethylamino-1-methylbutylamino), b0.15 233-9° (dipicrate, m. 199-200° ; di-HBr salt, m. 216-20°). 4-p-Chloroanilino-2-(3-dibutylaminopropylamino)pyrimidine-2HCl m. 155-7° (from EtOH-AcOEt). p-[4-(2-Diethylaminoethylamino)-6-methyl-2-pyrimidylamino]phenol-2HCl m. 270-2° ;p-[2-(3-diethylaminopropylamino)-6-methyl-4-pyrimidylamino]phenol-2HCl m. 269-71° (decompn.); p-[2-(3-dibutylaminopropylamino)-6-methyl-4-pyrimidylamino]phenol-2HCl m. 120-2° .2-(3-Diethylaminopropylamino)-6-methyl-4-p-nitroanilinopyrimidine-2HCl, blunt yellowish needles from slightly dild. EtOH, m. 273-5° . 2-p-Chloroanilino-4-(3-diethylaminopropylamino)-6-methylpyrimidine b0.15 210-18° (dipicrate, m. 225-6° ;di-HCl salt, m. 252-4°). 4-(3-Diethylaminopropylamino)-2-(p-dimethylaminoanilino)-6-methylpyrimidine (tri-HBr salt, made by addn. of AcOH to the base in HBr, m. 256-8°). 2-Substituted 4-(3-diethylaminopropylamino)-6-methylpyrimidine-2HCl: (2-naphthylamino), m. 259-60° (decompn.); (4-chloro-o-toluidino), m. 150-2° ;o-chloroanilino, m. 238-9° ,m-chloroanilino, m. 215-17° ;(2,4-dichloroanilino), m. 208-10° (free base, b0.02 208-10° ;dipicrate, m. 210-11°); (3,4-dichloroanilino), m. 237-9° ; (2,5-dichloroanilino), m. 248-50° (free base, m. 98-100° (decompn.)); (6-bromo-2-naphthylamino), m. 259-60° (decompn.); (3-chloro-p-toluidino) m. 230-2° ;(3,4-dimethylanilino), m. 222-40° ;(3,5-dimethylanilino), m. 306-8° ; (3,5-dibromoanilino), m. 264-6° ;p-bromoanilino, m. 255-7° ; p-butylanilino, m. 188-90° ;p-nitroanilino, m. 226-32° . 2-p-Chloroanilino-4-(3-diethylaminopropylamino)pyrimidine-2HCl m. 208-10° . Me p-[4-(3-dimethylaminopropylamino)-6-methyl-2-pyrimidylamino] benzoate-2HCl, m. 263-5° . 2-(4-Biphenylylamino)-4-[3-(?)-diethylaminoethyl(propyl?)amino]-6-methylpyrimidine-2HCl m. 244-6° .p-[4-(3-Diethylaminopropylamino)-6-methyl-2-pyrimidylamino] benzonitrile-2HCl m. 249-51° . 4-p-Chloroanilino-2-(4-diethylamino-1-methylbutylamino)-6-methylpyrimidine b0.15 220-3° (di-HBr salt, m. 200-1° (from EtOH-AcOEt); dipicrate, m. 189-90° (from EtOH-EtOCH2CH2OH)). 2-Substituted 4-(4-diethylamino-1-methylbutylamino)-6-methylpyrimidines: p-chloroanilino, b0.15 204-6° (dipicrate, m. 168-70°);o-chloroanilino, b1.0 207-10° (di-HCl salt, m. 106-8°);m-chloroanilino, b1.5 235-7° (di-HCl salt, m. 205-7°);p-bromoanilino, b1.0 240-2° (di-HCl salt, m. 244°);(3,4-dichloroanilino), b1.0 242-6° (di-HCl salt, m. 257°);p-methoxyanilino, b1.0 237-31° (di-HCl salt, m. 245°);o-methoxyanilino, b1.8 229-31° (di-HCl salt, m. 225-7°). 4-p-Chloroanilino-2-(2-diethylaminoethylamino)-6-methylpyrimidine b0.65 193-200° ,m. 97° (from petr. ether) (dipicrate, m. 227-8°);4-p-toluidino analog m. 66-8° (dipicrate m. 191-3°);4-p-nitroanilino analog m. 161-2° . 2-(4-Diethylamino-1-methylbutylamino)-4-p-nitroanilino-6-methylpyrimidine (dipicrate, m. 173-6° ;di-HCl salt, m. 114-18°); 4-(6-bromo-2-naphthylamino) analog (dipicrate, m. 238-41° ;di-HCl

L16 ANSWER 102 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
salt, m. 260-2°). 2-(3-Dibutylaminopropylamino)-4-(2,4-dichloroanilino-6-methylpyrimidine b0.12, 220-2° (dipicrate m. 226-7°);4-(3,4-dichloroanilino) isomer (dipicrate, m. 192-3° ;di-HCl salt, m. 240-2°). 2-(3-Diethylaminopropylamino) -5-ethyl-6-methyl-4-p-nitroanilinopyrimidine m. 126-8° . 2-(3-Dibutylaminopropylamino)-4-p-nitroanilinopyrimidine m. 111-14° (dipicrate, m. 206-7°). 4-(6-Bromo-2-naphthylamino)-2-(3-butylaminopropylamino)-6-methylpyrimidine, an oil (dipicrate, m. 219-20° ;di-HCl salt, m. 301-3°). 2-[3-(2-Diethylaminoethoxy)propylamino]-6-methyl-4-p-nitroanilinopyrimidine m. 108-9° ;2-(3-butylaminopropylamino) analog m. 141-3° ;2-(3-dimethylaminopropylamino) analog m. 184° . 4-p-Chloroanilino-2-[3-(2-diethylaminoethoxy) propylamino]-6-methylpyrimidine, an oil (dipicrate, m. 148-50° ; di-HCl salt, m. 178-80°). 4-p-Chloroanilino-2-(3-[(2-diethylaminoethyl)methylamino] propylamino]-6-methylpyrimidine-3HCl m. 239-40° . 4-m-Chloroanilino-2-(3-dibutylaminopropylamino)-6-methylpyrimidine (dipicrate, m. 180-1° ;di-HCl salt, from AcOEt-MeOH and then from BuOH-AcOEt, colorless, thick prisms, m. 221-3°). 4-(2-Diethylaminoethylamino)-6-methyl-2-m-nitroanilinopyrimidine (di-HCl salt, m. 258-60° (from EtOH); dipicrate, m. 196-7°). 2-(3-Dibutylaminopropylamino)-6-methyl-4-p-nitroanilinopyrimidine m. 118-19° (di-HCl salt, m. 224-5°). 2-p-Chloroanilino-4-(3-diethylaminopropylamino)-6-methyl-5-nitropyrimidine m. 94-6° :the 4-(2-diethylaminoethylamino) analog m. 95-7° .

IT 878777-67-4P, Pyrimidine, 2-(4-chloro-1-naphthylamino)-4-(2-diethylaminoethylamino)-6-methyl-, dihydrochloride
RL: PREP (Preparation)
(preparation of)

RN 878777-67-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-chloro-1-naphthalenyl)-N4-[2-(diethylamino)ethyl]-6-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

L16 ANSWER 103 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1948:8848 CAPLUS
DN 42:8848
OREF 42:1972c-f
TI 4-Hydroxypyrimidine derivatives
IN Curd, Francis H. S.; Raison, Clifford G.; Rose, Francis L.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2433439		19471230	US	<--

AB The compds. are prepared by heating in EtOCH2CH2OH the appropriate arylamine and a 4-hydroxypyrimidine substituted in the 6-position by a hydrocarbon radical and in the 2-position by an alkylmercapto or substituted alkylmercapto group. The preparation of the following 2-derivs. of 4-hydroxy-6-methylpyrimidine is described: p-chloroanilino, colorless thick laminas, m. 294° ;p-methoxyanilino, m. 212-13° ; p-ethoxyanilino, m. 187-9° ;p-bromoanilino, m. 284-6° ; p-butylanilino, m. 195-6° ;p-carbomethoxyanilino, m. 274-6° ; p-phenyl-anilino, m. 258-9° ;p-cyanoanilino, m. 330° ; (2-naphthylamino), colorless needles, m. 243-5° ;(1-naphthylamino), m. 256-7° ;(4-chloro-1-naphthylamino), m. 298-301° ; (6-bromo-2-naphthylamino), colorless crystals, m. 286-8° ; (6-methoxy-2-naphthylamino), colorless crystals, m. 238-9° ; (2,4-dichloroanilino), m. 278-80° ;(3,4-dichloroanilino), m. 250-2° ;(2,5-dichloroanilino), m. 244-6° ; (2-methyl-4-chloroanilino), m. 252-4° ;(3-chloro-4-methylanilino), m. 252-4° ;(3-chloroanilino), m. 227-9° ;(2-chloroanilino), m. 244-6° ;anilino, m. 244-6° ;(3,4-dimethylanilino), m. 238-9° ;(3,5-dimethylanilino), m. 268° ;(3,5-dibromoanilino), almost colorless needles, m. 325° ; (2-methoxyanilino), colorless needles, m. 245-6° ; (2-methylanilino), m. 204° ;(3-methylanilino), m. 212-13° ; (4-dimethyl-aminoanilino), m. 240-2° ;p-toluidino, colorless crystals, m. 230° ;(p-methylmercaptoanilino), m. 210-12° ; p-nitroanilino, m. above 300° . 2-p-Ckloroanilino-4-hydroxy-6-phenylpyrimidine, colorless needles, m. 312-13° . Cf. C.A. 40, 5054.6.

IT 857413-67-3P, 4-Pyrimidinol, 2-(4-chloro-1-naphthylamino)-6-methyl-
RL: PREP (Preparation)
(preparation of)

RN 857413-67-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(4-chloro-1-naphthalenyl)amino]-6-methyl- (CA INDEX NAME)



L16 ANSWER 104 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1948:8847 CAPLUS
DN 42:8847
OREF 42:1971h-i,1972a-c
TI 4-Halo-6-methylpyrimidine derivatives
IN Curd, Francis H. S.; Raison, Clifford G.; Rose, Francis L.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2433440		19471230	US	<--

AB The compds. are prepared by heating a 4-hydroxy derivative of 6-methylpyrimidine (I), e.g. 2-p-chloroanilino-4-hydroxy-6-methylpyrimidine, and a halogenating agent, e.g. POCl3. The excess POCl3 is distilled in vacuo, ice and water are mixed in, then NH3 is added to faint alkalinity with stirring. The solidified product is crystallized from EtOH. The following 2-derivs. of 4-chloro-6-methylpyrimidine are reported: p-chloroanilino, m. 126-7°; p-methoxyanilino, m. 103-5°; (p-ethoxyphenyl), m. 116-18°; p-toluidino, irregular colorless tabular crystals, m. 104-6°; (p-methylmercaptoanilino), m. 81-2°; p-cyanoanilino, m. 215-16°; p-nitroanilino, m. 248-50°; (2-naphthylamino), colorless thick prisms, m. 145-7°; (6-bromo-2-naphthylamino), needles, m. 152-3°; (6-methoxy-2-naphthylamino), m. 148-50°; (2,4-dichloroanilino), m. 120-2°; (3,4-dichloroanilino), m. 134-6°; (3,5-dibromoanilino), m. 131-2°; (2-methyl-4-chloroanilino), m. 107-8°; (3-chloro-4-methylanilino), m. 115-17°; (2,5-dichloroanilino), m. 101°; (3,4-dimethylanilino), m. 128-9°; (3,5-dimethylanilino), m. 86-8°; (4-bromoanilino), m. 140-1°; (4-butylanilino), m. 51-3°; (3-chloroanilino), m. 116-18°; (2-chloroanilino), m. 99-100°; (2-methylanilino), m. 116-18°; (3-methylanilino), m. 101-2°; anilino, colorless needles, m. 92-4°; (2-methoxyanilino), m. 103-4°; (4-dimethylaminoanilino), m. 157-9°; (4-carbomethoxyanilino), m. 223-5°; (4-phenylanilino), m. 124-5°; (1-naphthylamino), m. 131-2°; (4-chloro-1-naphthylamino), m. 170°. 2-(4-Chloroanilino)-4-chloro-6-phenylpyrimidine m. 166-8°. Cf. C.A. 40, 5054.6.

IT 856975-81-0P, Pyrimidine, 4-chloro-2-(4-chloro-1-naphthylamino)-6-methyl-
RL: PREP (Preparation)
(preparation of)

RN 856975-81-0 CAPLUS
CN 2-Pyrimidinamine, 4-chloro-N-(4-chloro-1-naphthalenyl)-6-methyl- (CA INDEX NAME)



L16 ANSWER 104 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L16 ANSWER 105 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1945:14222 CAPLUS
DN 39:14222
OREF 39:2206e-i,2207a-e
TI Azo dye intermediates
IN Sparks, Chiles E.
PA E. I. du Pont de Nemours & Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2361327		19441024	US 1940-345172	19400712 <--

GI For diagram(s), see printed CA Issue.

AB The new intermediates are mono- and bis(aminoaryloxyacyl)diamino arylenes of the benzene, naphthalene, and biphenyl series. These compds. are produced by condensing nitro acid halides of the type: with aromatic diamines or nitroarom. monoamines of the type: where Q is a straight or branched aliphatic radical of 1-6 C atoms, R is H, halogen, lower alkyl, or lower alkoxy radical, R' is R or a carboxy, sulfonic acid, or lower carboxy-alkoxy radical, R'' is H, halogen, carboxy, or sulfonic acid radical, R''' is H, a lower alkyl, or lower alkoxy radical, Y is a nitro or amino group and n is 1 or 2. The preparation of these intermediates is exemplified by the following: Add 4-nitrophenoxyacetic acid 69 and 3-nitroaniline 48.3 to toluene 298 parts. While agitating the mixture distil off 58 parts of toluene. Cool the residue to 30° and add slowly PCl3 24.1 parts; in doing so avoid raising the temperature above 50%. Raise the temperature over a period of 1-1.5 h. to 111-14° under a reflux condenser, maintain this temperature for 3.5 h. longer and then cool to 25°. Dilute with 117 parts of H2O, add slowly NaOH until faintly alkaline to phenolphthalein, stir for 10 min. and filter. Wash the filter cake and dry it at 60-5°. The product is 98.5% pure 3-nitro-α-(p-nitrophenoxy)acetanilide, m. 177-80°. By similar methods were prepared 2,4-bis[α-(p-nitrophenoxy)acetamido]benzenesulfonic acid, 91.2% pure; the corresponding diamino compound 66% pure; 1,3-bis(p-nitrophenoxyacetamido)benzene, m. 239°, 96.8% pure; and the corresponding diamino compound, m. 151-3°, 99% pure. In addition to the above the following were prepared: 5'-nitro-α-(p-nitrophenoxy)-o-acetaniside, m. 223-4° (97.4% pure); diamino analog, m. 97-100° (74.3%); 2,5-dimethoxy-4-nitro-α-(p-nitrophenoxy)acetanilide, m. 216-17° (60.7); diamino analog, m. 102; α-(2-methoxy-4-nitrophenoxy)-p-nitroacetanilide, m. 179° (97.0%); diamino analog, m. 93° (79.6%); α-(2-methoxy-4-nitrophenoxy)-m-nitroacetanilide, m. 207° (96.4%); diamino analog; 5-nitro-α-(p-nitrophenoxy)-o-acetotoluide, m. 214° (99.5%); diamino analog, m. 135° (100%); 5-nitro-2-[α-(p-nitrophenoxy)acetamido]benzoic acid (84.9%); diamino analog (78.4%); 4-nitro-α-(p-nitrophenoxy)-o-acetaniside, m. 210° (98.8%); diamino analog, m. 95° (90.0%); 2-chloro-4-nitro-α-(p-nitrophenoxy)acetanilide, m. 200-2° (97.8%); diamino analog, m. 133°; 4,4'-bis[α(p-nitrophenoxy)acetamido]-2,2'-biphenyldisulfonic acid (87.3%); diamino analog; N-(4-nitro-1-naphthyl)-α-(p-nitrophenoxy)acetamide, m. 168° (92.4%); diamino analog, m. 167° (89.4%); 2,5-bis[α-(p-nitrophenoxy)acetamido]benzenesulfonic acid; diamino analog; 5,8-bis[α-(p-nitrophenoxy)acetamido]-2-naphthalenesulfonic acid; diamino analog; p-nitro-α(p-nitrophenoxy)acetanilide (97.4%); diamino analog, m. 105-8° (95.9%); 4-nitro-α-(p-nitrophenoxy)o-acetotoluide, m. 175° (98.7%); diamino analog, m. 90° (91.7%); p-nitro-α-(o-nitrophenoxy)acetanilide, m. 231° (90.0%); diamino analog, m. 130-2°.

IT 855879-48-0P, Acetamide, N-4-nitro-1-naphthyl-α-(p-nitrophenoxy)-
RL: PREP (Preparation)
(preparation of)

L16 ANSWER 105 OF 105 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 855879-48-0 CAPLUS
CN Acetamide, N-(4-nitro-1-naphthalenyl)-2-(4-nitrophenoxy)- (CA INDEX NAME)



```
=> => d que l23 stat
L17          17 SEA FILE=CAPLUS ABB=ON  PLU=ON  "CADILLA RODOLFO"/AU
L18          12 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("LARKIN ANDREW"/AU OR "LARKIN
                ANDREW L"/AU OR "LARKIN ANDREW LAMONT"/AU)
L19          48 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("STEWART EUGENE"/AU OR
                "STEWART EUGENE L"/AU OR "STEWART EUGENE LEE"/AU)
L20          17 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("TRUMP RYAN P"/AU OR "TRUMP
                RYAN PAUL"/AU)
L21          33 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("TURNBULL PHILIP"/AU OR
                "TURNBULL PHILIP S"/AU OR "TURNBULL PHILIP STEWART"/AU OR
                "TURNBULL PHILLIP STEWART"/AU)
L22          95 SEA FILE=CAPLUS ABB=ON  PLU=ON  L17 OR L18 OR L19 OR L20 OR
                L21
L23          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L22 AND ?NAPHTH?


=> d 1-15 bib abs
```

L23 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1312622 CAPLUS
DN 146:62449
TI Nonsteroidal tertiary arylamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors and their preparation and use for treatment of diseases
IN Turnbull, Philip Stewart; Cadilla, Rodolfo; Larkin, Andrew Lamont; Stewart, Eugene Lee; Stetson, Katherine
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 191pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133216	A2	20061214	WO 2006-US21966	20060606
	WO 2006133216	A3	20070426		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1888512	A2	20080220	EP 2006-772527	20060606
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
PRAI	US 2005-687895P	P	20050606		
	WO 2006-US21966	W	20060606		

OS MARPAT 146:62449
GI



AB This invention relates to non-steroidal compds. of formula I that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compds. Compds. of formula I wherein R1 is CN, NO2 and halo; n is 0, 1, and 2; each R3 is independently CN, NO2, halo, (halo)alkyl, alkenyl, alkynyl, OH, (halo)alkoxy, and aryl; R3 is (Rx)aR7; Rx is (un)substituted C1-4 alkylene; a is 0 and 1; R7 is H, (halo)alkyl, cycloalkyl, alkenyl, alkynyl, CN; R4 and R5 are independently H, (halo)alkyl, and cycloalkyl; R6 is (un)substituted aryl and (un)substituted heterocyclyl; and their

L23 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
pharmaceutically acceptable salts, and solvates thereof are claimed. Example compd. II was prepd. by substitution of 4-fluoro-2-trifluoromethylbenzonitrile with (R)-(+)-1-(2-naphthyl)ethylamine; the resulting 4-[[(1R)-1-(2-naphthyl)ethyl]amino]-2-trifluoromethylbenzonitrile underwent N-alkylation with cyclopropanemethyl bromide to give compd. II. All the invention compds. were evaluated for their androgen, glucocorticoid, mineralocorticoid, and progesterone receptor modulatory activity. From the assay, it was detd. that some of the compds. exhibited pIC50 values of ≥ 5.0.

L23 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1122964 CAPLUS
DN 145:455269
TI Preparation of N-cyanoaryl amino acid amides for treating endometriosis or uterine fibroids
IN Jones, David G.; Kaldor, Istvan; Liang, Xi; Turnbull, Philip Stewart; Hammond, Marlys; Kallander, Lara S.; Thompson, Scott Kevin; Washburn, David
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 71pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006113552	A2	20061026	WO 2006-US14286	20060414
	WO 2006113552	A3	20070531		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1871379	A2	20080102	EP 2006-750349	20060414
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008536868	T	20080911	JP 2008-506790	20060414
	US 20080194536	A1	20080814	US 2007-911537	20071015
PRAI	US 2005-671592P	P	20050415		
	WO 2006-US14286	W	20060414		

OS MARPAT 145:455269
AB The invention relates to amino acid amides NC-Ar-N(CHR1R1')CR2R2'CONR3R3' [Ar is Ph or naphthyl which may be further substituted; R1, R1' are independently H, (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, or together form a cycloalkyl or cycloalkenyl group; R2, R2' are independently H, (un)substituted alkyl, cycloalkyl, or R4(CH2)m-X-, where R4 is cycloalkyl, Ph, or pyridyl, m is 0-4, and X is a bond, O, or S; R3, R3' are independently (un)substituted alkyl, alkenyl, propargyl; or NR3R3' is heterocycloalkyl (with provisos)] or their pharmaceutically-acceptable salts and their use for treating endometriosis or uterine fibroids. Thus, N2-[(2-chlorophenyl)methyl]-N2-[4-cyano-3-(trifluoromethyl)phenyl]-N1,N1-dimethyl-L-alaninamide was prepared via amidation, arylation, and alkylation reactions. One hundred twenty-two synthesized compds. showed IC50 < 10 μM in the PR binding assay.

L23 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:886453 CAPLUS
DN 145:292730
TI Preparation of Naphthalene derivatives as modulators of the glucocorticoid receptor
IN Rafferty, Stephen William; Turnbull, Philip Stewart; Stewart, Eugene Lee; Caldwell, Richard Dana
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 249pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091592	A1	20060831	WO 2006-US6096	20060221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1851204	A1	20071107	EP 2006-720935	20060221
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
	JP 2008531503	T	20080814	JP 2007-556400	20060221
PRAI	US 2005-655603P	P	20050223		
	WO 2006-US6096	W	20060221		

OS MARPAT 145:292730
GI



AB Naphthalene derivs. I, wherein n is an integer from 1-4; R1 is cyano or nitro; Y is a carbonyl; Z is an alkylene or an (un)substituted alkylene ether; ; R2 is alkyl, cyano, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, etc; m and o are 0 or 1 are prepared for use in treating diseases related to that are modulation of the glucocorticoid receptor. Thus, II was prepared and tested in a variety of biol. studies, including, but not limited to glucocorticoid, androgen and progesterone receptor fluorescence polarization assays; cellular tyrosine aminotransferase assay and an in vivo gluconeogenesis model on mice (no data). Further, I can be used to treat ailments such as type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, metabolic syndrome X, diabetic dyslipidemia, bipolar disorder (manic depression),

L23 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
drug dependency, sleep disorders, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and generalized anxiety disorder.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:11154 CAPLUS
DN 144:108105
TI Phenoxynaphthalene derivatives as selective estrogen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy
IN Heyer, Dennis; Fang, Jing; Navas, Frank, III; Katamreddy, Subba Reddy; Peckham, Jennifer Poole; Turnbull, Philip Stewart; Miller, Aaron Bayne; Akwabi-Ameyaw, Adwoa
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
PAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006002185	A1	20060105	WO 2005-US21963	20050621
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005258085	A1	20060105	AU 2005-258085	20050621
	CA 2571309	A1	20060105	CA 2005-2571309	20050621
	EP 1773750	A1	20070418	EP 2005-760839	20050621
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	CN 101006042	A	20070725	CN 2005-80028557	20050621
	JP 2008503588	T	20080207	JP 2007-518209	20050621
	BR 2005012395	A	20080311	BR 2005-12395	20050621
	IN 2006KN03786	A	20070615	IN 2006-KN3786	20061215
	US 20070276000	A1	20071129	US 2006-570838	20061218
	MX 2006PA15152	A	20070228	MX 2006-PA15152	20061220
	NO 2007000379	A	20070321	NO 2007-379	20070119
PRAI	US 2004-581913P	P	20040622		
	WO 2005-US21963	W	20050621		

OS MARPAT 144:108105
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to phenoxynaphthalene compds. of formula I, which are useful for selective estrogen receptor modulation. In compds. I, R1 is H, OH, halo, or (un)substituted alkoxy; R2 is H, OH, or halo; R3 is (un)substituted alkyl, haloalkyl, (un)substituted cycloalkyl, (un)substituted alkoxy, or (un)substituted alkoxyalkyl; R4 is H or (un)substituted alkoxy; R5 is H, halo, or haloalkyl; R6 is R7-Y-, where Y is a bond, (un)substituted ethenyl, or ethynyl and R7 is (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl, cyano, carboxy, etc.; and R8 is

L23 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(un)substituted aryl or (un)substituted heteroaryl. The invention also relates to the prepn. of I, pharmaceutical compns. comprising a compd. I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment or prevention of conditions or disorders affected by selective estrogen receptor modulation. Hydride redn. of ketone II followed by mesylation, bromination, and substitution with phenylacetic acid gave carboxylic acid III, which underwent cyclization to the corresponding dihydronaphthalenone, oxidative acetylation, and hydrolysis to give naphthol IV. 3,4-Difluorobenzaldehyde was substituted with IV followed by Wittig olefination with tri-Bt phosphonoacetate, ester hydrolysis, and demethylation, resulting in the formation of (E)-propenoic acid V. The tested compds. of the invention exhibited pIC50 values ranging from 1 nM to 10 μM in an estrogen receptor competition binding assay.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:191394 CAPLUS
TI Ab initio conformational studies of imine and ketone analogs: Implications for ChAT inhibitors
AU Bowen, J. Phillip; Zhong, Haizhen; Stewart, Eugene L.; Kontoyianni, Maria
CS Center for Drug Design, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, 27402-6170, USA
SO Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005 (2005), MEDI-060 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69GQMP
DT Conference; Meeting Abstract
LA English
AB The enzyme choline acetyltransferase (ChAT) has known, inferred, and unknown functions. From a human health perspective some diseases affecting peripheral and central acetylcholine-mediated systems have been implicated or inferred to be related with the performance of this enzyme. It has been suggested that ChAT inhibitors, alone or coupled with other agents, might be used as potential prophylactic protecting agents for those who might be exposed to nerve gases that block acetylcholine esterase as their mechanism of action. Analogs of trans N-methyl-4-(1-naphthylvinyl)pyridine (NVP) have been shown to inhibit ChAT. Interestingly, replacing the CH=CH linkage with -N =CH is favorable while a -CH=N- is not. Whether or not this has conformational implications for ChAT inhibition remains to be answered. The potential energy surfaces (PES) for imines, ketones, and aldehydes have important differences. The PES of 2-butanone, 2-butanimine, 1-butenamine, propanal, and propanimine have been explored with ab initio calcns. at the RHF/6-311G** and MP2/6-311G** levels of theory. Our calcns. suggest that for 2-butanone and propanal, the steric and the bond dipole interactions are primarily responsible for the conformational preferences of these compds. Addnl. charge-charge interaction might also play an important role in determining the imine conformations. For enamines, however, steric interactions play a critical role, with bond dipole interaction exerting some influence. The calcns. and implications for ChAT inhibitors are presented.

L23 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:128293 CAPLUS
DN 142:391947
TI Ab Initio and DFT Conformational Studies of Propanal, 2-Butanone, and Analogous Imines and Enamines
AU Zhong, Haizhen; Stewart, Eugene L.; Kontoyianni, Maria; Bowen, J. Phillip
CS Center for Drug Design Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, 27402, USA
SO Journal of Chemical Theory and Computation (2005), 1(2), 230-238
CODEN: JCTCCE; ISSN: 1549-9618
PB American Chemical Society
DT Journal
LA English
AB The potential energy surfaces (PES) of 2-butanone, 2-butanimine, 1-butenamine, propanal, and propanimine were explored with ab initio and DFT calcns. at the RHF/6-311G**, MP2/6-311G**, and B3LYP/6-311G** levels of theory. In agreement with previous exptl. and computational results, the PES provides two min. for each of the above mols. with the exception of 2-butanone, which clearly shows three distinct min. Factors influencing the conformational preferences are also elaborated. Calcns. suggest that for 2-butanone and propanal, the steric and the bond dipole interactions are primarily responsible for the conformational preferences of these compds. Addnl. charge-charge interactions might also play an important role in determining the imine conformations. For enamines, however, steric interactions play a critical role, with bond dipole interactions exerting some influence. Results also suggest that for imine formation from butanone and/or propanal, the imine is the predominant product, not the enamine, which is consistent with exptl. observations. Therefore, these calcns. should provide a better understanding of the ketone/aldehyde to imine and enamine transformations. This transformation may introduce an important imine moiety for the analogs of trans-N-methyl-4-(1-naphthylvinyl)pyridine (NVP), a choline acetyltransferase (ChAT) inhibitor.
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1127314 CAPLUS
DN 142:74362
TI Preparation of substituted 1-naphthalenamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors
IN Cadilla, Rodolfo; Larkin, Andrew L.; Stewart, Eugene Lee; Trump, Ryan Paul; Turnbull, Philip Stewart
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004110978	A2	20041223	WO 2004-US18456	20040609
WO 2004110978	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636167	A2	20060322	EP 2004-776434	20040609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007505164	T	20070308	JP 2006-533682	20040609
US 20060142287	A1	20060629	US 2005-560017	20051208
PRAI US 2003-477256P	P	20030610		
WO 2004-US18456	W	20040609		

OS MARPAT 142:74362
GI



I

AB The title compds. I [R1 = CN, NO2, halo, etc.; R2 = H, CN, NO2, etc.; R3, R4 = (CH2)xR5 (wherein x = 0-6; R5 = H, alkyl, OH, etc.); R9 = H, CN, NO2, halo, etc.] that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors (no data), were prepared Thus, reacting (cyclopropylmethyl)propylamine with 4-chloro-1-nitronaphthalene afforded 96% I [R1 = NO2; R2 = H; R3 = Pr; R4 = cyclopropymethyl; R9 = H]. The pharmaceutical composition comprising the compound I is disclosed.

L23 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:634832 CAPLUS
TI Cyclobutenone-based synthesis of ligands for the estrogen receptor
AU Turnbull, Philip
CS Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
SO Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), MEDI-224 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69EKY9
DT Conference; Meeting Abstract
LA English
AB Organolithium addns. to squarate esters afforded highly substituted cyclobutenones. Thermolytic ring opening of these cyclobutenones and subsequent 6-π electrocyclization gave highly substituted naphthols that are difficult to access through standard aromatic substitution methods. Further functionalization of the naphthol scaffolds furnished highly potent ligands for the estrogen receptor.

L23 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:716258 CAPLUS
DN 137:247718
TI Preparation of piperazinyltriazines as estrogen receptor modulators
IN Hale, Ronnie Lee; Henke, Brad Richard; Lambert, Millard Hurst, III; Lu, Amy Tsai; Spearing, Paul Kenneth; Turnbull, Philip Stewart
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002072561	A1	20020919	WO 2002-US1758	20020123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002249971	A1	20020924	AU 2002-249971	20020123
US 20040072829	A1	20040415	US 2003-466847	20030721
US 6943162	B2	20050913		
PRAI US 2001-264362P	P	20010126		
WO 2002-US1758	W	20020123		

OS MARPAT 137:247718
GI



I

AB Triazine derivs. (shown as I; e.g. 4-[2-[[4-[[3-(4-chlorophenyl)propyl](methyl)amino]-6-(1-piperazinyl)-1,3,5-triazin-2-yl]amino]ethyl]phenol), which exhibit pharmacol. activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. In I, X is NR3, S, or O; R is 2-(hydroxyphenyl)ethyl or 5-, 6-, 7-, or 8-hydroxy-1,2,3,4-tetrahydro-2-naphthyl; R' is H, -(C1-C6)alkyl, -C(O)R4, -(CH2)mR4, -CR5:CHC(O)R4, -(CH2)mC(O)NR6R7, or -CH2CH:CHR4, -C(O)OR4, or -S(O)2R4; m is 0-3; R2 is -(CH2)n-(Z)p-(Z')q; Z is H, aryl, or (C3-C7)cycloalkyl; Z' is aryl; n is 0-3; p is 0, 1; q is 0, 1; R3 is H or -(C1-C6)alkyl; R4 is H, hydroxy, aryl, heteroaryl, heterocyclic, or -(C2-C6)alkenyl; R5 is H or -(C1-C6)haloalkyl; and R6, R7, R8, R9, and R10 are each independently selected from H or -(C1-C6)alkyl. The described invention also includes compns. and medicaments containing the triazine derivs. as well as processes for the preparation (not claimed) and use of such compds., compns. and medicaments. Results of α and β estrogen

L23 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
receptor binding by 24 claimed compds. are reported. Although the methods of prepn. are not claimed, 27 intermediate and 24 target compd. prepns. are included.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:651755 CAPLUS
DN 130:24884
TI Synthesis and Evaluation of a Carbocyclic Analog of the CC-1065 and Duocarmycin Alkylation Subunits: Role of the Vinylogous Amide and Implications on DNA Alkylation Catalysis
AU Boger, Dale L.; Turnbull, Philip
CS Department of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of Organic Chemistry (1998), 63(22), 8004-8011
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 130:24884
GI

I

AB The synthesis and chemical properties of 1,2,9,9a-tetrahydro-1H-cyclopropa[c]benz[e]inden-4-one (I; X = CH2), a carbocyclic C-ring analog of the alkylation subunits of CC-1065 and the duocarmycins, are detailed. The core structure of I (X = CH2) was prepared with an intramol. Heck reaction for assembly of the key tricyclic skeleton and a final Winstein Ar-3' spirocyclization to install the reactive cyclopropane. A study of the solvolysis reactivity of I (X = CH2), regioselectivity, and mechanism revealed that removal of the nitrogen and resulting vinylogous amide stabilization increased the reactivity 2200+ (pH 3) and reversed the inherent regioselectivity, but did not alter the SN2 reaction mechanism. Thus, the vinylogous amide found in the naturally occurring alkylation subunits is responsible for their unusual stability and significantly impacts the regioselectivity without altering the inherent SN2 mechanism of nucleophilic addition More importantly, this solvolysis reactivity proved independent of pH throughout the range of 4-12 including the physiol. relevant range of 5.0-8.0 where I (X = NH, NCO2CMe3) is completely stable. Rate consts. of 0.093 ±0.001 M-1 s-1 and 4.2 ±0.4 + 10-5 s-1 for the resp. acid-catalyzed and uncatalyzed reactions were established, and the uncatalyzed reaction dominates at pH ≥ 4. These observations have important implications on the source of catalysis for the CC-1065/duocarmycin DNA alkylation reaction supporting the recent proposal that it is not derived from acid catalysis and C4 carbonyl protonation but rather a DNA binding-induced conformational change that disrupts the cross-conjugated vinylogous amide stabilization.
RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:558868 CAPLUS
DN 127:190556
OREF 127:36953a,36956a
TI Synthesis and Evaluation of CC-1065 and Duocarmycin Analogs Incorporating the 1,2,3,4,11,11a-Hexahydrocyclopropa[c]naphtho[2,1-b]azepin-6-one (CNA) Alkylation Subunit: Structural Features that Govern Reactivity and Reaction Regioselectivity
AU Boger, Dale L.; Turnbull, Philip
CS Department of Chemistry, Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of Organic Chemistry (1997), 62(17), 5849-5863
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 127:190556
AB The synthesis of 1,2,3,4,11,11a-hexahydrocyclopropa[c]naphtho[2,1-b]azepin-6-one (CNA) (I), a seven-membered C-ring analog of the alkylation subunits of CC-1065 and the duocarmycins, is detailed. The core structure of I was prepared through the implementation of an intramol. Heck reaction for assemblage of the key tricyclic tetrahydronaphtho[2,1-b]azepine skeleton and a final Winstein Ar-3' spirocyclization for introduction of the reactive cyclopropane. A study of the solvolysis reactivity of N-BOC-CNA revealed that incorporation of the seven-membered fused C-ring system increased the reactivity 4750+ compared to the corresponding five-membered C-ring analog. Solvolysis occurs with SN2 nucleophilic attack at the more substituted carbon of the activated cyclopropane to afford exclusively the abnormal ring expansion product in a reaction that was shown to proceed with complete inversion of configuration at the reaction center. Single crystal X-ray structure analyses of N-CO2Me-CNA (II) and I and their comparisons with X-ray structures of the corresponding five- and six-membered C-ring analogs revealed the structural origins of the solvolysis regioselectivity and reactivity. The regioselectivity may be attributed to the stereoelectronic alignment of the two available cyclopropane bonds with the cyclohexadienone π-system which for II resides with the bond that extends to the more substituted cyclopropyl carbon. The increased reactivity may be due in part to the geometric alignment of the cyclopropane but more significantly is linked to a twist in the N2 amide. X-ray anal. provides documentation of the disruption in the vinylogous amide stabilization as measured by a lengthening of the diagnostic C-N bond that accompanies the twist in the χ1 dihedral angle of the N2 amide. As the cross-conjugated vinylogous amide stabilization is diminished, the cyclopropane conjugation, bond lengths, and resulting reactivity increase. The unusual stability of the five-membered C-ring bearing alkylation subunits characteristic of the natural products is intimately linked to the extent of this vinylogous amide conjugation, and the studies support the proposal that catalysis for the DNA alkylation reaction may be due to a DNA binding-induced conformational change in the agents which serves to twist the linking N2 amide, disrupting the vinylogous amide stabilization, and activating the agents for SN2 nucleophilic attack.

L23 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:191962 CAPLUS
DN 124:316912
OREF 124:58769a,58772a
TI Rearrangement of 2-Dienylcyclobutenones. Synthesis of Highly Substituted Annulated Furans
AU Turnbull, Philip; Heileman, Matthew J.; Moore, Harold W.
CS Department of Chemistry, University of California, Irvine, CA, 92717, USA
SO Journal of Organic Chemistry (1996), 61(8), 2584-5
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 124:316912
AB The thermolysis of 2-(1,3-dienyl)(alkoxy)cyclobutenones and 2-(arylethenyl)(alkoxy)cyclobutenones gave phenols, naphthalenols and annulated furan derivs. The starting materials were 3-(1-methylethoxy)-4-(phenylethynyl)-3-cyclobutene-1,2-dione, 3-(1-methylethoxy)-4-(phenylethynyl)-3-cyclobutene-1,2-dione and 3-(1-hexynyl)-4-(1-methylethoxy)-3-cyclobutene-1,2-dione. For example, thermolysis and rearrangement and cyclization of (Z)-3,4-dibutyl-4-hydroxy-2-(2-phenylethenyl)-2-cyclobuten-1-one gave 2,3-dibutylnaphtho[1,2-b]furan. The cyclization of (Z)-2-(2-butyl-3-methyl-1,3-butadienyl)-4-methoxy-3,4-dimethyl-2-cyclobuten-1-one gave 5-butyl-2,3,6-trimethylbenzofuran.

L23 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:579022 CAPLUS
DN 123:55466
OREF 123:9975a,9978a
TI Stereocontrolled Synthesis of 3-Acyl-4-alkoxy-5-aryl-1,2,4(E)-pentatrienes and Their Subsequent Electrocyclization to Naphthalenes
AU Turnbull, Philip; Moore, Harold W.
CS Department of Chemistry, University of California, Irvine, CA, 92717, USA
SO Journal of Organic Chemistry (1995), 60(11), 3274-5
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 123:55466
AB Upon treatment with lithium reagents some 2-alkynyl-3-alkoxy-4-arylcyclobutenones undergo conrotatory electrocyclic ring opening and form stable 2-acyl-4-alkoxy-5-aryl-1,2,4-(E)-pentatrienes. Heating of the latter gave highly substituted naphthalenes.

L23 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:337439 CAPLUS
DN 122:187093
OREF 122:34263a,34266a
TI Regioselective Synthesis of Highly Substituted Naphthols
AU Turnbull, Philip; Moore, Harold W.
CS Department of Chemistry, University of California, Irvine, CA, 92717, USA
SO Journal of Organic Chemistry (1995), 60(3), 644-9
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 122:187093
GI



AB 2,3,4-Trisubstituted 4-hydroxy-2-cyclobutenones, e.g., I, prepared by regiospecific reduction of substituted cyclobutenediones, undergo Lewis acid facilitated ionization to cyclobutenyl cations, which are trapped by trialkylsilanes in a regioselective sense. Thermolysis of the resulting cyclobutenones affords phenols, e.g., naphthol II, in high yields.

L23 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:308988 CAPLUS
DN 122:159929
OREF 122:29469a,29472a
TI Concerning the Mechanism of the Hooker Oxidation
AU Lee, Kwan; Turnbull, Philip; Moore, Harold W.
CS Department of Chemistry, University of California, Irvine, CA, 92717, USA
SO Journal of Organic Chemistry (1995), 60(2), 461-4
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 122:159929
AB The mechanism of the rearrangement of 2-[1-13C]ethyl-3-hydroxy-5,7-dimethoxy-1,4-naphthoquinone (I) to 3-[13C]methyl-2-hydroxy-5,7-dimethoxy-3-methyl-1,4-naphthoquinone (II) (Hooker oxidation) was investigated. 13C NMR studies of the starting naphthoquinone and its lower homolog product showed the enriched C-atom to be sp3 hybridized in I and sp2 hybridized in II. These data agree with the mechanism of the Hooker oxidation originally proposed 50 yr ago by Fieser and Fieser.

```
=> d his full

     (FILE 'HOME' ENTERED AT 10:48:29 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:44 ON 07 OCT 2008
L1                STRUCTURE UPLOADED
                  D
L2             13 SEA SSS SAM L1
L3            875 SEA SSS FUL L1
                  D QUE L3 STAT
L4            537 SEA ABB=ON  PLU=ON  L3 AND ED<06/09/2004
L5            587 SEA ABB=ON  PLU=ON  L3 AND REF.CAPLUS<=6
L6            288 SEA ABB=ON  PLU=ON  L3 NOT L5
L*** DEL        2 S LL6 AND ED<06/09/2004
                  D 1-2 IDE CAN
L7            115 SEA ABB=ON  PLU=ON  L6 AND ED<06/09/2004
                  D 1-115 IDE CAN

     FILE 'CAPLUS' ENTERED AT 10:57:25 ON 07 OCT 2008
L8            931 SEA ABB=ON  PLU=ON  L3
L9            765 SEA ABB=ON  PLU=ON  L8 AND PY<2004
L10           438 SEA ABB=ON  PLU=ON  L5
L11           369 SEA ABB=ON  PLU=ON  L10 AND PY<2005
L12           347 SEA ABB=ON  PLU=ON  L11 AND PY<2004
                  D 300-325 BIB ABS HITSTR
L13            79 SEA ABB=ON  PLU=ON  L12 AND THU/RL
                  D 1-79 BIB ABS HITSTR
L14            22 SEA ABB=ON  PLU=ON  L11 NOT L12
                  D 1-22 BIB ABS HITSTR
L15           268 SEA ABB=ON  PLU=ON  L12 NOT L13
```

DICTIONARY FILE UPDATES: 6 OCT 2008 HIGHEST RN 1057750-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE CAPLUS

FILE COVERS 1907 - 7 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 6 Oct 2008 (20081006/ED)



G1 CN,NO2

Structure attributes must be viewed using STN Express query preparation.
L25 6 SEA FILE=REGISTRY SUB=L3 SSS FUL L24

100.0% PROCESSED 81 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

=> d 1-6 ide can

L25 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 927702-79-2 REGISTRY
ED Entered STN: 20 Mar 2007
CN 1-Naphthalenecarbonitrile, 4-(dipropylamino)- (CA INDEX NAME)
MF C17 H20 N2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:287642

L25 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 813430-20-5 REGISTRY
ED Entered STN: 15 Jan 2005
CN 1-Naphthalenecarbonitrile, 4-[propyl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)
MF C16 H15 F3 N2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:74362

L25 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 813430-08-9 REGISTRY
ED Entered STN: 15 Jan 2005
CN 1-Naphthalenecarbonitrile, 4-(propylamino)- (CA INDEX NAME)
MF C14 H14 N2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:74362

L25 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 813430-06-7 REGISTRY
ED Entered STN: 15 Jan 2005
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)
MF C18 H20 N2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:287642

REFERENCE 2: 142:74362

L25 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 813430-01-2 REGISTRY
ED Entered STN: 15 Jan 2005
CN 1-Naphthalenamine, 4-nitro-N,N-dipropyl- (CA INDEX NAME)
MF C16 H20 N2 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:287642

REFERENCE 2: 142:74362

L25 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2008 ACS on STN
RN 813429-99-1 REGISTRY
ED Entered STN: 15 Jan 2005
CN 1-Naphthalenamine, N-(cyclopropylmethyl)-4-nitro-N-propyl- (CA INDEX NAME)
MF C17 H20 N2 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:287642

REFERENCE 2: 142:74362

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 11:25:33 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Oct 2008  VOL 149 ISS 15
FILE LAST UPDATED: 6 Oct 2008  (20081006/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l25
L26           2 L25

=> d 1-2 bib abs hitstr
```

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1343064 CAPLUS
DN 146:287642
TI Design and Synthesis of an Array of Selective Androgen Receptor Modulators
AU Trump, Ryan P.; Blanc, Jean-Baptiste E.; Stewart, Eugene L.; Brown, Peter J.; Caivano, Matilde; Gray, David W.; Hoekstra, William J.; Willson, Timothy M.; Han, Bajin; Turnbull, Philip
CS GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
SO Journal of Combinatorial Chemistry (2007), 9(1), 107-114
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
AB We describe the design, using shape comparison and fast docking computer algorithms, and rapid parallel synthesis of a 1300 member array based on GSK7721, a 4-aminobenzonitrile androgen receptor (AR) antagonist identified by focused screening of the GSK compound collection. The array yielded 352 submicromolar and 17 subnanomolar AR agonists as measured by a cell-based reporter gene functional assay. The rapid synthesis of a large number of active compds. provided valuable information in the optimization of AR modulators, which may be useful in treating androgen deficiency in aging males.
IT 813429-99-1P 813430-01-2P 813430-06-7P
927702-79-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Design and Synthesis of an Array of Selective Androgen Receptor Modulators)
RN 813429-99-1 CAPLUS
CN 1-Naphthalenamine, N-(cyclopropylmethyl)-4-nitro-N-propyl- (CA INDEX NAME)



RN 813430-01-2 CAPLUS
CN 1-Naphthalenamine, 4-nitro-N,N-dipropyl- (CA INDEX NAME)



RN 813430-06-7 CAPLUS

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)



RN 927702-79-2 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(dipropylamino)- (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:1127314 CAPLUS
DN 142:74362
TI Preparation of substituted 1-naphthalenamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors
IN Cadilla, Rodolfo; Larkin, Andrew L.; Stewart, Eugene Lee; Trump, Ryan Paul; Turnbull, Philip Stewart
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004110978	A2	20041223	WO 2004-US18456	20040609
WO 2004110978	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1636167	A2	20060322	EP 2004-776434	20040609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007505164	T	20070308	JP 2006-533682	20040609
US 20060142387	A1	20060629	US 2005-560017	20051208
PRAI US 2003-477256P	P	20030610		
WO 2004-US18456	W	20040609		

OS MARPAT 142:74362
GI



AB The title compds. I [R1 = CN, NO2, halo, etc.; R2 = H, CN, NO2, etc.; R3, R4 = (CH2)xR5 (wherein x = 0-6; R5 = H, alkyl, OH, etc.); R9 = H, CN, NO2, halo, etc.] that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors (no data), were prepared Thus, reacting (cyclopropylmethyl)propylamine with 4-chloro-1-nitronaphthalene afforded 95% I [R1 = NO2; R2 = H; R3 = Pr; R4 = cyclopropymethyl; R9 = H]. The pharmaceutical composition comprising the compound I is disclosed.
IT 813429-99-1P 813430-01-2P 813430-06-7P
813430-08-9P 813430-20-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of substituted 1-naphthalenamines as modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors)
RN 813429-99-1 CAPLUS
CN 1-Naphthalenamine, N-(cyclopropylmethyl)-4-nitro-N-propyl- (CA INDEX NAME)



RN 813430-01-2 CAPLUS
CN 1-Naphthalenamine, 4-nitro-N,N-dipropyl- (CA INDEX NAME)



RN 813430-06-7 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[(cyclopropylmethyl)propylamino]- (CA INDEX NAME)



RN 813430-08-9 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-(propylamino)- (CA INDEX NAME)



L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 813430-20-5 CAPLUS
CN 1-Naphthalenecarbonitrile, 4-[propyl(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)



```
=> d his full

     (FILE 'HOME' ENTERED AT 10:48:29 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:44 ON 07 OCT 2008
L1              STRUCTURE UPLOADED
                D
L2           13 SEA SSS SAM L1
L3          875 SEA SSS FUL L1
                D QUE L3 STAT
L4          537 SEA ABB=ON  PLU=ON  L3 AND ED<06/09/2004
L5          587 SEA ABB=ON  PLU=ON  L3 AND REF.CAPLUS<=6
L6          288 SEA ABB=ON  PLU=ON  L3 NOT L5
L*** DEL      2 S LL6 AND ED<06/09/2004
                D 1-2 IDE CAN
L7          115 SEA ABB=ON  PLU=ON  L6 AND ED<06/09/2004
                D 1-115 IDE CAN

     FILE 'CAPLUS' ENTERED AT 10:57:25 ON 07 OCT 2008
L8          931 SEA ABB=ON  PLU=ON  L3
L9          765 SEA ABB=ON  PLU=ON  L8 AND PY<2004
L10         438 SEA ABB=ON  PLU=ON  L5
L11         369 SEA ABB=ON  PLU=ON  L10 AND PY<2005
L12         347 SEA ABB=ON  PLU=ON  L11 AND PY<2004
                D 300-325 BIB ABS HITSTR
L13          79 SEA ABB=ON  PLU=ON  L12 AND THU/RL
                D 1-79 BIB ABS HITSTR
L14          22 SEA ABB=ON  PLU=ON  L11 NOT L12
                D 1-22 BIB ABS HITSTR
L15         268 SEA ABB=ON  PLU=ON  L12 NOT L13
L16         105 SEA ABB=ON  PLU=ON  L15 AND PATENT/DT
                D 1-105 BIB ABS HITSTR
                E CADILLA RODOLFO/AU
L17          17 SEA ABB=ON  PLU=ON  "CADILLA RODOLFO"/AU
                E LARKIN ANDREW/AU
L18          12 SEA ABB=ON  PLU=ON  ("LARKIN ANDREW"/AU OR "LARKIN ANDREW
                L"/AU OR "LARKIN ANDREW LAMONT"/AU)
                E STEWART EUGENE/AU
L19          48 SEA ABB=ON  PLU=ON  ("STEWART EUGENE"/AU OR "STEWART EUGENE
                L"/AU OR "STEWART EUGENE LEE"/AU)
                E TRUMP RYAN/AU
L20          17 SEA ABB=ON  PLU=ON  ("TRUMP RYAN P"/AU OR "TRUMP RYAN PAUL"/AU)

                E TURNBULL PHILIP/AU
L21          33 SEA ABB=ON  PLU=ON  ("TURNBULL PHILIP"/AU OR "TURNBULL PHILIP
                S"/AU OR "TURNBULL PHILIP STEWART"/AU OR "TURNBULL PHILLIP
                STEWART"/AU)
L22          95 SEA ABB=ON  PLU=ON  L17 OR L18 OR L19 OR L20 OR L21
L23          15 SEA ABB=ON  PLU=ON  L22 AND ?NAPHTH?
                D QUE L23 STAT
                D 1-15 BIB ABS

     FILE 'REGISTRY' ENTERED AT 11:23:55 ON 07 OCT 2008
L24             STRUCTURE UPLOADED
                D
L25           6 SEA SUB=L3 SSS FUL L24
                D QUE L25 STAT
                D 1-6 IDE CAN

     FILE 'CAPLUS' ENTERED AT 11:25:33 ON 07 OCT 2008
```

L26 2 SEA ABB=ON PLU=ON L25
D 1-2 BIB ABS HITSTR

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2008 HIGHEST RN 1057750-28-3
DICTIONARY FILE UPDATES: 6 OCT 2008 HIGHEST RN 1057750-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE CAPLUS

FILE COVERS 1907 - 7 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 6 Oct 2008 (20081006/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.38	1877.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-199.20

STN INTERNATIONAL LOGOFF AT 11:26:17 ON 07 OCT 2008